rp
bung
lectur
pele
molecular
cell
biolog
rehovot
israel
two
schwann
mechan
control
presenc
na
channel
node
ranvier
cluster
nodal
complex
protein
ii
restrict
nodal
protein
within
nodal
gap
paranod
junction
mechan
depend
specif
cell
adhes
molecul
mediat
contact
myelin
glia
underli
axon
form
node
paranod
junction
myelin
na
channel
initi
cluster
heminod
border
myelin
segment
process
requir
gliomedin
nrcam
neurofascin
three
cell
adhes
molecul
cam
mediat
interact
schwann
cell
microvilli
axon
na
channel
cluster
activ
gliomedin
tightli
regul
two
distinct
function
oppos
proteolyt
event
cluster
activ
gliomedin
enhanc
shed
surfac
schwann
cell
furin
proteas
activ
neg
regul
bone
morphogenet
protein
metalloproteinas
cleavag
enzym
restrict
activ
gliomedin
nodal
area
prevent
format
ectop
cluster
along
axon
devoid
myelin
segment
well
myelin
internod
henc
proteolyt
process
gliomedin
facilit
yet
limit
cluster
na
channel
specif
site
along
axon
time
manner
furthermor
contact
mediat
gliomedin
node
play
role
na
channel
cluster
develop
also
contribut
mainten
na
channel
node
ranvier
addit
cluster
gliomedin
distribut
na
channel
restrict
two
grow
myelin
segment
flank
paranod
junction
site
contact
mediat
distinct
set
cell
adhes
molecul
ie
caspr
contactin
also
delin
underli
axon
glial
cytoskeleton
paranod
restrict
na
channel
node
mediat
paranod
axon
cytoskeleton
ak
asburi
lectur
illa
unit
neurolog
depart
hospit
santa
creu
sant
pau
universitat
de
barcelona
barcelona
spain
chronic
inflammatori
demyelin
polyradiculoneuropathi
cidp
autoimmun
disord
peripher
nerv
clinic
immunolog
heterogen
current
diagnosi
cidp
base
clinic
electrophysiolog
criteria
take
consider
presenc
immun
biomark
sever
autoantibodi
protein
node
ranvier
patient
cidp
describ
antibodi
defin
specif
cidp
subtyp
sometim
refer
nodopathi
diagnost
prognost
implic
antibodi
describ
presenc
antibodi
small
subset
patient
cidp
patient
share
phenotyp
poor
respons
ivig
antibodi
predominantli
patholog
studi
skin
sural
nerv
biopsi
patient
show
morpholog
chang
paranod
experiment
data
support
pathogen
antibodi
includ
demonstr
vitro
antibodi
disrupt
bind
complex
b
intraneur
inject
antibodi
progress
specif
disrupt
paranod
junction
c
chronic
infus
antibodi
induc
clinic
electrophysiolog
worsen
anim
experiment
autoimmun
neuriti
ean
antibodi
antibodi
neurofascin
first
report
patient
gb
cidp
subsequ
antibodi
specif
isoform
found
small
group
patient
cidp
studi
us
confirm
other
demonstr
patient
cidp
antibodi
distinct
phenotyp
often
includ
tremor
poor
respons
ivig
autoantibodi
predominantli
subtyp
passiv
transfer
monoclon
antibodi
recogn
neurofascin
isoform
mice
ean
strongli
exacerb
sever
patholog
studi
yet
demonstr
antibodi
pathogen
pathogen
role
antibodi
howev
support
sural
nerv
biopsi
patient
cidp
antibodi
show
paranod
demyelin
absenc
inflamm
loss
junction
interposit
cellular
process
paranod
loop
axolemma
alter
reminisc
found
mice
suggest
antibodi
may
specif
disrupt
complex
paranod
antibodi
nodal
protein
recent
report
main
target
autoantibodi
five
patient
igg
reactiv
node
ranvier
antibodi
predominantli
patient
present
clinic
featur
distinct
patient
antibodi
four
patient
subacut
onset
sensori
ataxia
without
tremor
presenc
antibodi
report
two
patient
inflammatori
neuropathi
one
classifi
cidp
gb
patient
intens
neuropath
pain
skin
biopsi
patient
show
paranod
disrupt
patient
whose
sera
show
nodal
paranod
reactiv
teas
nerv
fiber
prepar
antibodi
nodal
protein
gliomedin
neuron
cell
adhes
molecul
nrcam
treatment
nodopathi
corticosteroid
report
effect
approxim
case
clinic
remiss
note
follow
rituximab
associ
autoantibodi
deplet
neurophysiolog
improv
conclus
clinic
immunolog
heterogen
cidp
unravel
descript
specif
autoantibodi
associ
diseas
phenotyp
autoantibodi
shown
clinic
valu
associ
treatment
respons
well
pathogen
role
immun
neuropathi
recogn
nodopathi
research
determin
addit
clinic
valuabl
immun
associ
subgroup
cidp
patient
jw
griffin
lectur
milbrandt
univers
school
medicin
washington
usa
axon
degener
form
program
subcellular
death
central
perhap
initi
event
mani
neurolog
disord
nad
metabol
play
central
role
process
also
requir
receptor
adaptor
map
kinas
includ
dlk
dismantl
damag
axon
prevent
nad
biosynthet
enzym
first
observ
studi
wld
mutant
mous
later
work
show
isoform
locat
axon
help
block
activ
degener
pathway
central
execution
axon
degener
pathway
activ
culmin
deplet
axon
nad
yet
ident
underli
deplet
enzym
unknown
discov
domain
commonli
appreci
scaffold
domain
intrins
nadas
nad
adpr
cyclic
adpr
nicotinamid
mutat
analysi
show
nadas
activ
necessari
axon
degener
injuri
suggest
repres
novel
therapeut
target
peripher
neuropathi
neurodegen
condit
pj
dyck
lectur
lewin
center
molecular
medicin
berlin
germani
skin
equip
special
mechanoreceptor
allow
percept
slightest
brush
inde
mechanoreceptor
detect
even
movement
movement
transform
electr
signal
via
gate
ion
channel
sensori
end
skin
sensit
piezo
ion
channel
control
requir
normal
mechanoreceptor
function
pathophysiolog
condit
follow
nerv
injuri
diabet
neuropathi
slightest
touch
produc
pain
present
unclear
whether
peripher
chang
sensori
mechanotransduct
may
underli
hypersensit
associ
neuropath
pain
examin
role
modul
channel
mechanoreceptor
nociceptor
pathophysiolog
condit
recent
develop
small
molecul
act
inhibitor
function
peripher
applic
inhibitor
allevi
hypersensit
model
neuropath
pain
data
strongli
suggest
tactil
evok
pain
model
peripher
neuropathi
may
least
partli
driven
sensit
sensori
mechanotransduct
driven
pk
thoma
lectur
coleman
van
geest
centr
brain
repair
cambridg
uk
axon
lost
earli
mani
neurodegen
disord
peripher
central
nervou
system
degener
transect
axon
wallerian
degener
slow
tenfold
overexpress
varieti
enzym
isoform
nmnat
relat
mutant
fusion
protein
wld
wallerian
degener
also
delay
delet
tlr
adapt
protein
protein
recent
report
promot
nad
degrad
import
understand
fulli
mechan
wallerian
degener
relat
mechan
contribut
axon
loss
number
diseas
model
includ
model
peripher
neuropathi
parkinson
diseas
multipl
sclerosi
glaucoma
new
data
also
suggest
role
hereditari
spastic
paraplegia
deplet
nad
attract
hypothesi
mechan
wallerian
degener
especi
nad
increas
dietari
method
explain
number
key
observ
inhibitor
nampt
block
nad
salvag
pathway
strongli
deplet
nad
includ
within
axon
howev
instead
kill
axon
nad
hypothesi
would
predict
precis
opposit
phenocopi
protect
effect
wld
moreov
ectop
express
bacteri
enzym
nmn
deamidas
protein
absent
mammal
protect
injur
axon
transgen
mice
primari
neuron
cultur
effect
nad
level
either
basal
condit
degener
nerv
observ
fit
better
propos
toxic
role
nad
synthesi
intermedi
nmn
model
also
explain
protect
effect
wld
full
understand
pathway
identifi
number
point
intervent
could
treatment
multipl
axonopathi
plenari
lectur
sejvar
center
emerg
zoonot
diseas
us
center
diseas
control
prevent
atlanta
ga
usa
medic
disciplin
expansoin
knowledg
fundament
scienc
behe
disord
human
nervou
system
come
part
parcel
chang
understand
epidemiolog
given
disord
group
disord
recent
advanc
fundament
understand
inflammatori
neuropathi
peripher
nervou
system
accompani
drastic
chang
understand
neuroepidemiolog
disord
specif
populationss
affect
peripher
neuropathi
well
vari
import
contribut
select
peripher
neuropathi
overal
burden
peripher
nervou
system
pn
diseas
shift
epidemiolog
understand
influenc
clinic
approach
diagnosi
manag
patient
pn
diseas
past
decad
wit
paradigm
shift
mani
aspect
pn
diseas
diagnosi
treatment
associ
human
immunodefici
viru
hiv
neuropathi
increass
recognit
hereditari
famili
peripher
neuropathi
increas
recognit
specif
neuropathi
multifoc
motor
neuropathi
conduct
block
addit
time
event
recent
increasingli
irrefutalb
evid
link
zika
viru
syndrom
rather
unexpect
resurg
peripher
neuropathi
due
previous
exot
etiolog
lepromat
neuropathi
requir
prompt
clinic
attent
plenari
session
aim
describ
evolv
neuroepidemiolog
peripher
nervou
system
disord
chang
may
influnec
clinic
approach
diagnosi
prognost
treatment
otherwis
unusu
periph
nerv
diseas
abdela
fledrich
rasch
stenzel
prukop
stassart
nave
sereda
neurogenet
experiment
medicin
germani
clinic
neuropatholog
univers
medic
center
germani
clinic
neurophysiolog
univers
medic
center
germani
diseas
common
inherit
neuropathi
duplic
peripher
myelin
protein
gene
caus
frequent
contrari
notion
manifest
second
decad
life
moder
walk
disabl
electrophysiolog
abnorm
usual
alreadi
present
childhood
earli
onset
development
natur
diseas
also
support
find
deriv
transgen
rat
model
cmt
rat
display
reduc
number
myelin
fiber
per
peripher
nerv
alreadi
earli
postnat
never
reach
wildtyp
level
throughout
develop
line
cmt
rat
schwann
cell
show
strongli
impair
lipid
biogenesi
requir
myelin
assess
rna
express
lipid
profil
peripher
nerv
transcriptom
myelin
composit
respect
importantli
overexpress
schwann
cell
also
reflect
impair
myelin
compet
vitro
dorsal
root
ganglia
neuron
remark
improv
schwann
cell
myelin
upon
supplement
phosphatidylcholin
vitro
led
hypothesi
exogen
supplement
lipid
vivo
may
improv
diseas
progress
inde
observ
improv
diseas
progress
histolog
electrophysiolog
behavior
level
cmt
rat
fed
chow
enrich
lecithin
adulthood
moreov
diseas
amelior
also
visibl
late
earli
treatment
effect
fade
treatment
cessat
therefor
continu
suppli
patient
exogen
lipid
may
consid
promis
therapeut
approach
diseas
alberti
lecchi
monza
pastori
fumgal
pozzi
becchetti
bostock
cavaletti
program
neurosci
school
medicin
surgeri
univers
monza
itali
biotechnolog
bioscienc
univers
milan
itali
program
translat
molecular
medicin
dimet
univers
milan
itali
colleg
london
london
uk
oxaliplatin
chemotherapi
colorect
cancer
serious
limit
neurotox
side
effect
fulli
understood
peripher
neurotox
oipn
compris
acut
syndrom
chronic
sensori
neuropathi
acut
symptom
notabl
cold
hyperalgesia
attribut
transient
ion
channel
dysfunct
wors
sever
chronic
neuropathi
ensu
design
combin
vitro
vivo
project
use
neurophysiolog
better
understand
pathogenesi
oipn
vitro
studi
differenti
cell
rat
drg
neuron
x
mous
neuroblastoma
cell
line
incub
hour
oxaliplatin
electrophysiolog
properti
studi
treat
cell
show
rel
depolar
rest
membran
potenti
significantli
decreas
fire
frequenc
increas
sodium
current
densiti
moreov
decreas
erg
gene
potassium
current
also
evid
vivo
studi
appli
nerv
excit
test
net
wistar
rat
model
oipn
investig
acut
syndrom
compar
behaviour
neurophysiolog
data
anim
cohort
control
oipn
rat
oxaliplatin
administr
iv
hour
inject
observ
differ
group
behaviour
cold
plate
test
superxcit
motor
axon
investig
chronic
neuropathi
compar
control
group
treat
group
oxaliplatin
mgkg
twice
weekli
x
week
iv
group
studi
behaviour
neurophysiolog
sensori
motor
nerv
conduct
studi
net
patholog
caudal
sciatic
nerv
skin
biopsi
drg
method
data
collect
baselin
end
treatment
week
treatment
obtain
full
net
profil
signific
chang
highli
translat
approach
oipn
vivo
net
chang
acut
chronic
rat
model
match
one
hand
find
vitro
experi
clinic
data
sinc
net
also
easili
appli
human
sindrup
dornonvil
de
la
cour
van
den
berg
jacob
andersen
harbo
neurolog
aarhu
univers
hospit
aarhu
denmark
neurolog
odens
univers
hospit
odens
denmark
clinic
neurophysiolog
danish
nation
hospit
copenhagen
denmark
neurolog
immunolog
erasmu
medic
centr
rotterdam
netherland
intern
gb
outcom
studi
igo
prospect
observ
intern
studi
aim
identifi
clinic
biolog
determin
diseas
progress
outcom
larg
cohort
gb
patient
demograph
clinic
characterist
first
includ
patient
analys
present
howev
within
igo
popul
base
control
group
therefor
import
assess
generaliz
result
denmark
uniqu
situat
conduct
epidemiolog
studi
facilit
danish
civil
registr
danish
nation
hospit
registri
dnhr
enabl
us
identifi
gb
patient
denmark
given
period
period
igo
cohort
includ
identifi
gb
patient
admit
seen
outpati
clinic
hospit
denmark
septemb
decemb
record
popul
base
danish
cohort
review
demograph
clinic
data
compar
patient
includ
igo
denmark
well
igo
europeamerica
cohort
period
patient
denmark
includ
igo
danish
group
compar
europeamerica
group
count
danish
patient
cohort
regard
sex
age
entri
gb
disabl
score
nadir
percentag
patient
need
mechan
ventil
danish
igo
group
male
median
age
year
mean
sd
gb
disabl
score
nadir
danish
group
need
mechan
ventil
europeamerica
group
male
median
age
mean
sd
gb
disabl
score
nadir
group
need
mechan
ventil
meet
compar
present
data
danish
popul
base
cohort
well
epidemiolog
data
allard
zeng
wang
kimpston
notini
li
sailer
conley
howard
scherer
su
pediatr
univers
north
carolina
chapel
hill
usa
neurolog
univers
north
carolina
chapel
hill
usa
neurolog
univers
pennsylvania
philadelphia
pa
usa
chronic
inflammatori
demyelin
polyneuropathi
cidp
common
autoimmun
diseas
peripher
nervou
system
pn
caus
sensorimotor
impair
mice
domin
autoimmun
regul
gene
air
mutat
diabet
nod
background
nodairegw
mice
develop
spontan
autoimmun
peripher
polyneuropathi
sapp
resembl
cidp
sapp
demyelin
caus
primarili
cell
howev
contribut
cell
schwann
cell
poorli
understood
identifi
popul
integrin
alpha
cell
pn
increas
frequenc
number
sapp
cell
coexpress
numer
schwann
cell
marker
includ
myelin
protein
zero
peripher
myelin
protein
suggest
cell
schwann
addit
sapp
cell
upregul
extracellular
matrix
protein
periostin
postn
recent
shown
promot
macrophag
recruit
activ
inflammatori
diseas
cancer
data
indic
macrophag
pathogen
sapp
therefor
hypothes
cell
promot
macrophag
recruit
sapp
via
postn
product
test
hypothesi
perform
vitro
chemotaxi
assay
condit
media
nodairegw
nerv
promot
significantli
macrophag
chemotaxi
condit
media
nerv
furthermor
postn
recombin
protein
suffici
induc
macrophag
chemotaxi
vitro
find
show
schwann
cell
mediat
macrophag
chemotaxi
upregul
postn
sapp
suggest
postn
novel
target
treatment
cidp
allen
pasnoor
burn
ney
cook
brannagan
iii
lawson
kissel
gorson
lewi
jensen
walton
neurolog
univers
minnesota
minneapoli
mn
usa
depart
neurolog
northwestern
univers
chicago
il
usa
neurolog
kansa
univers
medic
center
kansa
citi
ks
usa
neurolog
univers
virginia
charlottesvil
va
usa
neurolog
northwestern
univers
chicago
il
usa
neurolog
boston
univers
medic
center
boston
usa
john
creek
john
creek
ga
usa
neurolog
columbia
univers
medic
center
new
york
ny
usa
neurolog
dartmouth
geisel
school
medicin
hanov
nh
usa
neurolog
ohio
state
univers
columbu
oh
usa
neurolog
st
elizabeth
medic
center
tuft
univers
school
medicin
boston
usa
neurolog
lo
angel
ca
usa
health
solut
briovarx
infus
servic
lenexa
ks
usa
health
solut
briovarx
infus
servic
lenexa
ks
usa
although
ivig
efficaci
treatment
cidp
demonstr
random
control
trial
optim
treatment
approach
patient
chronic
therapi
unknown
herein
updat
progress
gripper
studi
prospect
evalu
ivig
fluctuat
patient
cidp
primari
outcom
measur
jamar
grip
strength
gs
perform
daili
month
home
nurs
visit
also
captur
overal
disabl
score
time
go
test
tug
overal
neuropathi
limit
scale
onl
modifi
fatigu
sever
scale
mfss
visual
analog
pain
sever
scale
va
weekli
month
qol
short
form
physic
compon
summari
collect
baselin
week
week
serum
igg
level
collect
surround
ivig
infus
peak
trough
total
recruit
anticip
subject
upon
studi
complet
frequenc
analyz
assess
proport
subject
given
degre
gs
rod
intracycl
fluctuat
proport
cycl
gs
fluctuat
occur
determin
extent
degre
differ
maximum
minimum
gs
tug
onl
va
score
analyz
current
subject
differ
site
enrol
site
elig
enrol
interim
studi
report
provid
preliminari
repres
data
demonstr
ivig
effect
gs
outcom
measur
better
understand
frequenc
extent
ivig
fluctuat
expect
result
help
facilit
develop
cidp
treatment
optim
strategi
also
expect
inform
import
form
hypothes
test
futur
studi
exampl
compar
differ
dosag
interv
optim
ivig
taper
guidelin
assess
outcom
cycl
cycl
clinic
fluctuat
almomani
marchi
lindsey
sopacua
santoro
smeet
lauria
boneschi
waxman
merki
faber
gerrit
propan
studi
group
clinic
genet
maastricht
univers
medic
center
maastricht
netherland
unit
ircc
foundat
carlo
besta
milan
itali
neurolog
maastricht
univers
medic
center
maastricht
netherland
genet
neurolog
complex
disord
institut
experiment
neurolog
insp
divis
neurosci
san
raffael
scientif
institut
milan
itali
neurolog
neurosci
regener
research
yale
univers
school
medicin
new
usa
neurosci
regener
research
veteran
affair
medic
center
west
usa
neurolog
st
elisabeth
hospit
willemstad
neuropath
pain
frequent
featur
peripher
neuropathi
caus
signific
impact
patient
qualiti
life
health
care
cost
resolv
genet
architectur
pain
neuropathi
lead
better
diseas
manag
strategi
risk
stratif
counsel
therefor
aim
develop
reliabl
techniqu
rapidli
accur
multipl
gene
larg
cohort
pain
neuropathi
patient
low
cost
whole
exom
sequenc
thousand
sampl
remain
expens
clinic
use
sever
target
enrich
approach
current
avail
select
enrich
genom
region
interest
studi
compar
sensit
specif
target
effici
reproduc
perform
cost
effect
custom
gener
sequenc
molecular
invers
next
gener
sequenc
method
method
construct
target
enrich
kit
captur
code
intron
sequenc
nine
sodium
channel
gene
express
nocicept
neuron
probe
design
two
method
use
respect
informat
pipelin
total
patient
diabet
idiopath
neuropathi
test
method
among
patient
patient
test
previous
sanger
sequenc
approxim
captur
sequenc
target
region
show
averag
coverag
manag
identifi
potenti
pathogen
mutat
polymorph
variant
moreov
observ
perfect
agreement
sanger
sequenc
data
obtain
use
ng
approach
show
softwar
design
probe
exhibit
similar
effici
although
overal
coverag
per
region
vari
across
differ
dna
sampl
suffici
detect
variant
region
versatil
assay
design
demonstr
high
degre
flexibl
probe
cheaper
reliabl
flexibl
inexpens
method
detect
genet
variat
thousand
patient
center
technolog
current
implement
routin
diagnost
tool
screen
sodium
channel
gene
pain
neuropathi
patient
illa
querol
diseas
unit
neurolog
depart
hospit
de
la
santa
creu
sant
pau
universitat
de
barcelona
spain
para
la
en
red
para
enfermedad
rara
ciber
madrid
spain
depart
hospit
universitario
dexeu
barcelona
spain
acut
demyelin
polyneuropathi
pathogenesi
includ
within
syndrom
spectrum
occasion
mechan
metabol
infecti
toxic
may
lead
present
pura
differ
brand
illeg
slim
product
sold
onlin
vendor
exact
composit
unknown
present
patient
acut
demyelin
polyneuropathi
secondari
intak
slim
product
pura
woman
remark
medic
histori
report
day
histori
distal
numb
feet
progress
one
week
knee
left
hand
upper
respiratori
tract
infect
ten
day
prior
symptom
neurolog
examin
show
absent
distal
vibratori
arthrokinet
sensat
arreflexia
lower
limb
decreas
vibratori
sensat
hand
atax
gate
lumbar
punctur
show
gl
protein
cell
emg
fulfil
diagnost
criteria
acquir
demyelin
intraven
immunoglobulin
therapi
start
symptom
kept
worsen
corticosteroid
start
patient
mention
slim
product
brain
mri
show
diffus
leukoencephalopathi
asymptomat
steroid
pura
alegria
slim
product
withdrawn
patient
recov
complet
one
year
pura
thermatrim
thermatrim
plu
slim
product
forbidden
spain
sever
case
acut
leukoencephalopathi
acut
polyneuropathi
exact
composit
unknown
although
spanish
drug
agenc
detect
pesticid
malonoben
tyrosin
kinas
inhibitor
among
compon
sinc
nine
case
pura
alegriathermatrim
neurolog
toxic
includ
leukoencephalopathi
polyneuropathi
describ
case
good
outcom
treatment
withdraw
although
recoveri
slow
may
incomplet
case
highlight
need
care
consid
drug
toxic
includ
dietari
supplement
differenti
diagnosi
gb
special
evolut
follow
typic
pattern
alvarez
klein
martini
moldovan
krarup
neurosci
univers
copenhagen
denmark
neurolog
development
neurobiolog
univers
hospit
germani
clinic
neurophysiolog
rigshospitalet
copenhagen
denmark
neuropathi
type
result
peripher
myelin
protein
kda
overexpress
common
hereditari
motor
sensori
neuropathi
human
transgen
mous
line
carri
copi
human
gene
slowli
progress
neuropathi
phenotyp
like
thin
abnorm
thick
myelin
profil
supernumerari
schwann
cell
addit
nerv
show
activ
macrophag
lead
compart
disrupt
maldistribut
k
channel
kohl
b
et
al
j
pathol
aim
present
studi
investig
motor
axon
excit
versu
wt
litterm
multipl
measur
motor
axon
excit
anesthesia
carri
stimul
tibial
nerv
ankl
plantar
compound
muscl
action
potenti
cmap
age
month
matur
nearli
complet
wt
cmap
show
increas
latenc
cmap
amplitud
decreas
although
mean
motor
unit
size
mscan
method
appear
unchang
indic
lack
collater
sprout
furthermor
show
abnorm
passiv
cabl
properti
voltag
depend
paramet
age
month
cmap
latenc
increas
compar
wt
contrast
mark
conduct
slow
along
tibial
nerv
month
age
progress
excit
chang
local
ankl
appear
modest
nevertheless
pool
data
month
increas
latenc
correl
spearman
p
increas
accommod
depolar
electrotonu
threshold
ms
reduct
late
subexcit
period
recoveri
cycl
threshold
chang
consist
redistribut
k
current
consist
maldistribut
k
channel
data
suggest
model
function
thu
potenti
revers
abnorm
k
channel
distribut
accumul
along
nerv
aggrav
conduct
impair
due
impair
myelin
format
mainten
alvarez
krarup
moldovan
neurosci
univers
copenhagen
denmark
clinic
neurophysiolog
rigshospitalet
copenhagen
denmark
mice
heterozyg
defici
myelin
protein
gene
show
mild
progress
dysmyelin
neuropathi
conduct
slow
impair
excit
phenotyp
similar
diseas
type
found
accumul
myelin
abnorm
parallel
progress
chang
motor
axon
function
result
neurotox
membran
depolar
rosberg
mr
et
al
neurobiol
di
aim
studi
investig
relationship
demyelin
motor
axon
function
demyelin
right
sciatic
nerv
topic
lysophosphatidylcholin
lpc
applic
carri
wt
mice
year
matur
year
age
group
multipl
measur
motor
axon
excit
anesthesia
carri
stimul
tibial
nerv
ankl
distal
lpc
demyelin
plantar
cmap
respons
live
imag
studi
cellvizio
mauna
kea
technolog
pari
franc
confoc
laser
endomicroscopi
carri
transgen
mice
express
fluoresc
report
yfp
peripher
nerv
axon
promot
matur
wt
sciatic
morpholog
electrophysiolog
demyelin
featur
follow
lpc
could
readili
observ
hour
disappear
week
morpholog
chang
could
observ
tibial
level
consist
conduct
excit
chang
could
observ
right
tibial
neve
level
compar
left
tibial
nerv
wt
contrast
motor
axon
function
impair
tibial
nerv
level
week
sciatic
lpc
demyelin
matur
although
cmap
amplitud
appear
preserv
distal
motor
latenc
prolong
wherea
excit
measur
show
reduc
deviat
threshold
electrotonu
increas
refractori
expens
superexcit
recoveri
cycl
consist
membran
depolar
furthermor
age
delay
tibial
conduct
associ
drop
cmap
amplitud
prolong
time
constant
taken
togeth
data
suggest
focal
demyelin
aggrav
membran
dysfunct
along
entir
motor
axon
provid
novel
experiment
model
explor
link
demyelin
axon
membran
dysfunct
amass
li
gundapaneni
schwartz
keohan
inc
new
york
ny
usa
health
inc
burlington
usa
number
factor
influenc
diseas
progress
transthyretin
famili
amyloid
polyneuropathi
rare
fatal
hereditari
amyloidosi
analysi
evalu
specif
role
baselin
neurolog
sever
neurolog
diseas
progress
predict
model
creat
base
longitudin
data
patient
particip
tafamidi
select
ttr
stabil
clinic
develop
program
data
popul
registr
studi
tafamidi
group
placebo
group
two
consecut
extens
studi
patient
receiv
tafamidi
use
second
extens
studi
ongo
formal
interim
analysi
conduct
date
decemb
analysi
focus
first
month
treatment
overal
studi
cohort
analyz
neuropathi
impair
limb
use
assess
neurolog
function
baselin
subsequ
studi
visit
linear
model
mmrm
analysi
baselin
treatment
interact
time
fix
effect
use
slope
intercept
patient
includ
random
effect
patient
primarili
caucasian
neurolog
diseas
baselin
mean
standard
deviat
tafamidi
placebo
across
group
diseas
progress
increas
increas
level
baselin
sever
p
howev
predict
magnitud
chang
baselin
month
tafamidi
consist
less
placebo
across
rang
observ
baselin
valu
suggest
effect
tafamidi
similar
find
observ
muscl
weak
subscal
mmrm
analysi
patient
demonstr
diseas
progress
strongli
depend
baselin
neurolog
impair
highlight
effect
tafamidi
across
rang
baselin
level
neurolog
sever
http
clinicaltrialsgov
identifi
amino
misawa
sekiguchi
shibuya
watanab
suichi
kuwabara
neurolog
chiba
univers
chiba
japan
syndrom
gb
potenti
life
threaten
neurolog
disord
respiratori
insuffici
one
critic
complic
eramu
gb
respiratori
insuffici
score
egri
method
predict
chanc
respiratori
insuffici
gb
howev
clinic
characterist
cours
vari
subtyp
gb
whose
occurr
differ
region
acut
inflammatori
demyelin
polyneuropathi
aidp
common
european
countri
wherea
acut
motor
axon
neuropathi
aman
frequent
seen
asian
countri
aim
studi
investig
use
egri
japan
aman
common
netherland
clinic
electrophysiolog
profil
consecut
gb
case
visit
hospit
within
day
symptom
onset
review
gb
patient
classifi
aidp
aman
accord
electrodiagnosi
criteria
ho
colleagu
higher
egri
score
correspond
higher
risk
respiratori
insuffici
total
gb
patient
well
aidp
patient
howev
patient
aman
egri
score
alway
match
chanc
respiratori
insuffici
patient
low
risk
egri
show
respiratori
failur
wherea
patient
high
risk
egri
need
intubationmechan
ventil
aman
associ
mechan
ventil
seen
rapid
progress
shorter
durat
onset
hospit
admiss
decreas
vital
capac
frequent
autonom
involv
egri
use
also
japanes
gb
patient
howev
aman
patient
use
discret
anoth
score
predict
respiratori
insuffici
might
requir
asian
countri
anandan
litchi
laughlin
leep
hunderfund
naddaf
clinic
rochest
usa
patient
suspect
ulnar
neuropathi
nerv
conduct
studi
nc
commonli
request
help
diagnosi
local
howev
routin
nc
often
normal
local
ulnar
nc
record
first
dorsal
inteross
muscl
thought
increas
diagnost
yield
electrodiagnost
test
although
commonli
consid
develop
qualiti
improv
strategi
routin
perform
ulnar
nc
record
abductor
digiti
minimi
muscl
well
ulnar
patient
refer
suspect
ulnar
neuropathi
util
dmaic
defin
measur
analyz
improv
control
model
process
improv
defin
problem
creat
map
current
process
ulnar
neuropathi
diagnosi
electromyographi
laboratori
determin
baselin
perform
via
review
recent
patient
refer
lab
suspect
ulnar
neuropathi
patient
review
patient
demonstr
electrodiagnost
evid
ulnar
neuropathi
ulnar
perform
patient
patient
ulnar
neuropathi
two
pure
sensori
neuropathi
one
dorsal
cutan
ulnar
neuropathi
remain
patient
abnorm
ulnar
neuropathi
localiz
elbow
patient
localiz
rest
defin
qualiti
gap
measur
baselin
perform
result
analysi
use
develop
target
intervent
intend
improv
perform
ulnar
data
remeasur
present
specif
address
degre
improv
diagnost
yield
electrodiagnost
test
ulnar
neuropathi
via
routin
perform
andersen
witt
dalsgaard
andersen
nawroth
flem
jensen
finnerup
jensen
lauritzen
charl
public
health
aarhu
univers
aarhu
denmark
diabet
neuropathi
consortium
aarhu
denmark
diabet
academi
odens
denmark
neurolog
aarhu
univers
hospit
aarhu
denmark
medicin
clinic
chemistri
univers
hospit
heidelberg
heidelberg
germani
diabet
center
copenhagen
denmark
clinic
medicin
danish
pain
research
center
aarhu
univers
aarhu
denmark
distal
sensorimotor
polyneuropathi
dpn
common
complic
diabet
risk
factor
beyond
hyperglycemia
proven
import
particularli
type
diabet
prospect
studi
exist
aim
studi
develop
dpn
first
year
diagnosi
studi
particip
elig
studi
dpn
assess
michigan
neuropathi
screen
instrument
questionnair
mnsi
four
dpn
defin
mnsi
score
particip
posit
mnsi
baselin
thu
exclud
studi
plot
evalu
cumul
incid
dpn
cox
proport
hazard
model
calcul
hazard
ratio
hr
intervent
group
addit
trial
variou
covari
propos
influenc
develop
dpn
model
adjust
step
intervent
group
age
sex
baselin
mnsi
treatment
studi
cohort
consist
particip
men
median
age
year
median
baselin
cumul
incid
seen
year
diabet
statist
signific
differ
hr
intervent
group
sex
significantli
higher
hr
ci
seen
age
per
year
highest
hr
found
histori
cardiovascular
diseas
myocardi
infarct
stroke
ten
year
prior
diabet
diagnosi
hr
weight
waist
circumfer
index
methylglyox
transform
show
modest
statist
signific
associ
incid
dpn
standard
hr
ci
ci
ci
ci
respect
studi
demonstr
fairli
low
cumul
incid
dpn
peopl
provid
evid
macrovascular
diseas
obes
oxid
stress
import
risk
factor
dpn
even
earliest
stage
azzedin
elmalik
tonekaboni
kabiraj
abdalla
mukhtar
ahm
katona
chaouch
leguern
wei
chaouch
salih
neuropatholog
aachen
germani
la
hospit
pari
franc
physiolog
colleg
medicin
king
saud
univers
riyadh
saudi
arabia
neurolog
ben
aknoun
hospit
algier
algeria
clinic
neurophysiolog
depart
neurosci
princ
sultan
medic
citi
riyadh
saudi
arabia
eye
center
omdurman
sudan
endem
diseas
faculti
medicin
univers
khartoum
sudan
physiolog
faculti
medicin
univers
khartoum
sudan
neurophysiolog
ben
aknoun
hospit
algier
algeria
pediatr
neurolog
colleg
medicin
king
saud
univers
riyadh
saudi
arabia
andermann
syndrom
also
known
agenesi
corpu
callosum
peripher
neuropathi
accpn
autosom
recess
disord
broad
spectrum
mild
sever
neuromuscular
psychiatr
consequ
gene
variant
caus
diseas
first
identifi
famili
present
studi
intend
phenotyp
genotyp
seri
famili
case
present
charcot
mari
tooth
disord
associ
agenesisdysgenesi
corpu
callosum
purpos
seven
famili
consanguin
marriag
studi
patient
clinic
investig
use
mri
electrophysiolog
mncv
sural
nerv
biopsi
taken
microsatellit
marker
around
accpn
locu
use
two
larg
famili
follow
sanger
sequenc
exon
boundari
gene
one
patient
famili
age
onset
diseas
birth
patient
largest
consanguin
famili
affect
individu
biopsi
one
patient
show
sever
demyelin
neuropathi
mani
hypomyelin
fibr
mostli
secondari
axon
chang
find
compat
electrophsiolog
data
mncv
demyelin
rang
dysgenesi
corpu
callosum
one
patient
agenesi
anoth
sib
reveal
mri
identifi
one
homozyg
truncat
mutat
famili
interestingli
caus
variant
found
patient
anoth
famili
show
homozyg
haplotyp
two
differ
heterozyg
variant
identifi
one
hit
two
patient
two
famili
genet
investig
continu
identifi
possibl
second
hit
remain
famili
variant
found
neg
famili
case
subject
ng
stage
tempt
specul
genet
heterogen
accpn
seri
baba
suzuki
ogawa
tomiyama
neurolog
center
aomori
prefectur
central
hospit
aomori
japan
introduc
stage
system
sever
diabet
polyneuropathi
dpn
nerv
conduct
studi
nc
lower
limb
sensori
nc
sural
nerv
motor
nc
tibial
nerv
system
consist
five
stage
normal
abnorm
mildli
abnorm
presenc
delay
mcv
scv
minim
latenc
posit
moder
abnorm
decreas
sural
snap
less
sever
abnorm
decreas
plantar
ultim
abnorm
plantar
lost
less
trace
examin
valid
system
conduct
prospect
observ
develop
diabet
foot
df
nc
stage
system
addit
occurr
ischem
heart
diseas
ihd
stroke
death
event
also
count
carri
nc
diabet
categor
nc
stage
system
anoth
follow
prospect
count
occurr
df
ihd
patient
mean
age
occurr
df
follow
occurr
df
ihd
andor
follow
death
group
two
group
found
dead
bed
driver
seat
two
group
die
sudden
cardiac
arrest
infect
foot
amput
summari
present
nc
grade
system
seem
work
satisfactori
diagnosi
sever
current
dpn
also
prognost
predict
foot
vascular
event
bacon
feeli
shi
iowa
hospit
iowa
citi
ia
usa
patient
diseas
also
known
hereditari
motor
sensori
neuropathi
rasch
modifi
valid
measur
symptom
impair
score
compris
nine
paramet
clinic
examin
includ
nerv
conduct
studi
nc
paramet
individu
score
rang
zero
four
composit
score
maximum
prior
rasch
modif
patient
complet
nc
cmt
exam
score
use
maximum
score
rasch
modif
one
paramet
vibrat
sens
use
rydel
tune
fork
measur
vibrat
sens
patient
feet
ankl
knee
score
determin
sever
reduc
vibrat
sens
patient
receiv
score
note
reduc
vibrat
sens
knee
order
captur
sensit
vibrat
measur
test
way
take
total
raw
score
rydel
tune
fork
point
vibrat
sens
toe
ankl
knee
bilater
score
rang
zero
reflect
full
vibrat
sens
modifi
measur
vibrat
sens
score
vari
wider
distribut
patient
captur
studi
modifi
vibrat
sens
score
result
potenti
sensit
total
score
bae
vincent
hospit
cathol
univers
korea
suwon
korea
diabet
lumbosacr
radiculoplexu
neuropathi
dlrpn
usual
subacut
pain
monophas
asymmetr
lower
limb
neuropathi
incomplet
recoveri
due
ischaem
injuri
microvascul
diagnosi
reli
mostli
clinic
suspicion
characterist
electromyograph
find
howev
acut
phase
neuroimag
import
diagnost
signific
electrophysiolog
studi
describ
mri
ultrasound
find
woman
dlrpn
diagnos
diabet
three
year
ago
receiv
treatment
histori
sever
pain
weak
muscl
innerv
left
femor
obtur
nerv
decreas
sensat
left
dermatom
nerv
conduct
studi
show
reduc
amplitud
left
femor
nerv
electromyographi
show
increas
insert
activ
left
iliopsoa
muscl
volit
activ
muscl
innerv
left
femor
obtur
nerv
ultrasound
reveal
increas
area
csa
left
femor
later
femor
cutan
nerv
mri
show
enhanc
left
nerv
root
proxim
femor
nerv
increas
signal
intens
left
iliacu
iliopsoa
diagnos
dlrpn
start
corticosteroid
nerv
ultrasound
previous
report
patient
dlrpn
case
show
ultrasound
may
valuabl
supplement
mri
electrophysiolog
studi
workup
dlrpn
baek
byun
kim
choi
choi
kwun
shin
sung
hong
univers
anam
hospit
seoul
south
korea
metropolitan
govern
borama
medic
center
seoul
south
korea
nation
univers
hospit
seoul
south
korea
univers
medic
center
seoul
south
korea
poem
polyneuropathi
organomegali
endocrinopathi
protein
skin
chang
syndrom
rare
caus
polyneuropathi
polyneuropathi
one
major
criteria
syndrom
usual
associ
demyelin
pattern
patient
poem
syndrom
reveal
polyneuropathi
earli
stage
diseas
therefor
poem
syndrom
often
misdiagnos
chronic
inflammatori
demyelin
polyneuropathi
cidp
aim
studi
investig
clinic
electrophysiolog
find
could
differenti
poem
syndrom
cidp
review
medic
record
nerv
conduct
studi
patient
enrol
patient
poem
syndrom
patient
cidp
fulfil
efnspn
criteria
definit
cidp
monoclon
gammopathi
undetermin
signific
mgu
without
mgu
median
age
onset
older
cidp
mgu
group
group
cidp
mgu
year
cidp
without
mgu
year
poem
year
neuropath
pain
frequent
poem
syndrom
group
poem
cidp
without
mgu
cidp
mgu
poem
syndrom
reveal
slower
conduct
veloc
ncv
ms
vs
ms
prolong
vs
higher
termin
latenc
index
tli
vs
p
median
motor
nerv
cidp
without
mgu
also
poem
syndrom
show
reduc
tibial
cmap
amplitud
vs
frequent
record
tibial
cmap
vs
p
cidp
without
mgu
hand
cidp
mgu
group
show
much
slower
ncv
vs
cidp
without
mgu
compar
poem
syndrom
cidp
mgu
group
reveal
prolong
termin
latenc
vs
lower
tli
vs
conclus
poem
syndrom
demonstr
much
slower
ncv
less
prolong
termin
latenc
higher
tli
especi
tli
much
higher
poem
cidp
withwithout
mgu
therefor
tli
might
help
distinguish
poem
cidp
balk
sprenger
wunderlich
stettner
fink
lehmann
hospit
cologn
germani
hospit
essen
germani
research
centr
germani
cabin
air
commerci
airlin
origin
aircraft
engin
auxiliari
power
unit
bleed
air
may
occasion
contamin
hydraul
fluid
engin
oil
contain
number
potenti
hazard
chemic
includ
tricresyl
phosphat
tcp
last
year
report
emerg
aircrew
member
experi
symptom
tingl
burn
extrem
addit
headach
vertigo
aerotox
syndrom
controversi
discuss
literatur
attribut
exposur
organophosph
contamin
cabin
air
sinc
tcp
associ
peripher
neuropathi
aim
determin
frequenc
peripher
neuropathi
among
frequent
flyer
civilian
air
crew
member
frequent
fli
passeng
f
median
age
year
median
exposit
time
aircraft
hour
examin
univers
hospit
cologn
frankfurt
airport
iata
code
fra
detail
questionnair
past
medic
condit
standard
neurolog
examin
nerv
conduct
studi
sural
tibial
ulnar
nerv
identifi
subject
clinic
electrophysiolog
evid
larg
fiber
peripher
neuropathi
incid
peripher
neuropathi
correl
exposit
time
aircraft
addit
subject
show
sign
ulnar
neuropathi
subject
report
abnorm
vibrat
sensat
subject
suffer
gait
imbal
individu
report
tingl
extrem
studi
show
preval
larg
fiber
peripher
neuropathi
among
frequent
flyer
comparison
data
preval
rate
control
group
reveal
possibl
associ
chronic
exposur
cabin
air
risk
peripher
neuropathi
high
incid
symptom
tingl
cohort
warrant
studi
determin
risk
small
fiber
neuropathi
condit
ballarini
mereg
carozzi
chiorazzi
canta
monza
fumag
pozzi
alberti
bossi
marjanov
scali
marmiroli
cavaletti
neurolog
unit
school
medicin
surgeri
univers
monza
itali
program
translat
molecular
medicin
dimet
univers
milan
itali
program
neurosci
univers
monza
itali
spa
loc
ai
conti
castelvecchio
pascoli
barga
lucca
itali
intraven
immunoglobulin
ivig
human
igg
deriv
plasma
pool
healthi
donor
although
studi
literatur
evalu
effect
differ
patholog
anim
model
data
possibl
role
bortezomib
btz
peripher
neuropathi
femal
wistar
rat
treat
follow
prevent
schedul
btz
ivig
week
therapeut
schedul
week
btz
treatment
follow
caudal
nerv
conduct
veloc
ncv
plantar
dynam
test
perform
differ
time
point
anim
sacrif
acut
phase
chronic
phase
tissu
sampl
dorsal
root
ganglia
sciatic
nerv
caudal
nerv
skin
collect
morpholog
morphometr
immunohistolog
analysisin
prevent
schedul
ivig
abl
rescu
caudal
ncv
reduct
caus
btz
neither
week
result
observ
therapeut
schedul
hand
evalu
mechan
allodynia
cold
hyperalgesia
show
ivig
inject
protect
btz
effect
treatment
schedul
morphometr
analysi
evidenc
even
statist
signific
prevent
schedul
tendenc
protect
caudal
nerv
btz
damag
result
consist
morpholog
evalu
nerv
also
nerv
fiber
densiti
preserv
prevent
schedul
therapeut
one
final
sciatic
nerv
drg
macrophag
infiltr
level
tend
reduc
therapeut
schedul
brought
back
ctrl
rat
treat
inject
ivig
alon
level
prevent
one
conclus
abl
demonstr
first
time
ivig
treatment
especi
use
prevent
treatment
option
may
reduc
neuropath
pain
point
possibl
role
inflamm
pathogenesi
invalid
patholog
work
support
kedrion
spa
bansagi
griffin
whittak
antoniadi
evangelista
miller
greenslad
forest
duff
bradshaw
kleinl
boczonadi
steel
ramesh
franko
pyle
chinneri
horvath
centr
neuromuscular
diseas
john
walton
muscular
dystrophi
research
centr
institut
genet
medicin
newcastl
univers
newcastl
upon
tyne
uk
neurosci
newcastl
univers
newcastl
upon
tyne
uk
genet
laboratori
patholog
scienc
north
bristol
nh
trust
southmead
hospit
bristol
uk
genet
center
munich
germani
paediatr
neurolog
royal
victoria
infirmari
newcastl
upon
tyne
foundat
hospit
nh
trust
newcastl
upon
tyne
uk
depart
clinic
neurosci
univers
oxford
oxford
uk
clinic
neurosci
cambridg
biomed
campu
univers
cambridg
cambridg
uk
studi
preval
molecular
caus
clinic
present
hereditari
motor
neuropathi
larg
cohort
patient
north
england
detail
neurolog
electrophysiolog
assess
next
gener
panel
test
whole
exom
sequenc
perform
patient
clinic
symptom
distal
hereditari
motor
neuropathi
dhmn
patient
axon
motor
neuropathi
motor
patient
complex
neurolog
diseas
predominantli
affect
motor
nerv
hmn
plu
patient
preval
dhmn
affect
individu
per
inhabit
confid
interv
north
england
caus
mutat
identifi
index
patient
diagnost
rate
dhmn
subgroup
higher
previous
report
detect
defect
neuromuscular
transmiss
case
identifi
potenti
caus
mutat
patient
demyelin
multifoc
motor
neuropathi
mani
gene
share
dhmn
motor
indic
ident
diseas
mechan
therefor
suggest
chang
classif
includ
dhmn
also
subcategori
cmt
abnorm
neuromuscular
transmiss
genet
form
provid
treatabl
target
develop
therapi
barohn
gajewski
pasnoor
brown
herbelin
kimminau
jawdat
park
shlemon
dimachki
studi
univers
kansa
medic
center
kansa
citi
ks
usa
cryptogen
sensori
polyneuropathi
cspn
common
slowli
progress
neuropathi
affect
adult
present
signific
neuropath
pain
multipl
medic
tri
includ
antiepilept
antidepress
topic
narcot
web
base
survey
among
neuromuscular
expert
suggest
pregabalin
effect
medic
howev
present
compar
studi
assess
effect
medic
object
studi
determin
pharmaceut
therapi
pregabalin
duloxetin
nortriptylin
mexiletin
effect
neuropath
pain
best
toler
cspn
achiev
object
perform
prospect
random
open
label
compar
effect
adapt
design
studi
cspn
patient
patient
center
outcom
research
institut
pcori
cspn
patient
fulfil
inclus
exclus
criteria
enrol
studi
patient
underw
baselin
neurolog
evalu
randomli
assign
one
neuropath
medic
month
primari
outcom
chang
pain
scale
secondari
outcom
includ
nih
pain
interfer
scale
nih
fatigu
interfer
scale
nih
sleep
disturb
scale
advers
event
outcom
measur
perform
baselin
month
statist
analysi
use
bayesian
adapt
design
develop
berri
consult
softwar
perform
determin
winner
loser
winner
greater
point
improv
pain
total
number
patient
enrol
recruit
challeng
number
recruit
techniqu
use
date
patient
screen
patient
random
us
site
anticip
complet
enrol
june
end
final
patient
assess
septemb
interim
analysi
perform
first
patient
complet
part
bayesian
adapt
design
analysi
occur
everi
week
distribut
random
patient
medic
last
adapt
design
random
medic
medic
medic
medic
studi
may
give
physician
patient
evid
futur
manag
cspn
patient
barroso
ando
schmidt
mundayat
neurolog
carrea
institut
neurolog
research
fleni
bueno
air
argentina
neurolog
graduat
school
medic
scienc
kumamoto
univers
kumamoto
japan
nacion
de
ciencia
salvador
mexico
transplant
medicin
univers
hospit
germani
new
york
ny
usa
transthyretin
amyloidosi
attr
encompass
group
disord
signific
clinic
variabl
caus
transthyretin
ttr
deriv
amyloid
deposit
clinic
aspect
autonom
nervou
system
involv
attr
partial
known
ongo
multin
longitudin
observ
transthyretin
amyloidosi
outcom
survey
thao
provid
opportun
expand
understand
dysautonomia
attr
data
symptomat
subject
enrol
thao
registri
diagnosi
attr
date
januari
assess
presenc
tempor
cours
autonom
symptom
genotyp
phenotyp
associ
clinic
burden
accord
frequenc
sever
symptom
symptomat
subject
enrol
thao
autonom
symptom
enrol
includ
gastrointestin
subject
urinari
erectil
dysfunct
orthostat
hypotens
xerophthalmia
dyshydrosi
subject
autonom
manifest
compar
without
younger
mean
age
standard
deviat
sd
vs
year
longer
durat
attr
symptom
vs
year
autonom
dysfunct
less
common
attr
subject
mutat
group
cardiac
mutat
mutat
similarli
time
mean
sd
year
first
attr
symptom
onset
autonom
symptom
longest
attr
follow
cardiac
mutat
autonom
symptom
present
diseas
onset
third
subject
autonom
dysfunct
less
frequent
subject
cardiac
phenotyp
subject
mix
neurolog
phenotyp
burden
autonom
symptom
mean
sd
vari
genotyp
cardiac
mutat
attr
phenotyp
mix
neurolog
cardiac
dysautonomia
common
signific
burden
subject
hereditari
form
attr
preval
higher
genotyp
neurolog
mix
phenotyp
ba
delmont
fatehi
boulay
chabrol
verschueren
pouget
lefebvr
grapperon
attarian
center
neuromuscular
diseas
al
la
timon
univers
univers
marseil
franc
faculti
univers
umr
marseil
franc
center
pediatr
neuromuscular
disord
la
timon
univers
hospit
univers
marseil
franc
univers
inserm
gmgf
marseil
franc
la
timon
univers
hospit
univers
marseil
franc
object
studi
assess
use
motor
unit
number
index
munix
techniqu
type
diseas
test
correl
munix
clinic
impair
munix
techniqu
perform
abductor
pollici
brevi
apb
abductor
digiti
minimi
adm
tibiali
anterior
ta
muscl
side
munix
sum
score
calcul
ad
munix
muscl
muscl
strength
measur
use
mrc
medic
research
council
scale
disabl
evalu
sever
function
scale
includ
cmt
neuropathi
score
version
overal
neuropathi
limit
scale
onl
patient
known
gene
duplic
enrol
munix
adm
apb
ta
muscl
correl
mrc
correspond
muscl
p
munix
sum
score
correl
clinic
scale
p
onl
p
conclus
munix
correl
muscl
strength
clinic
measur
disabl
patient
munix
techniqu
evalu
motor
axon
loss
correl
disabl
munix
sum
score
may
use
outcom
measur
diseas
progress
ba
delmont
le
troter
fatehi
verschueren
pouget
lefebvr
grapperon
bendahan
attarian
center
neuromuscular
diseas
al
la
timon
univers
univers
marseil
franc
faculti
univers
umr
marseil
franc
cnr
la
timon
univers
hospit
univers
marseil
franc
la
timon
univers
hospit
univers
marseil
franc
univers
inserm
gmgf
marseil
franc
object
studi
assess
use
mri
type
diseas
test
correl
muscl
fat
fraction
clinic
impair
mri
perform
lower
limb
patient
healthi
control
fat
fraction
tibiali
anterior
muscl
cross
section
area
volum
sciatic
nerv
determin
muscl
strength
dorsiflexion
measur
use
dynamomet
disabl
evalu
cmt
neuropathi
score
version
patient
known
gene
duplic
enrol
fat
fraction
tibiali
anterior
muscl
significantli
increas
patient
compar
healthi
control
correl
muscl
strength
p
score
p
cross
section
area
volum
sciatic
nerv
significantli
increas
patient
compar
healthi
control
conclus
mri
fat
fraction
correl
muscl
strength
clinic
measur
disabl
patient
may
thu
use
outcom
measur
diseas
progress
basta
peric
cobelj
bjelica
bozov
kacar
nikol
rakocev
stojanov
stevic
lavrnic
clinic
clinic
center
serbia
school
medicin
univers
belgrad
belgrad
serbia
complet
lack
data
epidemiolog
clinic
featur
chronic
inflammatori
demyelin
polyneuropathi
cidp
serbia
surround
countri
furthermor
strike
scarciti
inform
qualiti
life
qol
cidp
patient
qol
studi
conduct
countri
high
standard
health
care
august
design
iness
inflammatori
neuropathi
studi
serbia
order
compris
mani
patient
cidp
serbia
republ
srpska
bosnia
herzegovina
montenegro
cover
popul
nine
million
peopl
first
aim
analyz
overal
impact
cidp
physic
mental
social
area
life
measur
gener
symptom
specif
diseas
specif
questionnair
inqol
respect
furthermor
aim
analyz
influenc
diseas
patient
work
statu
presenc
depress
mood
measur
beck
inventori
follow
featur
patient
includ
sociodemograph
data
clinic
aspect
diseas
level
disabl
sever
sensori
symptom
presenc
comorbid
electrophysiolog
characterist
well
fatigu
autonom
symptom
neuropath
pain
intend
defin
signific
predictor
decreas
qol
order
focu
patient
highest
risk
improv
care
cidp
also
want
see
cidp
patient
complet
remiss
per
clinic
find
still
reduc
qualiti
life
recruit
patient
far
expect
includ
around
subject
overal
present
first
data
studi
pn
meet
beaudonnet
prudhon
cauquil
labeyri
bouilleret
adam
chu
le
kremlin
franc
chu
le
kremlin
franc
famili
amyloid
neuropathi
fap
diseas
autosom
domin
inherit
due
transthyretin
ttr
gene
mutat
protein
current
treatment
slow
natur
cours
indic
first
object
symptom
aim
evalu
two
neurophysiolog
marker
sympathet
skin
respons
ssr
heart
rate
variabl
hrv
earli
detect
sympathet
damag
due
fap
ssr
hrv
assess
ttr
gene
mutat
patient
neither
clinic
electroneuromyograph
abnorm
control
match
gender
age
case
recruit
consecut
current
care
french
refer
center
rare
diseas
bicetr
univers
hospit
ssr
record
two
palm
sole
left
foot
stimul
hrv
regist
three
condit
second
normal
breath
deep
breath
cycl
second
inspir
second
expir
valsalva
manoeuv
second
valsalva
ratio
defin
ratio
longest
shortest
rr
interv
significantli
higher
control
group
bonferroni
correct
mean
respect
p
signific
differ
two
group
ssr
paramet
although
mean
amplitud
systemat
higher
control
among
case
result
confirm
autonom
nervou
fiber
damag
earli
clinic
electroneuromyograph
asymptomat
patient
mutat
ttr
gene
valsalva
ratio
seem
discrimin
marker
test
repetit
confront
cardiolog
assess
help
precis
test
could
use
current
care
might
help
identifi
high
risk
patient
propos
appropri
earli
treatment
could
use
follow
treatment
efficaci
yildiz
kurn
tan
neurolog
hacettep
univers
ankara
turkey
diseas
research
laboratori
hacettep
univers
ankara
turkey
content
antigen
properti
central
peripher
myelin
differ
therefor
simultan
autoimmun
central
peripher
demyelin
extrem
rare
condit
present
uniqu
patient
diagnos
recurr
acut
immun
mediat
central
peripher
demyelin
eighteen
man
admit
due
gener
weak
respiratori
insuffici
electrophysiolog
evalu
compat
acut
inflammatori
demyelin
polyneuropathi
aidp
treat
intraven
immunoglobulin
ivig
second
week
treatment
start
suffer
vision
loss
left
eye
cranial
magnet
reson
imag
mri
show
multipl
subcort
lesion
contrast
enhanc
compat
acut
demyelin
encephalomyel
adem
complaint
benefit
day
mg
methylprednisolon
twelv
year
later
refer
gener
weak
respiratori
insuffici
bilater
shoulder
abduct
elbow
flexion
extens
hip
flexion
foot
dorsiflexion
accord
medic
research
council
scale
diagnos
aidp
cranial
mri
depict
right
cerebellar
tempor
bilater
frontopariet
subcort
contrast
enhanc
activ
lesion
igg
index
high
oligoclon
band
posit
cerebrospin
fluid
csf
protein
mgdl
serum
csf
antibodi
neg
patient
success
treat
plasma
exchang
mri
month
normal
previous
five
patient
multipl
sclerosi
chronic
inflammatori
demyelin
polyradiculoneuropathi
follow
institut
neg
howev
report
patient
simultan
syndrom
adem
report
defer
patient
due
recurr
cours
benson
dasgupta
patholog
laboratori
medicin
indiana
univers
school
medicin
indianapoli
usa
veteran
affair
richard
l
roudebush
veteran
affair
medic
center
indianapoli
usa
cardiolog
depart
intern
medicin
indiana
univers
school
medicin
indianapoli
usa
famili
amyloidot
polyneuropathi
fap
origin
character
andrad
axon
neuropathi
subsequ
found
associ
number
mutat
plasma
protein
transthyretin
previous
name
prealbumin
recogn
cardiomyopathi
may
signific
factor
major
patient
hereditari
form
transthyretin
amyloidosi
fap
mani
transthyretin
ttr
mutat
associ
cardiomyopathi
minim
sign
peripher
neuropathi
also
call
senil
cardiac
amyloidosi
senil
system
amyloidosi
recogn
usual
decad
life
fact
major
patient
male
transthyretin
neuropathi
proven
nerv
biopsi
rare
report
popul
report
experi
patient
character
cardiomyopathi
also
vari
degre
peripher
neuropathi
clinic
neuropathi
appear
typic
axon
mix
axonaldemyelin
neuropathi
seen
fap
patholog
two
type
ttr
deposit
found
intraneur
ttr
amyloid
deposit
seen
fap
present
patient
patient
extens
vascular
deposit
amyloid
perineur
arteri
vein
without
deposit
within
nerv
trunk
conclus
peripher
neuropathi
may
definit
part
clinic
present
increas
number
cardiomyopathi
patient
identifi
import
ascertain
whether
evid
peripher
neuropathi
due
amyloidosi
compound
syndrom
diabet
mellitu
type
ii
besora
santo
izquierdo
bruna
velasco
unit
hospit
universitari
de
doncologia
lhospitalet
barcelona
spain
oncolog
depart
institut
doncologia
lhospitalet
barcelona
spain
cell
biolog
physiolog
immunolog
institut
neurosci
universitat
de
barcelona
centro
de
en
red
sobr
enfermedad
neurodegenerativa
cibern
bellaterra
spain
oxaliplatin
oxa
chemotherapi
agent
treatment
colorect
cancer
crc
peripher
neuropathi
frequent
retreat
oxa
frequent
consid
patient
salvag
treatment
patient
receiv
chemotherapi
regimen
least
twice
institut
review
aim
studi
investig
whether
retreat
oxa
increas
risk
develop
worsen
previou
peripher
neuropathi
sever
neuropathi
measur
nation
cancer
toxic
criteria
nci
total
neuropathi
score
tn
nerv
conduct
studi
one
hundr
crc
patient
includ
median
age
year
chemotherapi
patient
develop
neuropathi
accord
nci
median
cycl
sever
neuropathi
grade
grade
grade
median
time
retreat
oxa
month
frequenc
neuropathi
retreat
follow
grade
grade
grade
retreat
sever
neuropathi
grade
grade
patient
develop
grade
patient
develop
neuropathi
peripher
neuropathi
reason
stop
prematur
treatment
retreat
patient
respect
worsen
previou
nci
score
observ
patient
great
major
patient
remain
within
nci
score
retreat
median
cycl
among
patient
develop
neuropathi
first
treatment
patient
develop
grade
respect
median
cycl
among
patient
initi
develop
grade
neuropathi
differ
score
finish
retreat
oxa
identifi
vs
retreat
oxa
crc
patient
feasibl
option
even
patient
develop
moder
sever
neuropathi
previous
lack
worsen
previou
neuropathi
observ
great
major
patient
neurolog
monitor
patient
candid
retreat
oxa
consid
bessaguet
sturtz
magi
desmoulier
bourthoumieu
demiot
myelin
mainten
peripher
neuropathi
faculti
medicin
pharmaci
univers
limog
limog
franc
neurolog
refer
center
rare
peripher
neuropathi
univers
hospit
limog
limog
franc
prolong
pressur
result
local
ischemia
wide
accept
primari
etiolog
skin
pressur
ulcer
pu
precis
mechan
format
remain
unclear
studi
want
studi
potenti
role
sensori
small
nerv
fiber
regul
inflamm
pu
format
achiev
goal
develop
mous
model
pure
sensori
neuropathi
induc
resiniferatoxin
rtx
model
seven
day
singl
inject
rtx
ip
mice
present
thermal
mechan
hypoalgesia
associ
larg
substanc
p
sp
calcitonin
peptid
cgrp
deplet
without
neurodegener
model
mimic
quit
well
observ
earli
stage
sensori
nerv
fiber
defect
studi
shown
sp
cgrp
involv
cutan
inflamm
regul
fact
neuropeptid
releas
sensori
fiber
mainli
recruit
immun
cell
vasodil
thu
studi
gene
express
pro
cytokin
rna
array
approach
pu
format
control
rtx
mice
seven
day
singl
inject
rtx
epidermi
dermi
subcutan
tissu
layer
pinch
magnet
plate
hour
pressur
induc
stage
pu
gene
express
evalu
compress
area
pressur
result
show
mainli
gene
express
pu
rtx
mice
compar
control
mice
decreas
cgrpsp
skin
sensori
small
fiber
increas
pu
format
associ
increas
interleukin
il
express
decreas
express
rtx
mice
supplementari
experi
cytokin
necessari
confirm
preliminari
result
observ
suggest
cgrpsp
role
regul
cytokin
express
pu
format
new
inflammatori
profil
exhibit
studi
might
help
design
new
treatment
improv
qualiti
life
neuropath
patient
prone
develop
bedsor
bhattacharyya
jayaraj
belmadani
ren
rathwel
hackelberg
miller
menichella
neurolog
northwestern
univers
chicago
il
usa
pharmacolog
northwestern
univers
chicago
il
usa
pain
diabet
neuropathi
pdn
one
common
intract
symptom
diabet
affect
diabet
patient
hallmark
pdn
neuropath
pain
small
fiber
degener
manifest
loss
dorsal
root
ganglion
drg
nociceptor
axon
neuropath
pain
associ
nociceptor
absenc
physiolog
appropri
stimuli
state
neuropath
pain
drg
nociceptor
becom
increasingli
respons
varieti
excitatori
influenc
includ
inflammatori
cytokin
particular
shown
stromal
cell
deriv
receptor
necessari
gener
neuropath
pain
mous
model
pdn
howev
molecular
mechan
lead
drg
nociceptor
pdn
unknown
mechan
lead
small
fiber
degener
fundament
gap
knowledg
repres
critic
barrier
progress
develop
novel
therapeut
approach
pdn
object
studi
identifi
molecular
cascad
link
chemokin
signal
drg
nociceptor
neuropath
pain
small
fiber
degener
pdn
drg
nociceptor
identifi
seri
molecular
marker
includ
express
sodium
channel
inde
drg
neuron
nociceptor
feed
mice
high
fat
diet
hfd
sever
week
induc
glucos
intoler
obes
mechan
allodynia
particular
pain
hypersensit
associ
pdn
use
hfd
model
combin
dreadd
receptor
technolog
shown
reduc
excit
neuron
prevent
revers
neuropath
pain
neuron
calcium
overload
mitochondri
dysfunct
small
fiber
degener
furthermor
shown
receptor
necessari
neuropath
pain
small
fiber
degener
pdn
taken
togeth
data
demonstr
nociceptor
hyperexcit
pdn
driven
activ
receptor
inhibit
hyperexcit
prevent
revers
develop
pdn
furthermor
observ
advanc
understand
chang
excit
calcium
influx
mitochondri
dysfunct
nociceptor
contribut
neuropath
pain
small
fiber
degener
pdn
critic
barrier
progress
effect
diseas
modifi
treatment
pdn
bianco
terenghi
gallia
nozza
scaral
fayoumi
giannotta
morenghi
medic
biotechnolog
translat
medicin
milan
univers
neuromuscular
neuroimmunolog
servic
humanita
clinic
research
center
rozzano
milan
itali
medic
oncolog
hematolog
humanita
clinic
research
centr
rozzano
milan
itali
unit
humanita
clinic
research
centr
rozzano
milan
itali
poem
polyneuropathi
organomegali
endocrinopathi
protein
skin
chang
syndrom
unusu
multisystem
diseas
neurolog
disabl
due
sever
disabl
polyneuropathi
high
mortal
multiorgan
failur
peripher
blood
stem
cell
transplant
pbsct
consid
treatment
choic
poem
lenalidomid
promis
therapi
patient
elig
pbsct
aim
present
studi
compar
effect
clinic
biolog
neurophysiolog
paramet
patient
poem
treat
lenalidomid
pbsct
clinic
biolog
neurophysiolog
data
review
poem
patient
treat
pbsct
n
lenalidomid
n
mrc
sumscor
muscl
onl
scale
vegf
serum
level
nerv
conduct
studi
assess
year
treatment
differ
compar
use
anova
combin
two
group
patient
signific
improv
treatment
mean
mrc
sumscor
p
mean
onl
score
p
ulnar
mean
distal
motor
latenc
msec
msec
msec
p
distal
compound
muscl
action
potenti
amplitud
mv
p
motor
conduct
veloc
msec
msec
msec
serum
vegf
level
vs
p
vs
p
differ
also
signific
separ
analyz
patient
treat
lenalidomid
pbsct
differ
two
group
analyz
paramet
treatment
pbsct
lenalidomid
significantli
similarli
improv
clinic
biolog
neurophysiolog
paramet
patient
poem
syndrom
two
year
sinc
pbsct
may
suitabl
patient
lenalidomid
may
repres
effect
valuabl
altern
patient
relaps
pbsct
induc
prolong
clinic
biolog
neurophysiolog
improv
bi
tao
abreu
sleiman
hakonarson
zuchner
inherit
neuropathi
consortium
jt
macdonald
depart
human
genet
hussman
institut
human
genom
univers
miami
miami
fl
usa
appli
genom
children
hospit
philadelphia
philadelphia
pa
usa
inherit
peripher
neuropathi
clinic
genet
heterogen
diseas
caus
distal
muscular
atrophi
sensori
loss
allel
one
hundr
differ
gene
shown
caus
peripher
neuropathi
yet
greater
axon
neuropathi
patient
receiv
genet
diagnosi
larg
scale
exom
studi
begin
suffici
power
perform
mutat
burden
analysi
approach
compar
damag
allel
frequenc
cmt
case
control
group
identifi
addit
caus
neuropathi
approach
also
identifi
gene
requir
oligogen
inherit
caus
phenotyp
deviat
classic
heurist
variant
filter
approach
gene
identif
perform
burden
analys
larg
cohort
cmt
famili
known
neuropathi
gene
saw
neuropathi
case
carri
averag
rare
variant
unrel
control
harbor
variant
enrich
rare
variant
cmt
diseas
gene
within
inherit
peripher
neuropathi
case
suggest
presenc
multipl
weaker
allel
individu
patient
also
perform
unbias
burden
analysi
rank
gene
multipl
test
correct
sever
new
candid
gene
identifi
need
follow
conform
studi
number
known
cmt
relat
gene
observ
list
top
candid
current
analyz
addit
aspect
sampl
activ
seek
cmt
exom
enlarg
studi
summari
statist
method
tradit
reserv
common
phenotyp
increasingli
becom
avail
rare
diseas
genet
bobylev
peter
vya
barham
klein
von
strandmann
neiss
lehmann
hospit
cologn
cologn
germani
cologn
cologn
germani
germani
univers
marburg
germani
peripher
neuropathi
common
side
effect
bortezomib
experiment
evid
bortezomib
induc
axon
degener
alter
microtubul
stabil
axon
transport
base
result
previou
studi
inhibitor
monastrol
enhanc
axon
transport
improv
neuron
regener
assess
util
monastrol
protect
bortezomib
induc
neuropathi
mice
treat
bortezomib
alon
combin
monastrol
neuropath
chang
assess
nerv
conduct
studi
histolog
analysi
analysi
axon
morpholog
perform
light
electron
microscopi
properti
monastrol
alon
combin
bortezomib
assess
differ
blood
cancer
cell
line
prolong
treatment
bortezomib
induc
sensori
neuropathi
mice
signific
chang
axon
morpholog
correl
reduc
function
peripher
nerv
administr
monastrol
substanti
amelior
morpholog
featur
axon
alter
sensori
neuropathi
cytotox
studi
blood
cancer
cell
line
show
interfer
monastrol
cytostat
effect
bortezomib
data
indic
monastrol
may
allevi
bortezomib
induc
neuropathi
favor
cytotox
profil
monastrol
make
interest
candid
neuroprotect
agent
prevent
neuropathi
boczonadi
meyer
bartsakoulia
roo
bansagi
zahedi
talim
bruni
kaspar
boycott
horvath
wtcmr
igm
newcastl
univers
newcastl
upon
tyne
uk
columbu
oh
usa
analytisch
dortmund
germani
foundat
brazil
pediatr
hacettep
univers
children
hospit
ankara
turkey
univers
bari
aldo
moro
bari
itali
neurosci
ohio
state
univers
columbu
oh
usa
genet
cheo
univers
ottawa
ottawa
canada
autosom
domin
mutat
gar
encod
synthetas
identifi
patient
peripher
neuropathi
distal
spinal
muscular
atrophi
type
v
autosom
recess
mutat
caus
mitochondri
diseas
affect
skelet
muscl
heart
gar
enzym
respons
normal
protein
translat
mitochondria
cytoplasm
studi
focus
mitochondri
function
gar
investig
mous
model
human
fibroblast
induc
neuron
progenitor
cell
line
inpc
mild
mitochondri
abnorm
detect
skelet
muscl
mice
tissu
affect
control
patient
fibroblast
harbor
gar
mutat
directli
convert
inpc
identifi
tissu
specif
impair
mitochondri
function
neuron
cell
carri
recess
also
domin
gar
mutat
suggest
effect
mitochondri
alterationscompar
proteom
analysi
inpc
show
signific
chang
mitochondri
protein
furthermor
reduct
membran
protein
b
vapb
downstream
pathway
inpc
suggest
alter
endoplasm
reticulum
er
membran
mam
may
also
contribut
motor
neuropathi
boczonadi
king
bansagi
roo
eyassu
borcher
lane
ramesh
pyle
griffin
smith
chinneri
alan
j
robinson
edmund
rs
kunji
horvath
wtcmr
igm
newcastl
univers
newcastl
upon
tyne
uk
biolog
unit
medic
research
council
cambridg
institut
analyt
scienc
isa
dortmund
germani
bc
proteom
centr
vancouv
canada
neurolog
royal
victoria
infirmari
newcastl
upon
tyne
foundat
hospit
nh
trust
newcastl
upon
tyne
uk
member
mitochondri
carrier
famili
transport
nucleotid
keto
acid
amino
acid
fatti
acid
inorgan
ion
across
mitochondri
inner
membran
sever
inherit
diseas
variabl
clinic
present
associ
dysfunct
mitochondri
carrier
report
patient
spinal
muscular
atrophi
mitochondri
myopathi
caus
homozyg
mutat
encod
mitochondri
oxodicarboxyl
carrier
odc
mutat
render
carrier
dysfunct
consequ
import
mitochondri
matrix
comput
model
metabol
defect
caus
mutat
predict
impair
transport
lead
accumul
pipecol
acid
known
neurotoxin
quinolin
acid
precis
confirm
target
metabolom
serum
urin
exposur
quinolin
acid
reduc
level
mitochondri
complex
cell
suggest
possibl
pathomechan
demonstr
quinolin
acid
toxic
spinal
motor
neuron
increas
level
may
contribut
neuropathi
bouhi
katona
juneja
haidar
holmgren
de
winter
irobi
wei
timmerman
neuropathi
research
group
institut
born
bung
univers
antwerp
antwerp
belgium
neuropatholog
univers
hospit
rwth
aachen
univers
aachen
germani
patient
distal
hereditari
motor
neuropathi
dhmn
develop
progress
motor
impair
weak
atrophi
distal
limb
muscl
sinc
first
descript
missens
mutat
small
heat
shock
protein
number
addit
dhmn
patient
famili
report
interestingli
mutat
target
amino
acid
residu
highli
conserv
domain
protein
spectrum
diseas
caus
mutat
gene
recent
expand
distal
myopathi
ubiquit
express
highli
express
motor
neuron
muscl
chaperon
particip
clear
misfold
contain
protein
mutant
huntingtin
involv
respect
huntington
diseas
ataxia
directli
interact
role
select
autophagi
well
describ
delin
molecular
deficit
function
consequ
mutat
gener
ki
mous
model
missens
mutat
mimick
neuropathi
phenotyp
observ
homozyg
mutant
mice
develop
progress
axonopathi
decreas
compound
motor
action
potenti
amplitud
loss
larg
medium
myelin
axon
result
locomotor
deficit
impair
perform
rotarod
grip
strength
test
ultrastructur
level
model
display
sever
sign
axon
degener
clear
myofibrillar
myopathi
observ
patient
mutat
interestingli
posit
aggreg
found
sciatic
nerv
gastrocnemiu
muscl
mutant
mice
addit
model
allow
us
gener
ko
mice
use
target
vector
strikingli
homozyg
anim
show
sign
axonopathi
display
much
milder
myopathi
anim
data
suggest
part
pathomechan
due
toxic
mutant
protein
boutahar
reynaud
nasser
antoin
hospit
franc
dysimmun
sensori
neuronopathi
snn
depend
neuron
cell
death
induc
inflammatori
reaction
dorsal
root
ganglia
recent
identifi
intracellular
tyrosin
kinas
trk
domain
fibroblast
growth
factor
target
antibodi
subset
patient
non
paraneoplast
snn
one
four
fgfr
involv
sensori
neuron
mainten
develop
cell
death
induct
axotomi
fgfr
ligand
fixat
result
activ
sever
intracellular
pathway
adapt
protein
interact
trk
domain
particular
ra
activ
may
lead
cell
prolifer
apoptosi
map
kinas
signal
mapk
pathway
also
involv
neuron
cell
death
induc
nmda
ampa
receptor
activ
cell
surfac
protein
human
antibodi
may
interfer
receptor
function
grow
number
evid
show
cell
surfac
antibodi
neurolog
diseas
test
hypothesi
develop
vitro
model
use
fvbn
mice
cortic
neuron
cultur
expos
rabbit
polyclon
antibodi
react
trk
domain
compar
normal
rabbit
igg
antibodi
induc
neuron
cell
death
dose
depend
manner
neuron
cell
expos
antibodi
concentr
lead
cell
death
absenc
presenc
mapk
inhibitor
express
subunit
ampa
receptor
subunit
nmda
receptor
measur
quantit
antibodi
induc
upregul
subunit
modul
chang
prevent
presenc
preliminari
result
indic
igg
may
interfer
function
intracellular
domain
protein
express
nmda
ampa
receptor
map
kinas
pathway
model
may
use
test
effect
human
igg
vitro
braathen
tveten
holla
busk
hilmarsen
svendsen
medic
genet
depart
laboratori
medicin
telemark
hospit
skien
norway
sequenc
ng
last
year
enter
clinic
diagnost
ng
proven
effici
diagnost
disord
multipl
gene
involv
target
gene
panel
consist
hereditari
neuropathi
gene
ie
mostli
gene
studi
retrospect
studi
clinic
sampl
receiv
may
februari
describ
identifi
novel
like
pathogen
sequenc
variant
accord
intern
guidelin
period
identifi
novel
previous
describ
like
pathogen
sequenc
variant
follow
gene
aar
gan
litaf
mme
mpz
nefl
yar
larg
rang
gene
caus
hereditari
peripher
neuropathi
mani
like
pathogen
sequenc
variant
like
pathogen
sequenc
variant
identifi
old
well
establish
neuropathi
gene
also
newer
gene
like
mme
brewer
attril
elli
ly
nicholson
menez
kennerson
neurosci
laboratori
anzac
research
institut
sydney
australia
medic
school
univers
sydney
sydney
australia
medicin
concord
repatri
gener
hospit
sydney
australia
institut
neurosci
muscl
research
children
hospit
westmead
sydney
australia
child
health
univers
sydney
sydney
australia
equal
last
author
laer
syndrom
bvvl
autosom
recess
neurodegen
diseas
caus
mutat
encod
riboflavin
transport
patient
defici
exhibit
proxim
distal
limb
weak
sensori
ataxia
diaphragmat
paralysi
optic
atrophi
sensorineur
deaf
bulbar
palsi
riboflavin
critic
biosynthesi
flavin
mononucleotid
flavin
adenin
dinucleotid
essenti
cofactor
carbohydr
lipid
metabol
mutat
reduc
abolish
express
result
impair
riboflavin
uptak
sensori
motor
neuron
riboflavin
treatment
improv
stabilis
patient
condit
howev
optimum
dose
long
term
effect
riboflavin
treatment
diseas
pathomechan
remain
poorli
understood
understand
pathophysiolog
consequ
mutat
propos
develop
anim
model
bvvl
caenorhabd
elegan
c
elegan
small
round
transpar
nematod
extens
use
studi
genet
molecular
biolog
neurodegen
diseas
two
c
elegan
riboflavin
transport
gene
base
protein
sequenc
homolog
express
profil
gene
ortholog
express
regul
riboflavin
avail
gene
sirna
perturb
c
elegan
develop
aim
develop
c
elegan
model
bvvl
human
c
elegan
protein
sequenc
align
clustal
omega
identifi
conserv
amino
acid
residu
associ
bvvl
mutat
amino
acid
involv
mutat
conserv
residu
creat
model
introduc
mutat
locu
c
elegan
genom
dna
use
technolog
bvvl
c
elegan
model
allow
us
explor
pathogen
consequ
defici
underli
motor
nerv
degener
evalu
drug
therapi
regim
determin
optim
riboflavin
dose
treatment
initi
trial
compound
may
improv
benefit
seen
riboflavin
supplement
brun
kremer
mondon
jacqu
chtourou
masiello
de
seze
inserm
biopathologi
de
la
neuroprotect
et
univers
strasbourg
de
translationnel
de
strasbourg
fmt
strasbourg
franc
neurolog
univers
hospit
strasbourg
strasbourg
franc
innov
therapeut
lfb
biotechnolog
loo
franc
usa
framingham
usa
chronic
inflammatori
demyelin
polyradiculoneuropathi
cidp
inflammatori
diseas
peripher
nervou
system
cidp
present
chronic
progress
cours
predominantli
affect
motor
also
sensori
nerv
fiber
caus
weak
proxim
distal
muscl
repres
common
chronic
autoimmun
neuropathi
patholog
character
focal
demyelin
follow
axon
degener
recent
develop
new
anim
model
cidp
induc
lewi
rat
activ
immun
peptid
model
fulfil
electrophysiolog
criteria
demyelin
axon
degener
result
confirm
immunohistopatholog
late
phase
chronic
diseas
character
accumul
cell
macrophag
sciatic
nerv
well
high
serum
level
reliabl
reproduc
anim
model
cidp
use
translat
drug
studi
chronic
human
inflammatori
diseas
peripher
nervou
system
particularli
cidp
real
need
new
immunotherapi
aim
studi
test
therapeut
efficaci
ivig
recombin
fc
fragment
fcrec
new
cidp
anim
model
treatment
ivig
fcrec
prove
effect
prevent
progress
cidp
rat
therapeut
treatment
decreas
maxim
clinic
score
cidp
rat
compar
albumin
treatment
also
abolish
diseas
chronic
interestingli
better
efficaci
fcrec
treatment
compar
ivig
demonstr
histolog
level
myelin
fiber
well
preserv
greatli
reduc
accumul
macrophag
cell
sciatic
nerv
ivig
fcrec
therapeut
activ
model
also
follow
measur
antibodi
serum
could
therefor
use
biolog
marker
current
studi
provid
first
time
direct
evid
ivig
effect
treatment
cidp
rat
suggest
novel
fcrec
compound
effect
ivig
contribut
develop
effect
safer
drug
treatment
autoimmun
peripher
neuropathi
like
cidp
buermann
singh
rapp
fassbend
dillmann
neurolog
medic
univers
saarland
homburg
germani
medic
biometri
epidemiolog
medic
informat
medic
univers
saarland
homburg
germani
prompt
correct
diagnosi
chronic
inflammatori
demyelin
polyradiculoneuropathi
cidp
import
initi
appropri
therapi
cidp
patient
normal
convent
nerv
conduct
studi
nc
use
detect
demyelin
especi
case
probabl
possibl
cidp
accord
efn
criteria
addit
electrodiagnost
paramet
indic
demyelin
precis
desir
studi
examin
variat
motor
nerv
conduct
veloc
appli
hopf
collis
techniqu
cidp
patient
collis
techniqu
perform
ulnar
nerv
cidp
patient
control
group
healthi
individu
time
one
measur
supramaxim
stimul
accord
convent
nc
anoth
measur
enhanc
stimul
intens
conduct
analyz
result
special
consider
minim
maxim
fiber
veloc
veloc
maxim
fiber
proport
result
detect
statist
signific
differ
cidp
patient
control
paramet
compar
control
cidp
patient
slower
minim
maxim
fiber
veloc
also
spectrum
motor
conduct
veloc
definit
shift
slower
veloc
slower
minim
conduct
veloc
could
detect
cidp
patient
use
enhanc
stimul
intens
interestingli
cidp
patient
convent
ulnar
nc
normal
collis
techniqu
show
fiber
conduct
veloc
less
ms
indic
demyelin
knowledg
first
studi
use
hopf
collis
techniqu
systemat
cidp
patient
signific
differ
variat
ulnar
motor
nerv
conduct
veloc
cidp
patient
control
could
detect
method
also
show
sign
demyelin
cidp
patient
normal
ulnar
ncv
enhanc
stimul
intens
threshold
supramaxim
stimul
convent
nc
collis
techniqu
may
even
valuabl
bunschoten
miri
vytopil
van
doorn
jacob
igo
consortium
neurolog
erasmu
medic
center
rotterdam
netherland
neurolog
lahey
hospit
medic
center
burlington
usa
immunolog
erasmu
medic
center
rotterdam
netherland
clinic
cours
syndrom
gb
highli
variabl
patient
may
develop
fluctuat
trf
indic
ongo
diseas
activ
temporari
treatment
effect
patient
present
gb
subsequ
develop
repetit
relaps
indic
chronic
inflammatori
demyelin
polyneuropathi
distinct
import
treatment
may
differ
determin
frequenc
clinic
present
patient
first
patient
includ
intern
gb
outcom
studi
igo
least
month
patient
exclud
altern
diagnos
remain
patient
least
one
trf
preliminari
analysi
show
signific
differ
group
sex
age
sensori
symptom
cerebrospin
fluid
result
mechan
ventil
patient
median
age
year
iqr
male
patient
treat
acut
phase
diseas
intraven
immunoglobulin
ivig
pe
methylprednisolon
mp
patient
median
age
year
iqr
male
patient
receiv
treatment
ivig
pe
patient
show
anteced
event
versu
higher
gb
disabl
score
nadir
versu
less
frequent
develop
ataxia
versu
patient
onset
nadir
longer
day
iqr
versu
day
iqr
total
gb
group
day
iqr
time
first
clinic
deterior
tend
longer
patient
median
day
iqr
versu
median
day
iqr
group
signific
diagnosi
made
median
day
iqr
conclus
first
analysi
identifi
distinct
characterist
support
differ
pathogenesi
may
help
earli
identif
disord
clinic
practic
addit
result
present
confer
bunschoten
van
lieverloo
adrichem
broer
van
der
pol
eftimov
jacob
ico
consortium
neurolog
erasmu
medic
center
rotterdam
netherland
neurolog
academ
medic
center
amsterdam
netherland
neurolog
univers
medic
center
utrecht
netherland
immunolog
erasmu
medic
center
rotterdam
netherland
chronic
inflammatori
demyelin
polyneuropathi
cidp
disord
highli
divers
clinic
present
electrophysiolog
phenotyp
respons
treatment
outcom
heterogen
may
indic
presenc
distinct
subtyp
cidp
may
differ
pathogenesi
requir
person
treatment
intern
cidp
outcom
studi
ico
prospect
observ
intern
studi
aim
describ
variat
clinic
electrophysiolog
subtyp
defin
clinic
biolog
determin
subtyp
diseas
activ
treatment
respons
outcom
addit
ico
aim
provid
infrastructur
conduct
new
therapeut
studi
cidp
similar
intern
gb
outcom
studi
igo
patient
fulfil
efnspn
diagnost
criteria
cidp
includ
ico
independ
age
durat
sever
diseas
treatment
collect
inform
neurolog
deficit
diagnost
characterist
variou
valid
clinic
outcom
measur
previou
current
treatment
collect
biomateri
dna
cerebrospin
fluid
nerv
biopsi
repeat
serum
sampl
ico
start
pilot
studi
dutch
univers
center
februari
patient
includ
ico
patient
recent
diagnos
cidp
previous
diagnos
patient
includ
male
femal
median
age
year
iqr
current
cohort
consist
classic
cidp
madsam
pure
motor
variant
patient
diagnos
past
patient
treat
intraven
immunoglobulin
ivig
prednisolon
subcutan
immunoglobulin
scig
dexamethason
ivig
methylprednisolon
mp
recent
diagnos
patient
receiv
treatment
ivig
dexamethason
patient
treat
pilot
studi
ivig
methylprednisolon
mp
protocol
evalu
adjust
share
research
via
inflammatori
neuropathi
consortium
igo
consortium
aim
includ
least
cidp
patient
worldwid
minimum
period
year
burgess
morelli
spauld
seburn
harper
jackson
laboratori
bar
harbor
usa
graduat
school
biomed
scienc
engin
univers
main
orono
usa
gene
therapi
research
institut
nationwid
children
hospit
columbu
oh
usa
domin
mutat
glycyl
trna
synthetas
gar
caus
inherit
axon
neuropathi
type
mutat
mous
gar
gene
caus
similar
phenotyp
repres
valid
diseas
model
routin
use
two
mous
strain
one
sever
neuropathi
one
milder
later
onset
neuropathi
use
mous
model
explor
mechan
gar
mutat
caus
peripher
axon
degener
effort
includ
ribosom
tag
isol
mrna
specif
motor
neuron
amino
acid
tag
visual
isol
newli
synthes
protein
take
advantag
anatomi
motor
neuron
abl
analyz
cell
bodi
separ
peripher
axon
approach
addit
use
mous
model
preclin
studi
test
gene
therapi
approach
treat
consist
previou
genet
studi
mice
knockdown
mutant
transcript
preserv
suffici
level
wild
type
success
approach
administ
onset
neuropathi
test
approach
mice
onset
symptom
mice
carri
mutant
gar
allel
associ
human
diseas
studi
potenti
translat
also
address
mechanist
question
time
cell
autonomi
pathophysiolog
burnor
yang
hao
patterson
quinn
scherer
lancast
univers
pennsylvania
philadelphia
pa
usa
second
xiangya
hospit
central
south
univers
hunan
china
autoantibodi
two
isoform
neurofascin
report
patient
syndrom
gb
chronic
inflammatori
demyelin
neuropathi
cidp
clear
respons
reliabl
distinguish
autoimmun
neuropathi
sever
neuropathi
respons
transient
versu
persist
respons
may
target
multipl
isoform
neurofascin
addit
approxim
neuropathi
patient
known
caus
unknown
whether
subset
patient
may
autoantibodi
neurofascin
studi
cohort
patient
autoimmun
neuropathi
genet
neuropathi
idiopath
neuropathi
igg
igm
respons
neurofascin
neurofascin
antibodi
found
patient
autoimmun
neuropathi
idiopath
neuropathi
patient
patient
genet
neuropathi
serum
sampl
avail
posit
case
persist
respons
associ
chronic
neuropathi
transient
respons
seen
gb
remiss
cidp
patient
respons
specif
either
howev
particularli
sever
form
cidp
approach
state
seen
patient
uniqu
respons
three
isoform
neurofascin
treatment
patient
rituximab
result
clinic
improv
resolut
neurofascin
antibodi
respons
conclus
autoantibodi
neurofascin
distinguish
autoimmun
neuropathi
sever
genet
neuropathi
clinic
phenotyp
may
depend
persist
isoform
specif
immun
respons
antibodi
common
domain
share
may
portend
sever
treatabl
neuropathi
subset
idiopath
neuropathi
patient
may
autoimmun
mechan
burn
sman
cornett
wojciechowski
walker
menez
mandaraka
rose
bray
sampaio
farrar
refshaug
raymond
fast
studi
group
sydney
new
south
wale
australia
children
hospit
network
randwick
westmead
new
south
wale
australia
new
south
wale
sydney
australia
exercis
undisput
benefit
human
health
potenti
treatment
neuromuscular
diseas
also
risk
harm
due
overwork
weak
report
result
randomis
trial
evalu
progress
resist
exercis
foot
dorsiflexor
muscl
pediatr
cmt
sixti
patient
age
year
randomli
assign
undergo
session
progress
resist
exercis
sham
exercis
primari
endpoint
chang
isometr
dorsiflexion
strength
group
assess
dynamometri
express
base
norm
refer
valu
posit
valu
indic
improv
strength
primari
safeti
endpoint
chang
muscl
fat
volum
muscl
respons
dorsiflexion
mri
group
secondari
outcom
function
balanc
long
jump
walk
test
walk
abil
gait
analysi
ankl
instabl
qualiti
life
physic
summari
psychosoci
summari
global
impress
chang
score
advers
event
children
complet
trial
adher
compar
exercis
sham
group
patient
experienc
muscl
sore
train
exercis
group
advers
event
differ
group
mean
dorsiflexion
strength
increas
exercis
group
decreas
sham
group
mirror
natur
histori
cmt
differ
ci
mean
scale
score
mri
muscl
volum
fat
volum
compar
group
month
p
global
impress
chang
score
favour
exercis
group
measur
effect
exercis
subgroup
analys
accord
age
year
vs
year
show
larger
treatment
effect
exercis
adolesc
target
progress
resist
exercis
effect
halt
progress
dorsiflexion
weak
without
detriment
effect
muscl
morpholog
sign
overwork
weak
children
cmt
univers
hospit
incheon
south
korea
metropolitan
govern
borama
medic
center
seoul
nation
univers
seoul
south
korea
ang
univers
hospit
seoul
south
korea
nation
univers
hospit
seoul
south
korea
year
old
femal
patient
visit
hospit
weak
upper
limb
month
suspicion
motor
neuron
diseas
find
extens
denerv
chang
electromyographi
whole
spine
mri
show
ventral
nerv
rootlet
enhanc
c
bundl
emg
confirm
activ
denerv
chang
muscl
innerv
bilater
root
cerebrospin
fluid
cultur
test
show
protein
csf
elev
mg
dl
got
steroid
puls
therapi
symptom
dri
mouth
dri
eye
recent
year
salivari
gland
scan
test
perform
possibl
syndrom
result
absorpt
contrast
agent
parotid
submandibular
gland
decreas
shammer
test
show
mm
right
side
mm
left
side
diagnos
syndrom
week
overal
strength
improv
observ
bilater
shoulder
abduct
improv
mrc
grade
higher
spine
mri
also
show
initi
seen
ventral
nerv
root
enhanc
disappear
case
visit
hospit
major
symptom
weak
atrophi
muscl
show
similar
pattern
motor
neuron
diseas
diagnos
inflammatori
polyradiculopathi
confirm
primari
ss
differenti
diagnosi
case
suggest
primari
ss
may
induc
inflammatori
polyradiculopathi
show
motor
symptom
major
symptom
rather
sensori
symptom
fast
accur
diagnosi
need
term
treat
steroid
appropri
immun
suppress
agent
caillaud
richard
vignaud
vallat
desmoulier
billet
myelin
mainten
peripher
neuropathi
faculti
medicin
pharmaci
univers
limog
limog
franc
neurolog
refer
center
rare
peripher
neuropathi
univers
hospit
limog
limog
franc
traumat
injuri
peripher
nerv
frequent
howev
effect
pharmacolog
treatment
lack
curcumin
polyphenol
found
rhizom
curcuma
longa
shown
develop
antioxid
neuroprotect
properti
howev
due
poor
hydrosolubl
extens
metabol
use
larg
curcumin
dose
requir
therapeut
purpos
aim
present
studi
investig
effect
local
infus
low
curcumin
dose
nerv
regener
function
recoveri
sciatic
nerv
injuri
rat
experi
conduct
g
sd
male
rat
submit
unilater
sciatic
nerv
crush
curcumin
solubil
polyethylen
glycol
continu
administ
use
osmot
pump
mgday
cathet
deliv
drug
near
lesion
site
function
analys
use
von
frey
beam
walk
static
sciatic
index
ssi
grip
strength
test
carri
refer
test
everi
week
injuri
addit
evok
electromyogram
perform
euthanasia
nerv
muscl
sampl
collect
analyz
light
electron
microscopi
function
signific
improv
mechan
sensit
observ
group
vs
vehicl
group
group
skill
walk
finger
space
ipsilater
paw
ssi
fulli
restor
respect
contrari
vehicl
group
furthermor
curcumin
treatment
improv
grip
strength
recoveri
electrophysiolog
result
indic
full
recoveri
motor
nerv
conduct
veloc
mncv
day
curcumin
treatment
mncv
remain
alter
vehicl
group
mncv
morphometr
analysi
nerv
section
use
show
improv
thick
myelin
sheath
curcumin
treat
anim
vs
vehicl
group
histolog
investig
gastrocnemiu
muscl
indic
decreas
neurogen
lesion
curcumin
group
proteom
analysi
current
investig
understand
mechan
involv
curcumin
effect
data
could
lead
develop
new
therapeut
strategi
peripher
nerv
regener
use
low
dose
curcumin
callaghan
reynold
averil
feldman
michigan
ann
arbor
mi
usa
previou
studi
suggest
metabol
syndrom
met
associ
distal
symmetr
polyneuropathi
dsp
diabet
obes
main
metabol
driver
aim
studi
investig
associ
met
compon
retin
cognit
function
bariatr
surgeri
cohort
prior
surgeri
patient
recruit
adult
bariatr
surgeri
clinic
univers
michigan
lean
control
research
websit
met
compon
base
ncepatpiii
definit
particip
underw
extens
metabol
phenotyp
includ
glucos
toler
test
fast
lipid
profil
dsp
defin
use
toronto
consensu
definit
probabl
clinic
neuropathi
retin
function
measur
frequenc
doubl
technolog
perimetri
averag
mean
deviat
cognit
function
nih
toolbox
composit
score
univari
linear
regress
model
use
evalu
associ
met
compon
retin
cognit
function
date
recruit
bariatr
surgeri
particip
lean
control
bariatr
popul
mean
sd
age
femal
compar
mean
age
femal
lean
group
bariatr
group
diabet
normoglycemia
dsp
preval
lean
control
normoglycem
diabet
bariatr
particip
p
trend
retin
function
trend
cognit
function
trend
group
lean
control
normoglycem
diabet
respect
ci
met
compon
associ
retin
function
waist
circumfer
one
associ
cognit
function
ci
dsp
retin
function
cognit
function
declin
worsen
glycem
statu
similar
previou
data
dsp
obes
associ
retin
cognit
function
respect
interestingli
clinic
dsp
common
popul
clinic
retinopathi
dementia
indic
dsp
may
first
metabol
complic
morbidli
obes
callegari
cortes
lauria
briani
luigetti
fazio
benedetti
marfia
clerici
carpo
corbo
mazzeo
ferrari
giannini
manganelli
manso
giannotta
berardinelli
zardini
romagnolo
gastaldi
spina
topa
dacci
lombardi
campagnolo
bisogni
cerri
de
mich
mataluni
stancanelli
mariotto
piccolo
schenon
moglia
marchioni
devaux
franciotta
consortium
univers
pavia
monza
policlinico
pavia
mondino
itali
centr
neuromuscular
diseas
nation
hospit
neurolog
neurosurgeri
ucl
institut
neurolog
queen
squar
london
uk
clinic
neurosci
ircc
foundat
carlo
besta
neurolog
institut
milan
itali
neurosci
univers
padova
padova
itali
geriatr
neurosci
orthoped
institut
neurolog
cathol
univers
sacr
heart
rome
itali
neurolog
san
raffael
scientif
institut
milan
itali
neurosci
rehabilit
ophthalmolog
genet
matern
child
health
dinogmi
univers
genoa
genoa
itali
neurosci
univers
rome
tor
vergata
rome
itali
neurolog
stroke
unit
ospedal
di
circolofondazion
macchi
vares
itali
unit
ospedal
treviglio
bergamo
itali
neurorehabilit
scienc
casa
cura
policlinico
ccp
milan
itali
neurosci
univers
messina
messina
itali
neurolog
movement
scienc
univers
verona
verona
itali
medicin
surgeri
neurosci
univers
siena
siena
itali
neurosci
odontostomatolog
reproduct
scienc
univers
napl
federico
ii
napl
itali
cnr
marseil
franc
medic
biotechnolog
translat
medicin
biometra
univers
milan
neurolog
humanita
clinic
research
center
rozzano
milan
itali
gener
neurolog
c
mondino
nation
institut
neurolog
foundat
ircc
pavia
itali
antibodi
protein
identifi
patient
chronic
inflammatori
demyelin
polyradiculoneuropathi
cidp
howev
preval
associ
clinic
featur
italian
cidp
patient
unknown
serum
sampl
patient
fulfil
enfspn
criteria
definit
cidp
test
antibodi
sera
addit
cidp
patient
test
reactiv
elisa
antibodi
found
cidp
patient
case
confirm
cba
subclass
half
cba
identifi
addit
seroposit
patient
whose
isotyp
current
test
sera
seroposit
patient
patient
antibodi
stain
paranod
indirect
immunofluoresc
mous
teas
nerv
fiber
note
seroneg
patient
known
antibodi
show
reactiv
node
andor
paranod
compar
seroneg
cipd
patient
seroposit
patient
frequent
subacut
onset
neuropathi
younger
age
onset
particularli
antibodi
weak
sever
often
associ
propriocept
loss
sensori
ataxia
tremor
neuropath
pain
featur
patient
frequent
find
increas
distal
motor
latenc
tempor
dispers
nerv
conduct
studi
higher
protein
level
csf
final
seroposit
patient
tend
higher
disabl
show
worst
respons
ivig
rituximab
effect
one
patient
antibodi
two
patient
antibodi
show
good
persist
recoveri
cyclophosphamid
preval
antibodi
italian
cidp
patient
presenc
associ
distinct
clinic
featur
determin
follow
character
igg
subclass
posit
case
clear
clinic
impact
help
guid
therapeut
choic
reactiv
nodal
paranod
compon
sera
patient
without
known
antibodi
suggest
target
could
play
role
autoimmun
respons
cidp
still
need
identifi
callegari
cortes
rossor
houlden
reilli
consortium
univers
pavia
monza
policlinico
pavia
mondino
itali
centr
neuromuscular
diseas
nation
hospit
neurolog
neurosurgeri
ucl
institut
neurolog
queen
squar
london
uk
molecular
neurosci
ucl
institut
neurolog
london
uk
nation
hospit
neurolog
neurosurgeri
queen
squar
london
uk
mutat
amynoacyl
trna
synthetas
arss
enzym
catalys
coval
attach
amino
acid
cognat
trna
respons
autosom
domin
intermedi
cmt
dhmn
report
case
male
italian
ancestri
first
present
bilater
ankl
clonu
three
month
follow
toe
walk
ankl
instabl
ankl
clonu
subsid
adolesc
third
decad
develop
progress
walk
difficulti
follow
distal
sensori
loss
neurolog
examin
age
reveal
steppag
gait
distal
lower
limb
weak
decreas
pinprick
ankl
reduc
vibrat
sensat
knee
reflex
brisk
upper
limb
reduc
knee
absent
ankl
muscl
tone
increas
lower
limb
plantar
respons
extensor
nerv
conduct
studi
reveal
axon
neuropathi
brain
spinal
cord
mri
normal
sanger
sequenc
mpz
gdap
neg
sureselect
focus
exom
sequenc
agil
technolog
santa
clara
ca
usa
demonstr
mutat
aar
mutat
aar
previous
report
famili
intermedi
axon
neuropathi
one
case
associ
deaf
cn
involv
previous
describ
mutat
mutat
aar
associ
rang
phenotyp
includ
cmti
dhmn
variabl
age
onset
rang
year
mean
year
note
aar
mutat
report
famili
pyramid
sign
studi
provid
evid
pyramid
tract
involv
earli
featur
due
mutat
aar
expand
spectrum
phenotyp
calvo
bennett
universidad
catolica
de
chile
santiago
chile
oxford
univers
uk
small
fibr
skin
vulner
damag
metabol
toxic
condit
diabet
mellitu
chemotherapi
result
small
fibr
neuropathi
associ
neuropath
pain
np
whether
injuri
distal
portion
sensori
small
fibr
due
primari
dermatolog
disord
caus
np
still
unclear
recess
dystroph
epidermolysi
bullosa
rdeb
rare
condit
mutat
protein
junction
lead
cycl
blister
follow
regener
skin
damag
exclus
skin
mucou
membran
known
direct
compromis
nervou
system
increasingli
recognis
rdeb
patient
experi
daili
pain
aetiolog
unclear
may
includ
inflamm
wound
musculoskelet
due
atrophi
retract
scar
limit
movement
np
studi
investig
incid
np
examin
presenc
nerv
dysfunct
rdeb
patient
around
three
quarter
patient
present
pain
neuropath
characterist
length
depend
distribut
quantit
sensori
test
foot
reveal
strike
impair
thermal
detect
threshold
combin
increas
mechan
pain
sensit
wind
ratio
tempor
summat
noxiou
mechan
stimuli
nerv
conduct
studi
show
normal
larg
fibr
sensori
motor
nerv
conduct
howev
skin
biopsi
show
signific
decreas
intraepiderm
nerv
fibr
densiti
autonom
nervou
system
test
reveal
abnorm
heart
rate
blood
pressur
variabl
howev
sympathet
skin
respons
foot
impair
sweat
gland
innerv
reduc
conclud
chronic
cutan
injuri
lead
injuri
dysfunct
distal
part
small
sensori
fibr
length
depend
distribut
result
disabl
np
find
also
support
use
neuropath
pain
screen
tool
patient
treatment
algorithm
design
target
neuropath
pain
calvo
richard
schimd
barroso
zhu
ivul
zhu
anwandt
bhat
court
mcmahon
bennett
universidad
catolica
de
chile
santiago
chile
card
king
colleg
london
uk
oxford
univers
uk
health
scienc
center
san
antonio
tx
usa
neuropath
pain
np
follow
peripher
nerv
injuri
associ
hyperexcit
damag
myelin
sensori
axon
begin
normalis
time
investig
composit
distribut
shaker
type
potassium
channel
channel
within
nodal
complex
myelin
axon
follow
injuri
neuroma
form
damag
express
normal
localis
juxtaparanod
markedli
decreas
contrast
hardli
detect
state
show
increas
express
within
juxtaparanod
paranod
follow
injuri
rat
human
within
dorsal
root
site
remot
injuri
also
note
redistribut
channel
toward
paranod
blockad
channel
injuri
reinstat
hyperexcit
axon
enhanc
mechanosensit
chang
molecular
composit
distribut
axon
channel
therefor
repres
protect
mechan
suppress
hyperexcit
myelin
sensori
axon
follow
nerv
injuri
petiot
antoin
vial
delmont
viala
magot
cauquil
zarea
iancu
ferfoglia
guegen
magi
kuntzer
steck
ferraud
lacour
svahn
francophon
cohort
group
neurolog
univers
hospit
cedex
franc
neurolog
hospit
hospic
civil
de
lyon
grand
rue
de
la
lyon
franc
neuromuscular
depart
ghe
neurolog
hospit
lyon
bron
cedex
franc
neurolog
timon
hospit
marseil
teach
hospit
marseil
franc
neurophysiolog
neuropatholog
ghu
pari
franc
refer
center
chu
nant
franc
neurolog
hospit
aphp
le
kremlin
franc
compet
center
chu
rouen
franc
center
neuromuscular
disord
neurolog
depart
hautepierr
hospit
strasbourg
franc
neuromuscular
disord
unit
depart
clinic
neurosci
geneva
univers
hospit
geneva
switzerland
neurolog
fondat
ophtalmologiqu
de
rothschild
pari
franc
neurolog
centr
de
neuropathi
rare
univers
hospit
limog
limog
franc
neurolog
nation
referr
center
rare
neuromuscular
diseas
univers
hospit
univers
pari
vi
pari
franc
unit
depart
clinic
neurosci
lausann
univers
hospit
chuv
lausann
switzerland
neurolog
basel
univers
hospit
basel
switzerland
member
francophon
cohort
group
list
appendix
appendix
francophon
cohort
group
member
francophon
cohort
group
provid
case
studi
alphabet
order
david
adam
sharam
attarian
chu
de
marseil
chu
de
rouen
bouhour
chu
de
lyon
boutt
chu
de
grenobl
guy
chauplannaz
chu
de
lyon
raquel
costa
perrin
devic
chu
de
lyon
chantal
grand
chu
de
lyon
guillemett
jousserand
chu
de
lyon
lenglet
pierr
lozeron
thierri
maisonob
cristina
muntean
yann
pereon
chu
de
nant
jean
pouget
chu
de
marseil
polyneuropathi
igm
antibodi
classic
progress
predominantli
sensori
distal
ataxia
sometim
tremor
assess
clinic
biolog
electrophysiolog
histopatholog
featur
patient
igm
gammopathi
antibodi
titr
higher
btu
focus
characterist
patient
accord
antibodi
titr
diagnosi
retrospect
prospect
analys
standard
report
form
patient
fourteen
neuromuscular
centr
mean
age
onset
year
rang
mean
time
symptom
onset
last
year
patient
present
variant
clinic
phenotyp
independ
titr
btu
includ
acut
chronic
sensorimotor
polyradiculoneuropathi
paucisymptomat
sensori
polyneuropathi
multifoc
neuropathi
sever
diseas
stage
patient
significantli
disabl
antibodi
titr
diagnosi
low
btu
medium
high
respect
patient
patient
present
mgu
macroglobulinemia
respect
case
sixteen
percent
patient
meet
electrodiagnost
criteria
definit
demyelin
neuropathi
independ
titr
btu
nerv
biopsi
perform
nineteen
patient
provid
support
diagnosi
neuropathi
particular
issu
low
titr
unusu
clinic
electrophysiolog
phenotyp
assess
degre
probabl
probabl
possibl
uncertain
patient
neuropathi
directli
relat
antibodi
accord
titr
electrophysiolog
data
nerv
biopsi
characterist
avail
appear
uncertain
patient
low
titr
whole
popul
clinic
phenotyp
nt
appear
differ
accord
antibodi
titr
mani
patient
low
titr
present
genuin
neuropathi
demonstr
edx
studi
clinic
present
sometim
nerv
biopsi
small
proport
patient
direct
relat
neuropathi
antibodi
uncertain
due
atyp
clinic
present
axon
neuropathi
pattern
nerv
biopsi
posit
antigangliosid
antibodi
petiot
antoin
vial
delmont
viala
magot
cauquil
zarea
iancu
ferfoglia
guegen
magi
kuntzer
steck
ferraud
lacour
svahn
francophon
cohort
group
neurolog
univers
hospit
franc
neurolog
hospit
hospic
civil
de
lyon
lyon
franc
neuromuscular
depart
ghe
neurolog
hospit
lyon
bron
cedex
franc
neurolog
timon
hospit
marseil
teach
hospit
marseil
franc
neurophysiolog
neuropatholog
ghu
pari
franc
refer
center
chu
nant
franc
neurolog
hospit
aphp
le
kremlin
franc
compet
center
chu
rouen
franc
depart
refer
center
neuromuscular
disord
hautepierr
hospit
strasbourg
franc
neuromuscular
disord
unit
depart
clinic
neurosci
geneva
univers
hospit
geneva
switzerland
neurolog
fondat
ophtalmologiqu
de
rothschild
pari
franc
neurolog
centr
de
neuropathi
rare
univers
hospit
limog
limog
franc
neurolog
nation
referr
center
rare
neuromuscular
diseas
univers
hospit
univers
pari
vi
pari
franc
unit
depart
clinic
neurosci
lausann
univers
hospit
chuv
lausann
switzerland
neurolog
basel
univers
hospit
basel
switzerland
member
francophon
cohort
group
list
appendix
appendix
francophon
cohort
group
member
francophon
cohort
group
provid
case
studi
alphabet
order
david
adam
sharam
attarian
chu
de
marseil
chu
de
rouen
bouhour
chu
de
lyon
boutt
chu
de
grenobl
guy
chauplannaz
chu
de
lyon
raquel
costa
perrin
devic
chu
de
lyon
chantal
grand
chu
de
lyon
guillemett
jousserand
chu
de
lyon
lenglet
pierr
lozeron
thierri
maisonob
cristina
muntean
yann
pereon
chu
de
nant
jean
pouget
chu
de
marseil
assess
therapeut
manag
respons
immunotherapi
advers
event
cohort
patient
present
igm
gammopathi
antibodi
titr
higher
btu
retrospect
prospect
analys
standard
report
form
patient
french
speak
neuromuscular
centr
mean
age
onset
year
rang
mean
time
symptom
onset
diagnosi
last
respect
year
antibodi
titr
diagnosi
low
btu
medium
high
patient
patient
present
mgu
macroglobulinemia
respect
case
seventi
eight
percent
n
patient
receiv
immunotherapi
transient
respons
ivig
plasma
exchang
six
month
observ
less
patient
respect
chemoimmunotherapi
rituximab
frequent
administ
group
patient
malign
hemopathi
n
compar
mgu
n
mean
line
therapi
rang
sd
versu
rang
sd
p
patient
n
receiv
rituximab
monotherapi
clinic
worsen
mostli
transient
revers
observ
patient
rituximab
clinic
respons
rituximab
month
andor
month
period
observ
patient
correl
titr
btu
respond
versu
patient
p
month
respond
patient
present
shorter
symptom
durat
compar
though
signific
logist
regress
year
rang
sd
respond
patient
versu
year
rang
sd
non
respond
patient
p
case
electrodiagnost
studi
record
rituximab
treatment
show
respond
patient
clear
improv
motor
conduct
veloc
data
may
support
anoth
clinic
trial
studi
benefic
rituximab
neuropathi
earli
diseas
rais
issu
valu
incorpor
electrodiagnost
paramet
campana
mantuano
azmoon
henri
shibayama
kim
pizzo
banki
gonia
anesthesiolog
ucsd
school
medicin
la
jolla
ca
usa
patholog
ucsd
school
medicin
la
jolla
ca
usa
neurosci
ucsd
school
medicin
la
jolla
ca
usa
experiment
medicin
sapienza
univers
rome
rome
itali
schwann
cell
sc
essenti
axon
integr
myelin
uninjur
pn
pn
injuri
sc
function
first
respond
undergo
phenotyp
orchestr
mani
process
lead
function
nerv
repair
receptor
sc
contribut
sc
repair
program
remain
incomplet
understood
identifi
member
ionotrop
glutam
receptor
igr
famili
receptor
sc
upregul
nerv
injuri
act
relat
protein
regul
sc
respons
pn
injuri
herein
use
pcr
profil
igr
express
cultur
rat
sc
oblig
receptor
subunit
requir
assembl
kainat
receptor
identifi
treatment
rat
sc
microm
glutam
microm
nmda
robustli
activ
akt
respons
transient
bimod
glutam
concentr
greater
microm
fail
activ
phosphoprotein
profil
demonstr
transcript
factor
regul
glutam
rat
human
sc
includ
glycogen
synthas
ribosom
kinas
creb
activ
glutam
sc
block
elimin
calcium
medium
select
antagonist
genet
silenc
express
oblig
subunit
phosphoinositid
function
essenti
upstream
activ
akt
sc
activ
glutam
promot
sc
migrat
glutam
microm
nmda
microm
inject
sciatic
nerv
robustli
activ
myelin
sc
vivo
result
identifi
igr
potenti
import
receptor
sc
may
promot
interact
understand
function
sc
import
given
current
effort
develop
drug
patient
pain
depress
alzheim
diseas
frequent
overlook
therapeut
context
sc
extrem
import
pathogenesi
chronic
neuropath
pain
drug
modul
activ
sc
sc
physiolog
respons
pn
injuri
may
alter
possibl
neuropath
pain
develop
increas
candayan
atkinson
durmu
tekc
parman
jordanova
battaloglu
molecular
biolog
genet
bogazici
univers
istanbul
turkey
molecular
neurolog
antwerp
univers
antwerp
belgium
medic
school
istanbul
univers
istanbul
turkey
cmt
diseas
group
inherit
peripher
neuropathi
affect
one
individu
worldwid
diseas
present
clinic
genet
heterogen
far
mutat
gene
loci
associ
cmt
autosom
domin
autosom
recess
mitochondri
inherit
despit
advanc
genet
test
approxim
cmt
patient
worldwid
remain
without
molecular
diagnosi
investig
unrel
cmt
patient
turkish
descent
duplic
exclud
previous
use
multiplex
amplif
specif
target
resequenc
mastr
assay
sequenc
exon
region
common
cmt
gene
recurr
mutat
identifi
case
mpz
gene
also
identifi
novel
variant
case
gar
aar
gene
rare
present
variat
databas
predict
pathogen
silico
tool
famili
segreg
analys
ongo
novel
variat
gene
commonli
mutat
caus
gene
cohort
case
without
molecular
diagnosi
mastr
test
candid
analys
whole
exom
sequenc
whole
genom
sequenc
outcom
current
studi
previou
experi
turkish
cmt
patient
suggest
high
genet
heterogen
insight
differ
genet
strategi
larger
panel
essenti
determin
caus
underli
cmt
especi
region
rare
recess
type
diseas
observ
due
high
frequenc
consanguin
marriag
capoccitti
giannini
ginanneschi
casali
insana
rossi
siena
siena
itali
sever
effort
made
elabor
new
electrophysiolog
criteria
earli
diagnosi
syndrom
gb
differenti
demyelin
aidp
axon
amanamsan
form
aim
verifi
diagnost
power
total
cmap
tcmap
durat
firstli
appli
gb
field
paramet
compar
commonli
use
neurophysiolog
measur
includ
neg
phase
cmap
durat
ncmap
ad
modifi
rajab
criteria
review
clinic
electrophysiolog
data
patient
gb
level
brighton
clinic
criteria
patient
underw
least
two
neurophysiolog
studi
first
within
week
second
week
symptom
onset
least
four
motor
three
sensori
nerv
conduct
studi
record
test
regard
earli
diagnosi
binari
logist
regress
model
multipl
variabl
includ
ncmap
durat
show
featur
predict
model
present
greater
signific
p
tcmap
durat
sural
spare
among
tcmap
durat
show
greater
signific
p
tcmap
diffus
prolong
aidp
compar
amanamsan
alreadi
first
examin
confirm
second
one
roc
analysi
tcmap
durat
aidp
vs
amanamsan
show
ms
auc
ppv
propos
tcmap
durat
new
use
electrophysiolog
measur
earli
diagnosi
gener
gb
earli
differenti
aidp
amanamsan
moreov
prolong
tcmap
presenc
sural
spare
repres
strongli
diagnost
predict
triad
aidp
castoro
wang
simmon
hu
li
neurolog
vanderbilt
univers
school
medicin
nashvil
tn
usa
factor
captur
great
attent
biomed
research
due
critic
role
regul
cell
apoptosi
flavoprotein
typic
locat
mitochondri
intermembran
space
associ
respiratori
chain
upon
insult
cleav
protein
releas
cytosol
peptid
may
enter
nucleu
trigger
chromosom
condens
fragment
initi
pathway
apoptosi
howev
nuclear
transloc
may
block
cytosol
bind
fad
domain
aa
mutat
gene
result
sever
clinic
phenotyp
includ
famili
clinic
deficit
patient
usual
involv
multipl
organ
studi
howev
identifi
famili
novel
missens
mutat
develop
sensori
motor
axon
polyneuropathi
nerv
conduct
criteria
proband
affect
sibl
exhibit
distal
muscl
weak
atrophi
normal
cognit
cranial
nerv
function
obviou
phenotyp
organ
interestingli
mutat
affect
highli
conserv
amino
acid
center
fad
domain
hypothes
mutat
impair
bind
lead
enhanc
signal
famili
therefor
provid
uniqu
opportun
explor
alter
apoptot
signal
affect
peripher
nerv
system
support
grant
nind
nation
center
advanc
translat
scienc
cauquil
noel
beaudonnet
laureng
de
menthon
labeyri
lazur
adam
goujard
lambott
adam
adult
chu
le
kremlin
franc
de
neurophysiologi
cliniqu
et
chu
franc
de
intern
et
immunologi
chu
franc
danatomopathologi
chu
franc
dimmunologi
chu
franc
chronic
inflammatori
demyelin
polyneuropathi
cidp
key
symptom
lead
diagnosi
associ
lymphoma
patient
diagnosi
cidp
accord
efnspn
criteria
associ
b
cell
lymphoprolif
disord
bld
one
center
novemb
novemb
includ
demograph
clinic
nerv
conduct
immunolog
histolog
data
respons
treatment
record
retrospect
eight
patient
men
median
age
includ
onset
polyradiculoneuropathi
either
chronic
acut
neurolog
condit
led
diagnosi
bld
one
case
onset
worsen
neuropathi
clinic
present
cidp
patient
plexopathi
one
lymphoma
type
lymphoplasmacyt
diffus
larg
b
cell
small
lymphocyt
margin
zone
unclassifi
small
b
cell
patient
present
lymphadenopathi
bld
diagnos
patient
myelogram
bone
marrow
biopsi
perform
cytopenia
atyp
sever
neuropathi
monoclon
gammapathi
identifi
patient
igm
igg
neuromuscular
biopsi
perform
patient
disclos
endoneur
infiltr
antigangliosid
antibodi
posit
patient
none
patient
present
system
autoimmun
diseas
hemolyt
anemia
associ
bld
immunomodul
treatment
administ
patient
ivig
plasma
exchang
steroid
immunosuppress
immunochemotherapi
lymphoma
initi
lymphoma
type
sever
case
case
associ
neuropathi
median
month
treatment
initi
four
patient
treat
within
month
neurolog
onset
improv
well
one
patient
whose
preexist
neurolog
condit
worsen
two
patient
present
neurolog
relaps
progress
lymphoma
two
patient
die
unusu
present
cidp
rapid
progress
treatment
failur
lead
test
associ
lymphoma
gener
symptom
lymphadenopathi
often
lack
diagnosi
requir
analysi
bone
marrow
lymphocyt
phenotyp
earli
treatment
immunochemotherapi
associ
better
prognosi
seri
cavalier
ferrari
medeiro
ferreira
macedo
westin
marqu
bittar
pupe
nascimento
feder
fluminens
uff
rio
de
janeiro
brazil
familiar
amyloidosi
group
diseas
character
tissu
deposit
amyloid
fibril
three
main
type
familiar
amyloidosi
transthyretin
ttr
apolipoprotein
gelsolin
cardiac
involv
lead
caus
morbid
mortal
one
new
describ
mutat
strongli
relat
isol
cardiac
amyloidosi
ttr
discoveri
test
allow
earli
diagnosi
cardiac
involv
amyloidosi
infer
etiolog
diseas
major
import
cohort
patient
differ
type
familiar
ttr
amyloidosi
aim
assess
role
acid
detect
myocardi
amyloid
infiltr
enrol
four
patient
diagnos
late
familiar
amyloidosi
mutat
document
deoxyribonucl
acid
analysi
three
patient
ttr
mutat
one
patient
ttr
mutat
three
patient
asymptomat
cardiac
involv
one
patient
mutat
previou
diagnosi
heart
failur
myocardi
uptak
scintigraphi
semiquantit
visual
assess
five
minut
three
hoursth
uptak
highli
demonstr
amyloid
cardiac
area
two
three
case
ttr
ttr
ttr
case
present
highest
uptak
due
exclus
deposit
amyloid
cardiac
area
result
sever
heart
failur
hereditari
amyloidosi
includ
mutat
ttr
cardiac
scintigraphi
identifi
infiltr
even
asymptomat
individu
allow
earli
diagnosi
cardiac
compromis
group
diseas
consid
test
would
tool
potenti
import
diagnosi
prognosi
earli
detect
cardiac
amyloidosi
give
emphasi
applic
famili
form
amyloidosi
cervellini
galino
zhu
birchmeier
bennett
univers
oxford
oxford
uk
molecular
medicin
berlin
germani
erkmapk
pathway
critic
role
pn
develop
sinc
involv
mani
physiolog
process
sustain
mapk
activ
schwann
cell
enhanc
myelin
growth
develop
overcom
signal
end
myelin
lead
continu
myelin
product
howev
strong
activ
erk
also
shown
caus
schwann
cell
dedifferenti
demyelin
vivo
aim
investig
whether
mild
activ
signal
pathway
adult
schwann
cell
sc
express
gain
function
allel
could
benefici
role
remyelin
regener
injuri
erkmapk
activ
adult
sc
mutant
mice
affect
myelin
develop
follow
sciatic
nerv
injuri
wallerian
degener
enhanc
mutant
push
toward
dedifferenti
stage
sc
previous
describ
howev
mapk
activ
detriment
regener
delay
function
recoveri
neg
impact
myelin
fibr
compar
control
one
month
injuri
total
number
axon
mutant
sciatic
nerv
half
control
although
differ
found
two
group
mutant
present
higher
number
myelin
axon
show
myelin
disrupt
start
myelin
decompact
lack
cajal
band
abund
sc
process
surround
axon
shorter
sc
elong
seen
decreas
internod
distanc
addit
found
neg
effect
mapk
activ
also
small
diamet
axon
presenc
abnorm
remak
bundl
structur
reduc
number
bundl
signific
decreas
intra
epiderm
nerv
fibr
densiti
skin
conclud
mild
mapk
activ
differ
role
develop
remyelin
neg
affect
axon
surviv
myelin
stabil
remak
bundl
format
small
fibr
regener
cervellini
galino
zhu
bao
bennett
univers
oxford
oxford
uk
medic
school
boston
usa
neprilysin
nep
endopeptidas
interest
due
potenti
role
neurodegener
pain
consequ
abil
degrad
amyloid
respect
nep
express
limit
cn
report
express
schwann
cell
node
incisur
interest
gene
relat
recent
find
associ
homozyg
heterozyg
nep
mutat
old
mice
lack
nep
subtl
morpholog
chang
report
aim
determin
whether
nep
express
modul
nerv
injuri
investig
role
axon
regener
find
nep
gene
express
decreas
nerv
crush
furthermor
depend
growth
factor
signal
control
mice
nep
express
transient
reduc
return
baselin
day
injuri
ko
mice
impair
express
still
decreas
day
assess
behaviour
measur
locomotor
sensori
function
one
month
sciatic
nerv
crush
nep
ko
mice
show
function
regener
compar
wt
seen
sciatic
function
index
measur
beam
toe
spread
test
signific
differ
observ
wt
ko
sensori
test
show
ko
mice
recov
faster
pinch
test
day
crush
result
test
baselin
differ
two
group
detail
histolog
analysi
nerv
repair
undertaken
use
electron
microscopi
differ
wt
ko
total
axon
number
axon
diamet
myelin
featur
one
month
post
crush
summari
although
nep
express
regul
nerv
injuri
depend
fashion
endopeptidas
dispens
axon
regener
nerv
injuri
rodent
chang
lin
tani
sung
medicin
colleg
medicin
taipei
medic
univers
taipei
taiwan
new
south
wale
sydney
australia
medic
univers
nation
health
research
institut
taipei
taiwan
fang
hospit
taipei
taiwan
diabet
neuropathi
common
complic
diabet
neuropath
pain
detriment
impact
qualiti
life
studi
investig
sensori
nerv
excit
properti
elucid
axon
chang
diabet
neuropathi
total
diabet
patient
type
ii
type
enrol
studi
clinic
assess
nerv
conduct
studi
nerv
excit
test
data
analyz
determin
axon
dysfunct
diabet
neuropathi
among
patient
seventeen
subject
complain
spontan
pain
sensat
feet
hand
pain
cohort
patient
sensori
symptom
decreas
sensat
foot
cohort
sensori
nerv
excit
pain
cohort
show
reduc
late
subexcit
increas
superexcit
compar
cohort
differ
diseas
durat
blood
glucos
level
two
cohort
find
suggest
possibl
pathogenesi
pain
sensori
axon
might
hyperpolar
slow
potassium
channel
dysfunct
insight
understand
pain
diabet
neuropathi
may
provid
basi
neuroprotect
therapeut
approach
pain
polyneuropathi
chanson
barriol
taith
zerroug
lhost
pereira
boyer
jean
clavel
univers
franc
neurophysiolog
depart
chu
gabriel
montpi
clermont
ferrand
clermont
ferrand
franc
depart
chu
gabriel
montpi
clermont
ferrand
clermont
ferrand
franc
unit
rci
chu
clermont
ferrand
clermont
ferrand
franc
main
purpos
studi
assess
clinic
feasibl
diffus
tensor
imag
dti
diagnosi
chronic
inflammatori
demyelin
polyradiculoneuropathi
cidp
march
decemb
prospect
enrol
patient
definit
cidp
accord
efn
criteria
two
control
group
healthi
volunt
match
age
sex
patient
use
magnet
reson
imag
scanner
obtain
dti
scan
brachial
plexu
group
prepar
fraction
anisotropi
fa
map
compar
valu
group
adc
valu
cervic
nerv
root
diamet
stir
sequenc
evalu
two
neuroradiologist
blind
clinic
inform
review
mri
studi
independ
patient
cidp
also
perform
clinic
evalu
electroneuromyographi
significantli
decreas
fa
valu
p
increas
adc
valu
observ
cidp
patient
compar
healthi
subject
signific
differ
cidp
cmt
group
concord
excel
fa
valu
p
moder
adc
valu
p
cervic
nerv
root
diamet
p
signific
correl
fa
diseas
durat
r
p
inclus
mrc
score
r
p
fa
mesur
incat
score
inclus
r
p
signific
correl
observ
fa
electrophysiolog
indic
compar
healthi
subject
cervic
nerv
root
diamet
significantli
increas
p
patient
cmt
cidp
contrari
fa
valu
moder
level
concord
found
measur
diamet
cclin
preliminari
data
prove
clinic
feasibl
reproduct
dti
evalu
plexu
cervic
nerv
root
patient
cidp
cheng
teng
goh
umapathi
loo
lin
school
medicin
nation
univers
singapor
singapor
neurolog
nation
neurosci
institut
singapor
pattern
sensori
nerv
action
potenti
snap
syndrom
gb
attribut
greater
immunolog
injuri
barrier
vulner
region
ask
entrap
site
median
nerv
wrist
predispos
distal
nerv
end
injuri
compar
median
snap
radial
snap
measur
antidrom
digit
gb
patient
whose
nerv
conduct
studi
show
pattern
termin
nerv
digit
similar
length
median
nerv
prone
compress
often
subclin
carpal
tunnel
radial
nerv
defin
pattern
greater
decreas
median
ulnar
snap
sural
compar
age
normal
control
total
gb
miller
fisher
patient
institut
databas
studi
patient
pattern
carpal
tunnel
syndrom
remain
patient
abnorm
median
snap
digit
abnorm
median
radial
snap
digit
none
isol
abnorm
radial
digit
snap
among
case
abnorm
median
radial
snap
digit
mean
percentag
decreas
compar
age
height
match
norm
greater
median
nerv
compar
radial
nerv
respect
patient
without
pattern
normal
snap
patient
inexcit
sensori
nerv
decreas
snap
latter
patient
unlik
differenti
decreas
median
snap
radial
snap
digit
find
suggest
disrupt
blood
nerv
barrier
entrap
site
rather
distal
nerv
end
may
underli
pathophysiolog
pattern
seen
gb
chiba
uchibori
gyohda
univers
tokyo
japan
serum
igg
antibodi
specif
biomark
fisher
syndrom
relat
disord
approxim
patient
seroneg
convent
assay
molecul
need
cation
interact
ligand
antibodi
properti
antibodi
report
found
also
present
igg
antibodi
major
patient
type
antibodi
patient
final
clinic
diagnos
fisher
syndrom
syndrom
ophthalmoplegia
bickerstaff
brainstem
enceph
acut
ophthalmoplegia
seroposit
igg
antibodi
antigen
isol
complex
two
convent
elisa
use
salin
remain
patient
eight
turn
posit
igg
antibodi
antigen
isol
seven
complex
one
elisa
use
salin
reaction
strength
increas
depend
concentr
reach
nearli
maximum
level
physiolog
concentr
patient
antibodi
also
posit
igg
antibodi
antigen
suggest
termin
disialo
residu
common
gangliosid
would
import
epitop
also
antibodi
patient
antibodi
two
show
increas
titer
igg
antibodi
ad
show
significantli
decreas
titer
differ
effect
antibodi
suggest
would
enhanc
reaction
four
singl
bond
two
pyranos
ring
termin
disialo
rotat
bond
make
possibl
disialo
structur
take
variou
conform
molecular
model
show
distanc
two
carboxi
group
disialo
could
vari
nearli
zero
approxim
pm
disialo
would
take
specif
conform
dival
cation
size
approxim
pm
diamet
interact
two
group
antibodi
might
recogn
particular
conform
choi
chung
jung
neurolog
samsung
medic
center
sungkyunkwan
univers
school
medicin
seoul
south
korea
biolog
scienc
kongju
nation
univers
gongju
south
korea
biochemistri
ewha
woman
univers
school
medicin
seoul
south
korea
diseas
cmt
genet
clinic
heterogen
disord
variabl
inherit
mode
character
loss
muscl
tissu
touch
sensat
predominantli
feet
leg
also
hand
arm
advanc
stage
diseas
sever
molecul
report
therapeut
effect
cmt
depend
underli
genet
caus
exact
genet
diagnost
becom
import
execut
person
therapi
synthetas
arss
gene
encod
enzym
respons
charg
trna
correspond
amino
acid
arss
ubiquit
express
essenti
enzym
respons
perform
first
step
protein
synthesi
specif
arss
attach
amino
acid
cognat
trna
molecul
cytoplasm
mitochondria
recent
studi
demonstr
mutat
gene
encod
arss
result
neurodegener
rais
mani
question
role
enzym
neuron
function
mutat
six
cytoplasm
ar
gene
report
caus
cmt
studi
perform
whole
exom
sequenc
identifi
genet
defect
korean
cmt
patient
unrel
famili
variant
sort
cmt
gene
list
includ
almost
gene
relat
cmt
neuropathi
addit
sort
we
data
ar
gene
capillari
sequenc
famili
member
control
reveal
five
novel
mutat
gar
mar
yar
gene
famili
mutat
site
well
conserv
differ
speci
mutat
locat
catalyt
domain
two
catalyt
domain
domain
silico
analysi
predict
mutat
may
affect
protein
function
clinic
featur
similar
report
countri
differ
term
age
onset
degre
disabl
believ
novel
ar
mutat
underli
caus
famili
choi
choi
kwon
ahn
kim
baek
shin
kim
hong
sung
univers
hospit
seoul
south
korea
nation
univers
hospit
seoul
south
korea
medic
center
seoul
metropolitan
govern
seoul
nation
univers
seoul
south
korea
man
present
weak
biltear
upper
limb
complain
intermitt
fascicul
upper
lower
limb
gradual
worsen
paresthesia
year
dysphagia
dysarthria
also
present
year
ago
patient
affect
muscl
weak
bulbar
symptom
famili
member
neurolog
examin
patient
weak
bilter
upper
lower
limb
mrc
grade
promin
distal
sensori
loss
combin
length
depend
pattern
deep
tendon
reflex
absent
bilatar
bicep
knee
joint
nerv
conduct
studi
consist
demyelin
sensorimotor
polyneuropathi
molecular
diagnost
analys
spinobulbar
muscular
atrophi
sbma
mutat
relat
peripher
myelin
protein
gene
perform
confirm
expans
expans
polymorph
cag
ar
gene
delet
gene
smba
also
known
kennedi
diseas
recess
trinucleotid
polyglutamin
disord
caus
expans
polymorph
cag
exon
ar
gene
chromosom
diseas
cmt
common
hereditari
neuropathi
cmt
case
motor
conduct
veloc
mcv
upper
limb
ms
defin
demyelin
mcv
ms
defin
axon
famili
link
duplic
gene
short
arm
chromosom
call
reciproc
delet
gene
respons
genet
defect
hereditari
neuropathi
liabil
pressur
palsi
hnpp
classic
phenotyp
hnpp
consid
determin
differ
mutat
mechan
gene
howev
overlap
hnpp
due
gene
delet
report
suggest
phenotyp
hereditari
neuropathi
may
differ
variabl
herein
report
patient
simultan
present
clinic
electrophysiolog
featur
smba
genet
confirm
cag
expas
delet
gene
cholet
laffair
guedj
murphi
chumakov
nabirotchkin
hajj
cohen
issi
le
moulineaux
franc
type
diseas
inherit
peripher
neuropathi
stem
overexpress
protein
schwann
cell
due
duplic
gene
lead
abnorm
schwann
cell
differenti
dysmyelin
eventu
lead
axon
loss
muscl
wast
approv
treatment
current
avail
conduct
system
biolog
level
analysi
signal
network
put
underli
process
drive
patholog
base
upon
identifi
test
three
repurpos
drug
baclofen
naltrexon
sorbitol
alon
combin
determin
abil
rescu
aberr
myelin
cultur
deriv
transgen
rat
overexpress
gene
end
studi
valid
vitro
model
sensori
neuron
schwann
cell
adapt
cultur
plate
model
allow
measur
appear
myelin
protein
index
physiolog
process
vivo
myelin
total
myelin
length
quantifi
automat
imag
analyz
follow
immunostain
first
determin
full
curv
singl
drug
emphas
promyelin
activ
test
binari
combin
low
inact
dose
drug
compar
activ
combin
three
name
wherea
combin
two
drug
significantli
activ
dose
test
combin
three
produc
synergist
improv
myelin
find
clearli
demonstr
necess
use
singl
compon
highlight
valu
pleiotrop
combin
repurpos
drug
low
dose
novel
approach
rapid
drug
develop
disord
cond
barreira
school
preto
univers
paulo
preto
sp
brazil
autonom
dysfunct
frequent
observ
syndrom
gb
affect
approxim
patient
shown
sweat
function
impair
gb
aim
present
investig
summar
current
knowledg
sweat
disturb
gb
patient
use
appropri
term
systemat
search
refer
publish
index
follow
databas
medlin
embas
lilac
cochran
inclus
criteria
diagnosi
gb
descript
method
use
test
sudomotor
function
search
limit
english
languag
relev
inform
studi
design
method
assess
deficit
sweat
patient
characterist
main
result
collect
select
origin
refer
final
analys
major
studi
natur
two
longitudin
studi
sever
sweat
impair
vari
accord
appli
method
rang
normal
almost
sympathet
nervou
system
failur
seven
research
paper
sympathet
skin
respons
use
evalu
sudomotor
function
patient
approxim
demonstr
abnorm
result
howev
research
use
differ
stimul
protocol
paramet
interpret
result
regard
sweat
test
four
research
paper
appli
thermoregulatori
sweat
test
patient
show
area
anhidrosi
lower
limb
eight
patient
present
sweat
impair
upper
limb
abdomin
wall
result
sudomotor
axon
reflex
test
suggest
pattern
sweat
loss
accord
one
case
report
anoth
studi
eight
gb
patient
test
distal
leg
foot
dorsum
author
propos
associ
sudomotor
function
antigangliosid
antibodi
present
literatur
review
show
studi
sweat
disturb
gb
patient
includ
small
cohort
futur
studi
larger
patient
sampl
size
necessari
investig
pattern
sweat
loss
gb
chang
along
follow
fund
grant
paulo
research
foundat
fapesp
cond
fusco
martinez
mc
marqu
w
barreira
neurosci
univers
paulo
medic
school
preto
sp
brazil
neurolog
faculti
medic
scienc
univers
campina
sp
brazil
sensori
neuronopathi
sn
repres
rare
subgroup
peripher
neuropathi
character
degener
primari
sensori
neuron
dorsal
root
ganglia
spinal
cord
depend
neuron
popul
affect
clinic
present
may
manifest
gait
ataxia
propriocept
sensori
loss
posit
neg
sensori
symptom
although
report
mention
area
anhidrosi
sn
abl
find
previou
case
seri
studi
sweat
function
sensori
neuronopathi
aim
present
investig
studi
distribut
sweat
anterior
posterior
surfac
patient
diagnos
sn
quantit
sensori
test
cold
warm
sensat
threshold
method
level
perform
dorsum
hand
feet
random
order
test
thermoregulatori
sweat
use
sweat
chamber
air
temperatur
rel
humid
oral
skin
temperatur
monitor
test
time
exceed
min
order
studi
sudomotor
axon
reflex
employ
devic
standard
bodi
site
test
perform
side
simultan
includ
seven
patient
three
male
mean
age
year
mean
diseas
durat
month
rang
confirm
diagnos
sn
patient
present
asymmetr
loss
cold
warm
threshold
hand
feet
compar
healthi
control
p
regard
tst
result
found
strike
variat
sweat
disturb
rang
small
area
anhidrosi
trunk
complet
failur
sympathet
nervou
system
two
patient
underw
axon
reflex
test
asymmetr
mostli
distal
pattern
sweat
loss
one
second
one
find
indic
great
variabl
sweat
loss
sn
overlap
sensori
loss
area
current
test
patient
order
confirm
result
fund
grant
paulo
research
foundat
fapesp
cooper
jack
ryal
hayley
escher
koch
britton
winter
mccarson
geiger
thyfault
wright
kansa
medic
center
kansa
citi
ks
usa
michigan
ann
arbor
mi
usa
diet
exercis
inflamm
establish
modul
peripher
nervou
system
function
includ
pain
prior
work
examin
exercis
consist
demonstr
benefit
heighten
pain
number
acut
chronic
pain
model
present
work
investig
sever
paramet
peripher
nerv
function
relev
pain
rat
bred
high
high
capac
runner
hcr
low
run
capac
low
capac
runner
lcr
longtim
select
breed
rat
substrain
creat
diverg
intrins
aerob
capac
predisposit
metabol
condit
lcr
hcr
rat
examin
role
sex
develop
chronic
pain
establish
key
differ
male
femal
understand
gender
specif
differ
studi
focus
femal
rat
understand
role
metabol
statu
peripher
nerv
function
femal
analysi
identifi
numer
paramet
peripher
nerv
function
relev
pain
neuropathi
differ
among
lcr
hcr
femal
rat
lcr
femal
rat
display
reduc
hind
paw
mechan
sensit
increas
hind
paw
intraepiderm
nerv
fiber
densiti
epiderm
axon
increas
number
langerhan
mast
cell
hind
paw
dermi
increas
overal
fat
mass
rel
bodi
weight
compar
femal
hcr
rat
examin
sensori
motor
nerv
conduct
veloc
thermal
sensit
mrna
express
select
gene
relev
peripher
sensat
found
differ
hcr
lcr
femal
togeth
result
suggest
genet
compon
aerob
capac
metabol
statu
influenc
sensori
sensit
specif
aspect
inflamm
immun
respons
peripher
tissu
may
lead
modifi
anim
respons
tissu
damag
pain
stimuli
lcr
hcr
rat
model
provid
use
model
futur
assess
involv
metabol
statu
develop
pain
cornblath
van
doorn
hartung
katzberg
merki
hopkin
univers
baltimor
md
usa
univers
medic
center
rotterdam
netherland
hein
univers
germani
toronto
toronto
canada
univers
medic
center
maastricht
netherland
ivig
often
consid
treatment
first
choic
chronic
inflammatori
demyelin
polyradiculoneuropathi
cidp
rapid
onset
action
rel
safe
advers
event
profil
clinic
trial
publish
far
focus
load
dose
gkg
ivig
andor
standard
mainten
dosag
gkg
ivig
everi
week
investig
differ
dose
option
studi
prospect
random
parallel
group
phase
iii
efficaci
studi
conduct
centr
canada
eu
russia
ukrain
australia
adult
patient
definit
probabl
cidp
accord
efnspn
criteria
enrol
random
receiv
either
gkg
gkg
gkg
ivig
seven
mainten
infus
interv
phase
start
load
dose
gkg
ivig
patient
primari
object
efficaci
measur
percentag
respond
decreas
adjust
incat
score
least
point
gkg
ivig
arm
given
everi
week
week
corrobor
exist
publish
evid
efficaci
ivig
cidp
secondari
outcom
percentag
respond
week
gkg
ivig
arm
rel
baselin
compar
gkg
arm
procid
studi
aim
confirm
publish
clinic
result
obtain
gkg
standard
dose
addit
evalu
one
higher
one
lower
mainten
dose
aim
offer
cidp
patient
adequ
dose
effect
treatment
polici
est
medicamento
se
encuentra
comercializado
en
cornett
menez
shi
moroni
pagliano
pareyson
estilow
yum
bhandari
muntoni
reilli
finkel
eiching
herrmann
bray
halaki
shi
burn
cmtped
studi
group
children
hospit
network
univers
sydney
sydney
australia
child
health
univers
sydney
sydney
australia
pediatr
carver
colleg
medicin
univers
iowa
iowa
citi
ia
usa
foundat
carlo
besta
neurolog
institut
milan
itali
program
children
hospit
philadelphia
pa
usa
neurolog
children
hospit
philadelphia
depart
neurolog
perelman
school
medicin
univers
pennsylvania
usa
institut
child
health
great
ormond
street
hospit
london
uk
centr
neuromuscular
diseas
ucl
institut
neurolog
queen
squar
london
uk
program
divis
neurolog
nemour
children
hospit
orlando
usa
neurolog
univers
rochest
rochest
usa
child
health
univers
sydney
sydney
australia
neurolog
carver
colleg
medicin
univers
iowa
iowa
citi
ia
usa
understand
rate
diseas
progress
patient
diseas
cmt
within
subtyp
import
clinic
prognosi
crucial
clinic
trial
design
due
progress
natur
cmt
interven
earliest
stage
diseas
prioriti
measur
progress
diseas
motor
sensori
deficit
requir
composit
scale
cmt
pediatr
scale
cmtped
psychometr
robust
scale
measur
fine
gross
motor
function
strength
sensat
balanc
children
adolesc
age
year
cmt
aim
studi
determin
rate
diseas
progress
children
adolesc
within
genet
subtyp
cmt
femal
particip
age
year
enrol
inherit
neuropathi
consortium
includ
studi
demograph
anthropometr
diagnost
inform
collect
baselin
diseas
progress
measur
cmtped
averag
cmtped
score
progress
rate
point
chang
baselin
p
differ
rate
diseas
progress
male
femal
common
genet
subtyp
particip
duplic
progress
point
chang
baselin
p
nine
particip
mutat
progress
point
chang
six
particip
mutat
progress
point
chang
seven
particip
mutat
progress
point
chang
particip
progress
faster
children
progress
consist
childhood
adolesc
children
progress
faster
childhood
adolesc
overal
children
cmt
progress
signific
rate
accord
cmtped
understand
rate
affect
children
deterior
essenti
adequ
power
clinic
trial
intervent
cortes
phetteplac
polk
poh
houlden
rossor
shi
reilli
centr
neuromuscular
diseas
nation
hospit
neurolog
neurosurgeri
ucl
institut
neurolog
queen
squar
london
uk
neurolog
univers
iowa
carver
colleg
medicin
iowa
citi
ia
usa
neurogenet
nation
hospit
neurolog
neurosurgeri
ucl
institut
neurolog
london
uk
molecular
neurosci
ucl
institut
neurolog
london
uk
nation
hospit
neurolog
neurosurgeri
queen
squar
london
uk
recent
year
target
ng
panel
chang
diagnost
patient
inherit
neuropathi
howev
limit
data
impact
target
ng
panel
diagnosi
cmt
patient
everyday
practic
aim
studi
investig
impact
target
ng
panel
diagnosi
cmt
across
two
tertiari
referr
centr
unit
kingdom
london
unit
state
iowa
london
patient
diagnosi
cmt
previou
duplic
common
cmt
gene
exclud
appropri
case
underw
target
ng
panel
sequenc
cover
gene
associ
cmt
addit
gene
associ
hsp
al
variabl
number
gene
rang
analys
depend
clinic
phenotyp
patient
definit
molecular
diagnosi
achiev
case
includ
pathogen
like
pathogen
mutat
case
case
includ
case
mutat
promot
region
case
case
aar
case
case
mpz
case
nefl
case
vu
identifi
patient
diagnost
rate
higher
demyelin
cmt
case
compar
case
axon
cmt
dhmn
hsn
iowa
patient
investig
ng
panel
cover
gene
associ
cmt
molecular
diagnosi
reach
particular
demyelin
axon
cmt
case
frequent
gene
identifi
case
case
case
case
vu
identifi
patient
includ
case
novel
variant
aar
warrant
addit
test
segreg
variant
famili
function
valid
studi
clinic
practis
target
ng
panel
repres
effect
approach
diagnosi
cmt
lower
diagnost
rate
london
like
due
prior
sanger
sequenc
exclus
mutat
common
cmt
gene
patient
popul
cortes
bugiardini
hugh
pittmann
rossor
houlden
reilli
centr
neuromuscular
diseas
nation
hospit
neurolog
neurosurgeri
ucl
institut
neurolog
queen
squar
london
uk
molecular
neurosci
ucl
institut
neurolog
london
uk
nation
hospit
neurolog
neurosurgeri
queen
squar
london
uk
gene
known
caus
cmt
even
larger
number
known
caus
peripher
neuropathi
part
complex
neurolog
disord
despit
use
custom
panel
signific
proport
patient
inherit
neuropathi
molecular
diagnosi
aim
studi
investig
diagnost
yield
gene
exom
sureselect
focus
exom
agil
technolog
santa
clara
ca
usa
diagnosi
cmt
case
complex
neurolog
syndrom
associ
neuropathi
patient
molecularli
undiagnos
inherit
neuropathi
analys
sureselect
focus
exom
sequenc
six
patient
complex
phenotyp
includ
learn
difficulti
cerebr
white
matter
chang
ataxia
pyramid
tract
involv
genet
diagnosi
achiev
case
detect
mutat
gene
mpz
case
aar
nefl
note
six
case
mutat
gene
cover
current
avail
diagnost
target
ng
panel
includ
polg
mme
case
novel
candid
gene
averag
coverag
higher
compar
usual
coverag
sequenc
target
cover
target
cover
studi
provid
evid
sureselect
focus
exom
use
tool
diagnosi
cmt
complex
neurolog
disord
provid
insight
phenotyp
spectrum
gene
associ
inherit
neuropathi
cortes
manol
simon
ashokkumar
tomaselli
rossor
gutowski
polk
poh
houlden
reilli
centr
neuromuscular
diseas
nation
hospit
neurolog
neurosurgeri
ucl
institut
neurolog
queen
squar
london
uk
molecular
neurosci
ucl
institut
neurolog
nation
hospit
neurolog
neurosurgeri
queen
squar
london
uk
neurodegen
diseas
ucl
institut
neurolog
queen
squar
london
uk
neurogenet
nation
hospit
neurolog
neurosurgeri
ucl
institut
neurolog
london
uk
chang
sequenc
gene
untransl
region
utr
increasingli
recognis
signific
caus
inherit
diseas
human
exampl
variant
region
account
mutat
cohort
cmtx
patient
one
biggest
challeng
analys
larg
number
variant
gene
identifi
polymorph
aim
studi
implement
reliabl
method
function
valid
variant
promot
region
cohort
cmtx
patient
previous
identifi
seven
mutat
g
c
c
c
promot
region
one
novel
mutat
consid
like
pathogen
base
clinic
phenotyp
segreg
affect
famili
member
absenc
control
databas
gener
report
system
optimis
hela
cell
line
mutat
promot
region
gener
mutagenesi
use
commerci
avail
promot
clone
genecopoeia
preliminari
result
show
reduct
luciferas
activ
c
mutat
compar
promot
differ
increas
transcript
factor
c
mutat
respect
valid
variant
current
ongo
success
studi
provid
use
tool
valid
mutat
region
moreov
constitut
approach
function
valid
variant
cmt
gene
known
caus
diseas
loss
function
cortes
polk
poh
rossor
tomaselli
blake
lunn
houlden
reilli
centr
neuromuscular
diseas
nation
hospit
neurolog
neurosurgeri
ucl
institut
neurolog
queen
squar
london
uk
neurogenet
nation
hospit
neurolog
neurosurgeri
ucl
institut
neurolog
london
uk
molecular
neurosci
ucl
institut
neurolog
nation
hospit
neurolog
neurosurgeri
queen
squar
london
uk
recess
domin
mutat
repeat
steril
associ
ubiquitin
ligas
contain
ring
domain
crucial
correct
protein
fold
ubiquitin
activ
date
major
domin
mutat
report
result
frame
shift
disrupt
major
portion
although
point
mutat
domain
also
describ
aim
studi
report
preval
clinic
featur
genet
find
patient
centr
perform
target
sequenc
genet
undiagnos
patient
identifi
case
heterozyg
mutat
unrel
famili
mutat
identifi
includ
frameshift
insert
delet
delet
missens
point
mutat
mutat
novel
locat
flank
ring
domain
averag
age
diseas
onset
decad
earlier
onset
report
two
case
four
posit
famili
histori
keep
autosom
domin
inherit
symptom
present
heterogen
encompass
distal
numb
unsteadi
distal
weak
upper
lower
limb
foot
deform
posit
sensori
symptom
includ
tingl
shoot
pain
cramp
also
frequent
report
neurolog
examin
show
mild
moder
distal
atrophi
weak
earli
ankl
plantar
flexion
involv
three
patient
loss
vibrat
reduc
joint
posit
sens
often
promin
lower
limb
appear
disproportion
degre
weak
impair
pinprick
sensat
ankl
jerk
absent
knee
upper
limb
reflex
could
normal
brisk
averag
diseas
durat
year
one
patient
abl
walk
independ
nerv
conduct
studi
show
sensori
motor
axon
neuropathi
normal
conduct
veloc
studi
highlight
mutat
relev
caus
associ
promin
larg
fibr
sensori
loss
cortes
polk
poh
houlden
rossor
reilli
centr
neuromuscular
diseas
nation
hospit
neurolog
neurosurgeri
ucl
institut
neurolog
queen
squar
london
uk
neurogenet
nation
hospit
neurolog
neurosurgeri
ucl
institut
neurolog
london
uk
molecular
neurosci
nation
hospit
neurolog
neurosurgeri
ucl
institut
neurolog
queen
squar
london
uk
recent
year
implement
ng
panel
molecular
diagnosi
cmt
increas
number
patient
genet
diagnosi
nevertheless
interpret
particular
variant
diseas
caus
challeng
especi
multipl
variant
identifi
singl
patient
report
two
illustr
case
challeng
first
index
case
born
healthi
parent
present
fall
earli
childhood
year
develop
foot
deform
progress
length
depend
weak
multipl
orthopaed
oper
feet
past
histori
also
notabl
kyphoscoliosi
sensorineur
deaf
age
bilater
cataract
nerv
conduct
studi
age
reveal
demyelin
neuropathi
consist
clinic
phenotyp
younger
brother
similar
although
sever
phenotyp
litaf
mutat
identifi
sanger
sequenc
present
affect
brother
also
unaffect
sister
ng
gene
therefor
perform
identifi
two
compound
heterozyg
pathogen
mutat
detect
segreg
diseas
famili
second
case
describ
brother
sister
earli
onset
demyelin
cmt
associ
scoliosi
cranial
nerv
involv
male
proband
underw
ng
singl
previous
report
pathogen
intron
mutat
c
found
rel
analysi
ng
perform
look
possibl
copi
number
variant
thu
identifi
delet
exon
confirm
long
pcr
servic
univers
hospit
miguel
servet
zaragoza
spain
unit
clinic
biochemistri
servic
univers
hospit
miguel
servet
zaragoza
spain
diseas
cmtd
defin
clinic
genet
heterogen
group
inherit
peripher
neuropathi
character
chronic
motor
sensori
impair
type
also
known
cowchock
syndrom
product
mutat
apoptosi
induc
factor
mitochondria
associ
gene
slowli
progress
recess
diseas
character
axon
neuropathi
deaf
cognit
impair
purpos
describ
new
case
brother
children
parent
characterist
phenotyp
new
mutat
gene
sibl
present
childhood
progress
weak
lower
limb
diffus
amyotrophi
need
tenotomi
year
due
equinovaru
foot
likewis
develop
sensori
deaf
one
requir
unilater
support
wheelchair
one
need
pacemak
atrioventricular
block
brain
function
normal
languag
sensori
deaf
proxim
distal
weak
four
limb
intens
amyotrophi
predominantli
distal
tactil
pain
sensit
decreas
glove
sock
pattern
extens
metabol
biochem
studi
normal
electroneurographi
demonstr
axon
neuropathi
without
respons
nerv
explor
electromyographi
shown
myogen
pattern
distal
predomin
brain
mri
normal
case
genet
studi
exoma
target
gene
associ
cmt
inherit
relat
neuropathi
identifi
homicigosi
mutat
gene
locat
chromosom
region
cowchock
syndrom
rare
entiti
case
describ
literatur
silico
analysi
indic
predictor
use
provean
sift
lrt
mutationtast
mutationassessor
condel
deleteri
variant
kazmi
hadden
depart
king
colleg
hospit
london
uk
depart
king
colleg
hospit
london
uk
neurolog
univers
hospit
miguel
servet
zaragoza
spain
audit
patient
peripher
neuropathi
caus
paraprotein
receiv
treatment
attend
king
colleg
hospit
peripher
nerv
servic
patient
identifi
retrospect
databas
patient
attend
peripher
nerv
outpati
clinic
clinic
inform
obtain
retrospect
hospit
electron
patient
record
exclud
patient
poem
syndrom
neuropathi
felt
caus
paraprotein
identifi
patient
diagnosi
paraproteinaem
neuropathi
exclud
four
fulfil
diagnost
criteria
eleven
receiv
treatment
diagnost
studi
includ
patient
final
audit
igm
paraprotein
haematolog
diagnosi
monoclon
gammopathi
undetermin
signific
mgu
waldenstrom
macroglobulinaemia
lymphoma
plasmacytoma
treatment
overal
patient
improv
neurolog
stabilis
worsen
patient
receiv
one
type
treatment
analys
outcom
accord
power
treatment
receiv
patient
receiv
rituximab
alon
improv
stabilis
worsen
nine
patient
receiv
rituximab
combin
cyclophosphamid
bendamustin
improv
stabil
worsen
eight
patient
receiv
intraven
immunoglobulin
improv
stabil
worsen
four
patient
receiv
chemotherapi
improv
stabilis
worsen
two
patient
receiv
corticosteroid
worsen
improv
mag
antibodi
without
improv
mgu
haematolog
malign
improv
kappa
light
chain
lambda
factor
associ
better
outcom
univari
analysi
neg
mag
antibodi
kappa
light
chain
haematolog
malign
signific
differ
treatment
proport
improv
cumberbatch
cox
hospit
cambridg
uk
treatment
patient
autoimmun
neuropathi
chronic
inflammatori
demyelin
polyradiculoneuropathi
cidp
multifoc
motor
neuropathi
mmn
centr
use
intraven
immunoglobulin
ivig
howev
ivig
therapi
associ
system
treatment
effect
regular
hospit
attend
subcutan
immunoglobulin
scig
efficaci
altern
flexibl
dose
home
avoid
peak
trough
observ
ivig
factor
may
combin
improv
patient
satisfact
allevi
hospit
capac
issu
report
clinic
patient
experi
switch
ivig
manual
push
scig
treatment
cidp
mmn
clinic
case
seri
patient
cidp
mmn
mean
age
year
clinic
stabl
ivig
wish
switch
manual
push
scig
start
scig
dose
equival
final
ivig
dose
patient
mean
gkg
week
clinic
efficaci
medic
research
council
sum
score
walk
modifi
inflammatori
neuropathi
caus
treatment
score
overal
neuropathi
limit
scale
romberg
test
outcom
short
form
health
survey
life
qualiti
index
lqi
assess
baselin
regular
interv
final
visit
month
switch
baselin
patient
cite
conveni
primari
reason
switch
scig
eight
patient
complet
full
assess
period
success
undertook
administr
home
via
servic
case
dose
adjust
base
clinic
need
requir
patient
treatment
efficaci
patient
qualiti
life
measur
maintain
switch
scig
overal
patient
satisfact
measur
lqi
increas
lqi
conveni
travel
timecost
significantli
improv
p
switch
scig
therapi
advers
event
includ
mild
erythema
localis
swell
expect
ml
subcutan
inject
find
suggest
manual
push
scig
therapi
viabl
altern
ivig
patient
cidp
mmn
maintain
diseas
stabil
conveni
patient
may
help
eas
hospit
capac
concern
cumberbatch
soar
regua
cox
hospit
cambridg
uk
intraven
immunoglobulin
ivig
use
treat
number
chronic
autoimmun
neurolog
diseas
centr
infus
given
slow
rate
percept
reduc
risk
advers
event
ae
result
longer
admiss
frequent
day
case
attend
impact
patient
qualiti
life
hospit
capac
howev
littl
evid
suggest
slow
infus
rate
requir
use
manufactur
recommend
optimis
infus
rate
reduc
time
patient
spend
hospit
report
retrospect
audit
describ
impact
differ
ivig
infus
rate
patient
clinic
condit
audit
compris
three
assess
period
cohort
infus
rate
mlkghr
n
cohort
mlkghr
n
cohort
mlkghr
n
clinic
data
review
determin
patient
demograph
durat
infus
time
spent
hospit
incid
ae
three
cohort
well
match
term
patient
demograph
patient
treat
treatment
period
cohort
significantli
shorter
treatment
episod
cohort
vs
hour
p
spent
less
time
unit
month
period
vs
hour
p
fewer
admissionspati
vs
p
overal
incid
confirm
ae
mainli
headach
similar
across
cohort
cohort
cohort
cohort
find
indic
increas
ivig
infus
rate
well
toler
significantli
reduc
treatment
time
benefit
patient
offer
potenti
cost
save
reduc
pressur
hospit
capac
healthcar
provid
cunningham
yao
meehan
barri
willison
glasgow
glasgow
uk
one
mechan
injuri
acut
motor
axon
neuropathi
aman
form
syndrom
gb
attack
peripher
nerv
axon
antibodi
agab
rodent
model
demonstr
bind
antibodi
activ
complement
cascad
result
insert
termin
compon
membran
attack
complex
mac
axon
membran
complement
activ
also
result
releas
anaphylatoxin
known
recruit
phagocyt
immun
cell
site
injuri
current
vivo
mous
model
agab
injuri
acut
sever
result
respiratori
distress
sever
hour
magnitud
warrant
termin
experiment
procedur
observ
potenti
target
immun
cell
infiltr
follow
agab
injuri
subacut
model
extend
day
requir
demonstr
develop
model
compar
differ
immun
cell
infiltr
subacut
control
injuri
condit
mice
endogen
express
egfp
monocyt
macrophag
underw
modifi
agab
injuri
result
less
sever
phenotyp
previous
publish
model
six
day
follow
injuri
immun
cell
diaphragm
compar
immunofluoresc
flow
cytometri
flow
cytometri
found
overal
presenc
neutrophil
significantli
increas
diaphragm
macrophag
also
increas
injur
mice
although
achiev
statist
signific
timepoint
result
reflect
immunofluoresc
stain
diaphragm
egfp
macrophag
quantifi
surround
neuromuscular
junction
primari
injuri
target
model
develop
extend
mous
model
agab
injuri
import
sinc
acut
model
take
consider
either
effect
activ
nerv
membran
recoveri
phase
futur
studi
look
effect
inhibit
complement
activ
presenc
immun
cell
distal
motor
nerv
cutrupi
brewer
de
mora
maciel
ly
drew
zuchner
nicholson
saporta
kennerson
neurosci
laboratori
anzac
research
institut
sydney
australia
medic
school
univers
sydney
sydney
australia
medic
school
foundat
sydney
australia
neurolog
univers
miami
miller
school
medicin
miami
usa
human
genet
hussman
institut
human
genom
univers
miami
miller
school
medicin
miami
usa
medicin
laboratori
concord
repatri
gener
hospit
sydney
australia
equal
last
author
larg
australian
famili
autosom
domin
form
dhmn
omim
group
neurodegen
disord
affect
lower
motor
neuron
lead
chronic
disabl
recent
report
novel
mb
chromosom
insert
within
locu
hypothesis
like
caus
diseas
dysregul
express
one
nearbi
gene
studi
gene
dysregul
peripher
nerv
diseas
challeng
relev
tissu
spinal
cord
peripher
nerv
easili
access
patient
therefor
altern
strategi
need
elucid
diseas
mechan
pathway
involv
peripher
nerv
degener
address
problem
devis
strategi
assess
dysregul
candid
gene
use
patient
lymphoblast
fibroblast
cell
line
cell
line
easili
establish
minim
invas
obtain
harbour
natur
mutat
genet
background
patient
strategi
firstli
use
lymphoblast
gene
express
profil
initi
screen
tool
prioritis
candid
gene
assess
alter
express
differenti
express
gene
model
celegan
behaviour
nerv
morpholog
assess
use
screen
candid
gene
patient
control
lymphoblast
cell
line
eighteen
candid
gene
express
lymphoblast
twelv
eighteen
gene
priorit
analysi
base
express
lymphoblast
neural
tissu
quantit
analysi
use
taqman
assay
reveal
differenti
express
patient
control
import
pattern
differenti
express
recapitul
neural
model
part
second
strategi
gener
patient
control
induc
pluripot
stem
cell
deriv
motor
neuron
reprogram
fibroblast
use
model
perform
qpcr
experi
examin
alter
gene
express
neural
tissu
predict
util
two
strategi
shed
light
pathogen
mechan
underli
insert
provid
use
insight
pathway
lead
peripher
nerv
degener
davidson
halstead
goodfellow
chavada
mallik
overel
lunn
mcconnachi
van
doorn
willison
neurolog
institut
neurolog
scienc
southern
gener
hospit
glasgow
uk
infect
immun
inflamm
colleg
medic
veterinari
life
scienc
univers
glasgow
glasgow
uk
clinic
neurophysiolog
institut
neurolog
scienc
southern
gener
hospit
glasgow
uk
neurolog
nation
hospit
neurolog
neurosurgeri
queen
squar
london
uk
centr
biostatist
boyd
orr
build
univers
glasgow
glasgow
uk
neurolog
erasmu
mc
rotterdam
netherland
outcom
syndrom
remain
unchang
sinc
plasma
exchang
intraven
immunoglobulin
introduc
year
ago
pathogenesi
studi
gb
identifi
termin
compon
complement
cascad
membran
attack
complex
key
diseas
mediat
thu
therapeut
target
inhibit
complement
syndrom
trial
look
first
use
pathway
inhibit
eculizumab
human
gb
randomis
trial
primari
outcom
look
safeti
toler
administr
concomitantli
ivig
context
sever
gb
disabl
score
greater
diseas
particip
recruit
month
period
regular
follow
subject
screen
randomis
two
main
caus
failur
proceed
particip
concern
around
eculizumab
side
effect
profil
specif
mening
risk
also
intercurr
infect
preclud
treatment
five
receiv
eculizumab
four
week
alongsid
standard
intraven
immunoglobulin
treatment
receiv
placebo
safeti
outcom
monitor
via
advers
event
captur
trial
visit
show
eculizumab
well
toler
safe
administ
conjunct
ivig
common
advers
event
mild
derang
transaminas
infect
infus
reaction
primari
secondari
efficaci
outcom
captur
via
gb
disabl
score
mrc
sum
score
rasch
overal
disabl
score
overal
neuropathi
limit
score
primari
efficaci
outcom
week
recruit
placebo
subject
improv
grade
gb
disabl
score
patient
improv
measur
paramet
trial
highlight
challeng
recruit
acut
unwel
patient
due
time
constraint
intercurr
infect
although
small
sampl
size
preclud
statist
meaning
analysi
pilot
data
indic
studi
complement
inhibit
gb
warrant
de
freita
dia
vidal
szklarz
nascimento
kok
fluminens
univers
brazil
paulo
univers
paulo
brazil
diseas
cmt
affect
one
peopl
current
gene
identifi
differ
phenotyp
major
case
western
countri
autosom
domin
classifi
demyelin
axon
accord
electroneuromyographi
enmg
clinic
condit
character
weak
predomin
sensori
chang
feet
hand
sometim
differ
phenotyp
recent
variant
heterozygot
har
gene
synthetas
describ
associ
cmt
call
type
report
case
phenotyp
probabl
new
mutat
har
gene
male
patient
adopt
son
caucasian
drug
addict
three
year
suffer
pain
lower
limb
great
intens
refractori
drug
treatment
examin
show
retrognath
abolit
patellar
achillea
reflex
pain
thermal
anaesthesia
apalesthesia
feetth
enmg
show
reduc
sensori
action
potenti
sural
superfici
fibular
nerv
laboratori
investig
pain
polyneuropathi
thick
fine
fibr
normal
sural
nerv
biopsi
reveal
axon
predomin
neuropathi
exom
sequenc
reveal
mutat
har
gene
pathogen
variant
heterozygos
replac
amino
acid
leucin
posit
arginin
patient
although
know
anteced
present
pain
polyneuropathi
whose
genet
research
although
unequivoc
indic
variant
call
cmt
w
case
variant
describ
sever
mutat
case
reveal
mutat
hitherto
unknown
conclud
import
thorough
genet
evalu
case
sensori
polyneuropathi
unknown
caus
de
greef
geert
faber
merki
hoeijmak
neurolog
school
mental
health
neurosci
maastricht
univers
medic
center
maastricht
netherland
neurolog
st
elisabeth
hospit
willemstad
small
fiber
neuropathi
sfn
condit
affect
small
lead
sever
neuropath
pain
autonom
dysfunct
sever
sodium
channel
gene
mutat
found
patient
sfn
mutat
frequent
current
avail
sodium
channel
blocker
select
treatment
often
result
numer
side
effect
lacosamid
anticonvuls
target
specif
sodium
channel
state
spare
normal
activ
sever
mutat
impair
found
patient
sfn
therefor
posit
effect
lacosamid
pain
reduct
patient
expect
primari
object
studi
determin
effect
lacosamid
versu
placebo
pain
subject
sfn
secondari
object
determin
effect
lacosamid
autonom
symptom
sleep
interfer
qualiti
life
examin
safeti
toler
n
sfn
lenss
studi
random
studi
subject
random
start
lacosamid
end
placebo
vice
versa
two
phase
studi
subject
treat
period
eight
week
bid
preced
titrat
period
end
taper
period
patient
fill
pain
diari
twice
daili
score
set
valid
questionnair
autonom
symptom
sleep
interfer
qualiti
life
multipl
studi
visit
total
patient
sfn
includ
novemb
februari
subject
median
age
year
rang
year
sixti
percent
patient
femal
final
result
studi
includ
primari
secondari
outcom
present
de
la
oliva
del
vall
navarro
cell
biolog
physiolog
immunolog
institut
neurosci
universitat
de
barcelona
centro
de
en
red
sobr
enfermedad
neurodegenerativa
cibern
bellaterra
spain
intraneur
interfac
must
intim
contact
nerv
fibr
proper
function
shown
compromis
due
foreign
bodi
reaction
fbr
fbr
first
respons
nonspecif
immun
system
implant
devic
character
first
inflammatori
phase
follow
second
antiinflammatori
fibrot
phase
process
result
format
tissu
capsul
around
interfac
caus
function
loss
due
physic
separ
activ
site
electrod
nerv
axon
take
account
test
sever
drug
dexamethason
ibuprophen
maraviroc
reduc
macrophag
activ
well
clodron
liposom
reduc
monocytemacrophag
infiltr
moreov
sildenafil
administ
antifibrot
drug
reduc
collagen
deposit
fbr
model
longitudin
parylen
intraneur
devic
implant
rat
sciatic
nerv
briefli
anim
system
treat
dexamethason
ibuprophen
sildenafil
maraviroc
clodron
liposom
two
week
nerv
damag
inflammatori
reaction
matrix
thick
around
implant
assess
treatment
dexamethason
ibuprophen
clodron
liposom
significantli
reduc
inflammatori
respons
nerv
comparison
salin
group
sildenafil
maraviroc
effect
posit
cell
infiltr
nerv
howev
dexamethason
abl
significantli
reduc
matrix
deposit
around
implant
two
week
treatment
result
support
idea
inflamm
trigger
foreign
bodi
respons
peripher
nerv
potent
treatment
dexamethason
could
benefici
effect
lengthen
intraneur
interfac
lifespan
de
la
oliva
del
vall
navarro
cell
biolog
physiolog
immunolog
institut
neurosci
universitat
de
barcelona
centro
de
en
red
sobr
enfermedad
neurodegenerativa
cibern
bellaterra
spain
intraneur
interfac
function
decreas
time
among
factor
due
foreign
bodi
respons
fbr
encapsul
implant
devic
physic
separ
activ
site
nervou
tissu
studi
fbr
parylen
c
polyimid
thin
devic
implant
rat
sciatic
nerv
assess
thick
tissu
capsul
sign
inflamm
nerv
damag
character
respons
cell
respons
sever
molecular
mediat
month
implant
find
differ
fbr
materi
week
implant
inflammatori
respons
due
surgeri
alreadi
decreas
wherea
implant
nerv
reach
highest
level
decreas
chronic
time
point
besid
amount
foreign
bodi
giant
cell
fbgc
result
macrophag
fusion
found
tissu
capsul
around
implant
also
increas
progress
reach
maximum
week
hand
molecular
analysi
environ
reveal
peak
inflammatori
cytokin
first
day
implant
return
standard
level
thereaft
howev
increas
ccl
molecul
found
later
materi
regard
capsul
thick
devic
surround
tissu
deposit
appear
soon
implant
howev
case
polyimid
devic
tissu
capsul
show
peak
week
implant
sign
remodel
thereaft
parylen
c
devic
show
second
increas
week
comparison
polyimid
devic
immunohistochem
electron
microscopi
analysi
reveal
two
differ
cell
type
implic
fbr
nerv
materi
macrophag
close
contact
interfac
fibroblast
appear
week
surround
tissu
capsul
although
analys
need
elucid
differ
fbr
parylen
c
polyimid
polym
result
help
determin
therapeut
target
order
reduc
respons
improv
intraneur
interfac
lifespan
delmont
antoin
paul
boucraut
attarian
centr
al
neuromuscular
diseas
marseil
franc
centr
neuromuscular
diseas
saint
etienn
franc
laboratori
saint
etienn
franc
laboratori
marseil
franc
peripher
neuropathi
antibodi
myelin
associ
glycoprotein
mag
chronic
sensori
neuropathi
character
presenc
igm
monoclon
gammopathi
high
level
antibodi
antibodi
recogn
specif
epitop
call
human
natur
killer
share
nk
lymphocyt
sever
compon
peripher
nerv
mag
sgpg
phosphocan
recent
elisa
test
develop
detect
antibodi
epitop
object
determin
sensit
specif
antibodi
diagnosi
neuropathi
know
antibodi
correl
sever
diseas
antibodi
assess
neuropathi
neg
control
chronic
inflammatori
demyelin
polyradiculoneuropathi
cidp
miller
fisher
syndrom
sensori
neuronopathi
axon
sensori
polyneuropathi
healthi
control
neuropathi
record
age
diseas
durat
incat
sensori
sum
score
iss
overal
neuropathi
limit
scale
onl
overal
disabl
scale
rod
mrc
sum
score
antibodi
titer
peak
dosag
igm
monoclon
gammopathi
antibodi
measur
mag
elisa
test
antibodi
autoantibodi
elisa
test
buhlmann
compani
antibodi
posit
neuropathi
control
sensit
specif
neuropathi
titer
correl
sensori
defici
evalu
iss
score
disabl
evalu
rod
r
onl
scale
titer
relat
age
diseas
durat
mrc
sum
score
antibodi
titer
peak
dosag
paraproteinemia
antibodi
titer
associ
none
characterist
patient
neuropathi
antibodi
good
sensit
specif
diagnosi
neuropathi
compar
antibodi
valu
titer
relat
diseas
sever
result
need
confirm
larger
prospect
cohort
delmont
manso
querol
cortes
berardinelli
belghazi
malissart
labaug
taieb
yuki
illa
attarian
devaux
center
al
neuromuscular
diseas
la
timon
univers
hospit
univers
franc
cnr
marseil
franc
diseas
unit
hospit
de
la
santa
creu
sant
pau
universitat
de
barcelona
barcelona
spain
c
mondino
nation
neurolog
institut
pavia
itali
neurolog
gui
de
chauliac
hospit
montpelli
univers
hospit
center
montpelli
franc
neurolog
mishima
hospit
niigata
japan
chronic
inflammatori
demyelin
polyradiculoneuropathi
cidp
heterogen
treatabl
disord
critic
lack
biomark
support
diagnosi
recent
evid
indic
paranod
protein
target
autoantibodi
subset
patient
cidp
show
distinct
clinic
present
particularli
biomark
appear
clinic
relev
help
orient
therapeut
choic
examin
five
patient
present
igg
reactiv
node
ranvier
axon
initi
segment
use
proteom
approach
assay
elisa
identifi
main
target
autoantibodi
node
ranvier
four
patient
display
predominantli
antibodi
subclass
wherea
one
patient
present
antibodi
activ
complement
pathway
vitro
antibodi
recogn
differ
epitop
previous
describ
suggest
differ
pathogen
function
accordingli
patient
igg
show
distinct
clinic
present
patient
sever
phenotyp
associ
conduct
block
decreas
distal
motor
amplitud
tremor
neuropath
pain
observ
four
patient
present
sensori
ataxia
interest
neuropathi
occur
concomitantli
nephrot
syndrom
two
patient
retroperiton
fibrosi
one
patient
suggest
autoantibodi
could
respons
occurr
disord
intraven
immunoglobulin
corticosteroid
effect
three
patient
one
patient
improv
follow
cyclophosphamid
rituximab
treatment
clinic
remiss
found
correl
deplet
antibodi
loss
igg
reactiv
toward
node
ranvier
addit
recoveri
conduct
block
distal
motor
amplitud
observ
follow
remiss
suggest
data
demonstr
nodal
antigen
target
autoantibodi
subgroup
patient
cidp
emphas
pathogen
mechan
involv
chronic
demyelin
neuropathi
broad
may
includ
dysfunct
node
ranvier
delorm
jacquier
zuchner
sole
schaeffer
stojkov
latour
de
neurologi
pari
franc
cnr
umr
inserm
lyon
franc
fonctionnel
de
chu
de
lyon
hcl
groupement
est
bron
franc
du
motoneuron
et
patholog
neuromusculair
chru
de
montpelli
montpelli
franc
john
macdonald
foundat
depart
human
genet
institut
human
genom
univers
miami
miller
school
medicin
miami
usa
de
de
maladi
neuromusculair
chu
de
bordeaux
bordeaux
franc
de
biotechnologi
cellulair
cbc
biotec
chu
de
lyon
hcl
groupement
est
de
lyon
est
bron
franc
de
myologi
pari
franc
mutat
neurofila
heavi
nefh
gene
recent
identifi
rare
caus
autosom
domin
axon
diseas
clinic
spectrum
condit
remain
delin
report
two
french
famili
axon
predominantli
motor
dominantli
inherit
form
cmt
caus
two
previous
unreport
mutat
nefh
gene
twelv
patient
belong
two
differ
famili
includ
studi
display
axon
motor
sensori
neuropathi
mutat
known
axon
gene
remark
featur
patient
earli
involv
proxim
muscl
lower
limb
occur
approxim
year
onset
motor
deficit
proxim
weak
affect
predominantli
iliopsoa
muscl
wherea
quadricep
hamstr
muscl
rel
preserv
muscl
weak
muscl
wast
progress
rapidli
patient
requir
walk
assist
year
diseas
evolut
three
patient
famili
brisk
reflex
veloc
studi
display
evid
motor
sensori
axon
neuropathi
predominantli
affect
lower
limb
origin
delet
nucleotid
near
end
code
sequenc
nefh
identifi
famili
famili
caus
frameshift
interestingli
frameshift
lead
loss
termin
codon
translat
addit
amino
acid
encod
cryptic
amyloidogen
element
suggest
type
mutat
could
induc
protein
aggreg
consist
show
overexpress
mutat
form
nefh
human
neuroblastoma
cell
induc
format
protein
aggreg
also
observ
trigger
caspas
activ
apoptosi
use
electropor
chick
embryo
spinal
cord
confirm
vivo
mutat
nefh
form
aggreg
trigger
apoptosi
spinal
cord
neuron
altogeth
suggest
mutat
nefh
caus
protein
aggreg
neurotox
neuron
express
nefh
progress
loss
neuron
would
explain
earli
motor
involv
pyramid
sign
observ
patient
result
provid
physiolog
explan
presenc
cmt
al
clinic
featur
affect
patient
del
vall
righi
santo
cutron
bossi
damico
micera
navarro
cell
biolog
physiolog
immunolog
institut
neurosci
universitat
de
barcelona
bellaterra
spain
de
en
red
sobr
enfermedad
neurodegenerativa
cibern
bellaterra
spain
biorobot
institut
scuola
superior
santanna
pontedera
itali
laboratori
enea
casaccia
research
center
rome
itali
chair
translat
neuroengin
center
neuroprosthet
institut
bioengin
school
engin
ecol
polytechniqu
federal
de
lausann
lausann
switzerland
neuroprosthet
devic
aim
restor
sensorimotor
limb
function
ampute
patient
requir
highli
select
electrod
design
establish
tight
relationship
nerv
allow
bidirect
transduct
signal
nerv
fibr
interfac
enabl
control
user
differ
intraneur
interfac
regen
nerv
electrod
design
enabl
electr
interfac
regrow
axon
bundl
injur
nerv
aim
achiev
high
select
record
stimul
howev
develop
design
pose
obstacl
regrowth
mechan
due
low
transpar
caus
impair
nerv
regener
work
present
novel
planar
regen
electrod
new
type
highli
transpar
regen
electrod
allow
select
stimul
record
separ
nerv
fascicl
design
consist
thin
flexibl
electrod
longitudin
insert
across
conduit
thu
creat
two
separ
aisl
regener
fascicl
independ
regrow
nerv
transect
electrod
implant
acut
transect
nerv
rat
show
capabl
select
stimul
record
differ
fascicl
insert
aisl
moreov
chronic
implant
electrod
nerv
gap
sciatic
nerv
section
allow
fascicl
regener
reinnerv
distal
muscl
confirm
high
number
myelin
axon
insid
aisl
good
biocompat
adequ
nerv
conduct
addit
three
six
month
implant
independ
stimul
record
separ
regener
fascicl
possibl
result
demonstr
potenti
contribut
regen
electrod
select
interfac
differ
fascicl
injur
nerv
deleteri
effect
nerv
regener
therefor
regen
electrod
may
suitabl
neuroprosthet
applic
prosthes
restor
hand
function
amput
sever
nerv
injuri
demich
garnero
franciotta
cortes
callegari
mancardi
schenon
leonardi
benedetti
neurosci
rehabilit
ophthalmolog
genet
matern
child
health
univers
genoa
ircc
aou
san
genoa
itali
neuroimmunolog
ircc
c
mondino
nation
neurolog
institut
univers
pavia
pavia
itali
neurolog
imperies
imperia
itali
querol
et
al
show
antibodi
identifi
chronic
inflammatori
demyelin
polyradiculoneuropathi
cidp
phenotyp
character
sever
polyradiculoneuropathi
poor
respons
intraven
immunoglobulin
ivig
disabl
tremor
neurolog
improv
therapi
rituximab
previous
report
three
patient
cidp
antibodi
herein
describ
case
cidp
posit
antibodi
resist
convent
therapi
respons
rituximab
patient
woman
present
acut
onset
ataxia
gait
disturb
symptom
progress
two
week
distal
weak
numb
paresthesia
appear
nerv
conduct
studi
suggest
polyradiculoneuropathi
mainli
demyelin
cerebrospin
fluid
analysi
show
elev
protein
level
normal
cellular
count
patient
initi
diagnos
syndrom
gb
treat
plasma
exchang
without
improv
ivig
cycl
start
partial
relief
time
admiss
rehabilit
center
patient
still
mark
weak
four
limb
six
month
present
clinic
deterior
restrict
wheelchair
respons
addit
treatment
ivig
puls
corticosteroid
treatment
determin
signific
clinic
improv
next
month
despit
mainten
steroid
therapi
patient
present
progress
deterior
restrict
wheelchair
postur
intent
tremor
appear
upper
limb
becam
progress
disabl
ab
dosag
result
posit
rituximab
administ
dosag
week
three
month
tremor
improv
allow
eat
independ
patient
abl
walk
bilater
support
antibodi
neg
six
month
walk
without
support
abl
stitch
crochet
previous
report
case
cidp
posit
develop
sever
polyradiculoneuropathi
predomin
distal
weak
ataxia
disabl
tremor
resist
convent
therapi
interestingli
onset
correct
identif
cidp
subtyp
diagnost
prognost
therapeut
implic
rituximab
con
use
patient
demir
neurosurgeri
univers
school
medicin
tokat
turkey
neurosurgeri
kent
hospit
giresun
turkey
still
challeng
problem
maintain
motor
sensori
function
peripher
nerv
nerv
transect
nerv
injuri
calcium
concentr
damag
area
increas
calcium
ion
act
like
cytotox
agent
damag
area
nifedipin
calcium
channel
blocker
aim
investig
effect
nifedipin
nerv
regener
modul
calcium
damag
area
swiss
albino
male
rat
divid
two
group
left
sciatic
nerv
transect
surgeri
perform
rat
group
transect
nerv
sutur
primarili
epineur
interfascicular
method
experiment
group
anastomosi
site
wrap
piec
gel
foam
soak
dilut
nifedipin
solut
control
group
anastomosi
site
wrap
piec
gel
foam
soak
salin
solut
evalu
effect
nifedipin
use
function
histopatholog
studi
surgeri
postop
second
week
walk
test
perform
sciatic
function
index
calcul
postop
third
week
electroneuronographi
enog
perform
signific
differ
two
group
nifedipin
improv
nerv
recoveri
function
p
p
postop
fourth
week
perform
histopatholog
examin
experiment
group
nifedipin
organ
axon
reach
aim
conclud
result
nifedipin
effect
nerv
protect
agent
use
local
anastomosi
site
transect
nerv
de
mora
maciel
saporta
mario
neurolog
univers
miami
miller
school
medicin
miami
fl
usa
human
genet
hussman
institut
human
genom
univers
miami
miller
school
medicin
miami
fl
usa
lack
effect
therapi
cmt
highlight
need
novel
preclin
model
suitabl
drug
discoveri
studi
rodent
model
cmt
tend
find
far
translat
poorli
clinic
trial
primari
induc
pluripot
stem
cell
ipsc
neuron
cultur
establish
model
neurolog
diseas
howev
due
random
distribut
neuron
bodi
neurit
happen
plate
cell
system
ideal
investig
axon
process
like
peripher
neuropathi
particularli
cmt
optim
model
system
develop
robust
human
platform
studi
axon
morpholog
physiolog
base
motor
neuron
neurospher
differenti
motor
neuron
human
induc
pluripot
stem
cell
purifi
magnet
sort
cultur
suspens
form
neurospher
float
neurospher
maintain
agit
month
reliabl
sourc
motor
neuron
neurospher
plat
axon
rapidli
grow
radial
fashion
resembl
dorsal
root
ganglia
cultur
configur
allow
better
visual
axon
imag
studi
continu
axon
growth
least
period
axon
grew
averag
rate
micrometersday
reach
cm
length
neurospher
fix
stain
allow
morpholog
analysi
investig
protein
distribut
axon
system
also
ideal
imag
studi
axon
transport
organel
neurofila
kinet
lastli
motor
neuron
neurospher
system
lend
well
high
content
screen
platform
neurospher
plate
plate
multipl
compound
test
axon
easili
imag
high
content
screen
microscop
summari
develop
new
platform
investig
motor
axon
vitro
particularli
use
studi
process
inherit
peripher
neuropathi
may
facilit
identif
new
therapeut
compound
use
high
content
screen
system
de
mora
maciel
cutrupi
rebelo
zuchner
saporta
neurolog
univers
miami
miller
school
medicin
miami
fl
usa
human
genet
hussman
institut
human
genom
univers
miami
miller
school
medicin
miami
fl
usa
mutat
neurofila
light
chain
nfl
gene
caus
autosom
domin
axon
neuropathi
nfl
major
compon
neuron
cytoskeleton
believ
function
conjunct
nfm
nfh
provid
structur
support
axon
regul
axon
diamet
despit
signific
advanc
understand
biolog
basi
still
effect
therapi
part
due
pauciti
preclin
model
suitabl
drug
discoveri
develop
novel
preclin
platform
faith
mimic
mechan
axon
degener
vitro
would
essenti
valuabl
resourc
better
understand
biolog
identifi
potenti
target
therapi
develop
address
gener
control
motor
neuron
cultur
suspens
form
neurospher
immunostain
neurospher
nfl
antibodi
reveal
numer
area
nfl
accumul
axon
resembl
accumul
mutant
nfl
protein
seen
process
catecholaminerg
neuron
cell
line
cad
overexpress
sever
nfl
mutant
analysi
demonstr
area
nfl
accumul
also
immunoposit
nfh
pnfh
nfm
least
nfl
nfm
area
deposit
taken
togeth
result
demonstr
abnorm
axon
neurofila
distribut
featur
motor
neuron
involv
three
neurofila
subunit
also
develop
imag
analysi
routin
allow
automat
quantif
neurofila
distribut
preliminari
quantif
nfl
signal
intens
reveal
axon
patient
weaker
nfl
signal
compar
control
axon
present
sever
signal
peak
rang
observ
control
relat
area
nfl
accumul
result
suggest
nfl
accumul
certain
region
axon
reduc
area
accumul
find
readili
adapt
high
content
screen
platform
use
identifi
compound
abl
revers
axon
phenotyp
summari
identifi
strong
axon
phenotyp
human
motor
neuron
potenti
screen
platform
drug
discoveri
de
simoni
hagen
breu
lang
varga
rath
zimprich
wanschitz
neurolog
medic
univers
innsbruck
austria
neurolog
medic
univers
vienna
austria
neurolog
smz
vienna
austria
pediatr
adolesc
medicin
medic
univers
vienna
austria
neurolog
medic
univers
vienna
austria
nodal
paranod
protein
identifi
antigen
peripher
inflammatori
neuropathi
howev
frequenc
clinic
relev
antibodi
respons
target
remain
poorli
investig
gb
patient
acut
onset
inflammatori
neuropathi
identifi
explor
local
databas
depart
neurolog
institut
neurolog
medic
univers
innsbruck
vienna
patient
data
electrophysiolog
classif
presenc
antibodi
retrospect
retriev
review
patient
record
patient
typic
clinic
present
electrophysiolog
result
consist
one
subtyp
gb
includ
studi
among
patient
classifi
aidp
six
aman
three
amsan
three
mf
two
gb
includ
patient
ten
patient
initi
suspicion
aidp
diseas
durat
month
reclassifi
cidp
patient
twenti
sera
control
patient
non
inflammatori
polyneuropathi
screen
optim
tissu
base
assay
use
rat
brain
immun
respons
surfac
antigen
assay
transfect
hek
cell
antibodi
tissu
base
assay
patient
show
light
neuropil
stain
none
gb
patient
sera
antibodi
reaction
assay
among
cidp
patient
two
patient
demonstr
reactiv
similar
clinic
present
previous
describ
none
control
patient
antibodi
reaction
perform
test
result
suggest
antibodi
respons
absent
austrian
gb
patient
although
patient
screen
substanti
preliminari
result
furthermor
remain
establish
whether
antibodi
may
predict
chronic
cours
acut
onset
inflammatori
neuropathi
doneddu
cocito
santoro
fazio
filosto
mazzeo
jann
cortes
beghi
carpo
clerici
luigetti
lauria
fierro
antonini
briani
cavaletti
rosso
benedetti
marfia
liberator
peci
manganelli
velardo
todeschini
toscano
verrengia
piccolo
humanita
clinic
research
center
milan
univers
milan
itali
della
salut
e
della
scienza
hospit
turin
itali
degli
studi
di
napoli
federico
ii
napl
itali
san
raffael
hospit
milan
itali
civili
hospit
univers
brescia
brescia
itali
ospedaliera
universitaria
g
martino
messina
itali
granda
hospit
milan
itali
fondazion
mondino
pavia
itali
mario
negri
institut
milan
itali
hospit
treviglio
itali
macchi
hospit
vares
itali
cattolica
del
sacro
cuor
rome
itali
carlo
besta
neurolog
institut
milan
itali
ospedaliera
universitaria
policlinico
paolo
giaccon
palermo
itali
hospit
unives
rome
rome
itali
di
padova
padua
itali
bicocca
univers
monza
itali
ulss
asolo
castelfranco
veneto
itali
santandrea
la
spezia
itali
tor
vergata
rome
itali
variant
chronic
inflammatori
demyelin
polyradiculoneuropathi
cidp
describ
frequenc
relat
possibl
evolut
remain
unclear
treatment
respons
possibl
differ
diagnost
criteria
use
data
databas
italian
patient
cidp
determin
frequenc
characterist
variant
possibl
evolut
treatment
respons
patient
assess
studi
entri
diseas
cours
inclus
analyz
includ
patient
men
women
age
year
median
year
mean
diseas
durat
year
rang
year
complet
data
avail
base
clinic
data
revis
diagnost
criteria
patient
classifi
atyp
cidp
onset
follow
two
year
includ
dad
motor
cidp
sensori
cidp
cisp
syndrom
recurr
cranial
neuropathi
studi
entri
patient
progress
typic
cidp
year
median
year
total
still
atyp
cidp
year
median
year
similar
proport
progress
within
group
diagnosi
atyp
cidp
entri
fulfil
efnspn
criteria
csf
studi
diagnost
patient
nerv
biopsi
nerv
imag
test
patient
similarli
typic
cidp
treat
patient
atyp
cidp
improv
treatment
proport
respons
vari
differ
form
patient
sensori
motor
cidp
howev
unsatisfactori
respons
steroid
studi
show
proport
patient
atyp
cidp
vari
cours
diseas
almost
patient
evolv
typic
cidp
within
year
onset
addit
respons
treatment
frequent
atyp
cidp
even
form
respond
therapi
doneddu
cocito
santoro
fazio
filosto
mazzeo
jann
cortes
beghi
carpo
clerici
luigetti
lauria
fierro
antonini
briani
cavaletti
rosso
benedetti
marfia
liberator
peci
manganelli
velardo
todeschini
toscano
verrengia
piccolo
humanita
clinic
research
center
milan
univers
milan
itali
della
salut
e
della
scienza
hospit
turin
itali
degli
studi
di
napoli
federico
ii
napl
itali
san
raffael
hospit
milan
itali
civili
hospit
univers
brescia
brescia
itali
ospedaliera
universitaria
g
martino
messina
itali
granda
hospit
milan
itali
fondazion
mondino
pavia
itali
mario
negri
institut
milan
itali
hospit
treviglio
itali
macchi
hospit
vares
itali
cattolica
del
sacro
cuor
rome
itali
carlo
besta
neurolog
institut
milan
itali
ospedaliera
universitaria
policlinico
paolo
giaccon
palermo
itali
hospit
unives
rome
rome
itali
di
padova
padua
itali
bicocca
univers
monza
itali
ulss
asolo
castelfranco
veneto
itali
santandrea
la
spezia
itali
tor
vergata
rome
itali
studi
investig
frequenc
anteced
event
comorbid
patient
chronic
inflammatori
demyelin
polyradiculoneuropathi
cidp
littl
known
role
possibl
predispos
factor
dietari
lifestyl
habit
onset
progress
diseas
use
data
databas
italian
patient
cidp
determin
frequenc
anteced
event
comorbid
possibl
role
predispos
factor
includ
lifestyl
dietari
habit
exposur
toxic
agent
use
structur
questionnair
partner
patient
serv
control
impair
evalu
use
mrc
sumscor
disabl
incat
scale
logist
regress
use
calcul
odd
ratio
confid
interv
ci
risk
cidp
sex
includ
covari
patient
enrol
complet
data
patient
anteced
event
comorbid
patient
control
lifestyl
habit
patient
report
anteced
event
mostli
infect
vaccin
one
comorbid
present
patient
includ
hypertens
thyroid
disord
diabet
influenc
choic
initi
therapi
exposur
toxic
environment
agent
odd
ratio
ci
cigarett
smoke
ci
dietari
supplement
ci
associ
higher
risk
cidp
rice
consumpt
associ
reduc
risk
ci
concern
diseas
sever
sever
affect
patient
frequent
consum
ci
white
meat
ci
rice
ci
soft
drink
consumpt
ci
physic
activ
associ
lower
disabl
ci
studi
confirm
comorbid
frequent
patient
cidp
often
influenc
choic
initi
therapi
addit
preliminari
data
show
toxic
exposur
lifestyl
dietari
habit
may
influenc
onset
progress
cidp
doppler
schuster
weishaupt
sommer
neurolog
univers
hospit
germani
autoantibodi
paranod
protein
recent
describ
patient
cidp
patient
autoantibodi
subclass
predomin
suppos
pathogen
role
far
unclear
present
studi
igg
three
differ
patient
one
one
low
titer
one
high
titer
control
inject
sciatic
nerv
lewi
rat
nerv
conduct
studi
inject
nerv
motor
sensori
test
perform
inject
conduct
block
motor
deficit
detect
two
patient
high
titer
patient
low
titer
percentag
conduct
block
rat
inject
igg
patient
inject
motor
deficit
detect
patient
conduct
block
appar
patient
inject
igg
patient
differ
sensori
test
observ
conduct
block
motor
deficit
improv
five
day
normal
seven
eight
day
data
give
first
evid
pathogen
autoantibodi
igg
patient
induc
sever
clinic
electrophysiolog
phenotyp
compar
patient
remark
reflect
clinic
phenotyp
patient
patient
show
sensorimotor
symptom
time
blood
withdraw
wherea
patient
present
chronic
cours
diseas
doppler
frank
koschker
reiner
sommer
neurolog
univers
hospit
germani
diabet
unit
depart
medicin
univers
hospit
germani
axogli
dysjunct
paranod
demyelin
discuss
potenti
mechan
nerv
fiber
damag
diabet
neuropathi
studi
human
tissu
limit
nerv
biopsi
invas
rare
perform
patient
confirm
diabet
neuropathi
skin
biopsi
recent
suggest
good
tool
analyz
paranod
nodal
chang
myelin
fiber
present
studi
analyz
paranod
nodal
region
myelin
fiber
skin
biopsi
patient
diabet
neuropathi
patient
diabet
mellitu
without
neuropathi
normal
control
immunofluoresc
skin
section
antibodi
caspr
neurofascin
sodium
channel
myelin
basic
protein
perform
assess
paranodalnod
architectur
segment
demyelin
myelin
nerv
fiber
stain
antibodi
protein
gene
product
use
quantifi
unmyelin
nerv
fiber
found
increas
elong
ranvier
node
dispers
neurofascin
distal
leg
patient
diabet
mellitu
without
neuropathi
finger
patient
diabet
neuropathi
increas
dispers
caspr
found
biopsi
finger
patient
diabet
neuropathi
data
show
skin
biopsi
appropri
tool
analyz
node
ranvier
patient
diabet
mellitu
structur
nodal
chang
detect
diabet
neuropathi
even
diabet
patient
without
neuropathi
dourado
fernand
vital
ramo
urbano
sena
queiroz
jeronimo
univers
rio
grand
nort
natal
brazil
erasmu
gb
outcom
score
ego
valid
prognost
model
use
acut
phase
clinic
characterist
determin
outcom
month
patient
gb
studi
aim
assess
valid
ego
rio
grand
nort
brazil
compar
anoth
european
studi
data
collect
prospect
cohort
patient
gb
rio
grand
nort
brazil
june
august
assess
nineti
patient
exclud
miss
data
diagnos
miller
fisher
syndrom
atyp
form
gb
calcul
ego
gb
disabl
score
assess
second
week
diseas
month
compar
studi
european
one
independ
group
proport
use
student
consid
statist
signific
p
patient
includ
divid
four
group
base
ego
thu
patient
ego
ego
ego
ego
first
second
third
fourth
group
patient
unabl
walk
independ
six
month
diseas
respect
overal
patient
analyz
poor
outcom
studi
european
paper
base
group
divis
unabl
walk
independ
compar
studi
patient
studi
younger
serious
ill
first
week
sensit
deficit
differ
rel
sex
cranial
nerv
deficit
presenc
antibodi
use
student
abil
walk
month
accord
ego
stratif
achiev
first
group
second
third
fourth
p
ego
good
capac
predict
abil
walk
month
gb
rio
grand
nort
brazil
dourado
fernand
vital
ramo
urbano
sena
fraiman
luz
queiroz
jeronimo
feder
univers
rio
grand
nort
natal
brazil
histor
syndrom
gb
epidem
rare
seen
treat
follow
case
gb
state
rio
grand
nort
yearli
incid
season
observ
mean
age
patient
year
rang
case
younger
year
demyelin
variant
frequent
subtyp
gb
march
first
report
autochthon
transmiss
zika
viru
zikv
determin
natal
brazil
later
month
document
increas
incid
gb
natal
brazil
incid
case
gb
diagnos
diagnos
march
may
coincid
outbreak
zikv
natal
brazil
eighteen
patient
case
histori
rash
fever
prior
onset
gb
symptom
median
age
year
rang
electroneuromyographi
studi
patient
indic
acut
inflammatori
demyelin
polyneuropathi
acut
motor
axon
neuropathi
inconclus
mean
time
onset
zikv
infect
symptom
onset
gb
day
rang
mean
time
nadir
day
rang
cranial
neuropathi
present
patient
nine
patient
bedridden
requir
mechan
ventil
mean
protein
content
central
spinal
fluid
gl
white
blood
cell
count
patient
treat
intraven
igev
improv
quickli
neg
patient
neg
dengu
chikungunya
zika
serum
igm
zika
dengu
made
patient
posit
prnt
zika
dengu
posit
summari
report
geograph
tempor
defin
cluster
gb
associ
outbreak
acut
rash
state
rio
grand
nort
brazil
dudel
iversen
frisch
jensen
function
integr
neurosci
mindlab
aarhu
univers
hospit
aarhu
denmark
diabet
neuropathi
consortium
aarhu
univers
aarhu
denmark
biomedicin
aarhu
univers
aarhu
denmark
danish
pain
research
centr
aarhu
univers
hospit
aarhu
denmark
neuroradiolog
aarhu
univers
hospit
aarhu
denmark
preval
diabet
mellitu
continu
increas
worldwid
diabet
complic
repres
grow
burden
patient
societi
distal
symmetr
polyneuropathi
dsp
common
complic
affect
diabet
patient
dsp
reduc
patient
qualiti
life
due
chronic
pain
ulcer
may
lead
lower
extrem
amput
despit
high
preval
mechan
underli
diabet
dsp
poorli
understood
sever
mechan
believ
play
role
hypothes
diabet
dsp
aris
microvascular
complic
characterist
diabet
specif
capillari
dysfunct
disturb
capillari
flow
pattern
like
candid
explain
develop
dsp
limit
oxygen
nutrient
deliveri
nervou
tissu
caus
nerv
dysfunct
damag
thu
develop
dsp
studi
hypothesi
util
blood
flow
imag
techniqu
visual
quantifi
endoneur
blood
flow
link
find
measur
dsp
eg
nerv
conduct
veloc
nerv
fibr
densiti
anim
model
includ
sever
anim
model
diabet
dsp
caus
either
type
type
diabet
two
photon
microscopi
optic
coher
tomographi
allow
visualis
quantif
capillari
transit
time
blood
flow
within
peripher
nerv
high
resolut
hypothesis
chang
blood
flow
pattern
subsequ
impair
nutrient
oxygen
deliveri
nervou
tissu
preced
onset
diabet
dsp
experi
support
predict
attempt
develop
intervent
improv
capillari
blood
flow
prevent
delay
develop
dsp
duman
saracoglu
haspolat
bozkurt
child
neurolog
akdeniz
univers
hospit
antalya
turkey
axon
polyneuropathi
heterogen
group
diseas
rare
seen
infantil
age
may
accompani
development
retard
sever
muscl
weak
progress
cours
aim
present
two
case
axon
sensorymotor
neuropathi
infantil
onset
atyp
cours
boy
patient
admit
clinic
progress
gait
loss
sinc
one
month
first
offspr
consanguin
parent
normal
prenat
natal
histori
electromyographi
reveal
axon
sensorymotor
polyneuropathi
metabol
cerebrospin
fluid
csf
examin
etiolog
normal
brain
spinal
magnet
reson
imag
mri
normal
partial
benefit
oral
steroid
treatment
cours
diseas
along
four
neuropathi
attack
signific
benefit
serial
intraven
immunoglobulin
treatment
two
year
clinic
cours
girl
first
offspr
nonconsanguin
parent
admit
clinic
acut
tetraparesi
axial
sensorymotor
polyneuropathi
detect
electromyographi
metabol
cerebrospin
fluid
csf
examin
normal
three
acut
polyneuropathi
attack
ivig
cessat
period
patient
reveal
serial
immunoglobulin
treatment
unrespons
riboflavin
treatment
aim
discuss
rare
seen
pathogenesi
complet
understood
case
cours
serial
ivig
treatment
may
helpful
patient
treatment
sahin
matur
poda
deymeer
parman
depart
istanbul
medic
faculti
istanbul
univers
istanbul
turkey
depart
medic
faculti
istanbul
bilim
univers
istanbul
turkey
depart
institut
experiment
medic
research
istanbul
univers
istanbul
turkey
medic
genet
istanbul
medic
faculti
istanbul
univers
istanbul
turkey
famili
amyloid
polyneuropathi
autosom
dominantli
inherit
disord
caus
mutat
transthyretin
ttr
gene
mutant
amyloidogen
transthyretin
protein
caus
system
accumul
amyloid
fibril
result
organ
dysfunct
fap
progress
fatal
diseas
left
untreat
consid
differenti
diagnosi
person
present
progress
polyneuropathi
particularli
accompani
autonom
involv
clinic
electrophysiolog
histopatholog
genet
characterist
patient
turkey
femal
male
eleven
famili
polyneuropathi
mutat
ttr
evalu
two
patient
famili
histori
consid
sporad
case
remaind
famili
case
display
autosom
domin
inherit
pattern
sequenc
analysi
ttr
gene
reveal
five
mutat
common
mutat
unrel
famili
mean
age
diseas
onset
year
rang
year
commonli
report
initi
complaint
paresthesia
feet
asymmetr
three
patient
four
patient
male
mutat
present
carpal
tunnel
syndrom
two
patient
mutat
show
episod
dysarthria
hemiparesi
consist
genotyp
seven
patient
die
period
result
system
involv
studi
suggest
cohort
patient
turkey
exhibit
clinic
genet
heterogen
ebenez
liu
judg
cunningham
truelov
carter
sebastian
byrn
polydefki
neurolog
john
hopkin
univers
baltimor
md
usa
cardiolog
john
hopkin
univers
baltimor
md
usa
epidemiolog
john
hopkin
bloomberg
school
public
health
baltimor
md
usa
effect
amyloid
deposit
cutan
nerv
assess
subject
pathogen
ttr
variant
control
subject
three
group
subject
includ
patient
healthi
subject
diseas
control
well
ttr
mutat
carrier
without
neuropathi
underw
neurolog
examin
skin
biopsi
micron
section
stain
congo
red
amyloid
burden
imagej
intraepiderm
ienfd
sweat
gland
sgnfd
pilomotor
densiti
pmnfd
measur
correl
amyloid
burden
fiber
subtyp
neuropathi
impair
ni
sensori
subscor
evalu
ienfd
sgnfd
pmnfd
significantli
reduc
patient
vs
healthi
control
mutat
carrier
intermedi
reduct
lower
nerv
fiber
densiti
associ
p
congo
red
stain
reveal
brilliant
red
amyloid
deposit
birefring
within
dermal
collagen
sweat
gland
arrector
pili
muscl
amyloid
infiltr
observ
endoneurium
perineurium
small
fiber
sensori
autonom
nerv
innerv
sweat
gland
arrector
pili
muscl
cutan
amyloid
deposit
detect
healthi
diseas
control
subject
al
subject
congo
red
posit
amyloid
burden
invers
correl
ienf
p
sgnf
p
pmnf
distal
leg
densiti
correl
ni
sensori
subscor
ttr
stain
less
promin
pathogen
ttr
carrier
diagnost
sensit
specif
detect
amyloid
skin
repeat
measur
amyloid
burden
section
imagej
p
differ
section
biopsi
p
conclud
endoneuri
amyloid
contribut
sensori
autonom
nerv
injuri
amyloid
burden
correl
strongli
sensoryautonom
axon
densiti
skin
punch
offer
conveni
altern
establish
tissu
diagnosi
amyloid
burden
attract
biomark
marker
treatment
effect
studi
support
grant
pfizer
ebenez
truelov
polydefki
neurolog
john
hopkin
univers
baltimor
md
usa
epidemiolog
john
hopkin
bloomberg
school
public
health
baltimor
md
usa
investig
differ
unmyelin
sensori
nerv
fiber
distal
limb
among
subject
bmi
overweightobes
subject
bmi
age
year
subject
underw
neurolog
examin
skin
punch
distal
leg
dl
thigh
dt
proxim
thigh
pt
site
micron
section
stain
antibodi
intraepiderm
nerv
fiber
densiti
ienfd
fibersmm
epiderm
thick
assess
second
dl
biopsi
process
electron
microscop
examin
thick
thin
section
examin
ultrastructur
chang
multivari
linear
regress
model
use
assess
effect
age
gender
height
weight
control
height
age
obes
femal
found
lower
distal
leg
ienfd
increas
age
height
significantli
associ
decreas
dl
ienfd
decreas
fibersmm
per
year
p
fibersmm
per
p
respect
even
control
height
overweightobes
associ
reduc
dl
ienfd
fibersmm
lower
dl
enfd
individu
find
remain
consist
across
distal
thigh
proxim
thigh
enfd
though
associ
remain
signific
epidermi
thicker
obes
subject
across
lower
limb
pronounc
distal
leg
sd
dt
pt
em
intact
dermal
nerv
bundl
identifi
proxim
thigh
site
atroph
degener
axon
seen
perineuri
infiltr
dens
collagen
obsessoverweight
subject
agegend
match
control
obes
acceler
attenu
epiderm
nerv
fiber
across
lower
limb
even
control
associ
factor
geuen
petiot
adriaenssen
haidar
capponi
maisonob
fournier
dubourg
dego
salacha
lenglet
eymard
delmont
pouget
junta
moral
goizet
latour
timmerman
stojkov
univers
hospit
strasbourg
franc
neuropathi
group
vib
depart
molecular
genet
institut
born
bung
univers
antwerp
antwerpen
belgium
univers
hospit
lyon
franc
univers
hospit
nant
franc
de
la
pari
franc
univers
hospit
nice
franc
univers
hospit
marseil
franc
univers
hospit
montpelli
franc
univers
hospit
bordeaux
franc
studi
describ
phenotyp
spectrum
distal
hereditari
motor
neuropathi
caus
mutat
small
heat
shock
protein
investig
function
consequ
newli
discov
variant
among
unrel
patient
distal
motor
neuropathi
identifi
mutat
index
index
gene
patient
slowli
progress
distal
proxim
weak
lower
limb
mild
lower
limb
sensori
involv
foot
deform
progress
distal
upper
limb
weak
mildli
rais
serum
creatin
kinas
level
central
nervou
system
involv
found
broad
rang
diseas
onset
patient
present
foot
drop
age
year
other
present
symptom
year
diseas
progress
slow
patient
even
diseas
durat
year
patient
still
abl
walk
none
patient
wheelchair
depend
muscl
patholog
nerv
patholog
electrophysiolog
show
case
slowli
progress
mostli
symmetr
predominantli
distal
motor
axon
neuropathi
mild
sensori
involv
observ
upon
nerv
conduct
studi
mostli
lower
limb
case
identifi
mutat
includ
respect
previous
report
transmiss
either
domin
recess
de
novo
three
missens
mutat
caus
hyperphosphoryl
neurofila
mutant
trigger
protein
aggreg
two
frameshift
mutat
creat
prematur
stop
codon
lead
proteasom
degrad
two
mutat
exhibit
increas
bind
demonstr
mutat
major
caus
inherit
motor
axon
neuropathi
mutat
lead
divers
function
outcom
demonstr
pleotrop
charact
small
heat
shock
protein
eftimov
querol
rajab
behalf
particip
enmc
workshop
medic
center
amsterdam
netherland
de
la
santa
creu
sant
pau
universitat
de
barcelona
spain
univers
birmingham
uk
although
chronic
inflammatori
demyelin
polyneuropathi
cidp
treatabl
neuropathi
research
urgent
need
defin
diagnost
clinic
electrophysiolog
boundari
cidp
subtyp
defin
role
biomark
support
diagnosi
monitor
diseas
activ
predict
respons
treatment
outcom
recent
year
sever
nation
registri
biobank
develop
enabl
systemat
data
collect
cidp
intern
registri
larg
number
patient
need
allow
answer
mani
import
question
develop
valid
prognost
model
predict
outcom
individu
patient
cidp
inflammatori
neuropathi
consortium
inc
meet
inc
member
agre
european
neuromuscular
center
enmc
workshop
would
ideal
set
reach
consensu
infrastructur
databas
biobank
enmc
workshop
take
place
may
particip
repres
differ
countri
primari
object
workshop
reach
consensu
inclus
exclus
criteria
core
set
recommend
set
clinic
data
diagnost
data
point
manual
oper
collect
biomateri
secondari
object
construct
infrastructur
allow
share
data
differ
databas
biomateri
conclus
consensu
meet
outlin
perspect
present
peripher
nerv
societi
meet
eiching
burn
cornett
bacon
shepherd
mountain
sowden
shi
shi
herrmann
neurolog
univers
rochest
rochest
ny
usa
sydney
children
hospit
westmead
sydney
australia
neurolog
carver
colleg
medicin
univers
iowa
iowa
citi
ia
usa
physic
therapi
carver
colleg
medicin
univers
iowa
iowa
citi
ia
usa
pediatr
carver
colleg
medicin
univers
iowa
iowa
citi
ia
usa
clinic
outcom
assess
measur
function
abil
import
endpoint
clinic
trial
dr
burn
led
developmentvalid
function
outcom
assess
cmtped
individu
charcot
mari
tooth
diseas
cmt
age
year
inc
rdcrn
cmtped
reliabl
sensit
chang
howev
valid
function
outcom
measur
fom
adult
cmt
need
data
indic
cmtped
could
modifi
adult
use
howev
item
cmtped
eg
balanc
beam
jump
floor
effect
adult
cmt
develop
adult
model
cmtped
refin
base
literatur
review
patient
interview
cmt
patient
survey
expert
opinion
scale
compris
item
combin
form
composit
score
quantifi
function
abil
adult
cmt
share
item
cmtped
four
item
ad
measur
function
abil
relev
adult
sit
stand
meter
walkrun
stair
climb
time
go
test
score
mirror
cmtped
gener
score
rang
raw
item
score
convert
z
score
base
norm
refer
valu
form
norm
project
categor
likert
along
continuum
impair
level
conduct
pilot
studi
adult
male
femal
age
yr
differ
sever
cmt
exam
score
cmte
rang
feasibl
individu
abl
complet
item
take
minut
perform
mean
score
rang
concurr
valid
support
associ
cmte
r
overal
score
demonstr
floor
ceil
effect
summari
adult
captur
upper
lower
limb
strength
dexter
balanc
speed
ambul
endur
requir
valid
larg
longitudin
cohort
prior
applic
clinic
trial
estilow
glanzman
burn
cornett
menez
shi
moroni
foscan
pagliano
pareyson
bhandari
muntoni
reilli
finkel
sowden
eiching
herrmann
shi
yum
ramchandren
behalf
inherit
neuropathi
consortium
children
hospit
philadelphia
philadelphia
pa
usa
sydney
children
hospit
westmead
sydney
australia
pediatr
carver
colleg
medicin
univers
iowa
iowa
citi
ia
usa
foundat
carlo
besta
neurolog
institut
milan
itali
centr
neuromuscular
diseas
ucl
institut
neurolog
queen
squar
london
uk
institut
child
health
great
ormond
street
hospit
london
uk
program
divis
neurolog
nemour
children
hospit
orlando
usa
neurolog
univers
rochest
rochest
ny
usa
neurolog
carver
colleg
medicin
univers
iowa
iowa
citi
ia
usa
neurolog
children
hospit
philadelphia
perelman
school
medicin
univers
pennsylvania
pa
usa
neurolog
univers
michigan
ann
arbor
mi
usa
cmt
associ
progress
impair
hand
reduc
impair
treat
children
earli
stage
diseas
crucial
studi
assess
measur
cmt
hand
function
children
associ
outcom
lack
analyz
upper
extrem
item
cmt
pediatr
scale
cmtped
pediatr
cmt
qualiti
life
scale
children
age
year
enrol
inherit
neuropathi
consortium
explor
relationship
measur
hand
function
impair
activ
activ
daili
live
outcom
weak
grasp
hand
pain
tremor
preval
impair
perform
activ
level
task
nine
hole
peg
test
function
dexter
test
fdt
impair
case
respect
patient
report
difficulti
sometim
alway
open
jarlid
zippingbutton
write
carri
plate
without
spill
food
put
shoe
patient
report
tremor
show
signific
differ
grip
strength
shown
moder
signific
correl
perform
fdt
p
stepwis
multipl
linear
regress
show
grip
strength
p
hand
pain
p
fdt
beta
p
predict
abil
open
jar
adjust
p
grip
strength
p
fdt
beta
p
predict
abil
carri
plate
without
spillag
adjust
p
grip
strength
p
p
fdt
beta
p
predict
abil
put
shoe
adjust
p
hand
pain
p
fdt
beta
p
predict
abil
zipbutton
adjust
p
hand
pain
p
beta
p
predict
abil
use
penpencil
adjust
p
children
cmt
present
frequent
limit
adl
perform
impact
qol
upper
limb
measur
cmtped
associ
hand
perform
intervent
improv
grip
strength
reduc
pain
investig
respect
impact
improv
function
ultim
qol
evan
morrow
wastl
sinclair
fischmann
shah
emira
hanna
yousri
thornton
reilli
centr
neuromuscular
diseas
ucl
institut
neurolog
london
uk
academ
unit
ucl
institut
neurolog
london
uk
basel
hospit
basel
switzerland
respons
outcom
measur
need
diseas
cmt
allow
adequ
power
clinic
trial
test
novel
therapeut
shown
high
respons
mri
quantifi
intramuscular
fat
accumul
calf
muscl
patient
month
aim
present
studi
assess
respons
longitudin
valid
quantit
mri
year
period
undertook
two
set
quantit
mri
myometr
clinic
assess
origin
mrc
centr
quantit
mri
cohort
mri
sequenc
includ
fat
quantif
use
point
dixon
separ
method
quantif
magnetis
transfer
imag
patient
genet
confirm
assess
baselin
male
mean
age
year
underw
repeat
assess
median
month
data
alreadi
publish
underw
repeat
assess
median
month
underw
final
assess
median
month
primari
outcom
measur
current
analys
mean
calf
muscl
fat
fraction
singl
axial
slice
fix
distanc
distal
knee
joint
result
analysi
correl
clinic
measur
present
peripher
nerv
societi
meet
fainmess
dori
drori
neurolog
neuromuscular
servic
medic
center
israel
neurolog
sheba
medic
center
ramat
gan
israel
faculti
medicin
tel
aviv
univers
israel
use
anabol
drug
wish
increas
lean
bodi
mass
widespread
well
supervis
medic
year
old
man
refer
evalu
slowli
progress
sensori
motor
disturb
distribut
left
ulnar
nerv
symptom
began
month
repeat
anabol
steroid
vitamin
e
bicep
tricep
brachii
muscl
bilater
examin
show
increas
muscl
mass
inject
muscl
consist
atrophi
weak
left
interossei
mild
weak
bilater
bicep
brachii
sensori
loss
ulnar
nerv
distribut
nerv
conduct
studi
show
left
ulnar
neuropathi
reduc
motor
sensori
respons
amplitud
denerv
left
first
dorsal
interosseu
well
mild
myopath
chang
significantli
reduc
insert
activ
bicep
muscl
mri
soft
tissu
arm
show
massiv
fibrosi
infiltr
fat
arm
muscl
compress
ulnar
median
nerv
left
neurolysi
left
ulnar
nerv
perform
ulnar
nerv
found
enclos
fibrot
mass
throughout
entir
length
upper
arm
brachial
arteri
median
nerv
similarli
enclos
fibrot
tissu
releas
biopsi
affect
muscl
show
muscl
necrosi
fibrosi
patient
treat
physiotherapi
losartan
mild
improv
consist
muscl
without
clinic
improv
ulnar
nerv
function
worsen
nerv
conduct
case
illustr
sever
peripher
nerv
damag
due
entrap
massiv
muscl
fibrosi
follow
improp
intramuscular
inject
anabol
steroid
cosmet
purpos
fabrizi
testi
braathen
squintani
bertolasi
ferrarini
taioli
cabrini
pancheri
cavallaro
tonin
neurosci
biomedicin
movement
univers
verona
depart
neurosci
aoui
verona
itali
medic
genet
depart
laboratori
medicin
telemark
hospit
skien
norway
inherit
diseas
nerv
muscl
may
overlap
phenotyp
coexist
facet
disord
two
famili
whose
proband
initi
diagnos
lower
lmn
syndrom
hereditari
distal
motor
neuropathi
dhmn
turn
repres
vcp
protein
syndrom
gne
kinas
distal
myopathi
condit
share
presenc
rim
vacuol
rv
muscl
biopsi
famili
male
proband
lmn
syndrom
manifest
age
year
wastingweak
cramp
fascicul
thigh
muscl
later
involv
distal
upper
limb
brother
lower
limb
weak
diffus
pain
bonesjoint
sinc
age
father
diagnos
muscular
dystrophi
thirteen
year
die
year
age
year
develop
behaviour
frontotempor
dementia
ftd
electrodiagnosi
edx
disclos
myopath
chang
ongo
denerv
togeth
mild
axon
polyneuropathi
proband
chronic
axon
polyneuropathi
brother
mri
show
fatti
replac
weaken
muscl
sibl
diffus
chang
bone
consist
paget
diseas
pd
elder
sibl
famili
african
woman
affect
weak
wast
start
distal
muscl
age
year
soon
progress
proxim
parent
consanguin
two
sister
six
sibl
deceas
thirti
complic
similar
diseas
edx
mainli
disclos
neurogen
process
ongo
denerv
muscl
biopsi
three
patient
proband
show
myopathi
rv
sequenc
demonstr
heterozyg
chang
vcp
lead
known
pathogen
substitut
patient
two
compound
heterozyg
chang
gne
proband
lead
known
substitut
vcp
known
caus
autosom
domin
amyotroph
later
diseas
type
inclus
bodi
myopathi
ibm
pd
ftd
ibmpfd
gne
caus
autosom
recess
nonaka
myopathi
alia
case
emphas
clinic
neurophysiolog
heterogen
disord
fargeot
vandendri
labeyri
viala
theaudin
adam
crmr
nnerf
aphp
filnemu
chu
le
franc
crmr
nnerf
aphp
filnemu
chu
le
franc
group
hospitali
universitair
pari
franc
diagnosi
cidp
often
challeng
especi
electrophysiolog
sign
demyelin
lack
plexu
mri
document
nerv
abnorm
small
seri
typic
cidp
contribut
patient
electrophysiolog
sign
demyelin
remain
prove
report
result
plexu
mri
seri
patient
suspect
cidp
without
efn
pn
definit
electrophysiolog
criteria
retrospect
studi
patient
consult
kremlin
bicetr
hospit
lumbar
brachial
plexu
mri
perform
assess
nerv
trophic
signal
intens
gadolinium
enhanc
well
topographi
abnorm
consensu
diagnosi
made
group
expert
base
clinic
data
support
criteria
allow
us
classifi
patient
cidp
diagnosi
practic
contribut
plexu
mri
diagnost
algorithm
studi
diagnosi
cidp
made
patient
mri
abnorm
cidp
patient
show
nerv
root
hypersignalhypertrophyenhanc
respect
patient
pattern
abnorm
often
asymetr
diffus
multifoc
unblind
mri
confirm
diagnosi
expert
patient
chang
diagnosi
patient
plexu
mri
shown
use
seri
confirm
diagnosi
expert
modifi
patient
classic
pattern
describ
definit
cidp
diffus
nerv
root
hypertrophi
hypersign
document
cidp
patient
wherea
less
typic
pattern
focal
multifoc
abnorm
hypersign
without
hypertrophi
found
plexu
mri
seem
useful
face
patient
suspect
cidp
electrophysiolog
criteria
met
symetr
diffus
asymetr
multifoc
pattern
found
alway
correl
clinic
examin
support
criteria
specif
abnorm
remain
studi
feeli
rebelo
abreu
tao
bacon
zuchner
shi
iowa
iowa
citi
ia
usa
john
macdonald
depart
human
genet
hussman
institut
human
genet
miller
school
medicin
univers
miami
miami
fl
usa
mutat
athanogen
shown
caus
distal
myofibrillar
myopathi
cardiomyopathi
sever
affect
children
affect
adult
depend
upon
particular
mutat
children
sever
cardiomyopathi
myopathi
also
develop
axon
peripher
neuropathi
consist
known
local
neuron
well
muscl
identifi
two
larg
autosom
domin
famili
adult
onset
diseas
ident
novel
missens
mutat
codon
previous
shown
caus
sever
mild
myopathi
depend
amino
acid
substitut
famili
expand
phenotyp
caus
mutat
includ
provid
addit
exampl
adult
onset
may
previous
diagnos
chronic
idiopath
axon
neuropathi
ciap
feeli
saad
shi
colleg
medicin
univers
iowa
iowa
citi
ia
usa
myelin
protein
zero
mpz
express
myelin
schwann
cell
sequenc
alter
previous
report
caus
demyelin
intermedi
axon
form
charcot
mari
tooth
cmt
diseas
describ
rare
duplic
mpz
caus
earli
onset
demyelin
form
cmt
patient
patient
product
normal
pregnanc
deliveri
earli
mileston
delay
began
walk
month
age
abl
keep
peer
slowest
runner
start
wear
smo
year
age
afo
year
age
diagnos
scoliosi
year
age
start
wear
brace
year
examin
year
age
show
fdi
apb
adm
bilater
weak
lower
extrem
includ
foot
evers
great
toe
dorsi
flexion
tight
heel
cord
bilater
pinprick
sensat
reduc
throughout
upper
lower
extrem
absent
toe
bilater
vibrat
sensat
rydel
tune
fork
absent
toe
ankl
reduc
knee
finger
nerv
conduct
studi
perform
reveal
respons
sensori
nerv
test
except
radial
nerv
normal
latenc
mildli
slow
conduct
veloc
ms
prolong
latenc
demyelin
rang
slow
ms
low
cmap
amplitud
almost
segment
median
ulnar
motor
nerv
also
observ
find
consist
hereditari
sensorimotor
demyelin
polyneuropathi
diffus
areflex
total
cmt
pediatr
score
cmtped
sever
rang
cmt
neuropathi
score
cmtn
moder
rang
duplic
mpz
previous
identifi
rare
caus
inherit
neuropathi
consortium
part
nih
rare
diseas
clinic
research
network
grant
feeli
saad
shi
colleg
medicin
univers
iowa
iowa
citi
ia
usa
mutat
caus
sever
demyelin
form
cmt
describ
novel
mutat
led
extrem
variabl
sever
famili
proband
year
old
girl
product
normal
pregnanc
deliveri
earli
mileston
time
problem
walk
start
year
age
unabl
use
stair
run
jump
wear
bilater
afo
use
wheelchair
start
breath
assist
night
lost
arm
lift
could
still
hold
pen
could
ambul
independ
breath
assist
requir
daynight
lost
abil
write
develop
head
drop
year
could
sit
exam
head
neck
muscl
upper
limb
deltoid
bicep
wrist
extflex
finger
ext
fdi
adm
bilater
tricep
finger
flexor
apb
bilater
lower
limb
contractur
right
sensori
examin
normal
diffus
areflex
ncv
absent
cmtn
cmt
pediatr
score
sever
exom
sequenc
reveal
variant
like
pathogen
proband
mother
also
mutat
report
symptom
age
strength
throughout
except
left
foot
evers
great
toe
dorsi
flexion
bilater
sensori
exam
show
decreas
vibrat
pinprick
sensat
left
toe
normal
gait
tandem
gait
could
toe
walk
heel
walk
diffus
areflex
ncv
show
absent
sensori
respons
motor
ncv
show
latenc
prolong
veloc
reduc
ms
cmtn
mild
addit
famili
member
mutat
evalu
includ
matern
grandmoth
moder
impair
matern
aunt
sever
mutat
could
caus
anoth
known
neuropathi
myopathi
identifi
mitochondri
sequenc
normal
inherit
neuropathi
consortium
part
nih
rare
diseas
clinic
research
network
grant
fisgun
luan
hoke
hopkin
univers
baltimor
md
usa
molecular
mechan
underli
slow
distal
axon
degener
seen
chemotherapi
induc
peripher
neuropathi
cipn
unclear
howev
sever
identifi
molecular
target
suggest
share
mechan
wallerian
degener
sinc
spontan
mutat
wld
mice
genet
delet
gene
lead
slow
wallerian
degener
ask
wld
knockout
ko
mice
resist
distal
axon
degener
induc
sever
chemotherapi
agent
chose
chemotherapeut
drug
differ
class
agent
paclitaxel
taxan
cisplatinum
drug
bertozomib
proteasom
inhibitor
model
cipn
mice
primari
outcom
measur
evalu
epiderm
nerv
fiber
hind
paw
plantar
footpad
secondari
outcom
measur
includ
thermal
sensat
nerv
conduct
studi
ko
mice
almost
protect
develop
sensori
neuropathi
protect
wld
mice
partial
studi
confirm
pivot
role
play
mediat
axon
degener
identifi
inhibit
activ
potenti
therapeut
target
prevent
cipn
florio
scapin
ferri
feltri
wrabetz
dantonio
biolog
unit
san
raffael
scientif
institut
milan
itali
buffalo
ny
usa
myelin
protein
zero
abund
structur
protein
myelin
pn
human
mutat
associ
hereditari
neuropathi
delet
serin
caus
cmt
diseas
human
similar
demyelin
neuropathi
mice
wrabetz
et
al
protein
misfold
retain
er
give
rise
unfold
protein
respons
upr
pennuto
et
al
upr
result
activ
transcript
translat
control
program
reduc
protein
synthesi
increas
fold
degrad
capac
cell
usual
first
respons
suffici
cell
may
activ
apoptosi
result
cell
death
howev
schwann
cell
cell
death
suggest
cell
may
respond
differ
chronic
stress
transcriptom
analysi
perform
nerv
show
increas
express
transcript
factor
normal
present
earli
phase
differenti
dantonio
et
al
order
understand
role
express
factor
peripher
nerv
myelin
use
ex
vivo
vivo
approach
show
act
neg
regul
myelin
result
suggest
express
may
contribut
hypomyelin
observ
mice
reason
ablat
could
amelior
phenotyp
surprisingli
ablat
factor
mous
sever
worsen
neuropathi
burst
schwann
cell
differenti
increas
express
wild
type
mutant
allel
concomit
exacerb
upr
suggest
overexpress
earli
differenti
factor
schwann
cell
chronic
adapt
mechan
limit
differenti
reduc
express
toxic
protein
fokkink
de
winter
van
gelder
koch
jacob
immunolog
erasmu
mc
univers
medic
center
rotterdam
netherland
neurolog
erasmu
mc
univers
medic
center
rotterdam
netherland
pharmaci
erasmu
mc
univers
medic
center
rotterdam
netherland
intraven
immunoglobulin
ivig
treatment
choic
syndrom
gb
work
mechan
ivig
gb
undefin
like
potenti
effect
dose
depend
pharmacokinet
pk
pharmacodynam
pd
ivig
gb
highli
variabl
patient
rapid
consumpt
clearanc
ivig
associ
poor
recoveri
current
studi
develop
model
predict
pk
standard
dosag
ivig
gkg
consecut
day
individu
patient
gb
model
nonmem
use
construct
model
base
cohort
gb
patient
total
sequenti
serum
igg
level
final
model
accur
describ
day
day
increment
igg
level
cours
initi
rapid
fall
graduat
declin
level
thereaft
explor
sever
potenti
covari
improv
predict
capabl
decreas
variat
model
model
includ
covari
evalu
success
bootstrap
analysi
numer
simul
studi
base
simul
gb
patient
conclus
first
accur
robust
nonmem
model
pkpd
standard
ivig
treatment
gb
develop
model
use
predict
pk
individu
patient
appli
simpl
baselin
characterist
addit
effect
differ
treatment
regimen
ivig
gb
popul
pkpd
level
simul
model
techniqu
new
tool
optim
pk
individu
patient
studi
design
new
trial
ivig
gb
fores
pellegatta
rivellini
podini
quattrini
previtali
taveggia
neurosci
insp
interact
unit
san
raffael
scientif
institut
milan
itali
neurosci
insp
neuromuscular
repair
unit
san
raffael
scientif
institut
milan
itali
neurosci
insp
experiment
neuropatholog
unit
san
raffael
scientif
institut
milan
itali
axon
neuregulin
type
iii
essenti
instruct
signal
peripher
nervou
system
pn
myelin
express
determin
whether
axon
myelin
well
thick
myelin
sheath
recent
demonstr
cleavag
type
iii
gener
axon
intracellular
fragment
transloc
nucleu
upregul
express
prostaglandin
synthas
gene
neuron
catalyz
convers
prostaglandin
prostaglandin
also
show
specif
inhibit
activ
impair
vitro
myelin
accordingli
myelin
null
mice
notic
thinner
thu
indic
new
modul
development
pn
myelin
previou
studi
shown
prostaglandin
involv
process
wallerian
degener
wd
axon
regener
injuri
thu
determin
whether
could
import
pn
regener
remyelin
perform
sciatic
nerv
crush
injuri
month
old
null
wild
type
control
mice
analys
nerv
morpholog
biochem
histolog
molecular
approach
differ
time
point
crush
focus
three
phase
degener
axon
regener
remyelin
result
indic
null
mice
amount
myelin
protein
synthes
crush
well
number
remyelin
fiber
chang
suggest
might
dispens
remyelin
howev
observ
increas
number
macrophag
null
nerv
regener
possibl
consequ
increas
barrier
bnb
permeabl
indic
potenti
alter
regener
process
null
mice
result
suggest
could
differ
role
development
pn
myelin
injuri
whether
prostaglandin
synthas
might
compens
activ
current
investig
fornasari
raimondo
ronchi
crosio
budau
el
souri
muratori
to
battiston
geuna
gambarotta
clinic
biolog
scienc
univers
turin
itali
institut
cavalieri
ottolenghi
turin
itali
unit
health
scienc
citi
cto
turin
itali
microsurgeri
surgeri
gaetano
pini
hospit
milan
itali
repair
nerv
gap
follow
sever
peripher
nerv
injuri
chitosan
tube
prove
give
good
result
compar
obtain
nerv
autograft
gold
standard
techniqu
improv
peripher
nerv
regener
use
chitosan
tube
conduit
enrich
strategi
develop
use
longitudin
skelet
muscl
fibr
previous
shown
good
filler
muscl
vein
experiment
paradigm
play
trophic
structur
role
aim
rat
median
nerv
gap
repair
use
two
differ
conduit
chitosan
tube
fill
longitudin
piec
pectorali
major
muscl
muscl
tube
hollow
chitosan
tube
sampl
harvest
earli
time
point
day
biomolecular
morpholog
analysi
later
month
stereolog
analysi
autolog
nerv
graft
use
gold
standard
posit
control
earli
time
point
biomolecular
analysi
carri
vitro
degener
muscl
muscl
tube
earli
time
point
show
muscl
produc
high
level
solubl
isoform
key
factor
schwann
cell
surviv
activ
usual
releas
schwann
cell
nerv
injuri
function
assay
stereolog
analysi
carri
distal
part
regener
nerv
month
nerv
repair
show
signific
differ
regener
outcom
hollow
chitosan
tube
muscl
tube
group
therefor
conclud
short
gap
hollow
chitosan
tube
muscl
tube
good
techniqu
repair
nerv
defect
suggest
muscl
tube
spontan
releas
might
promis
strategi
promot
regener
gap
longer
repair
delay
time
foucquier
bertrand
jouv
truillet
mandel
laffair
blin
magi
lehert
hajj
guedj
cohen
attarian
franc
marseil
aphm
marseil
franc
dupuytren
limog
franc
melbourn
melbourn
vic
australia
econom
louvain
belgium
diseas
type
rare
diseas
belong
group
inherit
progress
chronic
motor
sensori
peripher
neuropathi
neuropathi
score
cmtn
shi
et
al
overal
neuropathi
limit
scale
onl
graham
hugh
consid
main
clinic
scale
evalu
progress
disabl
associ
cmt
slowli
progress
neurodegen
diseas
choic
endpoint
abil
monitor
small
chang
time
remain
major
concern
clinic
drug
develop
mind
studi
cohort
french
patient
rang
month
year
result
merg
two
multicentr
clinic
trial
micallef
et
al
attarian
et
al
studi
unpublish
sensit
chang
cmtn
onl
assess
use
mix
effect
model
estim
annual
progress
time
year
cmtn
onl
baselin
valu
covari
studi
centr
fix
factor
patient
random
effect
account
repeat
measur
diseas
progress
estim
point
per
year
cmtn
p
point
per
year
onl
p
correspond
deterior
impair
disabl
endpoint
similar
favour
properti
set
observ
led
us
conclud
onl
could
promis
monitor
diseas
progress
frasquet
lupo
ma
chumilla
sevilla
universitari
la
fe
valencia
spain
de
sanitaria
la
fe
valencia
spain
de
felip
valencia
spain
valencia
spain
de
en
enfermedad
rara
ciber
valencia
spain
medicina
universitat
de
valencia
valencia
spain
mutat
gene
caus
domin
spinal
muscular
atrophi
lower
extrem
predomin
smale
report
six
patient
belong
three
spanish
famili
carri
three
differ
novel
mutat
gene
describ
clinic
electrophysiolog
magnet
reson
imag
mri
data
provid
result
muscl
biopsi
one
patient
skin
biopsi
studi
epiderm
nerv
fiber
densiti
enfd
two
patient
genet
diagnos
reach
use
gene
panel
genet
test
cmt
dhmn
three
novel
mutat
gene
segreg
diseas
detect
frequent
clinic
phenotyp
consist
mild
weak
proxim
muscl
lower
limb
combin
foot
deform
one
patient
promin
sensori
symptom
abnorm
sensori
examin
two
patient
minor
sensori
abnorm
examin
one
patient
sensori
motor
nerv
action
potenti
reduc
rest
patient
electrophysiolog
studi
show
normal
motor
sensori
nerv
respons
chronic
denerv
predominantli
muscl
lower
limb
mri
studi
level
tight
calf
perform
patient
affect
muscl
rectu
femori
vastu
laterali
medial
gastrocnemiu
mri
studi
level
feet
obtain
five
patient
show
fatti
infiltr
intrins
foot
muscl
mri
level
pelvi
muscl
perform
four
patient
show
mark
fatti
infiltr
gluteu
mediu
muscl
two
muscl
biopsi
perform
one
patient
show
myopath
featur
skin
biopsi
perform
two
patient
famili
older
patient
minor
sensori
abnorm
examin
mark
reduct
enfd
follow
pattern
conclus
report
three
new
pathogen
mutat
gene
studi
includ
mri
find
level
pelvi
feet
allow
us
better
defin
pattern
muscl
involv
relat
gene
result
also
rais
subject
possibl
sensori
involv
diseas
studi
fund
grant
ii
la
fe
isciii
pi
grupo
eresa
fridman
skorupinska
sillau
shi
reilli
colorado
hospit
aurora
co
usa
centr
neuromuscular
diseas
ucl
institut
neurolog
queen
squar
london
uk
iowa
hospit
clinic
iowa
citi
ia
usa
hereditari
neuropathi
liabil
pressur
palsi
hnpp
autosom
domin
disord
usual
result
delet
gene
neuropathi
uniqu
manifest
recurr
common
site
compress
spontan
recoveri
episod
nerv
injuri
usual
occur
often
incomplet
time
patient
may
develop
length
depend
polyneuropathi
given
relapsingremit
natur
hnpp
symptom
standard
clinic
score
cmt
neuropathi
score
effect
captur
sever
progress
diseas
specif
tool
therefor
need
measur
clinic
sever
hnpp
prepar
emerg
clinic
trial
current
studi
evalu
new
pilot
measur
hnpp
sever
score
hnpp
score
compos
patient
report
question
address
current
prior
sensori
motor
symptom
impact
symptom
qualiti
life
follow
item
base
motor
examin
total
score
vari
higher
score
indic
increas
diseas
sever
studi
hnpp
administ
patient
genet
confirm
hnpp
ucl
institut
neurolog
subject
includ
male
femal
mean
age
year
rang
mean
hnpp
point
rang
data
demonstr
major
skew
cronbach
alpha
hnpp
item
base
physic
examin
show
least
variabl
modest
correl
observ
hnpp
cmt
examin
score
pearson
correl
ci
conclud
hnpp
may
use
measur
clinic
sever
hnpp
refin
larger
patient
cohort
fridman
sillau
behalf
inherit
neuropathi
consortium
inc
colorado
hospit
aurora
co
usa
iowa
hospit
clinic
iowa
citi
ia
usa
common
hereditari
neuropathi
hn
autosom
domin
demyelin
neuropathi
result
duplic
gene
recent
advanc
defin
pathomechan
diseas
led
increas
number
potenti
therapi
howev
absenc
reliabl
natur
histori
data
pauciti
sensit
clinic
outcom
measur
barrier
effect
clinic
trial
charcot
mari
tooth
neuropathi
score
cmtn
develop
quantifi
impair
measur
progress
hn
observ
score
discrimin
well
mildli
sever
impair
patient
tend
cluster
togeth
patient
middl
rang
sever
improv
score
sensit
rasch
weight
categori
respons
develop
report
longitudin
studi
weight
cmtn
cmt
examin
score
cmte
time
frame
patient
baselin
one
year
two
year
three
year
score
avail
patient
respect
mean
wcmtn
sd
wcmte
sd
score
follow
baselin
one
year
two
year
three
year
mix
regress
model
show
signific
chang
wcmtn
wcmte
year
mean
chang
baselin
year
point
wcmtn
point
wcmte
signific
chang
compar
baselin
also
seen
year
mean
chang
baselin
point
wcmtn
point
wcmte
conclud
weight
score
show
chang
first
three
year
inherit
neuropathi
consortium
natur
histori
studi
help
measur
progress
fridman
novak
david
macklin
walsh
k
oakland
brown
hornemann
eichler
gener
hospit
boston
usa
massachusett
medic
school
worcest
usa
hospit
zurich
zurich
switzerland
autosom
domin
sever
sensori
motor
polyneuropathi
caus
mutat
serin
transferas
mutat
shift
substrat
prefer
serin
alanin
lead
format
neurotox
treatment
shown
reduc
accumul
improv
neuropathi
transgen
mice
report
clinic
trial
evalu
safeti
efficaci
oral
eighteen
subject
equal
random
mgkgd
placebo
year
placebo
group
particip
took
one
addit
year
sixteen
subject
complet
visit
seriou
advers
event
relat
report
particip
random
experienc
declin
charcot
mari
tooth
neuropathi
score
cmtn
year
rel
placebo
unit
ci
p
group
improv
second
year
studi
diminish
differ
cmtn
week
unit
ci
skin
biopsi
distal
leg
site
larg
devoid
nerv
fiber
ienf
year
greater
increas
ienf
densiti
seen
particip
versu
placebo
median
chang
vs
level
declin
among
particip
versu
placebo
one
year
treatment
decreas
deoxysphinganin
vs
increas
placebo
p
placebo
particip
experienc
similar
declin
level
cross
conclud
safe
potenti
efficaci
treatment
fu
liong
yusuf
neuromuscular
clinic
queen
elizabeth
hospit
univers
hospit
birmingham
birmingham
uk
life
health
scienc
aston
brain
centr
aston
univers
birmingham
uk
relationship
syndrom
gb
malign
uncertain
diagnost
criteria
paraneoplast
neurolog
syndrom
pn
euronetwork
neuropathi
definit
onconeur
antibodi
identifi
due
gb
classifi
paraneoplast
disord
retrospect
analyz
data
consecut
patient
admit
gb
birmingham
uk
calcul
rel
cancer
risk
use
differ
definit
determin
characterist
gb
patient
classifi
accord
definit
case
malign
exclud
preced
diagnos
year
gb
evid
malign
diseas
activ
time
gb
diagnosi
malign
diagnos
year
onset
per
pn
criteria
total
number
gb
patient
malign
total
patient
fulfil
requir
inclus
gb
per
exist
criteria
pn
associ
malign
consist
angioimmunoblast
lymphoma
poorli
differenti
squamou
cell
carcinoma
nasal
septum
gastric
adenocarcinoma
hepatocellular
carcinoma
due
hepat
b
rectal
carcinoma
liver
metastasi
myelodysplast
syndrom
malign
global
common
gb
cohort
compar
gener
popul
odd
ratio
ci
p
howev
unconfirm
paraneoplast
criteria
appli
gb
patient
cancer
significantli
like
older
p
hyponatrem
p
demonstr
electrophysiolog
axon
loss
p
cerebrospin
fluid
csf
protein
level
lower
malign
group
p
neurolog
improv
less
like
p
mortal
significantli
higher
patient
malign
p
none
patient
malign
group
posit
antibodi
antibodi
yo
ri
conclud
global
cancer
risk
higher
gb
gener
popul
although
applic
strict
publish
criteria
paraneoplast
syndrom
reduc
number
case
suggest
absenc
link
malign
requir
consider
elderli
hyponatrem
subject
normal
csf
protein
sever
electrophysiolog
axon
loss
fail
improv
fu
liong
emilien
julien
shahram
yusuf
neuromuscular
clinic
queen
elizabeth
hospit
univers
hospit
birmingham
birmingham
uk
centr
neuromuscular
diseas
al
univers
hospit
la
timon
marseil
franc
de
maladi
neuromusculair
de
lenfant
et
de
ladult
centr
hospitali
universitair
danger
anger
franc
centr
neuromuscular
diseas
al
univers
hospit
la
timon
marseil
franc
univers
cnr
umr
medicin
faculti
marseil
franc
centr
neuromuscular
diseas
al
univers
hospit
la
timon
marseil
franc
univers
inserm
umr
medic
genet
function
genom
marseil
franc
neuromuscular
clinic
queen
elizabeth
hospit
univers
hospit
birmingham
birmingham
uk
school
life
health
scienc
aston
brain
centr
aston
univers
birmingham
uk
associ
glycoprotein
antibodi
neuropathi
slowli
progress
neuropathi
result
disabl
distal
sensori
motor
deficit
tremor
current
treatment
neuropathi
effect
diseas
qualiti
life
qol
patient
popul
unknown
object
assess
determin
qol
patient
neuropathi
questionnair
assess
patient
marseil
anger
franc
birmingham
unit
kingdom
routin
clinic
evalu
includ
mrc
sum
score
incat
sensori
score
inflammatori
rasch
built
overal
disabl
score
ataxia
score
jamar
grip
dynamometri
time
neuropath
pain
symptom
inventori
npsi
score
fatigu
sever
score
fss
male
femal
mean
age
year
sd
year
mean
diseas
durat
year
sd
year
signific
differ
french
uk
cohort
term
gender
distribut
age
diseas
durat
antibodi
titr
physic
assess
includ
mrc
sum
score
jamar
grip
dynamometri
onl
irod
incat
sensori
score
time
walk
ataxia
score
tremor
score
compar
preval
andor
sever
pain
fatigu
restless
leg
syndrom
cramp
also
similar
physic
compon
summari
pc
mental
compon
summari
mc
questionnair
significantli
lower
report
normal
subject
countri
p
qol
domain
correl
except
mc
signific
howev
approach
pc
correl
mrc
sum
score
ataxia
score
time
tremor
jamar
grip
dynamometri
npsi
pain
score
fss
level
social
support
mc
correl
exclus
fss
level
social
support
multivari
regress
pc
associ
independ
p
npsi
pain
score
wherea
mc
associ
independ
fss
qol
accur
predict
neuropathi
fss
lend
support
use
clinic
research
set
effect
measur
improv
qol
includ
tremor
neuropath
pain
treatment
fatigu
manag
improv
social
support
fu
liong
yusuf
neuromuscular
clinic
queen
elizabeth
hospit
univers
hospit
birmingham
birmingham
uk
life
health
scienc
aston
brain
centr
aston
univers
birmingham
uk
electrophysiolog
diagnosi
syndrom
gb
depend
number
abnorm
affect
differ
paramet
peripher
nerv
nerv
conduct
studi
nc
diagnost
sensit
vari
differ
electrodiagnost
criteria
practic
well
extens
nerv
studi
howev
effici
method
perform
electrophysiolog
syndrom
gb
unknown
retrospect
analyz
electrophysiolog
data
consecut
gb
patient
birmingham
uk
studi
week
first
identifi
abnorm
nerv
variou
region
produc
gb
electrodiagnosi
use
recent
describ
criteria
rajab
et
al
subsequ
use
hypothet
nerv
conduct
studi
protocol
determin
potenti
optim
method
achiev
electrodiagnosi
found
sensit
electrophysiolog
gb
subtyp
depend
upper
lower
limb
nerv
test
acut
inflammatori
demyelin
polyneuropathi
aidp
abnorm
predomin
arm
wherea
leg
abnorm
predomin
axon
gb
aidp
common
abnorm
paramet
distal
motor
latenc
conduct
block
frequent
affect
nerv
median
prolong
present
absent
mcv
least
frequent
abnorm
demyelin
rang
slow
significantli
lower
cb
dml
prolong
p
case
axon
gb
reduc
motor
amplitud
conduct
block
common
paramet
frequent
abnorm
nerv
tibial
absent
motor
nerv
unexcit
significantli
common
lower
limb
nerv
compar
upper
limb
nerv
comparison
differ
hypothet
nc
protocol
unilater
protocol
nerv
nerv
well
protocol
exclus
bilater
upper
limb
lower
limb
test
unilater
median
ulnar
common
peron
tibial
test
produc
highest
diagnost
sensit
aidp
axon
gb
electrodiagnost
sensit
gb
thu
depend
nerv
test
paramet
consid
subtyp
preferenti
involv
specif
nerv
paramet
find
may
help
interpret
improv
electrodiagnost
sensit
reduc
patient
discomfort
funakoshi
nagashima
kokubun
hirata
yuki
neurolog
dokkyo
medic
univers
tochigi
japan
neurolog
mishima
hospit
nagaoka
japan
recent
igg
complex
gsc
antibodi
report
patient
miller
fisher
syndrom
research
et
al
report
igm
antibodi
multifoc
motor
neuropathi
mmn
chronic
neuropathi
ten
eleven
mmn
patient
antibodi
decreas
reactiv
compar
singl
antigen
similarli
one
two
chronic
inflammatori
degen
polyradiculoneuropathi
cidp
patient
antibodi
decreas
reactiv
compar
relationship
defin
neg
interact
one
cidp
antibodi
reactiv
increas
although
neg
posit
interact
japan
hand
correl
remain
unclear
sera
investig
one
mmn
patient
yo
male
antibodi
one
cidp
patient
yo
femal
one
subacut
sensori
motor
polyradiculoneuropathi
male
igm
antibodi
gsc
test
mixtur
pmolwel
antigen
antibodi
judg
posit
interact
optic
densiti
greater
sum
antibodi
individu
neg
interact
optic
densiti
less
compar
antibodi
individu
antibodi
least
one
combin
two
six
gangliosid
similarli
test
judg
posit
neg
interact
one
mmn
neg
interact
one
cidp
neg
interact
one
subacut
sensori
motor
polyradiculoneuropathi
variou
antibodi
includ
neg
interact
cidp
patient
mention
posit
interact
relationship
attenu
reactiv
presum
driven
adjac
gangliosid
mechan
chronic
neuropathi
need
clarifi
galino
cervellini
zhu
fricker
lee
lalli
bennett
nuffield
depart
clinic
neurosci
john
radcliff
hospit
univers
oxford
oxford
uk
card
king
colleg
london
guy
campu
london
uk
schwann
cell
sc
myelin
cell
peripher
nerv
system
import
normal
peripher
nerv
develop
repair
rala
ralb
small
gtpase
implic
neural
tube
closur
neurit
branch
describ
upstream
effector
protein
involv
cell
migrat
membran
dynam
due
potenti
role
sc
function
investig
genet
ablat
transgen
anim
one
gtpase
import
sc
function
adulthood
nerv
repair
show
ral
gtpase
dispens
sc
function
state
howev
ral
signal
provid
rala
ralb
requir
effect
remyelin
axon
follow
nerv
injuri
moreov
absent
ral
signal
produc
defect
axon
reinnerv
distal
organ
delay
motor
function
recoveri
nerv
injuri
also
studi
ral
depend
cellular
mechan
may
respons
impair
sc
remyelin
note
abnorm
sc
lamellipodia
format
prevent
normal
axial
radial
axon
remyelin
work
demonstr
first
time
novel
mechan
ralgtpas
control
sc
lamellipodia
format
import
normal
sc
function
peripher
nerv
repair
ariza
cobianchi
navarro
bosch
de
inc
uab
barcelona
spain
de
biologia
molecular
uab
barcelona
spain
de
en
red
enfermedad
neurodegenerativa
cibern
insituto
de
salud
carlo
iii
madrid
spain
biologia
fisiologia
immunologia
uab
barcelona
spain
de
recerca
estudi
icrea
barcelona
spain
mixta
vall
dhebron
institut
de
recerca
vhir
barcelona
spain
tumor
necrosi
factor
tnf
alpha
implic
pathogenesi
diabet
peripher
neuropathi
dpn
among
inflammatori
demyelin
diseas
neuropath
pain
tnf
alpha
cytokin
act
sever
stage
demyelin
process
produc
schwann
cell
sc
peripher
nervou
system
pn
nerv
injuri
releas
local
environ
attract
activ
macrophag
site
injuri
contribut
wallerian
degener
vivo
studi
demonstr
local
inflamm
sciatic
nerv
rat
inject
tnf
alpha
follow
demyelin
axon
degener
furthermor
applic
tnf
alpha
result
acut
mechan
hiperalgesia
main
characterist
neuropath
pain
therefor
tnf
alpha
postul
biomark
pain
chang
nerv
injuri
aim
character
tnf
alpha
effect
chronic
neuropath
pain
diabet
neuropathi
transgen
mous
model
overexpress
tnf
alpha
cdna
peripher
myelin
protein
promot
gener
character
overexpress
tnf
alpha
myelin
sc
differ
stage
myelin
postnat
day
show
high
level
tnf
alpha
sciatic
nerv
lead
downregul
major
pn
myelin
protein
mbp
mag
compar
wild
type
mice
correl
loss
structur
myelin
increas
marker
immatur
sc
sciatic
nerv
stain
show
high
level
macrophag
infiltr
sciatic
nerv
spinal
cord
tissu
compar
wild
type
anim
stress
condit
induc
sciatic
nerv
crush
surgeri
recoveri
subsequ
remyelin
delay
transgen
mice
evalu
sciatic
function
index
sfi
electrophysiolog
test
hand
mechan
thermal
nocicept
seem
unalt
without
lesion
model
could
help
character
role
tnf
alpha
pain
develop
injuri
dpn
well
develop
effici
therapeut
strategi
modul
patholog
condit
sobrido
pardo
neurolog
hospit
santiago
de
compostela
spain
research
group
instituto
de
investigacion
sanitaria
idi
santiago
de
compostela
spain
medicin
group
centr
biomed
network
research
rare
diseas
ciber
spain
neurophysiolog
hospit
santiago
de
compostela
spain
cmt
diseas
genet
heterogen
group
hereditari
motor
sensori
neuropathi
gene
involv
diseas
pathogenesi
object
studi
assess
genet
distribut
cmt
diseas
galicia
northwestern
spain
patient
diagnos
cmt
consist
neurolog
andor
neurophysiolog
examin
sensori
motor
neuropathi
posit
famili
histori
total
cmt
adult
patient
femal
evalu
median
age
year
molecular
diagnosi
achiev
patient
higher
success
global
duplic
frequent
find
follow
mutat
mpz
expcept
duplic
pathogen
variant
nefl
mpz
gene
common
pathogen
variant
account
patient
sever
patient
refer
institut
diagnos
hereditari
motor
neuropathi
hmn
pathogen
variant
gene
frequent
pathogen
variant
previous
relat
cmt
identifi
mpz
nefl
gene
sporad
autosom
recess
ar
cmt
account
diagnos
genet
epidemiolog
cmt
galicia
follow
similar
pattern
popul
although
remark
featur
axon
demyalin
pathogen
variant
well
seemingli
elev
proport
ar
case
germano
onofr
bordini
gouvea
barreira
marqu
w
neuromuscular
diseas
depart
neurosci
behaviour
scienc
clinic
hospit
preto
univers
paulo
preto
brazil
mutat
mpz
gene
associ
wide
rang
phenotyp
particular
associ
sever
earli
onset
diseas
cmt
patient
respond
immunosuppress
immunomodulatori
treatment
harbour
mpz
mutat
present
case
brazilian
femal
sever
present
acut
episod
worsen
febril
exanthemat
diseas
complain
tingl
stop
walk
without
support
could
rais
arm
emg
show
asymmetr
reduct
motor
cv
reduc
amplitud
sever
tempor
dispers
possibl
conduct
block
csf
protein
normal
cell
count
diagnos
gb
receiv
ivig
curious
markedli
improv
regain
function
statu
youth
recov
function
long
lost
emg
motor
amplitud
improv
significantli
cv
remain
review
care
past
histori
identifi
motor
fluctuat
along
adult
life
age
pregnant
develop
posit
sensori
symptom
becam
unabl
get
chair
could
walk
without
assist
deliveri
improv
return
baselin
one
year
later
present
new
transitori
function
worsen
influenza
ill
parent
healthi
two
children
sever
cmt
first
daughter
never
walk
die
age
six
six
month
treatment
ivig
face
new
relaps
puls
corticosteroid
great
respons
remain
stabl
date
four
month
treatment
episod
fluctuat
evid
respons
treatment
clearli
suggest
associ
immunomedi
process
fast
improv
amplitud
mainten
cv
suggest
anoth
mechan
addit
demyelin
axon
degener
involv
propos
exist
associ
channelopathi
fund
cnpq
faepa
prona
ministri
healthi
germano
moreira
marqu
santo
onofr
barreira
marqu
w
neuromuscular
diseas
depart
neurosci
behaviour
scienc
clinic
hospit
preto
univers
paulo
preto
brazil
gb
acut
neuropathi
compris
three
major
subtyp
aidp
aman
amsan
clinic
ground
distinct
base
nerv
conduct
studi
nc
aidp
demyelin
neuropathi
aman
axon
motor
neuropathi
amsan
axon
sensori
motor
neuropathi
recent
demonstr
axon
gb
addit
axon
degener
may
present
conduct
block
cb
progress
axon
regener
revert
characteris
revers
conduct
failur
rcf
find
usual
associ
good
prognosi
patient
present
axon
cb
frequent
diagnos
aidp
mistak
avoid
two
set
nc
one
earli
possibl
second
three
week
diseas
follow
recommend
retrospect
classifi
brazilian
group
gb
follow
institut
submit
two
nc
set
septemb
januari
patient
fulfil
clinic
criteria
gb
clinic
hospit
preto
one
nc
accomplish
least
four
motor
nerv
median
ulnar
peron
posterior
tibial
five
sensori
nerv
medial
ulnar
radial
sural
peron
superfici
evalu
examin
accord
routin
procedur
first
nc
reveal
patient
aidp
case
axon
gb
aman
amsan
patient
equivoc
result
studi
patient
classif
chang
main
shift
aidp
axon
group
equivoc
result
aidp
aidp
increas
n
axon
gb
increas
n
aman
amsan
equivoc
patient
although
major
studi
shown
aidp
frequent
western
countri
axon
gb
predomin
eastern
countri
found
differ
pattern
distribut
popul
predomin
axon
subtyp
consider
increas
axon
gb
studi
reinforc
serial
emg
mandatori
accur
diagnosi
gb
subtyp
prospect
studi
carri
order
confirm
result
fund
faepa
gertz
comenzo
landau
sanchorawala
weiss
zonder
wall
kinney
koller
schenk
guthri
liu
liedtk
clinic
rochest
usa
medic
center
boston
usa
sloan
ketter
cancer
center
new
york
usa
univers
school
medicin
boston
usa
pennsylvania
philadelphia
usa
cancer
institut
detroit
usa
consult
hillsborough
usa
bioscienc
inc
south
san
francisco
usa
univers
school
medicin
stanford
usa
amyloid
light
chain
al
amyloidosi
misfold
light
chain
lc
accumul
caus
progress
peripher
neuropathi
pn
progress
failur
critic
organ
heart
kidney
progress
ascend
sensorimotor
neuropathi
often
relat
clinic
find
deposit
toxic
lc
amyloid
peripher
nerv
associ
paresthesia
pain
muscl
weaknesss
orthostat
hypotens
diarrhea
constip
approxim
patient
al
amyloidosi
approv
treatment
al
amyloidosi
current
therapeut
approach
al
amyloidosi
intend
limit
lc
product
directli
target
misfold
lc
deposit
amyloid
organ
report
phase
trial
result
investig
monoclon
antibodi
target
misfold
lc
may
neutral
circul
lc
aggreg
clear
insolubl
deposit
trial
inclus
criteria
one
plasma
treatment
complet
enrol
partial
greater
hematolog
respons
previou
therapi
persist
organ
dysfunct
administ
intraven
everi
day
phase
patient
mgkg
studi
design
expans
phase
patient
mgkg
assess
safeti
toler
pharmacokinet
immunogen
organ
respons
base
consensu
criteria
pn
respons
use
neuropathi
impair
limb
treatment
associ
toxic
seriou
advers
event
discontinu
antidrug
antibodi
develop
patient
n
patient
measur
pn
baselin
n
achiev
pn
respons
base
score
month
treatment
result
median
score
reduct
mean
baselin
best
respons
analysi
patient
n
patient
n
met
respect
criteria
organ
respons
improv
neuropathi
previous
shown
al
amyloidosi
result
demonstr
monthli
infus
safe
well
toler
associ
respons
across
three
differ
organ
system
gervai
ross
goodman
khouri
muzyka
smith
clinic
arizona
scottsdal
az
usa
work
describ
clinic
examin
electrophysiolog
find
cohort
patient
length
depend
sensorimotor
peripher
neuropathi
ldsmpn
ventral
abdomin
sensori
loss
ldsmpn
affect
longest
nerv
fiber
name
innerv
structur
feet
hand
less
well
appreci
length
depend
involv
sensori
nerv
fiber
ldsmpn
thorac
segment
give
rise
ventral
abdomin
sensori
loss
consecut
patient
seen
ldsmpn
n
evalu
presenc
absenc
ventral
abdomin
sensori
loss
demograph
variabl
symptom
quantit
neurolog
find
neuropathi
impair
score
ni
examin
use
descript
statist
final
diagnos
note
ventral
abdomin
sensori
loss
pinprick
asymptomat
patient
test
document
ldsmpn
patient
mean
age
year
rang
f
gender
ratio
mean
ni
rang
ncsemg
abnorm
found
patient
remain
show
object
evid
small
fiber
sensori
involv
ldsmpn
patient
without
ventral
abdomin
sensori
loss
mean
age
rang
f
mean
ni
rang
patient
dorsal
torso
sensori
loss
shoulder
buttock
level
either
side
diagnos
ldsmpn
patient
vs
without
ventral
abdomin
sensori
loss
includ
charcot
mari
tooth
hereditari
neuropathi
abnorm
carbohydr
metabol
vs
idiopath
hypothyroid
vs
inflammatori
vs
vs
ventral
abdomin
sensori
loss
appear
common
patient
diagnos
ldsmpn
varieti
caus
includ
inherit
neuropathi
addit
innerv
distal
limb
territori
distal
sensori
fiber
thorac
region
repres
anoth
categori
length
depend
involv
ldsmpn
clinic
examin
ldsmpn
includ
ventral
abdomen
gibbon
garcia
casasola
freeman
israel
deaco
medic
center
harvard
medic
school
boston
usa
object
determin
relationship
measur
autonom
function
electrochem
sweat
conduct
esc
ienfd
sudomotor
nerv
fiber
densiti
sgnfd
background
structur
function
measur
small
fiber
neuropathi
studi
patient
diabet
littl
inform
compar
techniqu
exist
designmethod
studi
patient
diabet
age
gender
healthi
control
subject
age
gender
subject
underw
examin
score
quantit
sensori
test
autonom
test
heart
rate
variabl
valsalva
maneuv
tilt
test
esc
millimet
punch
skin
biopsi
distal
leg
distal
thigh
ienfd
sgnfd
result
strong
correl
exam
score
biopsi
ienfd
p
distal
leg
p
distal
thigh
sgnfd
p
distal
leg
p
distal
thigh
moder
correl
note
exam
score
qst
r
valu
p
ienfd
qst
modest
correl
note
esc
parasympathet
function
p
modest
correl
note
esc
ienfd
p
distal
leg
esc
p
correl
exam
score
autonom
function
note
correl
detect
esc
sgnfd
esc
sympathet
adrenerg
function
conclus
differ
test
expect
base
understand
pathophysiolog
natur
histori
diabet
neuropathi
exam
score
qst
result
biopsi
result
correl
consist
prior
studi
contrast
littl
relationship
test
autonom
function
exam
score
similar
prior
studi
understand
autonom
function
differ
p
esc
littl
correl
either
exam
score
biopsi
ienfd
sgnfd
modest
correl
esc
parasympathet
function
exact
relationship
esc
diabet
peripher
neuropathi
clear
research
studi
need
determin
role
techniqu
clinic
practic
gibbon
wang
mccormick
freeman
israel
deaco
medic
center
harvard
medic
school
boston
usa
object
determin
optim
tissu
thick
skin
biopsi
section
studi
cutan
nerv
fiber
background
although
analysi
nerv
fiber
densiti
ienfd
routin
report
use
thick
tissu
section
mani
recent
studi
peripher
deposit
use
frozen
section
paraffin
embed
tissu
section
designmethod
compar
result
biopsi
patient
parkinson
diseas
pd
use
tissu
section
thick
tissu
stain
stain
phosphoryl
total
number
dermal
structur
hair
follicl
sweat
gland
pilomotor
muscl
quantifi
nerv
densiti
analyz
frequenc
posit
result
also
studi
paraffin
embed
tissu
sampl
patient
pd
result
biopsi
patient
pd
differ
number
sweat
gland
hair
follicl
pilomotor
muscl
section
significantli
fewer
blood
vessel
note
section
compar
section
p
ienfd
sgnfd
declin
tissu
thick
increas
variabl
result
thinner
tissu
section
highli
signific
reduct
posit
section
thinner
tissu
section
p
tissu
compar
section
paraffin
embed
tissu
section
significantli
lower
nerv
densiti
posit
result
p
compar
frozen
tissu
section
thick
thinner
tissu
section
carri
greater
risk
fals
posit
result
indetermin
result
due
difficulti
interpret
overlap
conclus
tissu
sampl
thick
play
critic
role
interpret
skin
biopsi
result
thinner
tissu
section
paraffin
embed
tissu
section
provid
equival
data
significantli
underestim
nerv
densiti
posit
result
increas
fals
posit
result
despit
similar
number
dermal
tissu
structur
glasser
walk
thoma
shi
deon
wilson
sherman
atti
pharma
cambridg
usa
minnesota
minneapoli
usa
univers
medic
center
hackensack
usa
iowa
iowa
citi
ia
usa
investig
protein
therapeut
act
local
ligand
trap
myostatin
neg
regul
muscl
growth
local
inject
gastrocnemiu
muscl
mdx
mice
produc
increas
muscl
mass
forc
without
system
effect
phase
dose
escal
studi
women
unilater
inject
rectu
femori
rf
tibiali
anterior
ta
muscl
gener
safe
well
toler
mean
percent
chang
baselin
muscl
volum
inject
muscl
rf
ta
highest
dose
administ
minim
chang
observ
contralater
side
subject
frequent
relat
ae
includ
inject
site
pain
pain
extrem
inject
site
discomfort
muscl
twitch
similar
incid
group
ae
grade
revers
togeth
preclin
clinic
result
support
studi
myogen
andor
neurogen
diseas
focal
loss
muscl
strength
function
includ
cmt
phase
studi
ongo
facioscapulohumer
muscular
dystrophi
fshd
studi
ongo
multicent
phase
studi
evalu
safeti
toler
pharmacodynam
efficaci
pharmacokinet
patient
cmtx
part
enrol
cohort
patient
per
cohort
part
random
enrol
addit
patient
administ
bilater
ta
muscl
everi
three
week
five
dose
safeti
review
team
meet
period
throughout
studi
review
safeti
data
make
dose
recommend
includ
recommend
dose
level
part
elig
patient
must
genet
confirm
cmtx
weak
ankl
dorsiflexion
safeti
toler
serv
primari
outcom
part
muscl
volum
evalu
mri
part
addit
outcom
measur
interest
includ
strength
quantit
muscl
test
function
motor
test
qualiti
life
index
questionnair
goede
van
der
pol
herraet
van
asseldonk
visser
van
den
berg
neurolog
umc
utrecht
utrecht
netherland
neurosci
brain
center
rudolf
magnu
umc
utrecht
utrecht
netherland
neurolog
clinic
neurophysiolog
st
elisabeth
hospit
tilburg
netherland
studi
aim
evalu
function
morpholog
consequ
cellular
humor
respons
chronic
inflammatori
demyelin
neuropathi
cidp
use
extens
standard
sonographi
hru
nerv
conduct
studi
nc
protocol
incid
patient
enrol
consecut
newli
diagnos
treatment
naiv
patient
cidp
addit
relev
clinic
examin
patient
underw
standard
nc
extens
hru
protocol
median
ulnar
tibial
fibular
sural
nerv
assess
standard
nerv
fascicl
size
echogen
found
focal
sonograph
enlarg
multipl
nerv
nerv
segment
without
nc
abnorm
degre
nerv
hypertrophi
associ
presenc
nc
featur
demyelin
ie
median
nerv
segment
show
enlarg
without
strong
decreas
motor
conduct
veloc
hypertroph
median
nerv
segment
reveal
conduct
block
lower
distal
cmap
median
nerv
relat
lower
mrc
p
found
correl
age
diseas
durat
mrc
nerv
size
cellular
humor
respons
cidp
may
lead
nerv
enlarg
along
length
nerv
detect
hru
wherea
nc
allow
identif
specif
focal
disrupt
nerv
function
murray
jensen
vaegter
research
institut
translat
neurosci
dandrit
partnership
depart
biomedicin
aarhu
univers
aarhu
denmark
intern
diabet
neuropathi
consortium
aarhu
univers
aarhu
denmark
anatomi
neurosci
univers
melbourn
victoria
australia
neurolog
danish
pain
research
center
aarhu
univers
aarhu
denmark
common
complic
diabet
peripher
neuropathi
preval
high
character
damag
neuron
schwann
cell
blood
vessel
within
nerv
concept
schwannopathi
integr
factor
pathogenesi
diabet
neuropathi
known
schwann
cell
cultur
hyperglycem
environ
underproduc
neurotrophin
exhibit
loss
axon
associ
indic
glial
cell
activ
function
furthermor
increas
express
myelin
sheath
around
fiber
suscept
axon
degener
diabet
neuropathi
suggest
import
role
molecul
diseas
progress
project
main
goal
evalu
disrupt
signal
schwann
cell
affect
pathophysiolog
diabet
neuropathi
use
fluoresc
livedeath
cell
viabil
assay
preliminari
data
indic
schwann
cell
cultur
present
increas
cell
death
rate
stimul
high
level
glucos
highli
recogn
role
activ
death
signal
absent
observ
schwann
cell
significantli
resist
apoptosi
hyperglycem
condit
role
receptor
signal
cell
commun
myelin
vitro
diabet
condit
investig
primari
schwann
neuron
eight
day
ascorb
acid
stimul
euglycem
hyperglycem
condit
myelin
assess
confoc
microscopi
use
specif
marker
neuron
myelin
result
highlight
compromis
abil
schwann
cell
myelin
axon
expos
hyperglycem
environ
even
intensifi
schwann
cell
lack
complement
vitro
studi
model
type
diabet
schwann
cell
condit
ko
mous
model
plan
investig
nerv
mrna
express
profil
disclos
genet
regul
depend
receptor
signal
modulatori
role
endoneuri
hypoxia
neuroinflamm
result
project
provid
integr
vision
impair
schwann
cell
activ
guid
neuropathi
progress
gondim
barreira
cruz
cunha
de
freita
mc
marqu
w
nascimento
oliveira
pereira
pupe
rotta
schestatski
behalf
scientif
depart
peripher
neuropathi
brazilian
academi
neurolog
brazil
neuropathi
one
common
neurolog
manifest
sever
diseas
sfn
progress
receiv
attent
medic
literatur
aim
studi
gener
set
recommend
defin
diagnos
sfn
brazil
group
neurologist
member
scientif
depart
peripher
neuropathi
brazilian
academi
neurolog
review
preliminari
draft
prepar
first
author
distribut
email
panelist
got
togeth
citi
fortaleza
brazil
discuss
finish
text
first
submiss
manuscript
sfn
defin
subtyp
neuropathi
character
select
involv
unmyelin
thinli
myelin
sensori
sometim
also
autonom
fiber
usual
character
sensori
paindysesthesiaspruritu
combin
sensori
autonom
complaint
associ
almost
entir
normal
neurolog
examin
except
sensori
chang
electromyographi
normal
grow
list
medic
condit
link
sfn
although
literatur
support
use
specif
set
screen
test
diagnos
etiolog
sfn
panelist
suggest
basic
screen
panel
sfn
may
also
serv
fallaci
use
terminolog
uncov
discrep
normal
valu
differ
neurophysiolog
laboratori
brazil
skin
biopsi
usual
perform
initi
form
leprosi
may
predomin
small
fiber
involv
sever
test
demonstr
involv
small
sensori
autonom
fiber
skin
wrinkl
test
sympathet
skin
respons
heart
rate
variabl
conduct
emg
machin
thermoregulatori
sweat
test
may
screen
altern
final
meet
finish
first
draft
submiss
arquivo
de
neuropsiquiatria
togeth
translat
portugues
supplementari
materi
offici
journal
brazilian
academi
neurolog
serv
sourc
definit
diagnosi
sfn
brazil
final
draft
submit
present
pn
meet
barcelona
grisold
grisold
finster
meng
neurolog
medic
univers
vienna
vienna
austria
boltzmann
institut
experiment
clinic
traumatolog
vienna
austria
neurolog
krankenanstalt
rudolfstiftung
vienna
austria
radiolog
kaiser
franz
josef
hospit
vienna
austria
anatomi
cell
biolog
medic
univers
vienna
vienna
austria
lower
cranial
nerv
lcn
includ
pair
glossopharyng
vagal
accessori
hypogloss
nerv
involv
execut
swallow
speech
phonat
tast
well
sensori
autonom
function
lcn
affect
central
peripher
nervou
system
diseas
studi
investig
use
ultrasound
us
detect
lesion
peripher
cours
lcn
addit
mri
use
unilater
lcn
local
lesion
demonstr
indirect
sign
nerv
lesion
muscl
atrophi
patient
examin
supin
posit
neck
maximum
extens
either
regular
portabl
us
system
logiq
e
logiq
ge
healthcar
milwauke
wisconsin
high
frequenc
transduc
mhz
accord
detect
patholog
longitudin
transvers
imag
record
seri
exemplari
observ
demonstr
one
case
paraganglioma
glossopharyng
nerv
carotid
sinu
found
anoth
patient
us
thyroid
gland
reveal
nerv
tumor
later
identifi
schwannoma
anoth
case
multipl
neurofibroma
identifi
vagal
nerv
routin
neurofibromatosi
screen
us
becom
also
import
investig
lesion
accessori
nerv
follow
damag
surgeri
nerv
continu
scar
format
distinguish
lesion
hypogloss
nerv
caus
tumor
infiltr
one
patient
infiltr
nerv
squamou
cell
carcinoma
anoth
case
low
grade
sarcoma
detect
addit
mri
demonstr
atrophi
tongu
identif
assess
lcn
point
exit
skull
endpoint
pursu
us
techniqu
describ
individu
nerv
us
easili
applic
addit
static
imag
mri
allow
assess
nerv
posit
differ
movement
well
detect
muscl
movement
fascicul
mri
also
use
detect
proxim
lesion
also
chang
skelet
muscl
denerv
hattenhau
wolffram
kleinschnitz
mausberg
stettner
hospit
essen
essen
germani
germani
chronic
inflammatori
demyelin
polyneuropathi
cidp
cell
suspect
play
crucial
role
myelin
destruct
cell
contribut
inflammatori
process
exact
mechan
myelin
damag
still
debat
elucid
molecular
interact
cell
myelin
sheet
compar
neuritogen
control
cell
live
imag
vitro
model
myelin
fibr
rat
dorsal
root
ganglia
drg
serv
model
peripher
nervou
system
drg
embryon
lewi
rat
cultur
myelin
initi
one
week
vitro
continu
two
addit
week
lewi
rat
immun
neuritogen
cell
lymph
node
obtain
ten
day
immun
control
cell
prepar
healthi
rat
vital
track
neuritogen
cell
stain
orang
cell
tracker
control
cell
label
cfse
myelin
detect
vital
cultur
assess
incorpor
fatti
acid
conjug
fluorophor
myelin
layer
experi
perform
condit
microscop
chamber
two
cell
popul
ad
simultan
drg
cultur
migrat
track
use
live
cell
imag
observ
differ
migrat
pattern
neuritogen
control
cell
veloc
well
direction
alter
initi
contact
neuriotgen
cell
close
proxim
myelin
subsequ
decreas
time
number
neuritogen
cell
close
myelin
remain
stabl
long
term
incub
neuritogen
cell
affect
myelin
integr
regard
intermod
length
well
myelin
ratio
experi
elucid
specif
effect
neuritogen
cell
deciph
role
cell
inflamm
pn
could
use
develop
target
therapi
gundapaneni
sultan
keohan
schwartz
health
inc
burlington
usa
inc
new
york
ny
usa
transthyretin
famili
amyloid
polyneuropathi
rare
disord
caus
protein
destabil
ttr
gene
mutat
broadli
classifi
common
mutat
worldwid
genotyp
tafamidi
medicin
approv
delay
neurolog
progress
object
analysi
compar
effect
tafamidi
neuropathi
progress
patient
genotyp
patient
particip
random
clinic
trial
tafamidi
patient
particip
tafamidi
studi
patient
group
three
cohort
tafamidi
placebo
tafamidi
baselin
diseas
sever
chang
diseas
sever
baselin
month
assess
use
neuropathi
impair
limb
effect
tafamidi
cohort
versu
placebo
cohort
determin
use
model
repeat
measur
mmrm
baselin
patient
cohort
older
longer
symptom
durat
advanc
neurolog
impair
cohort
month
mean
standard
error
chang
compar
tafamidi
tafamidi
cohort
respect
chang
smaller
observ
placebo
cohort
vs
vs
indic
less
diseas
progress
base
predict
valu
mmrm
analysi
size
chang
across
full
rang
baselin
score
remark
similar
tafamidi
tafamidi
cohort
consist
smaller
observ
placebo
cohort
moreov
three
cohort
baselin
increas
predict
level
diseas
progress
also
increas
conclus
control
baselin
diseas
sever
tafamidi
delay
diseas
progress
compar
extent
patient
similar
trajectori
diseas
progress
across
patient
suggest
two
genotyp
group
may
similar
previous
consid
http
clinicaltrialsgov
identifi
gutmann
shi
iowa
iowa
citi
ia
usa
post
tetan
potenti
ptp
physiolog
phenonmenon
seen
disord
neuromuscular
junction
nmj
caus
influx
ca
termin
axon
tetanu
result
increas
number
acetylcholin
ach
vescicl
releas
axon
action
potenti
myasthen
syndrom
result
improv
nmj
function
increas
probabl
achiev
larg
enough
end
plate
potenti
gener
muscl
action
potenti
ptp
differ
appear
depend
whether
nmj
defect
defect
common
syndrom
increas
amplitud
muscl
action
potenti
tetanu
persist
minut
prolong
ptp
report
disord
one
genet
determin
neuropathymyasthen
basi
acquir
toxic
origin
prolong
ptp
minut
report
famili
motor
neuropathi
leg
weak
foot
deformit
congenit
myasthen
syndrom
caus
heterozyg
mutat
synaptotamin
ii
gene
g
electrophysiolog
test
show
featur
presynapt
defect
prolong
ptp
persist
minut
phenomenon
note
acquir
defect
caus
botululinum
toxin
ptp
continu
minut
synapt
vescicl
calcium
sensor
termin
axon
allow
fusion
ach
contain
vescicl
presynapt
membran
synchron
releas
ach
fusion
requir
complex
assembl
process
involv
snare
protein
gene
mutat
botulinum
toxin
affect
normal
function
mutat
alter
amino
acid
domain
toxin
bind
well
gangliosid
neural
membran
mechan
ptp
prolong
remain
unknown
prolong
ptp
appear
uniqu
physiolog
abnorm
result
alter
phenomenon
decrib
occur
mutat
caus
congenit
motor
neuropathymyasthen
syndrom
botul
abnorm
may
repres
physiolog
marker
presynapt
nmj
defect
involv
alter
hachisuka
senger
curran
chan
physic
medicin
rehabilit
univers
alberta
edmonton
canada
rehabilit
medicin
univers
occup
environment
health
kitakyushu
japan
plastic
surgeri
univers
alberta
edmonton
canada
background
motor
unit
number
estim
mune
techniqu
valuabl
tool
neuromuscular
diseas
among
multipl
point
stimul
mp
one
common
use
contamin
distant
singl
motor
unit
potenti
smup
gener
neighbor
muscl
potenti
confound
factor
particularli
problemat
ulnar
neuropathi
one
common
neuropathi
human
reason
ulnar
nerv
innerv
major
hand
muscl
goal
studi
test
hypothes
distant
smup
initi
posit
deflect
elimin
smup
gener
distal
muscl
significantli
lower
mune
result
hypothenar
muscl
method
address
first
hypothesi
test
subject
stimul
median
nerv
record
smup
simultan
hypothenar
thenar
muscl
second
hypothesi
carri
mp
mune
hypothenar
muscl
use
record
place
ulnar
innerv
intrins
muscl
across
hand
smup
initi
posit
deflect
detect
hypothenar
electrod
origin
system
track
record
channel
result
first
seri
experi
accord
dipol
theori
smup
record
hypothenar
record
electrod
initi
posit
polar
second
seri
experi
studi
carri
subject
distant
smup
gener
muscl
hypothenar
emin
repres
overal
sampl
mune
calcul
use
smup
gener
hypothenar
muscl
compar
smup
includ
p
extent
increas
mune
highli
correl
proport
distant
smup
found
studi
r
p
conclus
contrari
studi
suggest
smup
distant
muscl
could
initi
neg
deflect
found
smup
distant
muscl
posit
deflect
exclus
smup
sampl
signific
impact
mune
result
hagiwara
konno
kihara
inou
fujioka
univers
tokyo
japan
matrix
metalloproteinas
mmp
play
crucial
role
develop
neuriti
syndrom
gb
anim
model
experiment
autoimmun
neuriti
ean
investig
intraneur
express
mmp
ean
effect
inhibitor
cilostazol
clz
ean
rat
treat
either
mgkgday
clz
vehicl
one
day
post
immun
dpi
induc
ean
femal
lewi
rat
immun
synthet
peptid
bovin
protein
cauda
equina
ce
remov
sever
time
point
total
rna
extract
obtain
cdna
subject
pcr
analysi
express
tissu
inhibitor
matrix
messag
messag
peak
dpi
presymptomat
phase
ean
rat
develop
motor
paralysi
dpi
messag
subsid
moment
howev
messag
reciproc
increas
dpi
persist
dpi
treatment
clz
suppress
motor
paralysi
ean
significantli
messag
peak
dpi
messag
peak
dpi
hand
messag
dpi
suppress
compar
untreat
ean
rat
messag
clz
treat
rat
peak
dpi
coincid
motor
paralysi
peak
messag
might
result
subsequ
upregul
final
downregul
mmp
activ
inflammatori
process
clz
treatment
suppress
delay
express
mmp
facilit
express
result
suppress
ean
precis
mechan
express
mmp
remain
unclear
howev
messag
peak
dpi
suggest
involv
cytokin
tumor
necrosi
clz
might
suppress
cytokin
result
mmp
regul
less
affect
clz
thu
stimul
express
dpi
clz
might
ration
treatment
neuropathi
via
mmp
modul
although
investig
especi
studi
need
haidar
de
winter
asselbergh
bouhi
timmerman
neuropathi
research
group
vib
univers
antwerp
antwerp
belgium
small
heat
shock
protein
gene
ubiquit
express
encod
chaperon
protein
essenti
cellular
function
lab
first
identifi
missens
mutat
respons
axon
neuropathi
sinc
becam
interest
understand
physiolog
function
associ
cmt
neuropathi
demonstr
involv
microtubul
stabil
link
autophagosom
format
intracellular
transport
microtubul
stabil
believ
process
could
regul
cellular
housekeep
process
autophagosom
target
envelop
degrad
aberr
protein
aggreg
damag
organel
strong
evid
essenti
role
autophagi
mainten
neuron
homeostasi
henc
impair
lead
neuropath
condit
data
indic
disrupt
mutat
combin
novel
microscopi
interactom
techniqu
unravel
way
differ
mutat
impair
autophag
pathway
data
present
impair
autophagi
possibl
pathomechan
mutat
hajjar
gautier
berthelot
gonzalez
gess
young
tricaud
neurosci
montpellli
inserm
univers
montpelli
montpelli
franc
klinik
schlafmedizin
und
erkrankungen
germani
common
diseas
result
duplic
peripher
myelin
protein
gene
gene
encod
small
protein
kda
mainli
produc
schwann
cell
excess
lead
demyelin
cure
diseas
one
approach
treatment
gene
therapi
transgen
rat
model
exist
possess
copi
mous
gene
goal
provid
proof
principl
gene
therapi
peripher
nerv
use
rat
model
strategi
reduc
overexpress
mous
protein
rat
schwann
cell
use
short
hairpin
rna
shrna
shrna
small
rna
specif
bind
target
mrna
result
degrad
test
effici
sever
shrna
target
mous
vitro
find
two
shrna
reduc
level
shrna
clone
serotyp
viral
vector
togeth
green
fluoresc
protein
order
detect
infect
cell
select
high
transduct
rate
myelin
schwann
cell
good
diffus
low
immunogen
plan
bilater
inject
sciatic
nerv
control
diseas
rat
effici
gene
therapi
check
assess
muscl
strength
grip
test
way
walk
catwalk
mobil
rotarod
nerv
conduct
veloc
treat
rat
versu
process
myelin
myelin
mainten
schwann
cell
analyz
biochemistri
electron
microscopi
biochem
test
includ
western
blot
protein
express
sciatic
nerv
immunohistochemistri
protein
express
myelin
schwann
cell
pcr
mrna
express
therapi
success
rat
could
possibl
later
use
clinic
trial
hamscha
grisold
grisold
meng
anatomi
cell
biolog
medic
univers
vienna
vienna
austria
neurolog
medic
univers
vienna
vienna
austria
boltzmann
institut
experiment
clinic
traumatolog
vienna
austria
radiolog
kaiser
franz
joseph
hospit
vienna
austria
ultrasound
tool
diagnos
carpal
tunnel
syndrom
ct
sever
differ
method
sonograph
evalu
median
nerv
damag
exist
calcul
ratio
cross
section
area
csa
median
nerv
variou
site
enabl
detect
actual
nerv
swell
proxim
carpal
tunnel
express
median
nerv
damag
insid
carpal
tunnel
seen
ct
comparison
diagnost
method
data
exist
preval
ct
like
chang
unselect
popul
seri
fresh
cadav
examin
arm
fresh
whole
bodi
cadav
examin
medic
record
allow
obtain
conclus
inform
peripher
nerv
use
regular
ultrasound
system
mhz
transduc
median
nerv
identifi
track
along
cours
forearm
csa
measur
median
nerv
perform
two
site
arm
halfway
elbow
joint
wrist
directli
proxim
carpal
tunnel
csa
ratio
calcul
follow
formula
csa
ratio
found
arm
csa
ratio
arm
csa
ratio
arm
csa
ratio
detect
women
men
overal
mean
sd
age
year
men
significantli
younger
women
p
weak
signific
correl
age
csa
ratio
found
women
spearman
men
mean
bmi
csa
ratio
sd
base
csa
ratio
criterion
ct
present
ultrasound
result
consist
averag
ct
preval
report
previou
studi
obtain
electrophysiolog
method
studi
larg
unselect
seri
cadav
confirm
compar
method
hanewinckel
drenthen
verlinden
darweesh
van
der
geest
hofman
van
doorn
ikram
epidemiolog
erasmu
univers
medic
center
rotterdam
netherland
neurolog
erasmu
univers
medic
center
rotterdam
netherland
neurosci
erasmu
univers
medic
center
rotterdam
netherland
clinic
neurophysiolog
erasmu
univers
medic
center
rotterdam
netherland
epidemiolog
harvard
th
chan
school
public
health
boston
usa
polyneuropathi
common
disabl
disord
data
import
outcom
abil
perform
activ
daili
live
risk
fall
relat
injuri
gait
pattern
scarc
therefor
extens
investig
associ
chronic
polyneuropathi
basic
instrument
activ
daili
live
badl
iadl
fall
gait
pattern
larg
prospect
popul
base
rotterdam
studi
total
particip
studi
mean
age
year
women
underw
polyneuropathi
screen
involv
symptom
questionnair
neurolog
examin
nerv
conduct
studi
screen
yield
four
group
possibl
probabl
definit
polyneuropathi
particip
interview
badl
stanford
health
assess
questionnair
iadl
instrument
activ
daili
live
scale
frequenc
fall
previou
year
random
subset
particip
gait
assess
electron
walkway
gaitrit
associ
polyneuropathi
badl
iadl
analyz
continu
linear
regress
dichotom
logist
regress
histori
fall
evalu
logist
regress
gait
chang
evalu
linear
regress
found
particip
definit
polyneuropathi
difficulti
perform
badl
iadl
particip
without
polyneuropathi
polyneuropathi
relat
wors
score
badl
especi
walk
three
iadl
compon
housekeep
travel
shop
particip
definit
polyneuropathi
two
time
like
fall
fall
often
result
injuri
particip
polyneuropathi
wors
gait
paramet
walkway
includ
lower
walk
speed
cadenc
error
tandem
walk
summari
chronic
polyneuropathi
strongli
associ
signific
impair
daili
life
recognit
polyneuropathi
relat
disabl
import
order
inform
support
possibl
treat
patient
prevent
futur
fall
depend
daili
function
hanewinckel
van
oijen
merki
noterman
vrancken
ikram
van
doorn
neurolog
erasmu
univers
medic
center
rotterdam
netherland
epidemiolog
erasmu
univers
medic
center
rotterdam
netherland
neurolog
maastricht
univers
medic
center
maastricht
netherland
neurolog
st
elisabeth
hospit
willemstad
neurolog
univers
medic
center
utrecht
netherland
patient
polyneuropathi
often
suffer
tingl
sensat
numb
weak
pain
symptom
use
sever
screen
questionnair
develop
patient
group
individu
diabet
mellitu
tool
equal
weight
appli
symptom
might
inform
other
evalu
diagnost
valu
frequenc
occurr
individu
symptom
chronic
polyneuropathi
construct
valid
simpl
screen
questionnair
reliabl
help
diagnos
polyneuropathi
patient
group
procedur
initi
compil
questionnair
concern
symptom
polyneuropathi
questionnair
complet
polyneuropathi
patient
control
headach
transient
ischem
attack
multipl
sclerosi
calcul
sensit
specif
likelihood
ratio
individu
symptom
next
stepwis
multivari
logist
regress
use
creat
compact
model
abl
discrimin
case
control
use
inform
symptom
simpl
score
system
subsequ
develop
base
regress
coeffici
reduc
model
extern
valid
subsequ
conduct
popul
case
chronic
idiopath
axon
polyneuropathi
control
without
polyneuropathi
perform
assess
discrimin
area
curv
auc
calibr
numb
tingl
feet
frequent
report
polyneuropathi
patient
highest
sensit
feel
walk
cotton
wool
allodynia
feet
highest
specif
multivari
logist
regress
yield
model
contain
four
symptom
complement
balanc
problem
tingl
hand
base
regress
analysi
erasmu
polyneuropathi
symptom
score
creat
score
rang
polyneuropathi
symptom
score
good
perform
auc
de
deriv
set
prove
valid
extern
popul
auc
studi
creat
simpl
valid
polyneuropathi
symptom
score
take
individu
valu
six
differ
symptom
frequenc
account
tool
help
screen
instrument
clinic
practic
futur
studi
polyneuropathi
hauck
jend
diem
weiler
heiland
wildemann
wick
hay
pfaff
pham
bendszu
kollmer
neuroradiolog
heidelberg
univers
hospit
heidelberg
germani
radiolog
hannov
medic
school
hannov
germani
neurolog
heidelberg
univers
hospit
heidelberg
germani
experiment
radiolog
depart
neuroradiolog
heidelberg
germani
neurolog
univers
michigan
ann
arbor
mi
usa
neuroradiolog
univers
hospit
germani
multipl
sclerosi
ms
tradit
view
central
nervou
system
diseas
date
unequivoc
evid
implic
involv
peripher
nervou
system
pn
studi
aim
prove
whether
pn
addit
affect
detect
local
quantifi
peripher
nerv
lesion
patient
multipl
sclerosi
ms
appli
mrn
larg
anatom
coverag
combin
standard
electrophysiolog
neurolog
test
prospect
enrol
patient
confirm
ms
year
two
patient
clinic
isol
syndrom
ci
healthi
volunt
potenti
caus
concomit
polyneuropathi
exclud
ms
patient
underw
detail
neurolog
electrophysiolog
test
tesla
mrn
larg
anatom
coverag
lumbar
plexu
spinal
nerv
ankl
level
perform
particip
use
tse
sequenc
trte
ms
dual
echo
tse
sequenc
tr
ms
ms
space
sequenc
tr
ms
effect
te
ms
use
imag
lumbar
plexu
manual
segment
spinalsciatictibialperon
nerv
perform
total
axial
slice
besid
evalu
nerv
detail
quantif
nerv
lesion
analyz
morphometr
nerv
calib
microstructur
marker
conduct
mean
lesion
load
thigh
level
higher
ms
vs
control
p
nerv
also
higher
ms
tibialperon
vs
control
tibialperon
p
contrast
time
significantli
higher
control
tibialperon
vs
ms
tibialperon
p
proxim
tibial
fibular
nerv
calib
also
significantli
higher
ms
tibial
p
fibular
first
time
pn
lesion
ms
patient
could
visual
quantifi
vivo
mrn
lesion
indic
increas
decreas
nerv
calib
morphometr
criterion
also
significantli
increas
studi
may
offer
new
insight
pathomechan
ms
might
futur
implic
therapeut
approach
hayat
babu
jahan
rahman
mahmud
hassan
islam
scienc
servic
divis
intern
centr
diarrheal
diseas
research
icddr
b
dhaka
bangladesh
physiolog
molecular
biolog
bangladesh
univers
health
scienc
dhaka
bangladesh
biochemistri
molecular
biolog
univers
dhaka
dhaka
bangladesh
immunoglobulin
g
igg
confer
divers
effector
function
link
cellular
humor
arm
immun
system
involv
pathogenesi
syndrom
gb
era
polymorph
relev
knowledg
becom
one
main
target
new
therapeut
strategi
treatment
gb
patient
differ
sever
frequenc
gb
subtyp
found
western
popul
attribut
genet
suscept
therefor
aim
determin
polymorph
allel
possibl
link
gb
current
avail
larg
gb
cohort
bangladesh
r
polymorph
gb
patient
healthi
control
genotyp
use
pcr
valid
carri
sequenc
sampl
allel
signific
differ
found
regard
distribut
genotyp
allel
frequenc
gb
patient
control
genotyp
significantli
predomin
patient
sever
diseas
compar
patient
mild
diseas
ci
signific
associ
found
gb
patient
candid
allel
diseas
sever
found
significantli
predomin
antibodi
posit
gb
patient
compar
antibodi
neg
patient
ci
allel
significantli
higher
patient
poor
prognosi
compar
patient
good
outcom
ci
signific
associ
genotyp
allel
found
gb
patient
diseas
sever
diseas
outcom
extens
subgroup
analysi
reveal
signific
associ
genotyp
allel
frequenc
aman
aidp
subtyp
conclus
igg
polymorph
constitut
signific
risk
marker
suscept
gb
howev
homozyg
might
involv
sever
form
gb
addit
might
play
import
role
molecular
mimicri
nerv
gangliosid
gb
studi
enrol
larg
number
patient
e
g
igo
requir
confirm
present
find
differ
geograph
area
hay
obrien
backu
feldman
neurolog
univers
michigan
ann
arbor
mi
usa
peripher
neuropathi
pn
common
complic
observ
patient
impair
glucos
toler
type
diabet
male
mice
fed
high
fat
diet
hfd
develop
metabol
impair
pn
serv
appropri
anim
model
studi
pn
develop
progress
well
document
femal
mice
fed
hfd
display
degre
protect
metabol
chang
mice
retain
rel
normal
insulin
sensit
protect
attribut
differ
fat
accumul
effect
estrogen
base
hypothes
femal
mice
would
also
exhibit
resist
develop
pn
present
studi
male
femal
mice
fed
either
standard
diet
kcal
fat
sd
high
fat
diet
kcal
fat
hfd
neuropathi
phenotyp
perform
group
complement
longitudin
metabol
assess
includ
insulin
toler
test
itt
neuropathi
phenotyp
consist
hindpaw
latenc
heat
stimulu
motor
sensori
nerv
conduct
veloc
ncv
termin
intraepiderm
nerv
fiber
ienf
count
assess
insulin
resist
itt
demonstr
earli
hfd
feed
femal
mice
exhibit
rel
normal
insulin
respons
male
hfd
mice
exhibit
insulin
resist
despit
find
femal
hfd
mice
display
similar
pattern
pn
male
counterpart
similar
hindpaw
latenc
sensori
motor
ncv
therefor
although
femal
mice
exhibit
resist
metabol
chang
display
pn
compar
male
mice
suggest
system
insulin
resist
mediat
pn
studi
underway
investig
role
insulin
signal
peripher
nerv
femal
mice
herrendorff
pfister
h
yang
demeester
hunzik
frey
steck
ernst
molecular
pharmaci
univers
basel
basel
switzerland
biomedicin
univers
hospit
basel
basel
switzerland
neurolog
univers
hospit
basel
basel
switzerland
glycoprotein
neuropathi
disabl
autoimmun
peripher
neuropathi
caus
monoclon
immunoglobulin
igm
autoantibodi
recogn
carbohydr
epitop
human
natur
glycoepitop
highli
express
adhes
molecul
mag
present
myelin
nerv
fiber
sinc
pathogen
demyelin
properti
autoantibodi
well
establish
current
treatment
aim
reduct
autoantibodi
level
howev
therapi
appli
far
primarili
immunosuppress
lack
select
efficaci
therefor
hypothes
signific
improv
diseas
condit
could
achiev
select
neutral
pathogen
antibodi
ligand
mimick
natur
glycoepitop
inhibit
assay
mimet
natur
epitop
inhibit
pathogen
igm
antibodi
patient
sera
howev
micromolar
affin
therefor
consid
multival
natur
interact
polylysin
polym
differ
size
substitut
mimet
promis
polylysin
glycopolym
inhibitori
effect
patient
sera
improv
factor
per
epitop
consequ
lead
low
nanomolar
inhibitori
potenc
sinc
clinic
studi
indic
correl
reduct
igm
level
clinic
improv
immunolog
surrog
mous
model
neuropathi
produc
high
level
igm
develop
observ
effici
remov
antibodi
glycopolym
repres
first
step
toward
therapi
neuropathi
hinder
mendelson
backu
feldman
michigan
ann
arbor
mi
usa
unit
state
children
young
adult
obes
risk
develop
prediabet
prediabet
patient
larg
develop
microvascular
complic
patient
type
diabet
includ
peripher
neuropathi
pn
moreov
recent
clinic
data
suggest
normoglycem
obes
patient
develop
pn
central
obes
character
excess
fat
storag
viscer
white
adipos
tissu
lead
system
metabol
dysfunct
larg
due
imbal
adipokin
product
subcutan
adipos
tissu
consid
benign
adopt
phenotyp
respons
metabol
stress
reduc
thermogen
reduc
brown
adipos
ident
increas
gene
express
poplit
adipos
tissu
pat
depot
correspond
subcutan
adipos
adjac
peripher
nerv
affect
pn
contain
lymph
node
lymphat
drainag
hind
limb
expand
follow
local
steril
hind
paw
inflamm
aim
current
studi
character
pat
chang
high
fat
diet
hfd
mous
model
obes
pn
consid
contribut
peripher
nerv
dysfunct
previous
report
mice
fed
hfd
wk
develop
obes
prediabet
pn
switch
mice
back
standard
diet
wk
improv
metabol
pn
phenotyp
wk
pat
bilater
dissect
lymph
node
remov
left
pat
process
histomorphometri
right
pat
wk
hfd
associ
signific
shift
adipocyt
distribut
greater
number
larger
adipocyt
switch
hfd
mice
back
standard
chow
wk
restor
distribut
toward
control
perform
assess
chang
thermogen
brown
adipos
identifi
cidea
steril
inflamm
wk
hfd
pat
reduc
thermogen
brown
adipos
identifi
increas
steril
inflamm
switch
toward
phenotyp
revers
hfd
mice
switch
back
standard
chow
summari
chang
pat
histomorphometri
adipos
ident
close
associ
pn
phenotyp
preliminari
data
suggest
potenti
role
signal
pn
hinder
backu
hay
feldman
univers
michigan
ann
arbor
mi
usa
peripher
neuropathi
pn
common
debilit
complic
obes
diabet
trigger
pain
loss
sensat
substanti
nerv
damag
occur
mani
patient
prior
notic
symptom
treatment
current
avail
therefor
critic
need
identifi
treatment
strategi
impact
underli
diseas
pathogenesi
vivo
fluxom
data
mous
model
type
diabet
pn
suggest
metabol
reprogram
occur
nerv
downregul
mitochondri
oxid
phosphoryl
substrat
deriv
glycolysi
fatti
acid
therefor
hypothes
distinct
system
metabol
alter
occur
obes
diabet
induc
metabol
reprogram
within
peripher
nerv
alter
fuel
util
ultim
lead
tissu
dysfunct
contend
identifi
conserv
bioenerget
profil
across
mous
model
pn
provid
insight
key
pn
mechan
current
studi
util
two
mous
model
pn
high
fat
diet
hfd
mous
model
obes
prediabet
wk
age
wk
hfd
leptin
model
wk
age
mitochondri
function
determin
primari
dorsal
root
ganglia
drg
neuron
sural
nerv
tissu
model
use
seahors
analyz
rest
mitochondri
oxid
metabol
upregul
drg
neuron
mice
pn
increas
rest
atp
product
maintain
mitochondri
coupl
contrast
rest
atp
gener
decreas
sural
nerv
mice
pn
decreas
coupl
effici
rel
spare
respiratori
capac
attenu
drg
neuron
sural
nerv
mice
pn
indic
mitochondria
less
abl
increas
respir
respons
energet
challeng
moreov
mitochondri
copi
number
unchang
drg
neuron
decreas
sural
nerv
tissu
mice
pn
compar
respect
control
data
suggest
chang
absolut
number
function
sural
nerv
mitochondria
conserv
bioenerget
profil
pn
current
explor
relationship
chang
pn
pathogenesi
hoang
umapathi
hospit
ho
chi
minh
citi
vietnam
neurosci
institut
singapor
ho
chi
minh
citi
hcmc
biggest
metropolitan
citi
southern
vietnam
popul
ten
million
adult
patient
neurolog
disord
seen
six
citi
public
hospit
includ
hospit
systemat
studi
guillain
syndrom
gb
hcmc
vietnam
gener
process
start
prospect
gb
databas
hope
expand
public
hospit
hcmc
describ
experi
saw
gb
patient
hospit
case
admit
raini
season
late
april
novemb
flaviviru
infect
common
patient
seen
first
week
ill
report
anteced
fever
two
patient
diarrhea
diagnos
made
larg
clinic
featur
cerebrospin
fluid
analysi
nerv
conduct
studi
clinic
find
includ
limb
weak
numb
vii
cranial
nerv
palsi
extraocular
eye
movement
affect
one
patient
none
respiratori
involv
sever
enough
requir
artifici
ventil
intens
care
pure
syndrom
case
suspect
might
relat
mild
deficit
prompt
hospit
nerv
conduct
studi
show
typic
featur
loss
f
wave
abnorm
blink
reflex
electrophysiolog
patient
domin
demyelin
chang
one
case
larg
axon
remain
patient
normal
electrodiagnost
studi
repeat
nerv
conduct
studi
feasibl
limit
resourc
neurologist
use
corticosteroid
main
treatment
intraven
immunoglobulin
plasma
exchang
costli
reimburs
medic
insur
current
prepar
systemat
studi
gb
southern
vietnam
specif
regard
possibl
role
anteced
flaviviru
infect
also
explor
possibl
use
low
volum
plasma
exchang
feasibl
therapeut
modal
hong
choi
yoon
sohn
baek
choi
park
kwon
sung
metropolitan
govern
borama
medic
center
seoul
nation
univers
seoul
south
korea
nation
univers
hospit
seoul
south
korea
univers
hospit
incheon
south
korea
univers
hospit
daejeon
south
korea
nation
univers
hospit
jinju
south
korea
patient
syndrom
gb
treat
intraven
immunoglobulin
ivig
plasma
exchang
deterior
initi
improv
phenomenon
term
fluctuat
trf
import
distinguish
acut
onset
cidp
earli
cours
diseas
therapeut
strategi
prognos
differ
herein
describ
patient
extend
progress
phase
exce
week
woman
admit
due
acut
onset
progress
leg
weak
diplopia
develop
week
prior
onset
neurolog
examin
right
facial
palsi
also
observ
lower
extrem
weak
moder
proxim
distal
muscl
mrc
grade
iv
absent
knee
ankl
jerk
sensori
examin
reveal
abnorm
modal
deni
recent
diarrhea
upper
respiratori
infect
vaccin
dissoci
note
csf
analysi
white
blood
cell
count
protein
level
mgdl
nerv
conduct
studi
reveal
demyelin
sensorimotor
polyneuropathi
prolong
distal
latenc
conduct
block
antibodi
igmg
igmg
igmg
neg
follow
ivig
treatment
discharg
consider
improv
day
later
due
deterior
leg
weak
hand
clumsi
anoth
ivig
treatment
discharg
clinic
improv
day
later
howev
admit
due
anoth
consider
deterior
four
extrem
weak
worst
time
mrc
grade
upper
extrem
grade
ii
lower
extrem
consid
given
progress
phase
exceed
week
decid
give
anoth
treatment
ivig
instead
switch
corticosteroid
uncertainti
regard
distinct
significantli
improv
follow
ivig
treatment
final
discharg
thereaft
deterior
year
conclus
rare
case
gb
extend
progress
phase
trf
propos
could
refer
subacut
inflammatori
demyelin
polyradiculoneuropathi
sidp
trf
hsieh
chao
taiwan
univers
hospit
taipei
taiwan
transthyretin
ttr
famili
amyloid
polyneuropathi
fap
constitut
major
etiolog
hereditari
neuropathi
worldwid
particular
mutant
ttr
taiwan
common
caus
acquir
genet
neuropathi
adult
onset
year
age
taiwanes
patient
fap
neuropathi
involv
motor
sensori
autonom
compon
peripher
nervou
system
earli
involv
small
fiber
major
symptom
earli
symptom
fap
sometim
minim
difficult
ascertain
mainli
relat
fact
convent
electrophysiolog
examin
sensit
enough
detect
small
fiber
neuropathi
skin
biopsi
quantif
intraepiderm
nerv
fiber
ienf
becom
one
standard
approach
diagnos
small
fiber
sensori
neuropathi
base
patholog
document
nocicept
nerv
degener
explor
issu
earli
biomark
fap
perform
skin
biopsi
compar
ienf
densiti
paramet
nerv
conduct
studi
nc
quantit
sensori
test
qst
subject
men
age
year
genet
confirm
patient
carrier
ienf
densiti
significantli
reduc
compar
control
carrier
vs
fibersmm
p
patient
vs
fibersmm
p
latter
consist
previou
report
neurolog
abnorm
rate
ienf
densiti
significantli
higher
nc
qst
respect
conclus
signific
skin
nerv
degener
carrier
compar
qst
nc
ienf
densiti
assess
highest
abnorm
rate
highest
sensit
detect
neuropath
chang
earli
stage
fap
hu
arpag
zuchner
li
neurolog
vanderbilt
univers
school
medicin
nashvil
tn
usa
institut
human
genom
univers
miami
miami
fl
usa
type
associ
mutat
ring
domain
ligas
studi
describ
famili
novel
missens
mutat
gene
explor
pathogen
mechan
american
famili
dominantli
inherit
axon
polyneuropathi
reveal
phenotyp
similar
previous
report
famili
affect
member
famili
novel
missens
mutat
alter
highli
conserv
cystein
ring
domain
mutat
lead
axon
degener
vitro
neuron
moreov
use
protein
mass
spectrometri
identifi
group
rna
bind
protein
includ
fu
protein
critic
involv
motor
neuron
degener
interact
interact
disrupt
mutat
result
reduct
intranuclear
protein
knockin
mous
creat
explor
mechan
therapeut
develop
togeth
find
suggest
mutant
may
aberrantli
affect
format
transcript
machineri
given
similar
mechan
report
motor
neuron
degener
amyotroph
later
sclerosi
abnorm
protein
complex
may
play
role
neuron
degener
support
grant
nind
nation
center
advanc
translat
scienc
hugh
cornblath
dalaka
merki
latov
sobu
geng
merschhemk
ervin
agoropoul
hartung
hospit
neurolog
neurosurgeri
london
uk
hopkin
medic
school
baltimor
md
usa
athen
medic
school
athen
greec
univers
medic
center
maastricht
netherland
st
elisabeth
hospit
willemstad
curacao
netherland
antil
cornel
medic
colleg
ny
usa
referr
center
neuromuscular
diseas
univers
hospit
pari
franc
clinic
research
center
milan
univers
rozzano
milan
itali
univers
hospit
nagoya
japan
neurolog
institut
hospit
montreal
quebec
canada
pharma
ag
basel
switzerland
neurolog
germani
multicent
trial
random
adult
particip
chronic
inflammatori
demyelin
polyradiculoneuropathi
treat
intraven
immunoglobulin
ivig
corticosteroid
mg
fingolimod
placebo
previou
treatment
discontinu
ivig
taper
corticosteroid
total
trial
popul
signific
differ
group
primari
outcom
confirm
worsen
increas
adjust
inflammatori
neuropathi
caus
treatment
incat
scale
vs
baselin
worsen
confirm
incat
assess
unconfirm
signific
differ
two
treatment
group
shown
secondari
outcom
chang
baselin
grip
strength
overal
disabl
scale
six
month
trial
end
analys
subgroup
perform
primari
secondari
outcom
confirm
worsen
fingolimod
vs
particip
hazard
ratio
confid
interv
analyz
previou
treatment
ivig
vs
corticosteroid
vs
baselin
incat
score
incat
vs
incat
vs
durat
cidp
year
vs
year
vs
year
vs
number
worsen
previou
year
worsen
event
vs
worsen
event
vs
worsen
event
vs
respect
hazard
ratio
show
signific
differ
treatment
group
subgroup
acknowledg
author
consult
employ
studi
sponsor
novarti
pharma
ag
basel
switzerland
hugh
cornblath
dalaka
merki
latov
sobu
geng
merschhemk
ervin
agoropoul
hartung
hospit
neurolog
neurosurgeri
london
uk
hopkin
medic
school
baltimor
md
usa
athen
medic
school
athen
greec
univers
medic
center
maastricht
netherland
st
elisabeth
hospit
willemstad
curacao
netherland
antil
cornel
medic
colleg
ny
usa
referr
center
neuromuscular
diseas
univers
hospit
pari
franc
clinic
research
center
milan
univers
rozzano
milan
itali
univers
hospit
nagoya
japan
neurolog
institut
hospit
montreal
quebec
canada
pharma
ag
basel
switzerland
neurolog
germani
trial
evalu
efficaci
safeti
fingolimod
chronic
inflammatori
demyelin
polyradiculoneuropathi
cidp
corticosteroid
intraven
immunoglobulin
ivig
plasma
exchang
recogn
treatment
option
immunomodul
demonstr
efficaci
control
trial
fingolimod
shown
efficaci
approv
treatment
relaps
multipl
sclerosi
result
experiment
autoimmun
neuriti
rat
suggest
might
show
effect
cidp
multicent
trial
cidp
particip
receiv
ivig
corticosteroid
random
fingolimod
mg
placebo
particip
stratifi
inflammatori
neuropathi
caus
treatment
disabl
incat
score
prior
treatment
previou
ivig
treatment
discontinu
one
final
cours
random
previou
corticosteroid
treatment
taper
week
primari
outcom
confirm
worsen
increas
adjust
incat
score
versu
baselin
secondari
outcom
includ
chang
grip
strength
overal
disabl
scale
score
baselin
month
trial
end
trial
stop
futil
independ
data
monitor
committe
interim
analysi
base
criteria
particip
receiv
fingolimod
ivig
corticosteroid
age
year
deviat
male
receiv
placebo
ivig
corticosteroid
age
year
male
percentag
confid
interv
particip
free
confirm
worsen
trial
end
significantli
differ
fingolimod
placebo
first
day
approxim
particip
experienc
worsen
trial
end
approxim
particip
worsen
signific
differ
six
month
trial
end
whichev
occur
earlier
secondari
endpoint
advers
event
report
particip
fingolimod
placebo
group
respect
death
nine
particip
fingolimod
group
placebo
group
seriou
advers
event
advers
event
lead
trial
drug
discontinu
occur
particip
fingolimod
none
placebo
new
safeti
signal
emerg
trial
acknowledg
author
consult
employ
studi
sponsor
novarti
pharma
ag
basel
switzerland
hullugundi
chernov
remacl
edding
angert
dolka
jone
iii
strongin
yaksh
shubayev
anesthesiolog
univers
california
san
diego
la
jolla
ca
usa
san
diego
healthcar
system
la
jolla
ca
usa
medic
discoveri
institut
la
jolla
ca
usa
pain
medicin
univers
california
san
diego
la
jolla
ca
usa
myelin
sheath
enwrap
mechanoselect
transmit
touchvibr
sens
promin
reduct
mechan
stimulu
requir
evok
withdraw
respons
rodent
phenomena
interpret
mechan
allodynia
aris
due
peripher
nervemyelin
damag
evid
emerg
nerv
mechan
allodynia
depend
adapt
immunet
cell
activ
femal
male
rodent
previous
demonstr
releas
cryptic
peptid
region
myelin
basic
protein
follow
sciatic
nerv
chronic
constrict
injuri
cci
direct
robust
abil
pure
peptid
induc
mechan
allodynia
inject
intact
sciatic
nerv
hypothes
contribut
sexual
dimorph
mechan
allodynia
pure
wt
histidin
mutant
scrambl
peptid
administ
intact
sciatic
nerv
fascicl
male
femal
rat
mice
follow
von
frey
test
peptid
induc
robust
last
allodynia
femal
contrast
male
respond
brief
mild
declin
mechan
sensit
one
day
wildtyp
control
peptid
alges
abil
diminish
mutant
present
molecular
chang
sciatic
nerv
drg
spinal
cord
inject
male
femal
anim
addit
use
peptid
goat
iggigm
antibodi
develop
elisa
quantit
assess
seroposit
specif
peptid
igmigg
autoantibodi
femal
male
rat
human
serum
femal
patient
multipl
sclerosi
use
control
work
corrobor
find
sexual
dimorph
mechan
hyperpathia
suggest
potenti
autoimmun
natur
femal
iijima
nishi
ikeda
kawagashira
koik
sobu
katsuno
univers
nagoya
japan
diabet
nod
knockout
ko
mice
character
chronic
progress
neuriti
expect
model
neuropathi
especi
cidp
weak
due
inflammatori
demyelin
follow
axon
degener
begin
around
twenti
femal
mice
thirti
clarifi
efficaci
immunoglobulin
therapeut
similar
pathogenesi
human
cidp
inject
intraperiton
immunoglobulin
ipig
bwweek
salin
control
total
forti
femal
mice
clinic
patholog
estim
sciatic
nerv
perform
time
seri
result
group
protect
weight
loss
could
relat
axon
loss
follow
muscl
atrophi
well
inflammatori
demyelin
thirti
compar
control
addit
patholog
find
sciatic
nerv
show
ipig
appar
suppress
inflammatori
infiltr
subset
inflammatori
infiltr
macrophag
lymphocyt
highli
exist
suggest
play
main
role
neuriti
thirti
macrophag
natur
disappear
thirti
without
therapeut
induct
immunoglobulin
effect
suppress
macrophag
although
suppress
lymphocyt
conclus
nod
ko
mice
respond
immunoglobulin
similar
manner
human
cidp
efficaci
due
suppress
pathogenesi
therefor
pathogenesi
main
target
immunoglobulin
therapi
focu
pathogenesi
might
play
import
role
immunoglobulin
ikeda
nishi
kawagashira
iijima
koik
katsuno
sobu
neurolog
nagoya
univers
graduat
school
medicin
nagoya
japan
divis
dementia
neurodegen
diseas
nagoya
univers
graduat
school
medicin
nagoya
japan
chronic
inflammatori
demyelin
polyneuropathi
cidp
acquir
polyradiculoneuropathi
character
heterogen
clinic
manifest
typic
cidp
defin
neuropathi
manifest
progress
manner
stepwis
manner
recurr
symmetr
proxim
distal
weak
sensori
impair
four
limb
although
occur
lower
proport
typic
cidp
atyp
form
multifoc
acquir
demyelin
sensori
motor
madsam
distal
acquir
demyelin
symmetr
dad
pure
sensori
pure
motor
focal
consid
cidp
subtyp
thu
far
patholog
featur
character
clinic
subtyp
fulli
elucid
analyz
clinic
patholog
correl
consecut
cidp
patient
underw
sural
nerv
biopsi
fulfil
definit
probabl
efnspn
criteria
male
femal
patient
age
biopsi
mean
sd
year
durat
onset
neuropathi
biopsi
month
percent
n
patient
classifi
typic
cidp
regard
atyp
cidp
madsam
n
dad
n
pure
sensori
n
subtyp
major
subtyp
pure
motor
focal
subtyp
rare
signific
differ
found
among
subtyp
term
sex
age
biopsi
diseas
durat
sural
nerv
biopsi
specimen
reveal
densiti
larg
myelin
fiber
significantli
decreas
madsam
subtyp
subtyp
p
addit
variat
nerv
fiber
among
fascicl
conspicu
madsam
subtyp
typic
cidp
patient
dad
subtyp
tend
show
format
conclus
patholog
find
sural
nerv
biopsi
specimen
differ
among
cidp
subtyp
studi
need
clarifi
mechan
lead
differ
patholog
featur
islam
islam
rahman
endtz
vo
vanderjagt
vandoorn
jacob
mohammad
centr
diarrhoeal
diseas
research
icddr
b
dhaka
bangladesh
erasmu
mc
rotterdam
netherland
centr
diarrhoeal
diseas
research
icddr
b
dhaka
bangladesh
adhunik
medic
colleg
hospit
dhaka
bangladesh
mc
rotterdam
netherland
fondat
lyon
franc
mc
rotterdam
netherland
institut
neurosci
dhaka
bangladesh
small
volum
plasma
exchang
svpe
afford
potenti
effect
altern
form
plasma
exchang
svpe
repeat
remov
small
volum
supernat
plasma
sever
day
via
sediment
patient
whole
blood
aim
studi
assess
clinic
feasibl
safeti
svpe
patient
gb
countri
twenti
adult
patient
gb
diagnos
per
criteria
gb
nation
institut
neurolog
commun
disord
stroke
nind
enrol
svpe
centr
bangladesh
seriou
advers
event
sae
defin
number
patient
develop
sever
sepsi
associ
central
venou
cathet
cvc
deep
venou
thrombosi
limb
cvc
place
svpe
svpe
procedur
consid
safe
less
gb
patient
sae
feasibl
eight
litr
plasma
could
remov
least
gb
patient
among
case
receiv
svpe
patient
male
age
rang
yr
patient
quadripleg
bedbound
enrol
svpe
median
mrc
score
iqr
cranial
nerv
involv
autonom
dysfunct
requir
assist
ventil
observ
patient
respect
electro
physiolog
patient
motor
axon
patient
demyelin
type
svpe
none
patient
experienc
sae
one
patient
experienc
central
line
associ
blood
stream
infect
common
advers
effect
transient
intraven
fluid
respons
hypotens
svpe
session
cv
cathet
insert
site
hemorrhag
hypersensit
reaction
fresh
frozen
plasma
patient
anemia
electrolyt
imbal
observ
patient
treat
svpe
improv
one
grade
gb
disabl
score
four
week
onset
svpe
observ
patient
conclus
svpe
safe
feasibl
cost
effect
altern
standard
pe
develop
countri
islam
islam
endtz
jacob
mohammad
scienc
servic
divis
intern
centr
diarrhoeal
diseas
research
icddr
b
dhaka
bangladesh
medic
microbiolog
infecti
diseas
erasmu
univers
medic
centr
rotterdam
netherland
immunolog
erasmu
univers
medic
centr
rotterdam
netherland
neurolog
institut
neurosci
hospit
agargaon
dhaka
bangladesh
lyon
franc
syndrom
gb
descript
diseas
entiti
defin
set
clinic
electrophysiolog
laboratori
criteria
variou
clinic
phenotyp
exist
may
trigger
differ
anteced
infecti
event
although
diseas
appear
affect
primarili
elderli
develop
countri
scenario
differ
develop
countri
bangladesh
made
impress
progress
toward
erad
poliomyel
new
case
report
sinc
gb
acut
polyradiculoneuropathi
frequent
caus
acut
flaccid
paralyi
crude
incid
rate
gb
year
age
report
appear
higher
report
literatur
conduct
hospit
base
observ
studi
includ
patient
fulfil
nation
institut
neurolog
disord
stroke
nind
criteria
gb
patient
dhaka
medic
colleg
hospit
dhaka
bangladesh
detail
clinic
electrophysiolog
serolog
microbiolog
data
obtain
gb
affect
predominantli
young
adult
male
live
rural
area
anteced
event
record
patient
frequent
event
gastroenter
upper
respiratori
tract
infect
patient
gb
disabl
score
entri
patient
requir
mechan
ventil
patient
receiv
specif
treatment
either
intraven
immunoglobulin
ivig
plasmapheresi
due
high
expens
treatment
cost
patient
die
hospit
patient
axon
variant
gb
evid
recent
c
jejuni
infect
c
jejuni
infect
significantli
associ
serum
antibodi
gangliosid
axon
neuropathi
greater
disabl
conclus
major
patient
receiv
standard
treatment
ivig
view
high
price
therefor
develop
treatment
strategi
conduct
safeti
feasibl
trial
small
volum
plasma
exchang
svpe
gb
patient
bangladesh
futur
essenti
conduct
phase
ii
clinic
trial
assess
efficaci
svpe
countri
islam
papri
ara
haqu
islam
mohammad
centr
diarrhoeal
diseas
research
icddr
b
dhaka
bangladesh
medic
microbiolog
infecti
diseas
erasmu
univers
medic
centr
rotterdam
netherland
institut
neurosci
hospit
nagar
agargaon
dhaka
bangladesh
prognosi
syndrom
gb
improv
last
two
decad
current
therapi
intraven
immunoglobulin
ivig
plasma
exchang
pe
prove
effect
two
third
patient
develop
world
unpredict
poorli
understood
clinic
cours
gb
hamper
treatment
develop
bangladesh
patient
affect
gb
afford
specif
treatment
ivig
pe
instead
receiv
support
care
therefor
aim
compar
outcom
ivig
treat
patient
support
care
patient
improv
gb
disabl
score
mrc
sum
score
use
world
largest
gb
cohort
bangladesh
conduct
prospect
observ
studi
enrol
gb
patient
dhaka
medic
colleg
hospit
nation
institut
neurosci
hospit
dhaka
bangladesh
gb
patient
receiv
standard
ivig
treatment
current
analysi
ivig
treat
patient
age
sex
sever
match
control
support
care
consid
outcom
group
compar
use
fisher
exact
chi
squar
test
surviv
analysi
perform
kaplan
meier
method
use
log
rank
test
among
patient
case
control
malefemal
median
age
year
patient
patient
requir
mechan
ventil
axon
found
signific
differ
treatment
outcom
case
control
group
gb
disabl
score
week
month
mrc
sum
score
week
month
surviv
analysi
reveal
differ
time
requir
independ
locomot
improv
one
gb
disabl
score
improv
mrc
score
statist
signific
treatment
ivig
support
care
patient
conclus
analysi
show
standard
dose
ivig
use
consider
advantag
improv
specif
outcom
measur
among
gb
patient
bangladesh
phenotyp
gb
bangladesh
differ
develop
world
therefor
efficaci
trial
ivig
need
develop
countri
like
bangladesh
new
target
therapeut
strategi
append
benefici
effect
gb
patient
isos
watanab
omori
sekiguchi
beppu
shibuya
amino
suichi
misawa
kuwabara
school
medicin
chiba
univers
chiba
japan
hospit
organ
chiba
east
nation
hospit
chiba
japan
diabet
neuropathi
frequent
caus
neuropath
pain
suggest
involv
addit
persist
peripher
input
could
caus
neuron
hyperexcit
complex
interact
nocicept
pathway
ie
central
sensit
investig
pathophysiolog
neuropath
pain
diabet
neuropathi
studi
evok
potenti
prep
select
intraepiderm
electr
stimul
i
diabet
patient
neuropath
pain
without
neuropath
pain
also
conduct
longitudin
studi
assess
chang
prep
pain
profil
patient
neuropath
pain
month
start
treatment
duloxetin
studi
regist
umin
clinic
trial
registri
i
appli
hand
foot
prep
record
cz
electrod
referenc
link
earlob
evalu
prep
latenc
amplitud
amplitud
ratio
prep
stimul
convent
nerv
conduct
studi
patient
neuropath
pain
significantli
show
conduct
slow
decreas
snap
amplitud
median
sural
nerv
compar
patient
without
neuropath
pain
sep
studi
signific
differ
prep
amplitud
latenc
fiber
stimul
patient
neuropath
pain
without
prep
amplitud
ratio
stimul
tend
increas
patient
neuropath
pain
compar
patient
without
pain
treatment
duloxetin
amplitud
ratio
significantli
decreas
hand
foot
stimul
numer
rate
scale
nr
score
intens
pain
patient
less
pain
relief
show
tendenc
higher
prep
amplitud
ratio
treatment
compar
patient
better
pain
relief
correl
reduct
prep
amplitud
ratio
nr
reduct
reach
statist
signific
sep
studi
demonstr
abnorm
cortic
respons
patient
neuropath
pain
could
improv
treatment
duloxetin
might
reflect
cortic
hyperexcit
central
sensit
conflict
interest
studi
fund
shionogi
co
ltd
sponsor
play
role
design
manag
studi
collect
analysi
data
interpret
result
write
write
report
jack
wright
kansa
medic
center
kansa
citi
ks
usa
peripher
nerv
injuri
commonli
associ
traumat
injuri
often
amen
surgeri
despit
improv
method
surgic
repair
function
recoveri
remain
challeng
clinic
problem
often
lead
signific
morbid
patient
altern
therapi
could
augment
surgic
repair
may
benefici
function
outcom
neuroinflamm
complex
pathway
differ
cellular
compon
cytokin
activ
follow
peripher
nerv
injuri
macrophag
respons
breakdown
debri
follow
injuri
well
promot
regen
signal
macrophag
polar
process
macrophag
take
phenotyp
distinct
function
base
local
environ
signal
cue
exercis
shown
drive
macrophag
polar
phenotyp
toward
phenotyp
numer
tissu
remain
uninvestig
peripher
nervou
system
purpos
studi
identifi
exercis
affect
macrophag
polar
motor
sensori
function
neuroregener
follow
sciatic
nerv
crush
mice
underw
sciatic
nerv
crush
injuri
given
access
run
wheel
exercis
given
access
run
wheel
sedentari
week
exercis
mice
ran
averag
km
per
night
injur
exercis
mice
protect
develop
thermal
hyperalgesia
compar
injur
sedentari
mice
exercis
mice
fewer
paw
slip
beam
walk
test
compar
sedentari
mice
differ
measur
mechan
sensit
motor
coordin
balanc
assess
rotarod
motor
nerv
conduct
veloc
significantli
reduc
injur
mice
compar
uninjur
control
motor
nerv
conduct
veloc
injur
exercis
anim
significantli
higher
injur
sedentari
anim
suggest
improv
nerv
recoveri
exercis
injur
sciatic
nerv
exercis
mice
demonstr
increas
macrophag
compar
sciatic
nerv
injur
sedentari
mice
behavior
chang
alter
macrophag
polar
correl
increas
epiderm
nerv
fiber
densiti
improv
myelin
increas
vitro
neurit
outgrowth
injur
exercis
anim
therefor
exercis
alter
macrophag
polar
toward
phenotyp
improv
repair
recoveri
injur
peripher
nerv
jack
shah
everist
reyna
hylton
kansa
medic
center
kansa
citi
ks
usa
diffus
tensor
imag
dti
long
use
evalu
locat
integr
white
matter
tract
brain
dti
use
quantit
data
direction
water
diffus
determin
axon
connect
nervou
system
technolog
recent
util
limit
set
peripher
nervou
system
due
challeng
technic
factor
lack
widespread
avail
magnet
reson
mr
neurographi
peripher
neurographi
techniqu
use
diffus
differenti
intraneur
perineur
tissu
allow
fascicl
pattern
visual
particularli
set
peripher
nerv
sheath
tumor
peripher
nerv
sheath
tumor
variou
patholog
caus
surround
nerv
involv
displac
rang
direct
techniqu
help
determin
anatom
locat
nerv
fiber
relat
mass
particularli
help
distinguish
neuroma
schwannoma
data
invalu
surgeon
ensur
safe
low
morbid
oper
technolog
benefit
particularli
surgic
plan
underutil
due
challeng
requir
complex
softwar
produc
fiber
track
inabl
translat
imag
oper
room
util
brainlab
softwar
commonli
avail
util
surgic
suit
produc
imag
radial
nerv
fiber
tract
associ
peripher
nerv
sheath
tumor
prior
surgic
resect
softwar
commonli
use
central
nervou
system
report
use
peripher
nervou
system
softwar
offer
high
usabl
produc
anatom
correct
reliabl
fiber
tract
techniqu
overcom
relianc
highli
special
softwar
extens
train
requir
use
tractographi
softwar
util
peripher
neurographi
case
allow
complet
surgic
resect
without
postop
deficit
data
offer
clinician
option
investig
peripher
nerv
fiber
variou
patholog
state
plan
appropri
oper
trajectori
peripher
nerv
patholog
improv
surgic
outcom
patient
peripher
nerv
sheath
tumor
jacobsen
parri
allen
walk
muley
ortega
neurolog
institut
phoenix
az
usa
minnesota
minneapoli
mn
usa
chronic
inflammatori
demyelin
polyneuropathi
cidp
immun
mediat
neuropathi
respons
immunomodulatori
agent
glucocorticoid
intraven
immunoglobulin
ivig
plasma
exchang
pe
specif
immunopathogen
mechan
cidp
remain
unclear
increas
interest
nodal
protein
site
immun
attack
even
though
major
patient
respond
one
aforement
immunomodulatori
agent
unrespons
incomplet
respons
first
line
agent
aggress
treatment
may
necessari
cyclophosphamid
stem
cell
transplant
may
effect
associ
consider
morbid
anecdot
report
suggest
rituximab
may
benefici
patient
fail
therapi
especi
antibodi
nodal
protein
present
four
patient
intract
cidp
respond
rituximab
one
three
patient
diabet
diseas
durat
prior
start
rituxan
short
month
two
patient
longer
month
two
patient
fail
treatment
glucocorticoid
ivig
two
plasma
exchang
also
ineffect
two
four
patient
quadriparet
two
gm
dose
two
week
apart
intraven
rituximab
institut
patient
patient
toler
treatment
well
without
advers
effect
patient
respond
within
four
week
continu
improv
six
month
immunomodulatori
agent
success
taper
total
discontinu
remain
unclear
whether
antibodi
nodal
protein
present
patient
conclus
although
rituximab
efficaci
remain
uncertain
basi
random
control
clinic
trial
may
benefici
select
patient
otherwis
intract
treatment
studi
necessari
better
understand
patient
may
benefit
rituximab
treatment
algorithm
rituximab
appli
jager
denk
richner
goncalv
pallesen
mcmahon
biomedicin
aarhu
univers
aarhu
denmark
colleg
london
london
uk
neuropath
pain
chronic
condit
seen
patient
suffer
direct
injuri
peripher
central
nervou
system
indirect
injuri
due
eg
diabet
multipl
sclerosi
current
treatment
option
fall
short
prevent
complet
reliev
patient
pain
year
research
focus
understand
role
neuron
neuropath
pain
pathogenesi
overlook
role
support
cell
gener
satellit
glial
cell
sgc
dorsal
root
ganglion
particular
cell
buffer
neuron
microenviron
also
involv
control
electr
activ
flow
neuron
neuropath
pain
pathogenesi
aim
project
understand
role
sgc
neuropath
pain
develop
therebi
aid
identif
new
drug
target
purifi
sgc
adult
mice
optim
fluoresc
activ
cell
sort
fac
protocol
success
purif
method
confirm
use
visual
inspect
sort
cell
final
run
rna
sequenc
sgc
peripher
nerv
injuri
compar
transcriptom
uninjur
cell
differ
time
point
result
studi
like
deepen
understand
sgc
contribut
develop
mainten
neuropath
pain
jahan
khalid
ahammad
mohmmad
islam
scienc
servic
divis
intern
centr
diarrheal
diseas
research
icddr
b
dhaka
bangladesh
biochemistri
erasmu
univers
medic
centr
rotterdam
netherland
institut
neurosci
hospit
nagar
agargaon
dhaka
bangladesh
syndrom
gb
disord
peripher
nervou
system
pn
trigger
molecular
mimicri
nerv
gangliosid
one
cell
surfac
receptor
fa
fasl
interact
transmit
apoptot
signal
elimin
b
gener
antibodi
nerv
cell
host
genet
polymorph
fa
fasl
may
alter
express
induc
aberr
apoptot
respons
develop
gb
therefor
determin
singl
nucleotid
polymorph
snp
fa
receptor
fasl
ligand
gb
patient
well
healthi
control
use
lightcycl
techniqu
serum
level
solubl
form
fa
fasl
measur
use
commerci
avail
sandwich
elisa
kit
comparison
genotyp
allel
haplotyp
frequenc
done
gb
subgroup
base
clinic
serolog
data
ag
heterozygot
polymorph
fa
receptor
promot
snp
significantli
associ
antibodi
posit
gb
patient
addit
haplotyp
predominantli
associ
axon
variant
gb
patient
serum
solubl
form
sfa
median
level
pgml
vs
pgml
sfasl
median
level
pgml
vs
pgml
found
elev
antibodi
posit
gb
patient
compar
neg
patient
signific
associ
found
genotyp
distribut
gb
patient
healthi
control
conclus
fasfasl
promot
snp
suscept
factor
gb
could
one
influenc
factor
develop
antibodi
gb
patient
bangladesh
furthermor
function
studi
larger
sampl
size
use
cohort
like
intern
gb
outcom
requir
explain
immun
pathogen
role
snp
gb
patient
jang
yoon
shin
yun
jo
park
shin
kj
kim
park
univers
busan
south
korea
univers
busan
south
korea
myelin
essenti
proper
function
nervou
system
schwann
cell
form
peripher
myelin
sheath
uniqu
abil
dedifferenti
destroy
myelin
sheath
variou
demyelin
condit
schwann
cell
demyelin
wallerian
degener
axon
injuri
schwann
cell
exhibit
myelin
junction
instabl
myelin
gene
express
autophag
myelin
decomposit
howev
inflammatori
demyelin
neuropathi
still
unclear
schwann
cell
react
contribut
segment
demyelin
myelin
scaveng
macrophag
activ
myelin
clearanc
show
schwann
cell
demyelin
mechan
involv
initi
demyelin
observ
mous
model
inflammatori
demyelin
neuropathi
use
ultrastructur
biochem
microarray
analys
myelin
uncompact
myelin
membran
instabl
gener
dedifferenti
schwann
cell
lead
cytoplasm
amput
myelin
sheath
schwann
cell
bodi
result
format
myelin
corps
therebi
allow
macrophag
phagocytos
myelin
corps
end
stage
segment
demyelin
found
myelin
corps
format
inflammatori
demyelin
process
similar
myelin
reject
wallerian
degener
appear
depend
schwann
cell
autophagolysosom
activ
sinc
schwann
knockout
mice
exhibit
delay
myelin
reject
follow
nerv
injuri
final
lysosom
inhibit
schwann
cell
prevent
segment
demyelin
also
delay
progress
clinic
stage
suppress
myelin
corps
format
inflammatori
demyelin
neuropathi
thu
find
indic
demyelin
schwann
cell
macrophag
might
part
process
includ
sequenti
divis
labor
respect
myelin
reject
digest
respect
conjunct
previou
studi
show
schwann
cell
dedifferenti
autophagi
toxic
hereditari
neuropathi
concept
schwann
cell
demyelin
provid
insight
develop
possibl
therapeut
strategi
prevent
schwann
cell
demyelin
peripher
demyelin
neuropathi
jerath
mankodi
crawford
grunseich
baloui
schindler
chrast
shi
neurolog
univers
iowa
carver
colleg
medicin
iowa
citi
ia
usa
branch
nation
institut
neurolog
disord
stroke
nation
institut
health
bethesda
md
usa
pediatr
neurolog
john
hopkin
univers
baltimor
md
usa
neurosci
depart
clinic
neurosci
karolinska
institutet
stockholm
sweden
neurolog
drexel
univers
colleg
medicin
philadelphia
pa
usa
object
analyz
describ
atyp
present
method
present
clinic
physiolog
featur
five
subject
caus
biallel
privat
mutat
result
case
manifest
scoliosi
nerv
conduct
studi
demyelin
rang
exhibit
sign
motor
impair
within
first
year
life
describ
two
differ
genet
diseas
patient
atyp
present
cmt
new
mutat
patient
discuss
new
era
unbias
genet
test
led
small
case
seri
individu
highlight
recognit
differ
genet
diseas
patient
accur
diagnosi
genet
risk
identif
therapeut
intervent
phenotyp
addit
appear
enrich
number
featur
unusu
broad
cmt
categori
jerath
shi
neurolog
univers
iowa
carver
colleg
medicin
iowa
citi
ia
usa
introduct
diseas
type
caus
duplic
peripher
myelin
protein
gene
chromosom
whether
bodi
mass
index
bmi
affect
electrophysiolog
clinic
data
patient
clear
relev
data
limit
method
electrophysiolog
data
charcot
mari
tooth
exam
score
cmte
bmi
patient
known
obtain
analyz
result
control
age
bmi
affect
studi
ulnar
motor
nerv
conduct
patient
rather
specif
compon
cmt
exam
score
cmte
loss
pinprick
sensat
motor
strength
lower
extrem
discuss
bmi
clinic
compon
cmte
correl
uncertain
primari
effect
ie
whether
reduct
pinprick
sensat
motor
strength
lower
extrem
lead
higher
bmi
higher
bmi
result
sign
jerath
shi
neurolog
univers
iowa
carver
colleg
medicin
iowa
citi
ia
usa
introduct
diseas
type
c
rare
dominantli
inherit
neuropathi
caus
mutat
tumor
necrosi
factor
litaf
small
integr
membran
protein
lysosomel
endosom
simpl
gene
method
present
case
seri
compris
patient
caus
substitut
encod
protein
focu
clinic
present
electrodiagnost
analys
find
context
previous
describ
case
result
mutat
caus
mild
form
cmt
patient
walk
time
less
weak
diseas
type
charcot
mari
tooth
neuropathi
score
cmtn
indic
mild
diseas
faster
ulnar
median
motor
nerv
conduct
veloc
compar
discuss
mutat
litaf
seem
clinic
indistinguish
mild
present
jha
russel
lee
rothstein
morrison
hopkin
univers
baltimor
md
usa
peripher
nerv
highli
depend
metabol
energi
maintain
basic
cellular
function
axon
transport
nak
ion
gradient
myelin
well
support
regener
follow
injuri
though
glucos
certainli
provid
metabol
support
recent
studi
shown
monocarboxyl
lactat
pyruv
keton
bodi
also
contribut
recoveri
peripher
nerv
injuri
monocarboxyl
transport
particularli
predomin
transport
monocarboxyl
peripher
nerv
recent
public
found
heterozyg
null
mice
express
less
cell
slow
nerv
regener
reduc
myelin
follow
sciatic
nerv
crush
studi
limit
global
reduct
wide
express
schwann
cell
sc
dorsal
root
ganglia
drg
neuron
endotheli
cell
macrophag
perineuri
cell
within
regener
peripher
nerv
better
understand
mechan
contribut
normal
nerv
function
nerv
regener
produc
valid
condit
null
mice
allow
select
delet
sc
drg
neuron
endotheli
cell
macrophag
mate
cre
line
current
quantifi
peripher
nerv
develop
age
regener
mous
line
follow
specif
knockdown
sensori
peripher
nerv
develop
demyelin
month
age
manifest
reduc
myelin
thick
increas
reduc
conduct
veloc
studi
ongo
cultur
sc
determin
mechan
demyelin
neither
sc
drg
knockdown
impair
nerv
regener
follow
sciatic
nerv
crush
result
suggest
critic
maintain
myelin
sensori
motor
peripher
nerv
age
also
suggest
express
peripher
nerv
cell
type
sc
drg
import
nerv
regener
ongo
studi
determin
contribut
peripher
nerv
cell
type
particularli
endotheli
cell
macrophag
normal
develop
regener
follow
injuri
result
clarifi
role
lactat
transport
peripher
nerv
function
potenti
suggest
novel
target
demyelin
neuropathi
nerv
injuri
joosten
sopacua
bovenkerk
potten
faber
merki
hoeijmak
univers
medic
center
maastricht
netherland
elisabeth
hospit
willemstad
small
fiber
neuropathi
sfn
condit
smallest
nerv
fiber
affect
character
neuropath
pain
autonom
dysfunct
accord
intern
criteria
sfn
diagnosi
base
clinic
symptom
combin
abnorm
temperatur
threshold
test
ttt
andor
reduc
intraepiderm
nerv
fiber
densiti
ienfd
skin
biopsi
skin
biopsi
moder
sensit
invas
process
time
consum
expens
ttt
wide
avail
diagnost
tool
lack
specif
previou
studi
introduc
stimul
skin
wrinkl
ssw
object
diagnost
tool
detect
sympathet
nerv
dysfunct
sfn
mean
categor
assess
howev
unpublish
data
shown
reliabl
categor
assess
ssw
quit
low
current
studi
use
new
digit
method
ssw
quantif
digit
wrinkl
primari
studi
object
defin
norm
valu
express
total
wrinkl
length
per
fingertip
surfac
subsequ
investig
applic
patient
definit
sfn
base
abnorm
iefnd
andor
ttt
determin
sensit
specif
well
valid
studi
includ
healthi
particip
patient
diagnos
sfn
elig
base
meet
inclus
exclus
criteria
provid
written
inform
consent
skin
wrinkl
induc
emla
eutect
mixtur
local
anesthet
applic
captur
take
pictur
primari
outcom
measur
total
length
wrinkl
per
shown
photograph
calcul
new
softwar
program
patient
stratifi
accord
age
gender
base
result
healthi
particip
norm
valu
defin
reliabl
determin
sfn
group
addit
correl
analysi
conduct
determin
correl
differ
outcom
measur
inventori
questionnair
visual
analogu
pain
scale
neuropath
pain
scale
overal
disabl
scale
ienfd
ttt
expect
provid
digit
quantifi
ssw
norm
valu
use
clinic
practic
diagnost
workup
sfn
juneja
azmi
baet
emmerson
bansagi
saveri
pisciotta
de
jongh
maudsley
horvath
pareyson
timmerman
neuropathi
research
group
univers
antwerp
belgium
univers
antwerp
belgium
genet
medicin
newcastl
univers
uk
clinic
neurosci
c
besta
neurolog
institut
milan
itali
character
axon
degener
inherit
motor
sensori
neuropathi
account
total
cmt
patient
subtyp
show
vast
genet
heterogen
mutat
known
gene
render
identif
relev
drug
target
therapi
challeng
far
hdac
inhibitor
shown
promis
result
mous
model
mediat
axon
cmt
albeit
singl
gene
approach
may
limit
relev
clinic
level
owe
limit
number
patient
per
genotyp
studi
investig
common
caus
molecular
player
associ
axon
degener
itraq
base
proteom
analysi
perform
five
patient
deriv
lymphoblast
bear
differ
causal
mutat
alongwith
respect
age
gender
match
unaffect
control
interpret
obtain
data
led
us
identifi
two
protein
significantli
downregul
patient
compar
control
two
protein
valid
use
western
blot
qpcr
patient
deriv
lymphoblast
fibroblast
result
prompt
us
unveil
whether
two
protein
use
potenti
biomark
identifi
patient
therefor
collabor
construct
cohort
patient
healthi
control
two
protein
exhibit
signific
downregul
cohort
suggest
potenti
new
role
protein
biomark
remark
also
abl
valid
signific
decreas
ineuron
neuron
differenti
patient
deriv
ipsc
strengthen
import
find
also
suggest
relev
protein
pathogensi
axon
cmt
first
studi
involv
multipl
cmt
causal
gene
therebi
hold
potenti
offer
new
drug
target
potenti
biomark
wider
applic
clinic
pharmaceut
jung
park
choi
kwak
hong
jung
kim
chung
choi
woman
univers
seoul
south
korea
univers
seoul
south
korea
nation
univers
gongju
south
korea
mesenchym
stem
cell
msc
repres
valuabl
sourc
stem
cell
therapi
differenti
variou
cell
type
investig
neuromuscular
potenti
human
msc
neuromuscular
regener
mice
consid
model
diseas
type
diseas
involv
hereditari
motor
sensori
peripher
neuropathi
differenti
toward
skelet
myocyt
evidenc
increas
express
skelet
marker
includ
troponin
type
myogenin
format
myotub
vitro
situ
transplant
myocyt
gastrocnemiu
mice
mous
model
enhanc
motor
function
identifi
recoveri
compound
muscl
action
potenti
cmap
amplitud
regener
shape
sciatic
nerv
skelet
muscl
immunochemistri
without
format
teratoma
furthermor
express
level
nerv
growth
factor
ngf
glial
cell
neurotroph
factor
gdnf
significantli
increas
compar
vitro
result
indic
transplant
therapeut
option
cell
therapi
neuromuscular
regener
hereditari
peripher
neuropathi
compris
diseas
kagiava
karaisko
richter
tryfono
lapath
sargiannid
christodoul
kleopa
laboratori
cypru
institut
neurolog
genet
nicosia
cypru
molecular
virolog
cypru
institut
neurolog
genet
nicosia
cypru
clinic
cypru
school
molecular
medicin
cypru
institut
neurolog
genet
nicosia
cypru
diseas
common
form
inherit
demyelin
peripher
neuropathi
result
mutat
affect
gap
junction
protein
use
knockout
ko
mous
model
diseas
shown
target
express
viral
deliv
result
morpholog
function
improv
sinc
patient
express
mutant
form
schwann
cell
could
potenti
interact
viral
deliv
wild
type
wt
effect
also
treat
mutant
mice
express
mutat
associ
ko
background
three
mutant
local
perinuclear
compart
myelin
schwann
cell
consist
retent
er
golgi
loss
physiolog
express
myelin
area
follow
intrathec
deliveri
human
gene
could
detect
viral
deliv
wt
correctli
local
myelin
area
mutant
mice
two
mutant
suggest
domin
effect
mutant
mutant
treat
ko
mice
show
improv
motor
perform
along
lower
ratio
abnorm
myelin
fiber
reduc
number
inflammatori
cell
tissu
examin
compar
anim
contrast
treat
mutant
mice
show
slight
statist
signific
improv
studi
provid
addit
proof
principl
clinic
translat
gene
therapi
treat
even
presenc
endogen
express
mutant
sinc
least
one
mutant
interfer
express
viral
deliv
allow
therapeut
benefit
similar
ko
mice
howev
mutant
may
interfer
viral
deliv
wt
approach
besid
gene
addit
may
need
effect
treatment
fund
muscular
dystrophi
associ
grant
mda
kak
kaida
kadoya
koik
iijima
takazaki
ogata
moriguchi
shimizu
nagata
takizawa
chiba
yamasaki
kira
sobu
ikewaki
defens
medic
colleg
tokorozawa
japan
univers
graduat
school
medicin
nagoya
japan
univers
fukuoka
japan
tokyo
tokyo
japan
univers
school
medicin
isehara
japan
univers
tokyo
japan
antibodi
glial
protein
neurofascin
nf
recent
identifi
approxim
patient
chronic
inflammatori
demyelin
polyneuropathi
cidp
cidp
may
distinct
subtyp
typic
cidp
term
clinic
featur
respons
immunotherapi
howev
diagnost
criterion
cidp
establish
yet
develop
optim
criteria
design
best
treatment
plan
cidp
procedur
determin
antibodi
simplifi
preval
reproduc
well
accur
assay
cba
hitherto
util
determin
antibodi
sera
patient
result
confirm
immunohistochemistri
ihc
use
teas
nerv
fiber
rodent
method
reliabl
techniqu
necessarili
easi
maintain
laboratori
present
studi
aim
valid
diagnost
util
convent
immunosorb
assay
elisa
determin
antibodi
igg
subclass
sera
patient
efnspn
cidp
examin
elisa
use
human
recombin
verifi
elisa
result
ihc
rat
sciatic
nerv
western
blot
wb
cba
use
naiv
cell
conduct
human
elisa
clearli
distinguish
sera
fifteen
cidp
patient
confirm
wb
ihc
cba
studi
none
diseas
control
healthi
subject
posit
result
sera
randomli
select
cidp
sera
also
neg
cba
activ
elisa
significantli
cba
p
analys
clinic
laboratori
find
show
cidp
character
younger
onset
distal
domin
phenotyp
tremor
sensori
ataxia
higher
protein
level
cerebrospin
fluid
poor
respons
ivig
consist
previou
studi
elisa
combin
determin
subclass
simpl
reliabl
method
initi
screen
antibodi
kanhangad
cornett
brewer
nicholson
ouvrier
ryan
smith
subramanian
young
kennerson
burn
menez
nelson
depart
neurolog
neurosurgeri
children
hospit
westmead
westmead
australia
sydney
camperdown
australia
neurosci
muscl
research
children
hospit
westmead
westmead
australia
neurosci
laboratori
anzac
research
institut
concord
australia
medicin
laboratori
concord
repatri
gener
hospit
concord
australia
neurolog
royal
children
hospit
parkvil
australia
children
research
institut
parkvil
victoria
australia
paediatr
univers
melbourn
parkvil
australia
neurolog
john
hunter
children
hospit
univers
faculti
health
newcastl
australia
paediatr
royal
north
shore
hospit
st
leonard
australia
gait
analysi
servic
new
south
wale
sydney
children
hospit
network
randwick
westmead
australia
genet
abnorm
respons
neuropathi
subtyp
recent
identifi
whole
genom
sequenc
kb
insert
chromosom
clinic
profil
childhood
well
describ
review
clinic
characterist
neurophysiolog
profil
cmt
pediatr
scale
cmtped
assess
children
genet
confirm
character
earli
onset
earli
progress
hand
weak
affect
children
symptomat
within
first
two
year
life
common
present
equinovaru
foot
deform
first
year
life
cmtped
analysi
children
reveal
progress
rapidli
year
grip
strength
second
decad
life
affect
male
two
standard
deviat
norm
refer
valu
sever
affect
individu
wheelchair
bound
year
age
two
individu
movement
small
muscl
hand
second
decad
life
singl
symptomat
femal
identifi
mild
sign
nerv
conduct
studi
show
demyelin
sensorimotor
neuropathi
motor
conduct
veloc
eight
children
one
child
sensorimotor
axon
neuropathi
understand
uniqu
phenotyp
essenti
direct
genet
test
insert
detect
snp
microarray
panel
sequenc
current
use
diagnosi
cmt
earli
onset
diseas
coupl
rapid
progress
mean
mani
children
sever
disabl
within
first
two
decad
life
henc
earli
diagnosi
need
earli
commenc
rehabilit
kapoor
catania
lunn
manji
reilli
carr
neuromuscular
diseas
nation
hospit
neurolog
neurosurgeri
london
uk
neurophysiolog
nation
hospit
neurolog
neurosurgeri
london
uk
convent
dose
ivig
cidp
mmn
base
treatment
trial
use
bolu
mainten
dose
ivig
rare
publish
articl
report
efficaci
higher
mainten
ivig
dose
present
three
case
inflammatori
neuropathi
current
stabil
ivig
dose
ivig
per
month
refractori
standard
dose
ivig
immunosuppress
first
case
cidp
present
episod
ascend
sensori
disturb
weak
diplopia
activ
relat
fluctuat
deterior
ivig
acut
deterior
mrc
sum
score
drop
even
addit
plasma
exchang
bilater
foot
drop
mrc
grade
fluctuat
persist
increas
ivig
clinic
stabl
ankl
dorsiflexion
mrc
grade
mrc
sum
score
mycophenol
ivig
weekli
case
male
fit
instructor
mmn
sjogren
syndrom
present
recurr
proxim
distal
weak
respond
ivig
deterior
iv
methylprednisolon
fluctuat
intermit
proxim
weak
persist
foot
drop
ankl
dorsiflexion
mrc
grade
worsen
mrc
grade
fluctuat
mrc
grade
increas
ivig
weekli
result
mmn
rod
score
improv
distal
power
return
full
capac
work
case
man
predominantli
upper
limb
cidp
receiv
ivig
without
benefit
respons
dose
plasma
exchang
dose
cyclophosphamid
dose
rituximab
sinc
receiv
ivig
improv
mrc
sum
score
case
highlight
patient
requir
much
higher
convent
prescrib
dose
ivig
dose
toler
year
without
seriou
advers
event
katona
schrempf
dogan
von
felbert
wieneck
heller
maier
hermann
lins
brandt
reichmann
schulz
schiefer
oertel
storch
wei
reetz
neuropatholog
rwth
aachen
univers
aachen
germani
neurolog
technisch
dresden
dresden
germani
neurolog
rwth
aachen
univers
aachen
germani
translat
brain
medicin
aachen
germani
dermatolog
allergolog
rwth
aachen
univers
aachen
germani
center
neurodegen
diseas
dzne
dresden
dresden
germani
neurosci
medicin
research
center
gmbh
germani
neurolog
philipp
univers
marburg
germani
neurodegen
diseas
depart
neurolog
technisch
dresden
germani
neurolog
univers
rostock
rostock
germani
idiopath
rapid
eye
movement
sleep
behaviour
disord
irbd
identifi
precursor
parkinson
diseas
dementia
lewi
bodi
multipl
system
atrophi
sever
studi
link
chang
cutan
innerv
central
nervou
system
patholog
neurodegen
disord
recent
small
fiber
neuropathi
deposit
skin
found
potenti
biomark
parkinson
diseas
evalu
epiderm
innerv
irbd
patient
age
control
skin
punch
biopsi
distal
leg
use
immunohistochemistri
furthermor
batteri
clinic
examin
perform
patient
control
alik
includ
structur
interview
clinic
motor
questionnair
rate
scale
eg
unifi
parkinson
diseas
rate
scale
updr
symptom
questionnair
beck
depress
inventori
epworth
sleepi
scale
evalu
cognit
olfactori
function
well
blood
sampl
irbd
patient
compar
control
show
signific
reduct
intraepiderm
nerv
fiber
densiti
p
wherea
axon
swell
ratio
differ
group
patient
irbd
report
symptom
frequent
control
updr
olfact
daytim
sleepi
differ
group
wherea
differ
regard
cognit
vivo
find
demonstr
small
fiber
neuropathi
irbd
patient
associ
symptom
indic
peripher
abnorm
may
occur
earli
irbd
warrant
larger
scale
longitudin
studi
order
investig
prognost
valu
katz
lewi
spatafora
pacif
med
center
san
francisco
usa
medic
center
lo
angel
usa
action
foundat
naf
santa
ana
usa
multifoc
motor
neuropathi
mmn
rare
condit
affect
everi
individu
worldwid
associ
motor
dysfunct
moder
sever
disabl
neuropathi
action
foundat
conduct
global
survey
determin
impact
mmn
patient
qualiti
life
qol
gap
patientprovid
educ
need
first
global
mmn
qol
survey
item
internet
questionnair
avail
januari
juli
survey
focus
three
primari
area
time
accur
diagnosi
efficaci
treatment
impact
diseas
patient
qol
survey
complet
patient
countri
major
respond
said
diagnos
age
year
report
took
one
year
diagnos
report
took
year
longer
accur
diagnos
respect
treatment
option
report
receiv
intraven
immun
globulin
report
receiv
subcutan
immun
globulin
therapi
therapi
use
treat
mmn
gabapentin
pregabalin
almost
half
said
mmn
often
impact
overal
schedul
half
particip
report
mmn
often
alway
interfer
employ
difficulti
type
comput
use
telephon
troubl
concentr
said
work
realli
hard
pay
attent
els
would
make
mistak
first
assess
mmn
patient
perspect
survey
highlight
critic
issu
relat
diagnosi
manag
impact
qol
individu
mmn
data
also
identifi
gap
insight
provid
educ
relat
proper
diagnos
manag
condit
patient
perspect
katz
levin
dimachk
barohn
norri
center
san
francisco
ca
usa
neurolog
institut
phoenix
az
usa
univers
medic
center
kansa
citi
ks
usa
unit
state
cidp
case
submit
insur
compani
determin
whether
ivig
therapi
appropri
done
use
specifi
diagnost
criteria
reduc
diagnosi
boolean
analysi
diseas
present
absent
leav
room
uncertainti
even
truli
exist
boolean
criteria
use
clinic
trial
fall
short
real
decis
made
uncertainti
base
perceiv
costbenefit
analysi
project
attempt
elucid
root
caus
uncertainti
find
solut
dilemma
ask
cidp
expert
select
singl
diagnosi
case
ivig
approv
use
submit
case
record
agreement
mani
case
five
uncertain
case
review
agre
singl
condit
chose
four
separ
entiti
among
least
three
review
diagnos
immun
neuropathi
five
root
caus
disagr
larg
degre
unclear
document
aunt
consist
past
miss
disorgan
data
review
miss
use
inform
admit
difficult
fulli
pars
record
resolv
uncertainti
review
admit
discount
certain
report
datum
help
fit
entiti
suspect
report
therapeut
respons
certain
electrodiagnosticexam
find
disagr
howev
reflect
complex
neuropathi
diagnosi
know
improv
due
natur
histori
treatment
unawar
rare
present
analyz
true
uncl
complex
case
review
use
bayesian
select
like
diagnos
list
fuzzi
logic
compar
best
fit
base
case
best
diagnosi
fit
base
case
data
improv
review
procedur
requir
elimin
aunt
collect
key
inform
simplifi
record
present
also
need
advanc
data
method
analyz
common
rare
borderlin
present
uncl
like
mama
v
pma
cidp
v
cspn
etc
develop
diagnost
algorithm
address
real
uncertainti
educ
prescrib
patient
process
creat
system
measur
outcom
longitudin
induct
taper
therapi
keisuk
miyuki
motoi
susumu
neurolog
faculti
medicin
kinki
univers
osaka
japan
antibodi
close
associ
clinic
phenotyp
specif
symptom
acut
neuropathi
igg
antibodi
specif
associ
miller
fisher
syndrom
mf
bickerstaff
brainstem
enceph
bbe
syndrom
gb
opthalmoplegia
addit
gangliosid
complex
gsc
contain
also
target
diseas
might
associ
clinic
featur
howev
factor
regul
clinic
phenotyp
diseas
yet
known
investig
differ
antibodi
reactiv
among
diseas
examin
use
combinatori
glycoarray
igg
antibodi
ten
individu
glycolipid
galactocerebrosid
lactosylceramid
laccer
sulfatid
glycolipid
complex
consist
two
glycolipid
list
sera
patient
posit
antibodi
elisa
patient
mf
clinic
triad
opthalmoplegia
ataxia
areflexia
patient
bbe
combinatori
glycoarray
overal
sensit
antibodi
gsc
contain
mf
bbe
respect
signific
differ
antibodi
reactiv
mf
bbe
notabl
antibodi
gsc
contain
frequent
found
patient
mf
bbe
patient
eg
p
respect
presenc
antibodi
reactiv
gsc
contain
may
possibl
relat
clinic
featur
includ
frequent
need
artifici
ventil
kennedi
carrol
paterson
ryan
mcginley
children
hospit
parkvil
australia
melbourn
parkvil
australia
children
research
institut
parkvil
australia
problem
walk
footwear
fit
often
report
children
adolesc
diseas
cmt
case
control
studi
gait
conduct
children
cmt
typic
develop
td
children
gait
assess
barefoot
two
type
particip
typic
footwear
optim
eg
athlet
shoe
suboptim
eg
footwear
aim
determin
differ
gait
variabl
children
cmt
td
children
investig
effect
footwear
choic
independ
ambul
children
age
year
confirm
genet
clinic
diagnos
cmt
age
gender
match
td
children
particip
mean
age
year
male
exclus
criteria
includ
development
disord
neuromuscular
condit
diseas
could
affect
gait
lower
limb
injuri
surgeri
preced
month
assess
includ
gait
pattern
footwear
characterist
metr
run
cmtped
gait
assess
speed
electron
walkway
trial
condit
primari
gait
variabl
assess
speed
variabl
includ
step
length
step
time
cadenc
base
support
width
gait
variabl
across
footwear
condit
children
cmt
walk
slowli
optim
cmt
ms
td
ms
suboptim
cmt
ms
td
ms
barefoot
cmt
ms
td
ms
p
shorter
step
optim
cmt
cm
td
cm
suboptim
cmt
cm
td
cm
barefoot
cmt
cm
td
cm
p
wider
base
support
optim
cmt
cm
td
cm
suboptim
cmt
cm
td
cm
barefoot
cmt
cm
td
cm
p
gait
perform
optim
footwear
group
significantli
faster
compar
suboptim
barefoot
children
cmt
significantli
greater
variabl
base
support
width
footwear
condit
children
cmt
walk
slower
td
children
shorter
wider
step
increas
variabl
footwear
type
affect
gait
khoshnoodi
truelov
polydefki
hopkin
univers
baltimor
md
usa
regener
cutan
unmyelin
axon
known
slow
densiti
intraepiderm
nerv
fiber
ienf
return
baselin
level
chemic
mechan
axotomi
howev
outcom
regener
dm
control
subject
known
addit
clear
regener
sensori
distal
axon
measur
rate
axon
regener
chemic
denerv
use
capsaicin
model
dm
patient
without
neuropathi
control
dm
skin
punch
perform
distal
thigh
baselin
day
blood
glucos
measur
baselin
day
healthi
control
skin
punch
distal
leg
proxim
thigh
baselin
capsaicin
chemic
axotomi
day
regener
rate
significantli
higher
thigh
healthi
control
fibersmmday
ci
fibersmmday
compar
dm
differ
fibersmmday
ci
fibersmmday
fibersmmday
ci
fibersmmday
compar
regener
rate
differ
time
interv
show
regener
significantli
slow
day
dm
patient
continu
rate
control
blood
glucos
effect
regener
rate
ienfd
return
baselin
control
baselin
dm
subject
ienfd
baselin
dm
vs
control
differ
regener
rate
ienfd
distal
leg
proxim
thigh
control
result
suggest
rate
outcom
regener
independ
length
axon
addit
diabet
patient
incomplet
nerv
regener
month
regardless
diabet
type
level
glycem
control
regener
axon
slow
time
patient
dm
reach
plateau
day
kiessl
watanab
langdon
tran
bari
christodoul
price
smith
byrn
brock
joll
pharma
monheim
germani
pharma
slough
uk
pharma
belgium
solut
ltd
london
uk
pharma
raleigh
durham
usa
hospit
wale
cardiff
uk
humanis
monoclon
igg
antibodi
develop
bind
human
neonat
fc
receptor
fcrn
select
inhibit
igg
salvag
recycl
condit
myasthenia
gravi
mg
characteris
pathogen
igg
autoantibodi
inhibit
fcrn
may
provid
suitabl
therapeut
phase
studi
evalu
safeti
pharmacolog
healthi
adult
mean
age
year
rang
randomis
receiv
singl
dose
intraven
iv
subcutan
sc
placebo
respect
singl
dose
iv
sc
mgkg
per
dose
per
administr
subject
follow
day
one
placebo
iv
subject
complet
studi
subject
receiv
receiv
placebo
report
advers
event
teae
mildmoder
intens
sever
teae
occur
four
subject
mgkg
iv
group
headach
back
pain
seriou
ae
occur
incid
infect
similar
placebo
frequent
report
infect
nasopharyng
teae
report
subject
receiv
receiv
placebo
common
group
headach
vomit
occur
frequent
iv
sc
rout
increas
plasma
profil
increas
dose
observ
serum
igg
reduc
manner
iv
sc
decreas
baselin
day
iv
mgkg
dose
respect
sc
dose
respect
data
indic
fcrn
inhibitor
effect
reduc
serum
igg
sc
administr
gener
better
toler
iv
observ
efficaci
safeti
toler
sc
treatment
mg
evalu
ongo
phase
ii
randomis
studi
eudract
akilesh
nat
rev
immunol
thank
alexandra
webster
msc
ime
comm
ashfield
compani
part
udg
healthcar
plc
provid
medic
write
support
fund
ucb
pharma
kim
heo
kim
song
park
park
ahn
kim
choi
neurolog
seoul
medic
center
seoul
south
korea
pulmonolog
critic
care
medicin
depart
intern
medicin
seoul
medic
center
seoul
south
korea
infecti
diseas
depart
intern
medicin
seoul
medic
center
seoul
south
korea
middl
east
respiratori
syndrom
mer
high
mortal
rate
pandem
potenti
howev
littl
inform
becom
avail
syndrom
sinc
first
erupt
studi
aim
evalu
frequenc
neurolog
complic
clinic
present
mer
review
medic
record
patient
diagnos
mer
coronaviru
cov
infect
subsequ
admit
singl
refer
center
mer
treatment
outbreak
korea
total
patient
report
neurolog
symptom
infect
potenti
diagnos
case
includ
bickerstaff
enceph
overlap
syndrom
critic
ill
polyneuropathi
toxic
infecti
neuropathi
neurolog
complic
appear
concomitantli
respiratori
symptom
instead
delay
week
neuromuscular
complic
rare
patient
may
previous
underdiagnos
understand
neurolog
manifest
import
infecti
diseas
like
mer
evalu
frequent
limit
treatment
interfer
prognosi
sometim
requir
modif
treatment
kim
hyun
kim
univers
cheonan
south
korea
diagnosi
carpal
tunnel
syndrom
ct
base
clinic
symptom
physic
examin
support
nerv
conduct
studi
nc
ultrasonograph
examin
perform
assess
peripher
nerv
less
discomfort
surround
anatom
structur
use
ultrasonographi
usg
ct
report
studi
date
compar
diagnost
util
variou
usg
find
ct
investig
correl
variou
usg
find
clinic
symptomssign
nc
find
patient
ct
hand
patient
ct
base
electrodiagnost
criteria
clinic
symptom
tingl
sensat
pain
first
third
finger
burn
sensat
paresthesia
weak
hand
grip
power
subject
examin
usg
area
csa
flatten
ratio
fr
median
nerv
calcul
level
joint
pisiform
hamat
swell
ratio
median
nerv
palmar
displac
flexor
retinaculum
also
calcul
clinic
assess
conduct
use
boston
carpal
tunnel
questionnair
bctq
scale
scale
analysi
correl
usg
find
clinic
symptom
scalesnc
find
perform
use
correl
analysi
csa
median
nerv
level
joint
signific
correl
bctq
scale
scale
distal
motor
latenc
conduct
veloc
cv
csa
median
nerv
level
pisiform
significantli
correl
scale
distal
motor
latenc
cv
fr
median
nerv
level
joint
significantli
correl
bctq
scale
scale
distal
motor
latenc
cv
swell
ratio
median
nerv
also
significantli
correl
distal
motor
latenc
cv
patient
ct
csa
median
nerv
level
joint
close
relat
nc
find
clinic
symptom
csa
median
nerv
joint
might
complementari
tool
diagnosi
ct
kitaoji
tsuji
ashida
yamada
ishii
tanaka
mizuno
neurolog
graduat
school
medic
scienc
kyoto
prefectur
univers
medicin
kyoto
japan
case
woman
first
notic
paresthesia
right
plantar
eight
month
admiss
left
plantar
four
month
admiss
three
month
admiss
develop
muscl
weak
feet
muscl
weak
paresthesia
extend
lower
leg
month
twenti
day
admiss
experi
difficulti
walk
admiss
muscl
weak
observ
leg
especi
right
tibial
anterior
muscl
ta
sever
sensori
disturb
loss
deep
tendon
reflex
leg
troubl
walk
due
weak
sensori
aphasia
nerv
conduct
studi
nc
conduct
block
observ
ankl
poplit
tibial
nerv
blood
level
angiotensin
convert
enzym
ace
elev
cerebrospin
fluid
analysi
normal
enhanc
lumbar
nerv
root
shown
mri
scintigraphi
show
hot
spot
bilater
hilar
lymph
node
mediastin
node
biopsi
mediastin
node
show
epithelioid
granuloma
therefor
diagnos
sarcoid
peripher
neuropathi
sarcoidosi
use
nerv
ultrasound
partial
nerv
enlarg
observ
part
conduct
block
left
tibial
nerv
start
treatment
methyl
prednisolon
oral
prednisolon
therapi
treatment
paresthesia
muscl
weak
leg
gradual
improv
partial
enlarg
left
tibial
nerv
also
improv
day
nc
conduct
block
improv
howev
compound
muscl
nerv
potenti
tibial
nerv
decreas
axon
damag
partial
nerv
enlarg
use
ultrasound
never
report
sarcoid
peripher
neuropathi
nerv
ultrasound
may
use
evalu
therapeut
effect
sarcoid
peripher
neuropathi
oksuz
demir
ersay
cevik
neurosurgeri
univers
tokat
turkey
neurolog
univers
tokat
turkey
peripher
nerv
injuri
still
debat
problem
world
poor
recoveri
absolut
need
new
therapeut
agent
improv
outcom
alter
nerv
regener
studi
literatur
therapeut
agent
use
case
peripher
nerv
injuri
despit
studi
agent
clinic
use
present
yet
experiment
studi
aim
analyz
effect
curcumin
cur
case
peripher
nerv
injuri
forti
rat
randomli
equal
divid
four
group
first
group
control
group
rat
group
oper
right
sciatic
nerv
injuri
perform
group
second
group
oper
group
therapeut
agent
third
group
oper
local
cur
appli
group
fourth
group
oper
system
cur
appli
group
electrophysiolog
evalu
perform
electroneurographi
enog
surgeri
system
use
cur
although
caus
improv
enog
valu
could
make
posit
contribut
nerv
regener
statist
addit
local
use
cur
made
neg
effect
nerv
regener
statist
accord
statist
result
could
recommend
cur
nerv
protect
agent
klein
wu
jentoft
mer
spinner
dyck
dyck
mauermann
clinic
rochest
usa
intraneur
perineurioma
hypertroph
peripher
nerv
tumor
immunoreact
epitheli
neg
origin
perineuri
cell
debat
similar
mening
cell
ip
metastas
motor
deficit
accumul
time
tumor
growth
nerv
plexu
schwannoma
neurofibroma
perineurioma
common
nerv
tumor
young
adult
chromosom
delet
report
one
patient
ip
case
previous
publish
clinic
cohort
avail
flash
frozen
ip
tissu
dna
isol
we
cnv
analysi
cgh
microarray
analysi
agil
perform
extract
dna
avail
germlin
dna
lymphocyt
buccal
tissu
compar
exom
data
onlin
control
data
examin
variant
less
frequenc
predict
damag
nonsynonym
we
identifi
three
novel
heterozyg
damag
mutat
tumor
necrosi
factor
factor
case
mutat
within
domain
within
exon
within
exon
map
limit
region
protein
structur
model
two
case
show
macroduplicationsdelet
multipl
chromosom
includ
chromosom
confirm
cgh
microarray
analysi
cnv
result
exom
data
analysi
four
discov
mutat
age
onset
sever
correl
type
mutat
studi
provid
strong
evid
specif
tumor
driver
ip
mutat
also
link
benign
intracrani
meningioma
suggest
share
pathogenesi
close
origin
perineuri
mening
cell
studi
support
mayo
foundat
mayo
center
individu
medicin
klein
bobylev
lehmann
hospit
cologn
cologn
germani
molecular
medicin
cologn
cmmc
cologn
germani
peripher
neuropathi
common
side
effect
paclitaxel
clinic
evid
suggest
deliveri
mechan
paclitaxel
formul
influenc
time
cours
sever
paclitaxel
induc
peripher
neuropathi
preclin
model
studi
access
distribut
toxic
two
paclitaxel
formul
nanoparticl
paclitaxel
nab
paclitaxel
peripher
nervou
system
pn
mice
treat
mgkg
mgkg
solvent
base
paclitaxel
kinet
paclitaxel
neuron
assess
newli
establish
immunostain
techniqu
neurotox
evalu
function
assay
nerv
morpholog
paclitaxel
accumul
mostli
dorsal
root
ganglia
wherea
distal
nerv
segment
show
low
uptak
paclitaxel
treatment
mice
two
paclitaxel
formul
result
paclitaxel
uptak
mostli
larger
fiber
neuron
cgrp
small
fiber
neuron
paclitaxel
less
frequent
detect
incorpor
rapidli
compar
paclitaxel
neuron
also
show
faster
clearanc
compar
solvent
base
paclitaxel
function
assay
nerv
conduct
studi
indic
less
neurotox
compar
paclitaxel
first
studi
character
detail
access
solvent
base
paclitaxel
pn
find
import
implic
understand
pathomechan
paclitaxel
induc
neurotox
develop
neuroprotect
strategi
prevent
access
paclitaxel
pn
kobayashi
takeuchi
suzuki
kitagawa
neurolog
tokyo
women
medic
univers
tokyo
japan
aim
studi
investig
etiolog
neuropathi
patient
rheumatoid
arthriti
ra
subject
neuropathi
patient
ra
admit
depart
laboratori
investig
nerv
conduct
studi
nc
sural
nerv
biopsi
perform
mean
patient
age
year
rang
year
mean
diseas
durat
year
rang
year
clinic
diagnosi
neuropathi
rheumatoid
vascul
rv
patient
rv
acut
motor
axon
neuropathi
chronic
inflammatori
demyelin
polyneuropathi
ra
rheumatoid
factor
rheumatoid
arthriti
particl
agglutin
high
tend
lower
rv
group
rv
antibodi
examin
patient
posit
result
case
diagnos
clinic
present
presenc
immunoglobulin
ig
g
antibodi
case
rv
examin
antibodi
posit
result
igg
antibodi
seen
one
patient
evalu
suralmedian
sm
ratio
sensori
nerv
action
potenti
snap
sm
ratio
low
rv
case
high
case
suggest
normal
sural
abnorm
median
pattern
neuropathi
case
show
moder
valu
sm
ratio
nerv
biopsi
reveal
thinli
myelin
nerv
fiber
case
compat
demyelin
rv
group
show
typic
patholog
necrot
vascul
rv
case
treat
prednisolon
psl
intraven
methylprednisolon
intraven
cyclophosphamid
increas
psl
dose
treat
intraven
ig
conclus
neuropathi
ra
divid
vasculit
group
nc
sm
ratio
snap
laboratori
paramet
particular
may
use
differenti
diagnosi
decid
treatment
strategi
koh
wong
loh
chng
pawa
ei
lee
subramaniam
umapathi
neurosci
institut
singapor
singapor
kong
chian
school
medicin
nanyang
technolog
univers
singapor
loo
lin
school
medicin
nation
univers
singapor
singapor
tock
seng
hospit
singapor
teck
puat
hospit
singapor
neuropathi
diabet
mellitu
dm
tind
acut
pain
autonom
neuropathi
develop
abrupt
improv
glycaem
control
typic
type
dm
patient
insulin
oral
hypoglycaem
agent
ohga
present
pain
neuropathi
autonom
dysfunct
within
week
rapid
improv
glucos
control
current
emphasi
achiev
good
glycaem
control
rapidli
may
inadvert
increas
incid
tind
henc
impetu
understand
risk
glycaem
control
therefor
set
studi
occurr
tind
dm
cohort
tertiari
hospit
screen
patient
two
measur
period
approxim
patient
seen
per
year
found
show
decreas
month
month
use
structur
checklist
tind
symptom
shortlist
case
scrutinis
classifi
probabl
tind
acut
pain
neuropathi
acut
dysautonomia
tempor
relationship
decreas
possibl
tind
acut
pain
neuropathi
acut
dysautonomia
uncertain
tempor
relationship
decreas
unlik
tind
altern
explan
exist
symptom
one
case
deem
probabl
tind
man
newli
diagnos
type
dm
present
emerg
depart
palpit
worsen
frozen
feet
sensat
disturb
sleep
decreas
week
symptom
improv
within
month
neuropath
pain
medic
resolv
month
later
also
develop
maculopathi
prolif
retinopathi
ten
month
later
develop
signific
proteinuria
four
case
classifi
possibl
tind
remain
unlik
tind
studi
limit
retrospect
design
relianc
hospit
record
nevertheless
find
suggest
tind
uncommon
gener
cohort
dm
patient
hand
number
patient
pain
neuropathi
acut
dysautonomia
symptom
contemporan
rapid
declin
rais
intrigu
possibl
form
frust
tind
exist
one
interrog
rate
declin
dm
patient
symptom
koik
kadoya
kaida
ikeda
kawagashira
iijima
kato
ogata
yamasaki
matsukawa
kira
katsuno
sobu
univers
graduat
school
medicin
nagoya
japan
defens
medic
colleg
tokorozawa
japan
citi
univers
graduat
school
medic
scienc
nagoya
japan
univers
fukuoka
japan
investig
morpholog
featur
chronic
inflammatori
demyelin
polyneuropathi
cidp
autoantibodi
direct
paranod
junction
molecul
particularli
focus
fine
structur
paranod
sural
nerv
biopsi
specimen
obtain
cidp
patient
antibodi
patient
antibodi
assess
antibodi
examin
use
sera
obtain
patient
cidp
fulfil
criteria
european
feder
neurolog
societiesperipher
nerv
societi
thirteen
cidp
patient
without
antibodi
also
examin
compar
patholog
find
characterist
light
electron
microscopi
find
transvers
section
patient
antibodi
indic
slight
reduct
myelin
fiber
densiti
scatter
myelin
ovoid
absenc
demyelin
onion
bulb
prepar
reveal
segment
demyelin
tend
found
patient
rel
high
frequenc
axon
degener
tandemli
found
consecut
node
ranvier
singl
fiber
assess
longitudin
section
electron
microscopi
reveal
detach
termin
myelin
loop
axolemma
frequent
found
paranod
cidp
patient
compar
cidp
patient
patient
antibodi
show
posit
correl
frequenc
detach
paranod
axon
degener
assess
prepar
p
conclus
paranod
dissect
without
classic
demyelin
characterist
featur
patient
cidp
autoantibodi
paranod
junction
molecul
koik
ikeda
takahashi
kawagashira
iijima
misumi
ando
ikeda
katsuno
sobu
univers
graduat
school
medicin
nagoya
japan
univers
kumamoto
japan
univers
hospit
matsumoto
japan
peripher
neuropathi
cardin
featur
famili
amyloid
polyneuropathi
fap
mechan
fulli
elucid
use
electron
microscopi
examin
schwann
cell
endoneuri
microvessel
sural
nerv
biopsi
specimen
fap
patient
transthyretin
mutat
assess
patient
consist
earli
onset
case
endem
foci
late
onset
case
area
loss
nerv
fiber
without
neighbor
amyloid
deposit
common
featur
amount
amyloid
deposit
greater
rel
extent
nerv
fiber
loss
earli
onset
case
late
onset
case
atrophi
schwann
cell
particularli
nonmyelin
cell
appos
amyloid
fibril
conspicu
earli
onset
case
late
onset
case
number
endotheli
cell
nuclei
endotheli
cell
profil
occlud
microvessel
significantli
increas
fap
patient
compar
patient
nutritionalalcohol
neuropathi
p
respect
find
suggest
disrupt
barrier
loss
tight
junction
fenestr
endotheli
cell
also
frequent
found
fap
patient
p
irrespect
presenc
absenc
amyloid
deposit
conclus
find
suggest
direct
insult
amyloid
fibril
caus
schwann
cell
damag
result
predomin
loss
axon
characterist
earli
onset
case
addit
vasculopathi
may
also
particip
pathogenesi
neuropathi
particularli
late
onset
case
kolb
smith
singleton
beck
howard
dittu
karafiath
mooney
vermont
burlington
vt
usa
utah
health
slc
ut
usa
chemotherapi
induc
peripher
neuropathi
cipn
major
caus
morbid
due
numb
pain
gait
instabl
prospect
studi
compar
current
standard
care
cipn
symptom
manag
new
care
deliveri
model
util
autom
symptom
track
program
pair
nurs
practition
led
intervent
trigger
moder
sever
symptom
particip
begin
taxan
platin
base
chemotherapi
call
telephon
base
autom
symptom
track
program
daili
symptom
care
home
sch
report
chemotherapi
relat
numb
tingl
sch
track
presenc
sever
neuropath
symptom
interfer
activ
daili
live
adl
scale
particip
random
two
group
usual
care
uc
group
advis
call
oncolog
provid
recommend
symptom
manag
nurs
practition
np
group
symptom
sever
particip
receiv
autom
self
care
strategi
call
nurs
practition
provid
treatment
recommend
base
consensu
guidelin
patient
particip
studi
mean
durat
follow
day
call
np
group
fewer
day
neuropath
symptom
vs
moder
sever
neuropath
symptom
vs
p
day
distress
neuropath
symptom
vs
day
moder
sever
symptom
particip
also
report
burn
weak
balanc
problem
trip
signific
differ
group
interfer
adl
np
vs
uc
overal
autom
telephon
system
effect
identifi
neuropathi
symptom
sever
compar
usual
care
patient
must
independ
reach
care
team
symptom
manag
sch
effect
decreas
symptom
preval
sever
distress
kouton
kremer
tard
moral
kuntzer
attarian
boucraut
delmont
centr
al
neuromuscular
diseas
marseil
franc
depart
strasbourg
franc
depart
lill
franc
depart
montpelli
franc
depart
lausann
switzerland
laboratori
marseil
franc
antibodi
protein
node
ranvier
recent
describ
sever
chronic
inflammatori
demyelin
polyradiculoneuropathi
cidp
target
paranod
protein
name
contactin
neurofascin
assay
elisa
avail
research
gold
standard
technic
admit
detect
routin
antibodi
object
evalu
flow
cytometri
analysi
effici
technic
detect
antibodi
larg
cohort
cidp
patient
flow
cytometri
analysi
perform
bd
human
embryon
kidney
hek
cell
transfect
either
sera
dilut
antibodi
reveal
use
fitc
conjug
anti
human
igg
antibodi
delta
mfi
mean
fluoresc
intens
calcul
mfi
transfect
cell
less
mfi
cell
measur
normal
use
posit
control
neg
control
healthi
blood
donor
sera
cidp
patient
differ
french
neuromuscular
referr
centr
analys
flow
cytometri
respect
delta
mfi
standard
deviat
standard
deviat
antibodi
cidp
antibodi
neg
patient
antibodi
found
patient
respect
mfi
two
patient
respect
mfi
isotyp
antibodi
patient
remain
patient
patient
sever
cidp
four
patient
poor
respons
intraven
immunoglobulin
ivig
treat
immunosuppress
drug
usual
report
patient
antibodi
postur
tremor
flow
cytometri
seem
effect
detect
antibodi
compar
assay
benefit
flow
cytometri
analys
larg
number
sera
time
give
object
numer
result
express
mfi
compar
result
sampl
studi
need
confirm
flow
cytometri
best
test
assess
antibodi
routin
kovalchuk
franssen
van
schelven
van
den
berg
sleutj
neuromuscular
disord
univers
medic
centr
utrecht
utrecht
netherland
medic
technolog
clinic
physic
univers
medic
centr
utrecht
utrecht
netherland
mechan
intraven
immunoglobulin
ivig
improv
peripher
nerv
function
multifoc
motor
neuropathi
mmn
unknown
rapid
clinic
improv
follow
ivig
could
relat
block
complement
deposit
epitop
chang
properti
affect
motor
axon
present
studi
investig
median
nerv
motor
excit
paramet
ivig
administr
well
peak
clinic
improv
patient
mmn
investig
nerv
character
either
conduct
block
n
demyelin
slow
without
block
n
motor
axon
loss
result
motor
excit
test
mmn
show
differ
post
ivig
record
clinic
assess
apb
muscl
show
increas
mrc
score
patient
decreas
patient
ivig
administr
patient
mrc
score
apb
remain
find
indic
clinic
chang
follow
ivig
administr
relat
excit
paramet
affect
motor
axon
mmn
kovalchuk
franssen
van
schelven
van
den
berg
sleutj
neuromuscular
disord
univers
medic
centr
utrecht
utrecht
netherland
medic
technolog
clinic
physic
univers
medic
centr
utrecht
utrecht
netherland
nerv
conduct
studi
nc
multifoc
motor
neuropathi
mmn
show
local
segment
mix
nerv
impuls
conduct
block
markedli
slow
motor
axon
normal
sensori
axon
sensori
symptom
sign
usual
absent
occasion
report
skin
area
innerv
nerv
promin
motor
axon
loss
although
mechan
select
motor
involv
mmn
unresolv
may
relat
differ
antigen
properti
motor
sensori
axon
differ
biophys
properti
object
present
studi
compar
activ
motor
sensori
axon
nerv
affect
mmn
affect
nerv
motor
conduct
block
demyelin
slow
motor
nc
motor
axon
loss
wherea
sensori
nc
normal
perform
excit
test
motor
sensori
axon
affect
median
nerv
mmn
patient
healthi
control
condit
test
stimuli
deliv
median
nerv
wrist
cmap
record
thenar
muscl
snap
digit
result
motor
excit
test
mmn
show
threshold
electrotonu
decreas
iv
slope
increas
superexcit
compat
persist
hyperpolar
rest
membran
potenti
motor
axon
sensori
excit
test
mmn
show
decreas
subexcit
otherwis
normal
may
indic
minim
involv
sensori
axon
mmn
krarup
moldovan
alvarez
ciano
pisciotta
pareyson
copenhagen
copenhagen
denmark
copenhagen
denmark
ircc
istituto
neurologico
c
besta
incb
milan
itali
mutat
gene
code
myelin
protein
zero
mpz
associ
differ
form
cmt
diseas
describ
famili
harbor
frameshift
mutat
gene
predict
result
nonfunct
truncat
earli
extracellular
domain
offer
rare
opportun
assess
consequ
defici
absenc
potenti
effect
mutat
convent
conduct
studi
multipl
measur
nerv
excit
threshold
track
carri
heterozygot
parent
age
two
homozygot
son
age
homozyg
patient
distal
limb
cmap
snap
absent
neurophysiolog
assess
spinal
accessori
nerv
stimul
neck
cmap
record
upper
trapeziu
muscl
eight
normal
subject
mean
age
use
control
two
sib
show
sever
phenotyp
earli
onset
sever
scoliosi
complet
loss
distal
movement
relev
proxim
weak
cmt
examin
score
cmte
heterozyg
parent
mild
neuropathi
cmte
control
subject
trapeziu
cmap
latenc
ms
amplitud
mv
heterozygot
mild
cmt
type
phenotyp
cmap
latenc
ms
amplitud
mv
wherea
homozygot
sever
neuropathi
cmap
latenc
ms
amplitud
mv
consist
homozygot
sever
impair
excit
rheobas
compar
heterozygot
control
deviat
excit
measur
similar
previou
report
mice
mathemat
model
indic
alter
passiv
cabl
properti
due
dysmyelin
depolar
featur
increas
na
current
data
suggest
defici
associ
impair
axon
na
channel
function
argu
translat
valu
na
channel
blocker
treatment
found
null
mous
model
krishnarajah
divino
mallick
dekoven
behr
king
prussia
pa
usa
fairfax
va
usa
chronic
inflammatori
demyelin
polyneuropathi
cidp
rare
neurolog
disord
peripher
nervou
system
object
retrospect
studi
compar
demograph
clinic
characterist
among
cidp
case
match
control
assess
cidp
treatment
util
adult
newli
diagnos
cidp
identifi
quintilesim
pharmetr
plu
health
plan
claim
databas
first
diagnosi
date
term
index
date
elig
requir
confirm
cidp
second
cidp
diagnosi
initi
cidp
therapi
within
year
initi
diagnosi
continu
health
plan
enrol
month
prior
diagnosi
year
follow
diagnosi
cidp
diagnosi
use
cidp
therapi
total
cidp
case
met
studi
elig
criteria
case
control
base
age
gender
region
health
plan
payer
type
index
charlson
comorbid
index
score
final
sampl
consist
case
match
control
mean
sd
age
male
altern
diagnos
among
case
includ
inherit
neuropathi
chronic
acquir
polyneuropathi
neuropath
pain
vs
back
pain
vs
use
opioid
vs
vs
significantli
higher
among
case
compar
control
p
median
total
healthcar
cost
higher
case
control
vs
p
median
total
healthcar
cost
higher
case
control
vs
p
mean
therapi
cost
account
total
healthcar
cost
case
major
case
initi
cidp
therapi
mean
day
initi
diagnosi
half
case
initi
treatment
corticosteroid
initi
ivig
case
use
corticosteroid
use
ivig
find
suggest
substanti
clinic
econom
burden
cidp
compar
match
control
corticosteroid
ivig
commonli
use
treat
cidp
kronlag
baeumer
p
pitarokoili
schwarz
schwehr
godel
heiland
gold
bendszu
yoon
neuroradiolog
heidelberg
univers
hospit
germani
neurolog
st
josef
hospit
ruhr
univers
bochum
germani
object
evalu
larg
coverag
magnet
reson
neurographi
mrn
chronic
inflammatori
demyelin
polyneuropathi
cidp
method
prospect
studi
patient
cidp
healthi
control
examin
standard
mrn
protocol
tesla
lumbosacr
plexu
imag
mm
isotrop
voxel
size
peripher
nerv
upper
lower
extrem
axial
sequenc
x
mm
resolut
lesion
character
nerv
cross
section
area
csa
signal
addit
sciatic
nerv
perform
use
sequenc
patient
receiv
complementari
electrophysiolog
exam
result
patient
cidp
exhibit
increas
nerv
csa
compar
control
p
proxim
predomin
pattern
roc
analysi
reveal
best
diagnost
accuraci
csa
lumbosacr
plexu
auc
sciatic
nerv
auc
csa
correl
multipl
electrophysiolog
paramet
demyelin
neuropathi
latenc
nerv
conduct
veloc
sciatic
median
nerv
correl
latenc
sciatic
median
nerv
indic
increas
cidp
due
increas
p
increas
time
conclus
csa
might
aid
diagnosi
cidp
csa
correl
robustli
electrophysiolog
paramet
sinc
best
diagnost
accuraci
shown
proxim
nerv
locat
mrn
may
use
complementari
tool
select
cidp
case
wetzel
moshourab
lewin
bih
berlin
germani
berlin
germani
berlin
germani
damag
peripher
sensori
nerv
due
diabet
herp
zoster
infect
chemotherapi
trauma
caus
chronic
neuropath
pain
common
symptom
includ
increas
pain
sensat
hyperalgesia
pain
allodynia
paresthesia
spontan
pain
current
poor
understand
underli
molecular
mechan
peripher
level
treatment
patient
suffer
neuropath
pain
inadequ
recent
studi
show
common
medic
yield
nnt
number
need
treat
still
unclear
extent
allodynia
attribut
chang
physiolog
properti
intact
sensori
affer
studi
aim
elucid
whether
chang
occur
intact
sensori
affer
innerv
plantar
skin
follow
induct
neuropath
symptom
question
particular
interest
consid
block
mechanotransduct
skin
allevi
mechan
hypersensit
neuropath
pain
model
wetzel
et
al
natur
neurosci
use
chronic
constrict
injuri
cci
model
mice
behaviour
character
robust
mechan
hypersensit
made
electrophysiolog
record
primari
affer
neuron
intact
axon
pass
constrict
innerv
plantar
skin
use
prepar
abl
record
myelin
affer
fiber
unmyelin
recept
field
control
uninjur
plantar
skin
well
plantar
skin
cci
mice
present
evid
chang
mechanosensit
sensori
fiber
innerv
glabrou
skin
may
contribut
symptom
neuropath
pain
kugathasan
evan
sinclair
hornemann
suriyanarayanan
phadk
miller
lauria
lombardi
polk
bennett
houlden
blake
reilli
centr
neuromuscular
diseas
london
uk
neuroradiolog
unit
ucl
institut
neurolog
uk
clinic
chemistri
univers
hospit
zurich
switzerland
neuropatholog
nation
hospit
neurolog
neurosurgeri
london
uk
foundat
carlo
besta
neurolog
institut
milan
itali
unit
nation
hospit
neurolog
neurosurgeri
london
uk
depart
clinic
neurosci
oxford
uk
clinic
neurophysiolog
norfolk
norwich
univers
hospit
uk
secondari
rare
slowli
progress
neuropathi
result
mark
sensori
loss
especi
nocicept
signific
motor
deficit
despit
patient
mutat
mark
heterogen
phenotyp
oral
supplement
suggest
potenti
therapeut
candid
howev
lack
outcom
measur
major
limit
factor
initi
clinic
trial
undertook
natur
histori
studi
identifi
outcom
measur
respons
enough
use
clinic
trial
assess
use
cmt
neuropathi
score
cmtn
version
cmtn
version
rasch
modifi
mri
calv
thigh
computeris
myometri
quantit
sensori
test
qst
comprehens
neurophysiolog
assess
proxim
thigh
skin
biopsi
nerv
fibr
densiti
ienfd
plasma
dsl
level
patient
base
questionnair
neuropath
pain
symptom
inventori
standardis
respons
mean
srm
mean
changestandard
deviat
chang
use
compar
respons
test
patient
recruit
mutat
analys
whole
cohort
proxim
calf
mri
fat
fraction
show
signific
chang
month
ienfd
plasma
dsl
level
npsi
show
minim
chang
chang
clinic
expect
direct
subset
remain
assess
show
highest
respons
cohort
cmtn
sever
cmtn
subgroup
subgroup
greatest
improv
respons
seen
computeris
myometri
ankl
plantarflexion
ankl
evers
sever
subgroup
qst
vibrat
detect
threshold
hand
face
pressur
pain
threshold
face
proxim
calf
mri
fat
fraction
srm
show
greatest
improv
focus
subgroup
classifi
accord
diseas
sever
improv
respons
test
highli
respons
rang
mri
still
best
outcom
measur
reduc
number
particip
requir
power
clinic
trial
might
possibl
solut
design
clinic
trial
rare
slowli
progress
diseas
heterogen
phenotyp
kugathasan
clark
suriyanarayanan
wilson
kalmar
greensmith
hornemann
reilli
bennett
centr
neuromuscular
diseas
london
uk
injuri
group
nuffield
depart
clinic
neurosci
univers
oxford
oxford
uk
clinic
chemistri
univers
hospit
zurich
switzerland
depart
motor
neurosci
movement
disord
ucl
institut
neurolog
london
uk
jointli
supervis
work
secondari
mutat
slowli
progress
sensori
motor
neuropathi
lead
profound
sensori
loss
variabl
often
sever
motor
deficit
gene
encod
essenti
enzym
serin
palmitoyltransferas
spt
catalys
rate
limit
step
sphingolipid
biosynthesi
mutat
two
gene
alter
substrat
specif
spt
lead
synthesi
accumul
atyp
metabolit
call
plasma
level
rais
patient
deoxysphingolipid
shown
toxic
avian
group
mammalian
primari
drg
motor
neuron
cultur
firstli
studi
look
effect
surviv
neurit
integr
human
ipsc
deriv
sensori
neuron
follow
exposur
differ
concentr
deoxysphingolipid
later
determin
autonom
product
patient
ipsc
deriv
sensori
neuron
sensori
neuron
differenti
human
ipsc
use
combin
small
molecular
inhibitor
deoxysphingolipid
found
neurotox
model
hour
treatment
control
line
signific
reduct
neuron
surviv
follow
treatment
clear
increas
express
axon
injuri
marker
seen
base
instanc
neurotox
similar
find
avian
mammalian
primari
neuron
cultur
autonom
product
seen
ipsc
deriv
neuron
obtain
three
differ
hsn
patient
level
significantli
greater
seen
multipl
control
line
first
studi
demonstr
human
ipsc
deriv
sensori
neuron
use
model
provid
great
opportun
probe
pathomechan
mediat
deoxysphingolipid
toxic
test
potenti
therapeut
agent
kuntzer
cuendet
maulucci
tsouni
magot
boucraut
devaux
attarian
delmont
chuv
lausann
switzerland
de
maladi
neuromusculair
chu
de
nant
nant
franc
marseil
franc
de
maladi
neuromusculair
et
sla
la
timon
marseil
franc
recent
studi
demonstr
associ
autoantibodi
direct
subpopul
cidp
patient
character
sensori
ataxia
tremor
poor
respons
ivig
treatment
report
clinic
featur
three
patient
develop
acut
chang
phenotyp
cours
neuropathi
potenti
clue
recogn
neuropathi
predominantli
humor
dysimmun
case
report
index
patient
develop
sensori
chang
week
follow
irregular
locomot
muscl
weak
gener
areflexia
first
run
ivig
improv
patient
week
relaps
within
day
second
ivig
cours
prednison
normal
deficit
within
day
ivig
run
rituximab
still
necessari
treat
relaps
obtain
complet
improv
cours
neuropathi
month
two
patient
encount
chronic
cours
period
worsen
improv
suggest
neuropathi
either
spontan
follow
immunomodul
treatment
three
extens
neg
posit
detail
repeat
nerv
conduct
studi
demonstr
fluctuat
conduct
block
discuss
report
underscor
chronic
cidp
patient
cours
could
encount
key
featur
neuropathi
yet
describ
characterist
cours
could
valu
decid
use
rituximab
instead
immunomodul
treatment
kusunoki
morikawa
kuwahara
ueno
samukawa
hamada
medicin
kindai
univers
japan
antibodi
often
detect
sera
patient
autoimmun
neuropathi
syndrom
gb
chronic
inflammatori
demyelin
polyradiculoneuropathi
cidp
multifoc
motor
neuropathi
mmn
individu
glycolipid
antigen
also
mixtur
two
differ
glycolipid
glycolipid
complex
sometim
recogn
serum
antibodi
investig
antibodi
activ
larg
number
glycolipid
complex
serum
sampl
patient
gb
mmn
cidp
examin
igm
igg
antibodi
glycolipid
galactocerebrosid
sulfatid
glycolipid
complex
consist
two
differ
glycolipid
list
use
combinatori
glycoarray
serum
obtain
patient
gb
patient
cidp
patient
mmn
acut
relaps
phase
serum
also
obtain
healthi
control
patient
neurolog
diseas
investig
relationship
clinic
featur
presenc
antibodi
high
titer
igg
antibodi
detect
almost
exclus
gb
patient
contrast
igm
antibodi
frequent
present
mmn
gb
among
complex
antibodi
gb
igg
antibodi
common
patient
respect
igg
antibodi
antigen
contain
significantli
correl
pure
motor
gb
p
antigen
contain
significantli
correl
gb
ophthalmoplegia
p
seven
patient
complex
antibodi
antibodi
specif
complex
rather
individu
suldfatid
antigen
moreov
four
patient
antibodi
complex
patient
mmn
igm
antibodi
antigen
contain
present
respect
glycoarray
effici
detect
antibodi
numer
glycolipid
complex
neuropathi
need
investig
diseas
use
larger
number
antigen
kuwabara
misawa
sekiguchi
susumu
studi
neurolog
chiba
univers
chiba
japan
neurolog
kindai
univers
osaka
japan
eculizumab
trial
syndrom
chiba
japan
syndrom
monophas
neuropathi
substanti
number
patient
sever
diseas
poor
recoveri
even
treat
immunoglobulin
recent
studi
suggest
complement
activ
play
pivot
role
axon
degener
eculizumab
monoclon
antibodi
specif
bind
complement
compon
inhibit
complement
activ
phase
random
trial
conduct
hospit
trial
aim
investig
safeti
efficaci
eculizumab
treatment
sever
gb
patient
randomli
assign
treatment
immunoglobulin
plu
either
eculizumab
mgday
placebo
weekli
week
primari
outcom
measur
safeti
efficaci
proport
subject
regain
abil
walk
independ
week
secondari
outcom
measur
includ
proport
subject
abl
walk
independ
week
measur
mrc
sum
score
nerv
conduct
paramet
enrol
trial
began
august
last
patient
complet
octob
analys
made
april
result
present
meet
trial
regist
http
clinicaltrialsgov
identifi
fund
japanes
agenc
medic
research
develop
alexion
pharmaceut
inc
kuwahara
oka
ogata
suzuki
yanagimoto
sadakan
fukumoto
yamana
yuhara
yoshikawa
morikawa
kawai
okazaki
kira
kusunoki
neurolog
faculti
medicin
kindai
univers
osaka
japan
neurolog
nation
hospit
organ
hospit
kyoto
japan
neurolog
neurolog
institut
graduat
school
medic
scienc
kyushu
univers
fukuoka
japan
neurofascin
paranod
protein
peripher
nerv
target
antigen
autoantibodi
subset
chronic
inflammatori
demyelin
polyneuropathi
cidp
cidp
character
onset
younger
age
tremor
refractori
ivig
treat
four
patient
cidp
kindai
univers
hospit
antibodi
detect
elisa
assay
patient
igg
subclass
predominantli
four
case
median
age
patient
admiss
year
rang
year
among
four
patient
three
tremor
two
sever
cerebellar
ataxia
cerebrospin
fluid
protein
level
remark
increas
median
mgdl
rang
mgdl
although
ivig
treatment
administ
four
patient
respons
poor
partial
contrast
plasma
exchang
pe
perform
four
patient
clinic
symptom
dramat
improv
two
corticosteroid
also
effect
two
patient
sural
nerv
biopsi
perform
four
patient
although
sensori
nerv
action
potenti
sural
nerv
patient
evok
transvers
semithin
section
sural
nerv
three
patient
reveal
slight
mild
loss
myelin
fiber
partial
paranod
demyelin
observ
fiber
three
patient
addit
abnorm
paranod
lesion
loss
transver
band
observ
electron
microscop
four
patient
electron
microscop
find
observ
control
patient
cidp
cidp
show
distinct
clinic
patholog
featur
labeyri
besson
vandendri
cauquil
beaudonnet
durand
adam
adult
chu
le
kremlin
franc
chu
le
kremlin
franc
bizet
pari
franc
de
neurophysiologi
cliniqu
chu
le
kremlin
franc
studi
proxim
portion
peripher
nervou
system
pn
difficult
less
access
electrophysiolog
explor
biopsi
indic
mri
increas
proxim
neuropathi
analys
morpholog
root
plexu
proxim
nerv
integr
nerv
bundl
inflamm
infiltr
structur
tomographi
detect
infiltr
proxim
segment
pn
hypermetabol
root
plexus
larg
nerv
trunk
also
use
detect
solid
neoplasm
infiltr
pn
primari
nerv
sheath
tumor
howev
spatial
resolut
pet
scan
limit
explor
root
plexus
moder
hypermetabol
believ
mild
hypermetabol
could
highlight
inflammatori
neuropathi
mild
tumor
infiltr
perform
fusion
whole
bodi
pet
perform
suspect
neoplasia
plexu
mri
imag
ten
patient
peripher
neuropathi
suspect
proxim
involv
mri
first
read
separ
merg
imag
nuclear
physician
neuroradiologist
five
ten
patient
present
hypermetabol
pn
hmpn
root
andor
dorsal
root
ganglia
median
sul
lesion
among
hmpn
patient
hypermetabol
alreadi
appar
case
merg
invalid
abnorm
seen
patient
mri
detect
addit
lesion
visibl
one
patient
hmpn
patient
hypersign
hypertrophi
pn
mri
either
diffus
multifoc
among
hypermetabol
abnorm
mri
multifoc
diffus
gadolinium
enhanc
found
patient
receiv
gadolinium
hmpn
patient
group
final
diagnos
hmpn
patient
neurolymphoma
one
idiopath
cidp
other
histolog
proof
nervou
root
biopsi
one
final
diagnosi
patient
cidp
sequela
neuropathi
relat
lymphoma
without
relaps
last
one
cidp
disabl
hmpn
group
vs
could
help
detect
proxim
inflamm
pn
plan
test
studi
need
evalu
prognost
valu
hmpn
lancast
li
liem
scherer
school
medicin
univers
pennsylvania
philadelphia
pa
usa
univers
school
medicin
new
york
ny
usa
heterozyg
nefl
mutant
mice
first
anim
model
diseas
peopl
mutat
sever
earli
onset
axon
neuropathi
axon
mutant
mice
reduc
number
neurofila
decreas
diamet
also
show
earli
onset
tremor
abnorm
hindlimb
clasp
behavior
measur
compound
action
potenti
cap
tail
everi
week
cohort
nefl
mutant
mice
wt
litterm
week
even
age
week
amplitud
mutant
cap
wt
cap
microv
vs
microv
cap
stay
substanti
smaller
wt
mice
week
microv
vs
microv
conduct
veloc
durat
cap
mutant
slower
wider
compar
wt
separ
cohort
mice
mutant
wt
sacrif
differ
time
point
analysi
light
microscopi
caudal
nerv
mutant
mice
number
axon
significantli
reduc
compar
wt
week
week
reduc
model
system
may
use
preclin
studi
treatment
sinc
anim
show
progress
neuropathi
week
object
measur
electrophysiolog
anatom
lassuthova
rebelo
ravenscroft
lamont
baxter
ong
davi
manganelli
tao
saghira
abreu
bai
isom
la
choi
seeman
shi
santoro
zuchner
laboratori
depart
paediatr
neurolog
faculti
medicin
charl
univers
pragu
univers
hospit
motol
pragu
czech
republ
john
macdonald
foundat
depart
human
genet
john
p
hussman
institut
human
genom
univers
miami
miller
school
medicin
miami
usa
medic
research
univers
western
australia
harri
perkin
institut
medic
research
nedland
australia
pharmacolog
sylvest
comprehens
cancer
center
center
comput
scienc
univers
miami
miami
usa
neurolog
samsung
medic
center
sungkyunkwan
univers
school
medicin
seoul
south
korea
neurolog
carver
colleg
medicin
univers
iowa
iowa
citi
ia
usa
neurosci
reproduct
scienc
odontostomatholog
napl
itali
despit
cmt
gene
identifi
today
least
patient
carri
mutat
gene
progress
gene
identif
recent
year
suggest
still
mani
diseas
gene
discov
howev
becom
rare
gather
support
multipl
larg
famili
allow
conclus
linkag
analysi
studi
multipl
extend
domin
famili
linkag
support
gene
chromosom
origin
czech
famili
yield
two
point
lod
score
locu
famili
southern
itali
show
lod
score
whole
exom
sequenc
multipl
famili
member
identifi
missens
mutat
gene
atpas
nak
transport
subunit
alpha
associ
human
diseas
thu
far
express
studi
teas
fiber
prepar
alreadi
confirm
predomin
express
node
ranvier
peripher
nerv
collabor
effort
inherit
neuropathi
consortium
beyond
identifi
five
addit
multigener
famili
via
exom
sanger
sequenc
result
total
seven
uniqu
segreg
missens
chang
five
mutat
fall
remark
narrow
motif
associ
sodium
bind
structur
flank
flexibl
hing
motif
function
studi
differ
model
system
mammalian
cell
line
xenopu
oocyt
patient
fibroblast
line
underway
determin
whether
loss
domin
repres
diseas
mechan
taken
togeth
show
strong
support
major
new
domin
gene
find
repres
new
pathway
attract
new
target
therapi
develop
axon
cmt
ramdharri
singh
kozyra
skorupinska
reilli
centr
neuromuscular
diseas
ucl
institut
neurolog
london
uk
rehabilit
scienc
st
georg
univers
londonkingston
univers
uk
nation
orthopaed
hospit
stanmor
uk
cmt
diseas
common
inherit
peripher
neuropathi
foot
deform
frequent
complic
orthopaed
surgeri
often
requir
howev
evid
base
guidelin
type
time
surgeri
studi
describ
result
surgic
procedur
evid
regard
optim
surgic
manag
patient
lack
prospect
studi
surgic
manag
cmt
patient
attend
centr
collect
data
assess
cmt
patient
surgeri
data
includ
histori
ankl
instabl
pain
skin
condit
detail
physiotherapi
orthot
manag
assess
lower
limb
strength
examin
score
cmte
foot
postur
index
ankl
dorsiflexion
rang
movement
specif
questionnair
foot
index
foot
questionnair
modifi
fatigu
sever
scale
modifi
fall
efficaci
scale
detail
surgic
procedur
patient
assess
yearli
surgeri
far
patient
male
femal
age
rang
evalu
prior
surgeri
patient
one
genet
confirm
cmt
cmtx
patient
assess
year
patient
year
patient
year
patient
year
surgeri
wide
rang
surgic
procedur
perform
one
dedic
orthopaed
surgeon
preliminari
result
show
reduct
number
fall
patient
improv
callos
patient
year
follow
also
signific
improv
align
oper
foot
pain
signific
chang
measur
strength
ankl
rang
motion
analysi
larger
number
patient
import
determin
outcom
surgeri
data
acquir
studi
help
develop
orthopaed
intervent
guidelin
identifi
area
research
oliveira
marqu
onofr
do
santo
nascimento
barreira
marqu
w
neuromuscular
diseas
neurogenet
depart
neurosci
behaviour
scienc
clinic
hospit
preto
univers
paulo
preto
brazil
neurolog
fluminens
feder
univers
rio
de
janeiro
brazil
fap
associ
ttr
mutat
defin
axon
sensori
motor
polyneuropathi
earli
stage
affect
mainli
small
nerv
fiber
associ
autonom
sensat
expect
emg
pattern
axon
sensori
motor
polyneuropathi
fact
sever
unexpect
pattern
may
found
studi
present
result
found
brazilian
popul
ttr
mutat
patient
divid
three
group
earli
onset
late
onset
ttr
first
group
earli
onset
examin
normal
axon
demyelin
fulfil
pidc
criteria
one
suggest
predomin
motor
polyneuropathi
final
one
present
lower
motor
neuron
diseas
pattern
second
group
late
onset
axon
pattern
intermedi
cv
demyelin
pattern
lumbossacr
pattern
final
one
definit
pattern
among
two
patient
ttr
one
present
axon
pattern
second
present
initi
axon
pattern
chang
demyelin
pattern
second
examin
patient
mutat
present
axon
neuropathi
associ
ct
patient
demyelin
intermedi
pattern
treat
corticosteroid
ivig
satisfactori
result
small
seri
patient
show
clearli
associ
sever
emg
pattern
addit
expect
sensori
motor
axon
polyneuropathi
variabl
present
famili
patient
differ
occas
clinician
alert
possibl
delay
diagnosi
treatment
identifi
mechan
involv
variabl
could
improv
knowledg
intrigu
diseas
lavin
manchest
neurosci
centr
salford
royal
hospit
manchest
uk
subcutan
immunoglobulin
scig
evid
small
trial
use
follow
intraven
igg
ivig
load
chronic
inflammatori
demyelin
polyneuropathi
cidp
potenti
advantag
scig
includ
stabl
igg
level
reduc
complic
rate
scig
de
novo
consid
igg
level
gradual
rise
subcutan
deliveri
mayb
benefici
patient
complic
concern
present
case
cidp
initi
subcutan
immunoglobulin
g
scig
hizentra
csl
behr
follow
corticosteroid
without
intraven
igg
load
patient
year
old
histori
ihd
progress
lower
limb
sensori
chang
sensori
ataxia
year
neurophysiolog
confirm
sensori
demyelin
chang
respond
corticosteroid
concern
rais
potenti
risk
orf
advers
cardiac
event
iv
immunoglobulin
scig
therapi
introduc
weekli
initi
therapi
well
toler
object
measur
score
jamar
grip
strength
hole
peg
remain
stabl
initi
month
patient
yr
old
male
past
histori
branch
retin
vein
thrombosi
develop
sensorimotor
polyneuropathi
year
neurophysiolog
fit
efn
criteria
cidp
given
concern
regard
previou
thrombosi
trial
scig
given
resolut
sensori
ataxia
improv
object
marker
jamar
grip
strength
score
hole
peg
month
unfortun
advers
event
occur
urticari
skin
reaction
patient
yr
old
male
present
motor
predomin
cidp
respons
corticosteroid
improv
follow
plasma
exchang
due
past
histori
transient
ischaem
attack
scig
start
posit
respons
month
improv
walk
distanc
stabl
object
marker
score
grip
pinch
strength
cohort
remain
neurolog
stabl
initi
scig
advers
reaction
experi
would
support
trial
area
regard
efficaci
scig
compar
ivig
short
long
term
casa
bosch
institut
uab
barcelona
spain
molecular
biolog
depart
uab
barcelona
spain
biolog
physiolog
immunolog
depart
uab
barcelona
spain
de
en
red
enfermedad
neurodegenerativa
cibern
insituto
de
salud
carlo
iii
spain
de
recerca
estudi
icrea
barcelona
spain
mixta
vall
dhebron
institut
de
recerca
vhir
barcelona
spain
diabet
peripher
neuropathi
common
debilit
complic
diabet
associ
neuropath
pain
amput
despit
econom
burden
human
cost
nowaday
specif
treatment
cure
diabet
peripher
neuropathi
hyperglycaemia
oxid
endoplasm
reticulum
stress
link
diabet
peripher
neuropathi
among
alter
pathway
order
studi
detail
molecular
mechan
lead
develop
diabet
peripher
neuropathi
set
vitro
model
diseas
use
motoneuron
sensori
neuron
cell
line
primari
cultur
dorsal
root
ganglia
motoneuron
expos
satur
fatti
acid
report
palmit
acid
abl
induc
endoplasm
reticulum
stress
oxid
stress
multipl
cell
type
includ
schwann
cell
myenter
neuron
result
good
model
stress
found
palmit
induc
upregul
molecular
chaperon
protein
homolog
protein
chop
mrna
downregul
apoptosi
marker
primari
cultur
moreov
palmit
acid
induc
loss
neuron
dendrit
cell
death
high
dose
upregul
heme
oxygenas
chop
lower
dose
cell
line
current
character
multipl
molecul
implic
oxid
stress
endoplasm
reticulum
stress
inflamm
pathway
cell
type
find
new
therapeut
target
treat
type
diabet
sensorimotor
polyneuropathi
subsequ
valid
dbdb
mous
model
pharmacolog
gene
therapi
strategi
lee
ohnmar
wong
koh
umapathi
kong
chian
school
medicin
nanyang
technolog
univers
singapor
neurosci
institut
singapor
neuropathi
diabet
mellitu
dm
tind
acut
pain
peripher
neuropathi
autonom
dysfunct
occur
within
week
tight
glycaem
control
therapi
either
insulin
oral
hypoglycaem
agent
ohga
may
result
tind
quantum
rate
declin
predict
develop
sever
tind
type
ii
dm
patient
prone
iatrogen
complic
besid
expect
morbid
associ
pain
somat
autonom
neuropathi
tind
patient
also
develop
eye
complic
maculopathi
greater
awar
pick
least
typic
case
tind
recent
month
howev
fourth
possibl
tind
case
feel
deserv
special
attent
circumst
surround
case
common
may
go
acut
hospit
man
histori
poorli
control
type
ii
dm
admit
partial
left
middl
cerebr
arteri
stroke
one
month
admiss
hospit
prolong
consider
disabl
requir
rehabilit
stay
week
blood
sugar
difficult
control
hyperglycaem
episod
requir
ohga
insulin
highest
capillari
blood
glucos
record
mmoll
also
episod
hypoglycaemia
three
week
hospit
develop
sever
orthostat
hypotens
came
attent
two
month
later
sent
autonom
screen
test
sever
postur
hypotens
spite
therapi
fludrocortison
midodrin
mark
orthostat
hypotens
suggest
sympathet
dysfunct
abl
discern
pain
neuropathi
aphasia
recent
ophthalmolog
review
suggest
diagnosi
possibl
tind
discharg
lower
dose
ohga
howev
day
discharg
attend
emerg
depart
syncop
episod
case
rais
intrigu
question
safeti
glucos
control
paradigm
commonli
employ
patient
acut
stroke
myocardi
infarct
well
possibl
role
major
fluctuat
blood
glucos
develop
tind
lee
kim
medic
center
jeonju
korea
univers
colleg
medicin
seoul
korea
occurr
peripher
neuropathi
tumor
within
compress
nerv
neurofibromatosi
nf
type
rel
well
known
howev
nf
present
demyelin
polyneuropathi
unrel
tumor
mass
rare
report
report
rare
present
nf
patient
demyelin
polyneuropathi
subacut
onset
woman
refer
hospit
paresthesia
limb
month
healthi
famili
histori
symptom
worsen
next
month
tremor
weak
limb
occur
although
treat
chronic
inflammatori
demyelin
polyneuropathi
cidp
intraven
steroid
immunosuppress
anoth
hospit
symptom
get
wors
bifaci
numb
left
eyebal
pain
occur
week
ago
visit
hospit
neurolog
examin
bilater
facial
sensori
hypoesthesia
symmetr
limb
weak
mrc
grade
iv
observ
decreas
touch
pinprick
sensat
limb
observ
like
distribut
reflex
sluggish
nerv
conduct
studi
sensorimotor
demyelin
polyneuropathi
conduct
block
tempor
dispers
observ
bilater
respons
prolong
facial
blink
test
mri
cervic
spine
brain
reveal
contrast
enhanc
enlarg
multipl
nerv
root
cranial
nerv
nerv
biopsi
perform
right
supraorbit
nerv
neurofibromat
chang
observ
symptom
deterior
stop
without
treatment
gene
test
dose
reveal
nf
type
review
literatur
polyneuropathi
nf
patient
result
tumor
mass
within
proxim
nerv
root
along
peripher
nerv
extramedullari
lesion
affect
neighbor
nerv
root
thu
axon
type
polyneuropathi
focal
amyotrophi
report
nf
demyelin
polyneuropathi
report
knowledg
although
etiolog
demyelin
polyneuropathi
nf
requir
clarif
author
claim
unknown
local
toxic
metabol
influenc
endoneuri
patholog
cell
adjac
nerv
fiber
patient
atyp
symptom
observ
cidp
cranial
nerv
involv
sensori
distribut
case
nerv
biopsi
help
accur
diagnosi
lee
yoo
kang
bae
neurolog
hallym
univers
seoul
korea
acut
dissemin
encephalomyel
adem
uncommon
inflammatori
demyelin
disord
central
nerv
system
syndrom
gb
prototyp
acut
peripher
neuropathi
previou
report
regard
coexist
rel
rare
diseas
suggest
certain
immunogen
within
central
peripher
nerv
may
share
common
autoimmun
process
diseas
cours
previou
healthi
year
old
man
admit
fever
headach
nausea
myalgia
depart
infecti
diseas
two
week
admiss
suffer
wateri
diarrhea
day
spontan
recov
initi
present
high
fever
headach
myalgia
intermitt
horizont
diplopia
day
admiss
began
complain
drowsi
mental
bilater
extrem
weak
especi
lower
limb
dysarthria
bilater
facial
paralysi
urinari
retent
dyspnea
neurolog
examin
mildli
drowsi
mental
symmetr
muscl
weak
score
bilater
hip
knee
flexion
finger
extens
sensori
symptom
show
gaze
evok
nystagmu
extraocular
muscl
palsi
deep
tendon
reflex
present
pulmonari
function
test
reveal
sever
restrict
pattern
csf
studi
disclos
dissoci
increas
protein
content
without
pleocytosi
anti
ganliosid
antibodi
assay
identifi
igg
posit
serum
nerv
conduct
studi
nc
show
prolong
motor
termin
latenc
slow
motor
conduct
veloc
multipl
nerv
contrast
sensori
nc
reveal
abnorm
find
imag
studi
unexpectedli
reveal
appar
symmetr
lesion
across
bilater
brainstem
basal
ganglia
suggest
diagnosi
adem
ivig
high
dose
steroid
treatment
remark
recov
disturb
mental
state
motor
weak
symptom
onset
could
walk
assist
aid
discharg
hospit
rehabilit
case
suggest
certain
compon
autoimmun
simultan
result
cn
pn
inflamm
specif
immunolog
mechan
remain
elucid
although
could
conclud
whether
cellular
compon
humor
compon
domin
case
presenc
anti
antibodi
suggest
role
humor
mechan
leitao
marqu
pamplona
gondim
anatomi
universidad
feder
brazil
fortaleza
brazil
public
health
universidad
feder
brazil
intern
medicin
fortaleza
brazil
peripher
neuropathi
primari
headach
common
patient
ibd
oliveira
inflamm
bowel
di
gondim
inflamm
bow
di
aim
studi
evalu
whether
peripher
neuropathi
headach
affect
subgroup
patient
ibd
sinc
establish
cohort
studi
evalu
preval
incid
neurolog
diseas
patient
ibd
period
year
patient
ibd
either
crohn
diseas
ulcer
coliti
invit
particip
studi
design
evalu
risk
factor
presenc
headach
peripher
neuropathi
ibd
separ
group
control
patient
rel
ibd
patient
also
form
clinic
interview
neurolog
examin
patient
invit
undergo
skin
wrinkl
test
swt
evalu
small
fiber
function
andor
electromyographi
headach
present
patient
ibd
common
patient
ulcer
coliti
control
patient
p
migrain
compris
case
headach
preval
patient
crohn
diseas
control
patient
p
tension
headach
also
common
affect
ibd
patient
electromyographi
abnorm
ibd
patient
test
swt
abnorm
ibd
patient
test
ibd
patient
abnorm
swt
neuropathi
symptom
patient
abnorm
swt
emg
like
headach
respect
overal
patient
symptomat
polyneuropathi
like
headach
patient
abnorm
swt
emg
also
like
migrain
respect
patient
abnorm
swt
emg
also
like
headach
respect
summari
although
highli
preval
popul
brazilian
ibd
patient
primari
headach
neuropathi
affect
subgroup
ibd
patient
studi
necessari
understand
mechan
condit
ibd
patient
leitao
marqu
pamplona
souza
nbraga
gondim
anatomi
universidad
feder
brazil
universitari
center
fortaleza
brazil
public
health
universidad
feder
brazil
intern
medicin
fortaleza
brazil
peripher
neuropathi
primari
headach
common
patient
ibd
oliveira
inflamm
bowel
di
gondim
inflamm
bow
di
aim
studi
evalu
whether
peripher
neuropathi
headach
affect
subgroup
patient
ibd
sinc
establish
cohort
studi
evalu
preval
incid
neurolog
diseas
patient
ibd
period
year
patient
ibd
either
crohn
diseas
ulcer
coliti
invit
particip
studi
design
evalu
risk
factor
presenc
headach
peripher
neuropathi
ibd
separ
group
control
patient
rel
ibd
patient
also
form
clinic
interview
neurolog
examin
patient
invit
undergo
skin
wrinkl
test
swt
evalu
small
fiber
function
andor
electromyographi
headach
present
patient
ibd
common
patient
ulcer
coliti
control
patient
p
migrain
compris
case
headach
preval
patient
crohn
diseas
control
patient
p
tension
headach
also
common
affect
ibd
patient
electromyographi
abnorm
ibd
patient
test
swt
abnorm
ibd
patient
test
ibd
patient
abnorm
swt
neuropathi
symptom
patient
abnorm
swt
emg
like
headach
respect
overal
patient
symptomat
polyneuropathi
like
headach
patient
abnorm
swt
emg
also
like
migrain
respect
patient
abnorm
swt
emg
also
like
headach
respect
summari
although
highli
preval
popul
brazilian
ibd
patient
primari
headach
neuropathi
affect
subgroup
ibd
patient
studi
necessari
understand
mechan
condit
ibd
patient
ceja
pantiu
rattagan
chave
mackinnon
marchesoni
pardal
calandra
rodriguez
muro
reisin
hospit
bueno
air
argentina
hospit
entr
argentina
cruce
hospit
bueno
air
argentina
bueno
air
argentina
classic
guillain
syndrom
gb
character
motor
weak
hyporreflexia
limit
sensori
deficit
sensori
variant
involv
either
small
larg
fiber
unusu
repres
diagnost
challeng
describ
patient
present
sensori
variant
gb
retrospect
analyz
clinic
electrophysiolog
find
patient
fulfil
criteria
sensori
gb
accord
oh
et
al
criteria
six
patient
identifi
mean
age
year
rang
year
four
previou
infect
consult
due
distal
pain
paresthesia
allodynia
examin
patient
present
normal
strength
normal
cranial
nerv
cours
diseas
reduc
knee
ankl
reflex
patient
distal
hyperesthesia
pinprick
identifi
one
addit
hyperhidrosi
constip
two
addit
patient
present
hypoesthesia
pinprick
temperatur
one
patient
distal
propriocept
sensori
loss
sensori
ataxia
csf
albumin
cytolog
dissoci
present
patient
nerv
conduct
studi
nc
identifi
sensori
motor
demyelin
neuropathi
patient
among
normal
nc
abnorm
cold
warm
threshold
qst
evalu
patient
receiv
symptomat
treatment
neuropath
pain
two
ivig
therapi
longstand
pain
fatigu
persist
find
patient
mean
follow
month
conclus
sensori
variant
gb
infrequ
present
diagnost
challeng
longstand
pain
fatigu
common
persist
find
leonhard
amorelli
barreira
cornblath
deen
moham
van
doorn
islam
marqu
jr
pardo
shahrizaila
umapathi
willison
jacob
consortium
neurolog
erasmu
medic
centr
rotterdam
netherland
infecti
diseas
secretari
state
health
feder
district
brazil
neurosci
medic
school
preto
univers
paulo
preto
sp
brazil
neurolog
john
hopkin
univers
school
medicin
baltimor
usa
institut
neurosci
hospit
nin
dhaka
bangladesh
scienc
servic
divis
icddr
b
dhaka
bangladesh
neurolog
univers
malaya
kuala
lumpur
malaysia
neurosci
institut
singapor
neurolog
univers
glasgow
glasgow
uk
immunolog
erasmu
medic
centr
rotterdam
netherland
epidem
zika
viru
zikv
throughout
america
asia
subsequ
rise
report
case
syndrom
gb
caus
worldwid
concern
januari
countri
report
evid
zikv
transmiss
countri
sudden
increas
gb
report
moreov
case
studi
studi
indic
zikv
may
trigger
gb
howev
accur
diagnosi
zikv
gb
mani
studi
disput
comprehens
descript
clinic
phenotyp
gb
relat
zikv
lack
intern
gb
outcom
studi
igo
prospect
observ
studi
factor
determin
onset
clinic
cours
outcom
gb
present
research
consortium
center
countri
includ
patient
igo
aim
investig
gb
igo
alreadi
occur
colombia
data
clinic
featur
ancillari
investig
collect
zikv
endem
area
accord
igo
protocol
modif
first
studi
design
defin
associ
gb
zikv
arbovirus
second
urin
sampl
collect
addit
question
preced
event
ask
focus
arboviru
infect
third
limit
requir
aim
recruit
addit
center
via
inflammatori
neuropathi
consortium
inc
center
arboviru
endem
region
will
particip
focu
accuraci
diagnosi
gb
zikv
defin
associ
clinic
phenotyp
cours
outcom
provid
opportun
combin
data
biobank
variou
geograph
region
use
standard
protocol
compar
data
data
biosampl
alreadi
collect
igo
studi
case
help
optim
diagnost
care
gb
patient
arboviru
endem
countri
provid
uniqu
opportun
understand
pathogenesi
gb
moreov
studi
design
network
use
adequ
respond
futur
viral
epidem
relat
gb
lerat
cinta
dzugan
magdelain
sturtz
lia
de
biochimi
et
chu
de
limog
limog
franc
de
neurologi
et
dexplor
fonctionnel
chu
de
toulous
toulous
franc
de
limog
limog
franc
pharc
syndrom
autosom
recess
neurodegen
patholog
lead
demyelin
polyneuropathi
hear
loss
cerebellar
ataxia
retini
pigmentosa
cataract
variou
symptom
occur
differ
age
pharc
syndrom
differenti
diagnosi
diseas
cmt
associ
deaf
mutat
report
patient
describ
mutat
compar
result
literatur
data
analys
next
gener
sequenc
ng
strategi
use
target
cmt
associ
neuropathi
panel
dna
old
male
suffer
demyelin
sensori
motor
polyneuropathi
ataxia
sinc
age
bilater
sensorineur
deaf
diagnos
age
five
bilater
congenit
cataract
oper
age
new
larg
complex
homozyg
mutat
one
delet
seven
base
pair
one
insert
base
pair
detect
analyz
patient
data
literatur
evalu
pharc
syndrom
sensorineur
deaf
alway
occur
first
featur
late
teen
ophthalmolog
symptom
cataract
occur
mean
age
yo
retini
pigmentosa
mean
age
demyelin
polyneuropathi
variabl
characterist
occur
thirti
report
first
larg
complex
homozyg
mutat
pharc
syndrom
certainli
therefor
seem
interest
includ
panel
five
symptom
especi
deaf
one
liberator
cocito
fazio
santoro
filosto
mazzeo
jann
cortes
carpo
clerici
luigetti
lauria
fierro
antonini
cavaletti
rosso
benedetti
briani
marfia
doneddu
peci
velardo
manganelli
todeschini
toscano
verrengia
piccolo
humanita
clinic
research
center
milan
univers
milan
itali
della
salut
e
della
scienza
hospit
turin
itali
san
raffael
hospit
milan
itali
degli
studi
di
napoli
federico
ii
napl
itali
brescia
spedali
civili
hospit
brescia
itali
ospedaliera
universitaria
g
martino
messina
itali
granda
hospit
milan
itali
fondazion
mondino
pavia
itali
hospit
treviglio
itali
macchi
hospit
vares
itali
cattolica
del
sacro
cuor
rome
itali
carlo
besta
neurolog
institut
milan
itali
ospedaliera
universitaria
policlinico
paolo
giaccon
palermo
itali
hospit
unives
rome
rome
itali
bicocca
univers
monza
itali
ulss
asolo
castelfranco
veneto
itali
santandrea
la
spezia
itali
di
padova
padua
itali
tor
vergata
rome
itali
chronic
inflammatori
demyelin
polyradiculoneuropathi
cidp
chronic
disabl
diseas
often
improv
immun
therapi
date
reliabl
diagnost
criteria
cidp
efnspn
revis
criteria
report
sensit
specif
implement
databas
collect
data
patient
cidp
follow
italian
center
expertis
cidp
determin
frequenc
characterist
cidp
variant
diagnost
criteria
use
diagnosi
possibl
evolut
typic
cidp
associ
specif
antibodi
respons
therapi
patient
evalu
time
inclus
follow
two
year
monitor
outcom
respons
therapi
februari
includ
patient
cidp
variant
men
women
age
year
median
mean
diseas
durat
year
rang
year
base
clinic
symptom
cidp
defin
typic
atyp
diagnosi
typic
cidp
fulfil
efnspn
criteria
patient
nerv
conduct
studi
diagnost
group
clinic
cidp
avail
analyz
frequenc
support
criteria
diagnosi
cidp
patient
clinic
cidp
found
increas
csf
protein
demyelin
cell
infiltr
nerv
biopsi
imag
abnorm
consist
cidp
us
nmr
present
patient
respect
relaps
cours
present
patient
clinic
cidp
increas
reliabl
diagnosi
cidp
addit
improv
one
therapi
report
patient
posit
respons
ivig
steroid
plasma
exchang
similarli
observ
patient
fulfil
efnspn
criteria
patient
clinic
cidp
two
supplementari
criteria
cidp
present
studi
larg
popul
patient
provid
use
inform
may
help
revis
current
diagnost
criteria
cidp
li
cannel
suragani
pearsal
kumar
pharma
inc
cambridg
usa
cmt
common
hereditari
peripher
neuropathi
character
demyelin
andor
axon
damag
peripher
nerv
muscl
weak
foot
drop
steppag
gait
foot
deform
typic
seen
cmt
patient
consequ
fall
commonli
report
patient
improv
dorsiflexor
muscl
function
prevent
fall
may
improv
qualiti
life
activ
daili
live
patient
cmt
ligand
trap
bind
growth
differenti
factor
gdf
activin
previous
shown
increas
muscl
mass
forc
duchen
muscl
dystrophi
dmd
amyotroph
later
sclerosi
al
mous
model
current
studi
evalu
therapeut
effect
improv
muscl
strength
trembler
mous
model
mice
harbor
mutat
peripher
myelin
protein
known
caus
old
mice
administ
twice
weekli
intramuscularli
one
unilater
tibiali
anterior
ta
muscl
week
contractil
ta
muscl
evalu
isometr
contract
data
compar
uninject
contralater
control
week
treatment
ta
muscl
mass
increas
p
physiolog
area
increas
p
increas
muscl
mass
correl
increas
strength
maximum
tetan
forc
twitch
forc
improv
p
p
respect
addit
tempor
properti
isometr
contract
maximum
rate
contract
relax
acceler
respect
p
ta
muscl
compar
contralater
patholog
biochem
assess
mice
show
enlarg
myocyt
area
p
reduc
mrna
express
p
togeth
result
demonstr
attenu
degre
muscl
atrophi
also
improv
muscl
function
mous
model
current
studi
provid
proof
concept
use
therapi
cmt
improv
dorsiflexor
muscl
function
allevi
foot
drop
li
lancast
yousaf
hanania
chan
lunn
kidd
svaren
scheidel
scherer
school
medicin
univers
pennsylvania
philadelphia
pennsylvania
usa
tarrytown
ny
usa
institut
technolog
pasadena
ca
usa
neural
inc
cleveland
oh
usa
wisconsin
madison
wi
usa
therapeut
llc
silver
spring
md
usa
gener
rat
model
diseas
harbor
mutat
whose
human
counterpart
result
sever
axon
neuropathi
mutat
made
use
zinc
finger
genom
edit
fertil
rat
egg
larg
cohort
mutant
wt
litterm
character
behavior
found
develop
multipl
motor
deficit
worsen
time
nerv
conduct
tail
caudal
nerv
perform
separ
cohort
mutant
wt
litterm
everi
week
week
mutant
rat
show
progress
declin
amplitud
compound
action
potenti
week
wherea
amplitud
progress
increas
wt
litterm
separ
cohort
rat
sacrif
week
analyz
light
microscopi
mutant
rat
reduc
densiti
myelin
axon
activ
axon
degener
distal
proxim
nerv
fasciculu
gracili
cervic
spinal
cord
week
find
present
cohort
mutant
rat
wt
rat
week
genet
authent
anim
model
develop
progress
axon
neuropathi
valuabl
tool
examin
pathogenesi
treatment
lindborg
niemi
defrancesco
zigmond
western
reserv
univers
cleveland
usa
tradit
role
immun
cell
nerv
degener
regener
focus
infiltr
inflammatori
monocyt
distal
nerv
nerv
injuri
phagocytosi
result
macrophag
myelin
axon
debri
therebi
clear
path
regener
axon
therefor
surpris
discov
knockout
ko
anim
entri
inflammatori
monocyt
occur
wallerian
degener
preced
normal
report
reason
neutrophil
schwann
cell
compens
decreas
macrophag
accumul
furthermor
nearli
complet
deplet
circul
neutrophil
system
inject
antibodi
lead
inhibit
myelin
clearanc
ko
wild
type
anim
hand
demonstr
second
site
macrophag
accumul
wild
type
anim
name
around
axotom
sensori
neuron
dorsal
root
ganglia
drg
blockad
accumul
exampl
occur
ko
anim
lead
dramat
impair
nerv
regener
examin
relationship
macrophag
regener
monocyt
chemokin
overexpress
drg
neuron
intact
anim
viral
infect
use
contain
code
sequenc
result
overexpress
led
accumul
macrophag
drg
even
though
injuri
taken
place
subsequ
increas
intrins
growth
capac
sensori
neuron
examin
chang
gene
express
drg
anim
reveal
increas
express
cytokin
leukemia
inhibitori
factor
increas
downstream
signal
pathway
involv
phosphoryl
nuclear
transloc
strikingli
pharmacolog
blockad
activ
inhibit
increas
neuron
growth
capac
produc
viru
result
reveal
unexpect
interact
immun
cell
neuron
facilit
nerv
degener
regener
could
lead
therapi
improv
regener
injuri
diseas
lin
qiao
huang
zhao
lu
neurolog
fudan
univers
shanghai
china
neurolog
huashan
hospit
fudan
univers
shanghai
china
use
termin
latenc
index
tli
tool
differenti
poem
syndrom
chronic
inflammatori
demyelin
polyradiculoneuropathi
cidp
comparison
median
ulnar
nerv
conduct
studi
includ
motor
conduct
veloc
mcv
distal
motor
latenc
dml
termin
latenc
index
tli
studi
poem
patient
match
cidp
patient
normal
control
cohort
averag
age
evalu
year
old
poem
group
cidp
patient
year
old
except
ulnar
termin
latenc
index
cidp
group
poem
cidp
patient
demonstr
prolong
distal
latenc
low
conduct
veloc
increas
termin
latenc
index
compar
normal
group
reduc
conduct
veloc
higher
termin
latenc
index
poem
group
cidp
group
found
increas
tli
demonstr
median
nerv
ulnar
nerv
poem
cidp
patient
median
nerv
ulnar
nerv
decreas
tli
found
median
ulnar
cidp
patient
none
poem
tempor
dispers
td
conduct
block
cb
often
seen
cidp
patient
increas
tli
poem
compar
cidp
poem
show
greater
slow
intermedi
nerv
segment
rel
uniform
demyelin
cidp
demonstr
distal
conduct
slow
td
cb
especi
increas
tli
termin
latenc
index
combin
td
cb
may
help
differenti
poem
cidp
lin
sung
chang
jowi
neurolog
taipei
municip
wanfang
hospit
taipei
taiwan
purpos
studi
exam
whether
electrophysiolog
chang
could
detect
prediabet
patient
discov
possibl
mechan
nerv
injuri
prediabet
stage
analysi
compar
nerv
excit
test
data
prediabet
patient
normal
control
subject
prediabet
defin
american
diabet
associ
ada
one
three
follow
fast
glucos
hour
oral
glucos
toler
test
mgdl
patient
radiculopathi
myelopathi
entrap
neuropathi
carpel
tunnel
syndrom
polyneuropathi
exclud
time
constant
sdtc
superexcit
show
signific
differ
p
two
group
also
find
increas
threshold
electrotonu
depolar
ted
reduc
rel
refractori
period
rrp
refractori
msec
earli
chang
prediabet
patient
similar
nerv
excit
featur
diabet
patient
howev
chang
found
motor
axon
excit
test
data
support
nerv
excit
test
may
use
less
time
depend
tool
detect
peripher
nerv
injuri
prediabet
stage
sensori
axon
vulner
motor
axon
superexcit
sensit
paramet
prediabet
lipowska
drac
rowczenio
gilbertson
philip
n
hawkin
chandoga
neurolog
medic
univers
warsaw
poland
amyloidosi
centr
univers
colleg
london
rowland
hill
street
london
uk
institut
medic
univers
warsaw
poland
neurolog
medic
univers
silesia
katowic
poland
ophthalmolog
medic
univers
warsaw
poland
centrum
lekarskej
genetiki
bratyslava
slovakia
famili
amyloid
polyneuropathi
autosom
domin
disord
caus
mutat
ttr
gene
associ
variabl
penetr
rare
except
endem
area
retrospect
studi
patient
diagnos
center
identifi
four
famili
differ
ttr
mutat
one
famili
mutat
nine
famili
member
four
gener
diagnos
follow
sinc
famili
index
case
differ
mutat
identifi
affect
famili
member
mutat
develop
sever
progress
polyneuropathi
cachexia
onset
diseas
age
three
patient
present
mark
visual
symptom
one
patient
underw
vitrectomi
nine
patient
die
year
diseas
onset
two
patient
sister
underw
liver
transplant
one
die
year
diseas
age
second
year
old
symptom
continu
progress
ttr
mutat
diagnos
index
case
three
famili
present
similar
clinic
pictur
predomin
progress
axon
sensori
motor
autonom
polyneuropathi
three
index
case
men
onset
symptom
year
numb
paresthesia
feet
follow
weak
autonom
dysfunct
excess
weight
loss
result
cachexia
diagnos
cardiomyopathi
patient
suffer
visual
symptom
three
patient
progress
stage
ii
walk
assist
time
diagnosi
year
due
advanc
stage
diseas
patient
suitabl
therapi
tafamidi
liver
transplant
ttr
confirm
de
novo
mutat
uncommon
remain
famili
carrier
ttr
mutat
identifi
follow
pedigre
analysi
famili
mutat
reveal
affect
member
high
probabl
die
studi
suggest
patient
poland
exhibit
clinic
genet
heterogen
liu
fan
neurolog
peke
univers
third
hospit
beij
china
object
identifi
gene
mutat
chines
pedigre
investig
correl
among
clinic
manifest
electrophysiolog
mechan
differ
genotyp
method
includ
pedigre
cmt
enrol
hospit
januari
decemb
record
clinic
featur
cmtn
electrophysiolog
data
diagnosi
patient
underw
mutat
analysi
mpz
use
mlpa
dhplc
sanger
gene
sequenc
result
found
duplic
pedigre
pedigre
pedigre
mpz
pedigre
conclus
chines
han
popul
proport
duplic
rel
low
major
clinic
manifest
classic
cmt
axon
cmt
show
isol
lower
extrem
injuri
central
nervou
system
involv
hmn
may
underestim
clinic
type
identif
done
caution
differenti
diagnosi
liu
liu
sebastian
wozniak
wu
slusher
polydefki
hopkin
school
medicin
baltimor
usa
peripher
neuropathi
cipn
common
toxic
treatment
mani
cancer
cipn
studi
preferenti
focu
sensori
fiber
loss
dysfunct
compar
structur
function
recoveri
autonom
fiber
sweat
gland
sweat
gland
nerv
fiber
densiti
sgnfd
sensori
fiber
fiber
densiti
ienfd
mous
footpad
exposur
maximum
toler
dose
mtd
sever
common
chemotherapi
agent
addit
assess
footpad
sweat
product
function
correl
sgnfd
reduct
femal
mice
treat
mtd
four
drug
paclitaxel
pca
mgkg
ixabepilon
ixa
mgkg
eribulin
erib
mgkg
vinoelbin
vino
mgkg
correspond
placebo
given
intraven
mwf
two
week
recoveri
assess
week
follow
last
dose
footpad
process
visual
epiderm
nerv
fiber
use
autonom
nerv
fiber
tyrosin
hydroxyl
mice
experienc
signific
reduct
sgnfd
ienfd
nadir
occur
later
time
point
recoveri
baselin
level
occur
quickli
ienfd
sgnfd
contrast
vinorelbin
eribulin
treat
mice
experienc
maximum
deficit
sgnfd
ienfd
sgnfd
recoveri
slower
compar
ienfd
anim
show
sever
ienfd
sgnfd
deficit
compar
agent
ienfd
sgnfd
recov
complet
reduct
compar
pronounc
decreas
agent
timepoint
anim
demonstr
reduct
footpad
sweat
droplet
number
therebi
provid
function
correl
togeth
data
indic
mous
model
cipn
autonom
nerv
fiber
affect
sever
sensori
nerv
fiber
also
recov
slowli
intraepiderm
nerv
fiber
autonom
dysfunct
may
import
consequ
chemotherapi
exposur
logan
mammel
robinson
chin
condon
robinson
center
neurosci
research
depart
neurolog
oregon
health
scienc
univers
portland
oregon
usa
graduat
program
oregon
health
scienc
univers
portland
oregon
usa
development
cancer
biolog
graduat
program
oregon
health
scienc
univers
portland
oregon
usa
institut
oregon
health
scienc
univers
portland
oregon
usa
pi
synthes
phosphatidylinositol
lipid
critic
endosom
membran
traffic
macroautophagi
human
genet
implic
dysregul
endosom
traffick
gener
recur
caus
demyelin
cmt
peripher
neuropathi
investig
role
mous
schwann
cell
select
delet
cell
type
cell
knockout
mice
show
sever
hypomyelin
peripher
nerv
schwann
cell
interact
abnorm
axon
delay
radial
sort
process
larg
axon
select
myelin
upon
reach
promyelin
stage
schwann
cell
significantli
impair
elabor
myelin
nerv
mice
contain
elev
level
protein
indic
impair
autophagi
howev
light
recent
demonstr
autophagi
dispens
myelin
unlik
hypomyelin
mice
caus
impair
autophagi
endosom
membran
traffic
also
disturb
schwann
cell
investig
activ
receptor
tyrosin
kinas
nerv
protein
play
essenti
role
schwann
cell
myelin
known
traffic
though
endosom
nerv
hyperphosphoryl
tyrosin
known
phosphoryl
respons
exposur
overal
level
also
decreas
myelin
find
suggest
loss
alter
traffick
endosom
abnorm
signal
may
contribut
hypomyelin
observ
mice
lombardi
devaux
cortes
dacci
benedetti
demich
lauria
foundat
carlo
besta
neurolog
institut
milan
itali
marseil
franc
c
mondino
nation
neurolog
institut
pavia
itali
genoa
ircc
aou
san
genoa
itali
recent
identif
nfascin
antibodi
group
patient
widen
spectrum
present
chronic
inflammatori
demyelin
polyradiculoneuropathi
cidp
patient
distinguish
disabl
tremor
poor
respons
intraven
immunoglobulin
distal
sensori
disturb
molecul
express
paranod
junction
pnj
node
ranvier
play
key
role
sodium
channel
cluster
interact
quantif
unmyelin
intraepiderm
nerv
fiber
ienf
use
paramet
employ
small
nerv
fiber
patholog
diagnosi
addit
immunohistochemistri
evalu
dermal
nerv
fiber
allow
examin
morpholog
chang
myelin
sheath
ranvier
node
structur
perform
immunofluoresc
coloc
studi
use
antibodi
visual
axon
neurofila
tubulin
sheath
myelin
specif
nodalparanodaljuxtaparanod
structur
pannfascin
caspr
potassium
sodium
channel
skin
tissu
seroneg
seroposit
cidp
patient
analyz
axon
myelin
sheath
damag
abnorm
architectur
morphometr
paramet
internod
length
ranvier
node
result
skin
biopsi
three
cidp
patient
reveal
complet
loss
stain
paranod
asymmetr
paranod
widen
node
dermal
myelin
nerv
fiber
one
cidp
patient
show
abnorm
nodalparanod
immunostain
differ
featur
compar
patient
suggest
specif
chang
howev
alter
found
four
seroneg
cidp
patient
data
support
hypothesi
examin
specif
axon
myelin
marker
could
provid
diagnost
prognost
clue
goal
studi
attempt
possibl
correl
presenc
serum
autoantibodi
structur
chang
nodalparanod
region
dermal
nerv
fiber
cidp
patient
knowledg
autoantibodi
express
peripher
myelin
nerv
cidp
patient
could
serv
stratifi
patient
potenti
guid
person
treatment
lunati
lerat
dzugan
rego
magdelain
bieth
calva
cinta
goizet
journel
magi
toutain
urtizberea
sturtz
lia
de
biochimi
et
chu
de
limog
limog
franc
de
limog
limog
franc
chu
de
limog
limog
franc
de
chu
de
toulous
toulous
franc
de
neurologi
et
dexplor
fonctionnel
chu
de
toulous
toulous
franc
de
chu
de
poitier
poitier
franc
de
chu
de
bordeaux
bordeaux
franc
de
centr
hospitali
bretagn
atlantiqu
vann
franc
de
neurologi
chu
de
limog
limog
franc
de
chu
de
tour
tour
franc
de
neuromusculair
marin
henday
franc
diseas
one
frequent
inherit
peripher
neuropathi
far
mutat
gene
identifi
caus
either
demyelin
form
type
axon
form
type
duplic
gene
frequent
caus
autosom
domin
demyelin
form
autosom
recess
demyelin
form
often
due
gene
mutat
patient
suffer
earli
sever
neuropathi
start
first
decad
scoliosi
deaf
often
observ
analys
patient
suffer
peripher
neuropathi
mlpa
follow
target
ng
use
custom
panel
design
diagnosi
associ
neuropathi
mutat
interest
verifi
sanger
sequenc
diagnosi
posit
patient
expect
frequent
mutat
duplic
detect
patient
delet
observ
patient
pathogen
point
mutat
detect
patient
gene
appear
frequent
mutat
nine
patient
diagnos
associ
known
mutat
four
new
mutat
identifi
two
nonsens
mutat
two
missens
mutat
patient
present
deaf
andor
scoliosi
appear
import
gene
involv
diseas
often
associ
deaf
scoliosi
import
pay
attent
associ
symptom
patient
order
guid
diagnosi
improv
medic
care
lupo
frasquet
barreiro
alberti
casasnova
camacho
sedano
pelayo
pardo
sobrino
sobrido
sevilla
de
felip
valencia
spain
ii
la
fe
rare
diseas
joint
unit
valencia
spain
universitari
la
fe
valencia
spain
rare
diseas
ciber
bellvitg
barcelona
spain
de
investigacion
sanitaria
idi
santiago
de
compostela
spain
galega
de
medicina
santiago
de
compostela
spain
de
octubr
madrid
spain
universitario
de
valdecilla
santand
spain
universitario
santiago
de
compostela
santiago
de
compostela
spain
mme
membran
metalloendopeptidas
mutat
inherit
autosom
recess
fashion
recent
identifi
japanes
proband
higuchi
et
al
thu
mme
includ
list
cmt
gene
new
autosom
recess
axon
form
mim
moreov
consid
strong
candid
genet
diagnosi
unsolv
case
fact
month
later
et
al
report
european
proband
autosom
domin
mutat
mme
investig
clinic
seri
patient
diagnos
motor
peripher
neuropathi
use
updat
version
custom
gene
panel
includ
mme
studi
report
proband
intermedi
cmt
homozyg
compound
heterozyg
mutat
mme
proband
heterozyg
mutat
mme
identifi
differ
type
mutat
novel
splice
donor
variant
frameshift
nonsens
missens
mutat
two
nonsens
chang
splice
donor
variant
detect
homozyg
compound
heterozyg
state
patient
frameshift
mutat
detect
homozyg
heterozyg
remain
patient
strikingli
two
nonsens
frameshift
mutat
previous
report
caus
et
al
three
missens
mutat
one
novel
two
report
control
databas
studi
show
autosom
recess
common
spanish
popul
moreov
suggest
screen
mme
use
gene
panel
test
could
help
improv
diagnosi
unclarifi
inherit
peripher
neuropathi
case
fund
isciii
per
amor
lart
lupo
frasquet
barreiro
alberti
pascual
casasnova
quintan
camacho
sedano
pelayo
pardo
sobrino
sobrido
sevilla
de
felip
valencia
spain
ii
la
fe
rare
diseas
joint
unit
valencia
spain
universitari
la
fe
valencia
spain
rare
diseas
ciber
la
paz
madrid
spain
bellvitg
barcelona
spain
virgen
del
rocio
sevilla
spain
de
investigacion
sanitaria
idi
santiago
de
compostela
spain
galega
de
medicina
centro
de
en
red
de
enfermedad
rara
ciber
spain
de
octubr
madrid
spain
universitario
de
valdecilla
santand
spain
universitario
santiago
de
compostela
santiago
de
compostela
spain
inherit
peripher
neuropathi
ipn
encompass
group
disord
highli
heterogen
clinic
genet
cmt
diseas
close
relat
distal
hereditari
motor
neuropathi
dhmn
distal
spinal
muscular
atrophi
dsma
patient
show
addit
sign
associ
amyotroph
later
sclerosi
al
target
gene
panel
exom
sequenc
consid
power
tool
diagnosi
disord
investig
clinic
seri
patient
diagnos
motor
peripher
neuropathi
famili
investig
exom
sequenc
case
test
use
differ
updat
version
gene
panel
version
compris
ipn
gene
respect
show
high
coverag
perform
percentag
analyz
target
base
coverag
exom
gene
panel
captur
librari
base
sureselect
captur
technolog
agil
technolog
sequenc
perform
miseq
hiseq
illumina
equip
identifi
novel
gene
novel
mutat
known
gene
broaden
phenotyp
spectrum
associ
ipn
exom
sequenc
allow
us
identifi
caus
gene
familiar
sporad
case
aar
gar
dao
gene
panel
test
mostli
perform
sporad
case
allow
us
identifi
either
candid
mutat
case
common
gene
mutat
updat
gene
panel
neuro
reveal
novel
mutat
gene
recent
associ
diseas
mme
respect
sum
strategi
help
us
achiev
accur
clinic
genet
reclassif
disord
imposs
challeng
use
convent
sequenc
method
studi
expand
clinic
phenotyp
previous
associ
known
ipn
emphas
gene
panel
consid
first
diagnosi
method
unclarifi
ipn
patient
fund
isciii
per
amor
lart
magi
mathi
goizet
tazir
vallat
laboratori
neurolog
nation
refer
center
rare
peripher
neuropathi
chu
limog
franc
neurolog
chu
bordeaux
franc
medic
genet
chu
bordeaux
franc
neurolog
chu
algier
algeria
cmt
diseas
hereditari
neuropathi
rel
homogen
phenotyp
genet
heterogen
moreov
nerv
conduct
studi
distinguish
differ
form
ad
anoth
level
complex
current
classif
cmt
difficult
understand
physician
scientist
patient
present
publish
propos
updat
classif
base
inherit
nerv
conduct
find
genemut
involv
input
colleagu
prompt
us
conduct
survey
order
tri
reach
consensu
propos
conduct
internet
survey
octob
decemb
link
complet
survey
sent
sever
time
email
introduct
peopl
particip
contact
email
list
last
cmt
meet
venic
septemb
addit
physician
scientist
involv
cmt
care
research
contact
well
one
hundr
seven
peopl
variou
countri
mainli
franc
itali
usa
answer
survey
particip
year
age
physician
scientist
vast
major
consid
propos
constitut
improv
histor
classif
wherea
want
keep
old
one
order
inform
particip
thought
mode
inherit
come
first
wherea
felt
phenotyp
place
begin
percent
peopl
thought
cmt
kept
gener
name
hereditari
sensori
motor
neuropathi
pure
sensori
neuropathi
favour
hsn
hsan
although
thought
opposit
particip
felt
dhmn
kept
distal
motor
neuropathi
nerv
conduct
find
particip
thought
intermedi
phenotyp
kept
favour
propos
replac
de
demyelin
ax
axon
final
respond
thought
genet
inform
includ
classif
cmt
overal
propos
new
classif
receiv
good
appreci
physician
scientist
implic
care
patient
hereditari
neuropathi
mallik
hubsch
gaida
barn
behr
kop
usa
behr
bern
switzerland
behr
ottawa
canada
risk
hemolyt
event
he
intraven
immunoglobulin
ivig
therapi
appear
link
isoagglutinin
level
specif
ivig
product
use
publish
titer
seven
ivig
product
correspond
rate
report
eudravigil
databas
develop
mathemat
model
predict
risk
patient
receiv
ivig
product
given
level
model
perform
separ
risk
patient
blood
group
b
ab
overal
popul
risk
estim
assum
blood
group
distribut
b
ab
appli
predict
model
calcul
risk
ivig
product
produc
via
chromatograph
process
csl
behr
without
isoagglutinin
reduct
measur
b
donor
screen
program
elimin
approxim
donor
high
titer
c
incorpor
specif
immunoaffin
chromatographi
iac
igisolotm
step
manufactur
process
sinc
measur
b
c
combin
well
ivig
product
produc
cold
ethanol
fraction
process
csl
behr
isoagglutinin
titer
ivig
product
measur
european
pharmacopoeia
direct
assay
provid
dr
c
bellac
swissmed
bern
switzerland
predict
risk
highest
chromatograph
purifi
ivig
without
isoagglutinin
reduct
case
expect
per
kg
ivig
use
donor
screen
reduc
predict
risk
kg
greater
risk
reduct
predict
iac
isoagglutinin
reduct
step
kg
combin
method
produc
littl
benefit
kg
versu
iac
alon
predict
hemolyt
risk
ivig
produc
ethanol
fraction
low
kg
observ
cohort
studi
confirm
hemolyt
risk
reduct
progress
present
observ
hemolyt
risk
donor
screen
appear
consist
predict
calcul
model
result
iac
isoagglutinin
reduct
expect
mandaraka
shi
kennedi
herbert
rose
menez
ryan
yiu
farrar
sampaio
estilow
moroni
yum
finkel
acsadi
eiching
reilli
muntoni
refshaug
shi
burn
sanmaneechai
inherit
neuropathi
sydney
sydney
australia
children
hospit
network
randwick
westmead
new
south
wale
australia
iowa
hospit
clinic
iowa
citi
usa
royal
children
hospit
univers
melbourn
victoria
australia
children
hospit
philadelphia
philadelphia
usa
neurologico
carlo
besta
milan
itali
children
hospit
orlando
usa
children
medic
center
hartford
usa
rochest
rochest
usa
centr
neuromuscular
diseas
ucl
institut
neurolog
queen
squar
london
uk
ormond
street
hospit
london
uk
hospit
mahidol
univers
bangkok
thailand
cmt
infant
scale
cmtinf
outcom
measur
function
abil
young
infant
children
age
year
cmtinf
align
cmt
pediatr
scale
cmt
neuropathi
score
measur
diseas
sever
across
lifespan
measur
gross
motor
fine
motor
function
cmtinf
compris
two
subscal
gross
motor
eg
head
control
crawl
walk
jump
hop
fine
motor
function
item
eg
grasp
reach
tear
paper
button
overal
function
express
base
norm
refer
valu
posit
indic
poorer
function
total
control
age
month
mean
age
sd
assess
across
australia
thailand
usa
total
cmtinf
differ
significantli
site
australia
vs
thailand
gender
data
collect
ongo
infant
age
year
elig
inclus
date
infant
male
age
month
mean
age
sd
rang
cmt
subtyp
unidentifi
gene
assess
cmtinf
mean
total
infant
cmt
sd
rang
significantli
higher
control
sd
rang
differ
affect
infant
control
larger
infant
older
month
infant
cmtinf
sd
less
affect
gross
motor
function
subscal
differ
significantli
cmt
case
control
sd
vs
sd
signific
differ
also
observ
fine
motor
function
subscal
sd
vs
sd
reliabl
factor
rasch
analysi
cmtinf
underway
assess
valid
initi
result
support
sensit
cmtinf
distinguish
infant
without
cmt
preliminari
analys
also
suggest
scale
sensit
genet
subtyp
increas
power
cmtinf
promis
becom
use
outcom
measur
diseas
sever
function
infant
cmt
manso
querol
mekaouch
illa
devaux
marseil
franc
de
barcelona
barcelona
spain
essenti
format
paranod
axogli
junction
autoantibodi
associ
subset
patient
chronic
inflammatori
demyelin
polyradiculoneuropathi
cidp
present
common
clinic
featur
autoantibodi
shown
pathogen
affect
paranod
axogli
junction
vivo
vitro
contrast
pathogen
effect
demonstr
purifi
cidp
patient
plasma
investig
effect
passiv
transfer
determin
whether
antibodi
pass
paranod
barrier
perform
intraneur
inject
autoantibodi
contrast
penetr
paranod
region
intraneur
inject
bound
surfac
schwann
cell
perform
chronic
exposur
lewi
rat
implant
intrathec
cathet
administr
daili
manner
three
week
control
induc
progress
clinic
deterior
character
gait
ataxia
hindlimb
paraparesi
deterior
associ
nerv
activ
loss
motor
spinal
nerv
select
loss
paranod
special
character
disappear
complex
paranod
passiv
transfer
thu
seem
induc
similar
pathogen
effect
howev
pathogen
mechan
lead
paranod
disappear
appear
differ
find
indic
direct
pathogen
show
antibodi
reliabl
biomark
specif
subset
cidp
patient
mark
shi
south
florida
tampa
usa
iowa
health
care
iowa
citi
usa
rare
diseas
clinic
research
network
rdcrn
contact
registri
inherit
neuropathi
consortium
inc
interact
onlin
platform
empow
patient
inherit
neuropathi
famili
member
provid
relev
inform
clinic
studi
conduct
inc
investig
enabl
particip
onlin
studi
facilit
commun
interact
inherit
neuropathi
commun
februari
individu
enrol
rdcrn
inc
contact
registri
includ
patient
cmtx
patient
multipl
unknown
cmt
diseas
type
unaffect
famili
member
patient
cmt
rdcrn
inc
contact
registr
particip
rdcrn
inc
contact
registri
studi
date
proven
essenti
inherit
neuropathi
consortium
result
complet
protocol
public
develop
outcom
measur
prom
current
investig
within
inc
clinic
site
result
made
larg
contribut
toward
goal
improv
care
peopl
inherit
neuropathi
recent
sever
enhanc
made
rdcrn
inc
contact
registri
better
fit
need
consortium
improv
patient
experi
enhanc
includ
creat
mobil
friendli
webpag
updat
enrol
form
content
access
custom
dashboard
abil
registr
explor
data
comparison
registr
review
enhanc
depth
demonstr
impact
growth
develop
rdcrn
inc
contact
registri
inherit
neuropathi
consortium
part
rare
diseas
clinic
research
network
rdcrn
initi
offic
rare
diseas
research
ordr
nation
center
advanc
translat
scienc
ncat
consortium
fund
collabor
ncat
nation
institut
neurolog
disord
stroke
nind
content
sole
respons
author
necessarili
repres
offici
view
nih
martinez
hubsch
watson
shebl
wallenhorst
simon
epidemiolog
statist
informat
gmbh
frankfurt
germani
bere
ag
bern
switzerland
behr
llc
king
prussia
usa
bere
gmbh
marburg
germani
hemolyt
anemia
ha
complic
intraven
immunoglobulin
ivig
treatment
particularli
patient
receiv
high
dose
ivig
immun
modul
syndrom
chronic
inflammatori
demyelin
polyneuropathi
primari
mechan
increas
risk
believ
passiv
acquisit
group
b
antibodi
isoagglutinin
ivig
product
reduc
quantiti
isoagglutinin
donor
screen
implement
ivig
donor
high
titer
exclud
contribut
pool
plasma
donor
screen
replac
sinc
immunoaffin
chromatographi
step
decreas
isoagglutinin
greater
extent
data
avail
test
clinic
effect
test
effect
donor
screen
two
cohort
patient
treat
start
donor
screen
identifi
administr
databas
us
hospit
outpati
discharg
diagnos
procedur
drug
util
laboratori
test
period
period
dose
per
kg
bodi
weight
estim
daili
quantiti
administ
us
popul
bodi
weight
estim
ha
within
day
use
assess
manual
record
review
incid
rate
ha
two
period
compar
incid
rate
ratio
irr
ha
adjust
sex
age
treatment
set
indic
dose
per
kg
bodi
weight
use
period
refer
incid
rate
ha
confid
interv
period
period
adjust
irr
significantli
less
ha
risk
found
high
dose
gkg
bodi
weight
irr
conclud
donor
screen
exclus
donor
high
titer
plasma
pool
associ
decreas
risk
ha
ivig
matsumoto
depart
neurolog
keijinkai
jozanki
hospit
sapporo
japan
subacut
neuropathi
smon
intox
clinoquinol
main
clinic
symptom
paresthesia
spastic
leg
symptom
consid
elicit
disturb
spinal
cord
peripher
nerv
intox
clinoquinol
howev
patient
smon
still
live
onset
diseas
examin
nerv
conduct
veloc
normal
rang
clinic
symptom
peripher
neuropathi
observ
order
investig
whether
peripher
neuropathi
observ
earli
stage
smon
investig
longtidun
chang
electrophysiolog
result
patient
could
examin
nerv
conduct
studi
earli
stage
smon
present
time
disturb
pyramid
tract
function
myelopathi
smon
patient
central
motor
conduct
time
calcul
transmagnet
stimul
motor
cortex
cervic
root
lumbar
root
peripher
nerv
conduct
veloc
sensori
nerv
examin
sural
nerv
result
patient
smon
could
examin
electrophysiolog
examin
earli
stage
smon
year
later
central
motor
conduct
time
leg
muscl
motor
cortex
lumbar
root
prolong
smon
patient
compar
normal
case
result
suggest
presenc
disturb
conduct
veloc
spinal
cord
conduct
veloc
sensori
nerv
velic
sncv
show
delay
sncv
sural
nerv
first
examin
onset
year
howev
year
later
sncv
case
cover
electrophysilog
examin
suggest
present
main
symptom
smon
disturb
myelopathi
disturb
peripher
nerv
function
recov
onset
smon
elaps
long
time
mausberg
heining
meyer
zu
horst
cord
kleinschnitz
kieseier
stettner
neurolog
univers
hospit
essen
essen
germani
neurolog
germani
neurolog
univers
germani
hematolog
oncolog
tumor
immunolog
charit
berlin
berlin
germani
natur
killer
nk
cell
part
innat
immun
system
regulatori
effector
function
compris
first
line
defenc
recognit
destruct
patholog
alter
cell
differ
studi
suggest
treatment
intraven
immunoglobulin
ivig
immunomodulatori
effect
nk
cell
ivig
treatment
variou
autoimmun
diseas
particular
chronic
inflammatori
demyelin
polyneuropathi
cidp
lack
predict
marker
ivig
respons
cidp
avoid
earli
preserv
patient
better
understand
effect
ivig
patient
cidp
test
whether
ivig
treatment
alter
nk
cell
statu
addit
analys
alter
popul
may
serv
surrog
marker
predict
outcom
ivig
treatment
use
pcr
flow
cytometri
peripher
blood
patient
cidp
analys
effect
ivig
nk
cell
popul
treatment
initi
first
dose
correl
chang
repons
ivig
ivig
administr
induc
reduct
express
sever
typic
nk
cell
gene
interestingli
reduct
nk
cell
revers
four
week
ivig
treatment
flow
cytometri
data
reveal
ivig
reduc
cytotox
nk
cell
popul
regulatori
nk
cell
remain
almost
unaffect
even
increas
interestingli
found
observ
effect
nk
cell
almost
exclus
occur
cidp
patient
respond
ivig
therapi
correl
chang
nk
cell
popul
treatment
effici
suggest
crucial
role
nk
cell
immunomodulatori
mechan
ivig
studi
warrant
investig
whether
differ
nk
cell
statu
patient
cidp
repres
reliabl
surrog
marker
predict
outcom
ivig
therapi
mccray
sullivan
woolum
aisenberg
lloyd
sumner
hopkin
univers
baltimor
usa
mutat
transient
receptor
potenti
vanilloid
ion
channel
caus
diseas
type
uniqu
repres
ion
channel
cmt
thu
potenti
therapeut
target
previou
work
suggest
mutat
lead
gain
channel
function
toxic
cultur
cell
mutat
larg
cluster
cytosol
ankyrin
repeat
domain
ard
known
mediat
interact
suggest
pathogenesi
may
relat
disrupt
interact
order
identifi
protein
perform
two
unbias
proteom
screen
identifi
multipl
protein
includ
neuron
protein
known
promot
axon
outgrowth
influenc
actin
cytoskeleton
cultur
cell
shown
highli
dynam
cellular
process
togeth
stimul
robust
neurit
extens
facilit
neuritogenesi
impair
mutat
also
shown
syndapin
reduc
calcium
influx
cultur
cell
rescu
toxic
mutant
addit
syndapin
suppress
mutant
phenotyp
drosophila
model
neuropathi
demonstr
treatment
drosophila
specif
channel
antagonist
amelior
mutant
toxic
togeth
data
highlight
import
interact
cytoskelet
protein
pathogenesi
specif
result
suggest
mutat
disrupt
normal
role
regul
cytoskelet
dynam
interact
cytoskeleton
reciproc
modul
channel
function
influenc
toxic
mutant
mcgonig
yao
barri
crawford
willison
glasgow
glasgow
uk
syndrom
gb
part
mediat
gangliosid
antibodi
induc
preced
infect
antibodi
target
plasma
membran
extens
distribut
glial
axon
membran
particularli
node
ranvier
antibodi
deposit
site
model
gb
associ
complement
deposit
conduct
block
structur
disrupt
ion
channel
macrophag
infiltr
wide
distribut
gangliosid
target
lead
unwant
complex
ascrib
patholog
outcom
injuri
membran
particular
unravel
consequ
paranod
schwann
cell
membran
injuri
axon
function
vice
versa
overcom
impass
gener
transgen
mice
glycosyltransferas
manipul
express
exclus
neuron
glia
thu
allow
us
specif
target
injur
axon
glial
membran
singl
gangliosid
antibodi
rout
creat
mous
model
axon
demyelin
form
gb
induc
singl
antibodi
thu
creat
otherwis
highli
compar
condit
show
antibodi
bind
restrict
nodal
axolemma
neuron
mice
convers
paranod
loop
glial
mice
antibodi
sourc
complement
ad
ex
vivo
injuri
paradigm
loss
axon
integr
ie
loss
neurofila
immunolabel
neuron
membran
target
neuron
convers
axon
integr
maintain
paranod
membran
decor
antibodi
complement
product
ex
vivo
glial
mice
passiv
immunis
model
vivo
neuron
mice
acut
develop
weak
respiratori
dysfunct
associ
complement
deposit
degen
patholog
distal
axon
contrast
glial
mice
significantli
fewer
abnorm
acut
condit
data
indic
high
vulner
axon
membran
acut
injuri
underlin
import
develop
specif
axon
protect
strategi
summari
target
nodal
axolemm
glial
membran
allow
us
studi
associ
nodal
patholog
determin
downstream
consequ
function
axon
fate
current
major
area
gb
clinic
research
memon
madani
schultz
grover
sripathi
ahmad
divis
depart
neurolog
henri
ford
hospit
detroit
michigan
usa
object
differenti
sensori
electrophysiolog
tli
treatment
respons
patient
paraproteinem
cidp
background
low
tli
report
use
electrophysiolog
marker
knowledg
comparison
sensori
electrophysiolog
tli
paraproteinem
cidp
subgroup
previous
report
method
retrospect
review
januari
patient
cidp
fulfil
electrophysiolog
criteria
aan
ad
hoc
subcommitte
alber
colleagu
cidp
patient
diabet
exclud
patient
divid
idiopath
paraproteinem
cidp
paraproteinem
cidp
mag
igg
compar
idiopath
cidp
group
compar
demograph
histori
cancer
csf
protein
sensori
conduct
tli
measur
respons
treatment
use
test
binari
categor
variabl
continu
measur
result
higher
proport
femal
compar
vs
idiopath
group
higher
proport
patient
monotherapi
vs
combin
therapi
vs
compar
higher
mean
csf
protein
compar
seen
idiopath
differ
idiopath
signific
overal
rx
respons
rx
respons
patient
variabl
patient
idiopath
group
higher
proport
patient
combin
therapi
lower
proport
treatment
offer
compar
patient
patient
histori
cancer
vs
none
differ
signific
group
differ
sensori
electrophysiolog
tli
conclus
sensori
electrophysiolog
tli
may
valu
differenti
paraproteinem
cidp
csf
protein
higher
idiopath
cidp
compar
higher
proport
femal
compar
higher
proport
patient
combin
therapi
compar
cancer
screen
consid
patient
memon
madani
ahmad
schultz
sripathi
neurolog
henri
ford
hospit
detroit
michigan
usa
introduct
sensori
electrophysiolog
termin
latenc
index
tli
differ
describ
variou
cidp
object
evalu
electrophysiolog
tli
treatment
respons
idiopath
diabet
cidp
method
retrospect
review
patient
cidp
underw
electrodiagnost
evalu
januari
patient
fulfil
electrophysiolog
criteria
describ
ad
hoc
subcommitte
american
academi
neurolog
aan
alber
et
al
exclud
patient
acut
inflammatori
demyelin
neuropathi
hereditari
sensorimotor
neuropathi
vascul
polyneuropathi
paraproteinemia
patient
divid
idiopath
diabet
group
group
compar
age
sex
histori
cancer
csf
protein
respons
treatment
sensori
respons
abnorm
tli
measur
use
test
binari
categor
variabl
continu
measur
test
level
result
group
differ
age
sex
histori
cancer
csf
protein
treatment
respons
signific
compar
tli
valu
measur
respons
differ
two
group
tibial
tli
signific
idiopath
group
lower
mean
compar
diabet
tli
valu
differ
median
ulnar
peron
nerv
signific
differ
abnorm
rate
sensori
respons
signific
sural
nerv
idiopath
group
lower
rate
compar
diabet
group
vs
p
differ
note
ulnar
median
radial
nerv
conclus
tibial
tli
sural
sensori
respons
valu
differenti
two
group
larger
prospect
studi
need
confirm
find
mielk
bril
van
geloven
hartung
lewi
sobu
lawo
durn
cornblath
merki
van
schaik
behalf
path
studi
group
behr
marburg
germani
king
prussia
pa
usa
medicin
neurolog
univers
health
network
univers
toronto
toronto
canada
biostatist
bioinformat
leiden
univers
medic
center
leiden
netherland
neurolog
heinrich
hein
univers
germani
neurolog
medic
center
lo
angel
ca
usa
neurolog
nagoya
univers
graduat
school
medicin
nagoya
japan
neurolog
john
hopkin
univers
school
medicin
baltimor
md
usa
neurolog
maastricht
univers
medic
center
maastricht
netherland
neurolog
academ
medic
centr
univers
amsterdam
amsterdam
netherland
ivig
import
treatment
option
cidp
although
recommend
treatment
guidelin
littl
known
consequ
temporari
ivig
withdraw
assess
ongo
immunoglobulin
need
path
random
trial
subcutan
immunoglobulin
scig
csl
behr
cidp
scig
random
subject
underw
period
ivig
withdraw
week
indic
clinic
deterior
ivig
restabil
csl
behr
subject
show
deterior
withdraw
period
withdrawn
studi
proceed
scig
random
subject
achiev
cidp
stabil
relev
chang
incat
score
last
two
restabil
visit
least
total
score
screen
subject
enter
ivig
withdraw
period
qualifi
restabil
subject
ivig
depend
withdrawn
reason
one
subject
withdrew
consent
dose
end
restabil
period
cidp
stabil
achiev
subject
reach
stabil
withdrawn
reason
inform
avail
subject
reach
stabil
improv
baselin
clinic
statu
mean
least
subject
improv
statu
restabil
period
subject
improv
least
one
predefin
outcom
measur
averag
subject
improv
point
incat
total
score
point
centil
score
kpa
mean
grip
strength
domin
hand
point
mrc
sum
score
improv
occur
median
day
first
dose
one
efficaci
outcom
measur
case
third
mainten
infus
headach
nasopharyng
frequent
report
advers
event
ae
restabil
ae
deem
causal
relat
mostli
mild
moder
unexpect
ae
laboratori
vital
sign
find
associ
occur
studi
summari
revers
neuromuscular
disabl
improv
activityparticip
previou
clinic
deterior
ivig
withdraw
period
miressi
derouault
dzugan
cinta
magdelain
sturtz
meril
lia
de
limog
limog
franc
de
biochimi
et
de
limog
limog
franc
de
neurologi
et
dexplor
fonctionnel
chu
de
toulous
toulous
franc
de
limog
limog
franc
duplic
frequent
caus
diseas
cmt
sinc
discoveri
gene
identifi
potenti
respons
cmt
diseas
howev
singl
nucleotid
variat
snv
small
indel
describ
could
due
new
sequenc
strategi
ng
especi
ng
amplicon
sequenc
whose
conveni
tool
avail
easili
usabl
detect
cnv
respons
inherit
diseas
overcom
problem
design
covcop
tool
abl
detect
cnv
among
amplicon
sequenc
data
use
run
coverag
file
provid
sequenc
covcop
simultan
analyz
patient
run
use
algorithm
contain
correct
normal
level
provid
easili
understand
output
show
variou
color
potenti
delet
duplic
amplicon
valid
method
sever
dataset
includ
target
ng
panel
screen
gene
known
involv
cmt
close
patholog
covcop
detect
easili
duplic
delet
patient
confirm
mlpa
addit
covcop
permit
detect
new
cnv
differ
duplic
cmt
patient
confirm
cnv
quantit
pcr
cgh
array
present
one
cnv
duplic
aar
gene
detect
cmt
patient
discuss
pathogen
new
cnv
addit
cnv
respons
cmt
diseas
probabl
still
discov
believ
covcop
help
molecular
geneticist
rapidli
identifi
misawa
sato
katayama
sekiguchi
amino
suichi
kuwabara
trial
studi
group
neurolog
graduat
school
medicin
chiba
univers
chiba
japan
research
center
chiba
univers
hospit
chiba
japan
poem
polyneuropathi
organomegali
endocrinopathi
skin
chang
syndrom
rare
caus
demyelin
neuropathi
associ
plasma
cell
dyscraisia
vascular
endotheri
vegf
overproduct
although
number
therapeut
intervent
plasma
cell
dysord
appli
poem
syndrom
random
clinic
trial
phase
doubl
blind
random
placebo
comtrol
trial
perform
investig
safeti
efficaci
thalidomid
patient
poem
syndrom
elig
transplant
primari
endpoint
reduct
rate
serum
vegf
concentr
week
intent
treat
analysi
addit
outcom
extens
studi
includ
surviv
poem
patient
randomli
assign
either
thalidomid
plu
dexamethason
placebo
plu
dexamethason
nov
juli
one
patient
placebo
group
exclud
analys
protocol
violat
adjust
mean
serum
vegf
reduct
rate
week
sd
thalidomid
group
compar
placebo
group
rate
surviv
month
thalidomid
group
compar
placebo
group
hr
ci
random
studi
period
mild
sinu
bradycardia
frequent
thalidomid
group
placebo
group
vs
thalidomid
suppress
serum
vegf
concentr
lengthen
surviv
poem
patient
inelig
stem
cell
transplant
although
thalidomid
treatment
risk
bradycardia
benefit
would
exceed
risk
studi
regist
umin
clinic
trial
registri
coutt
vidal
courel
rebelo
abreu
zuchner
saporta
neurolog
univers
miami
miami
usa
human
genet
univers
miami
miami
usa
autosom
domin
mutat
synapt
vesicl
protein
function
calcium
sensor
neurotransmiss
previous
link
presynapt
neuromuscular
junction
nmj
dysfunct
motor
neuropathi
two
famili
pathogen
mutat
locat
domain
essenti
neurotransmitt
releas
nmj
report
famili
new
missens
mutat
domain
similar
phenotyp
character
slowli
progress
predominantli
motor
neuropathi
evid
presynapt
nmj
dysfunct
nerv
conduct
studi
index
case
woman
gradual
progress
weak
extrem
normal
development
mileston
found
bilater
high
arch
feet
hammerto
occasion
fall
around
age
gradual
develop
progress
leg
weak
worsen
bilater
hand
cramp
weak
handgrip
mild
paresthesia
distal
extrem
famili
histori
remark
similar
symptom
report
matern
grandfath
two
matern
uncl
mother
younger
sister
neurolog
exam
reveal
inabl
walk
heel
toe
signific
distal
lower
extrem
weak
absent
ankl
deep
tendon
reflex
cranial
nerv
examin
coordin
normal
sensori
chang
lower
extrem
emgnc
reveal
normal
sensori
respons
throughout
howev
motor
nerv
evalu
demonstr
global
reduc
amplitud
increment
brief
isometr
contract
electrophysiolog
evalu
slow
repetit
nerv
stimul
right
ulnar
motor
nerv
reveal
decrement
respons
amplitud
increas
amplitud
immedi
period
sustain
muscl
contract
rapidli
extinguish
one
minut
calcium
channel
vgcc
antibodi
chest
ct
normal
target
sanger
sequenc
reveal
mutat
locat
domain
predict
impair
protein
function
neuropathi
rare
diseas
suspect
patient
present
combin
nmj
dysfunct
resembl
myasthen
syndrom
predominantli
motor
neuropathi
especi
context
posit
famili
histori
moor
ekin
tockarshewski
nguyen
miller
glasser
atti
johnson
statland
ramchandren
walk
nussbaum
neuropathi
foundat
new
york
usa
pharma
cambridg
usa
kansa
medic
center
kansa
citi
usa
michigan
ann
arbor
usa
minnesota
minneapoli
usa
fit
new
york
usa
cmt
diseas
affect
roughli
individu
describ
inherit
peripher
neuropathi
primarili
affect
distal
muscl
limit
studi
detail
impact
muscl
weak
function
activ
anonym
survey
develop
input
clinic
expert
patient
interview
aim
better
understand
preval
impact
variou
cmt
clinic
manifest
patient
live
survey
administ
onlin
hereditari
neuropathi
foundat
hnf
patient
contact
databas
ongo
june
present
preliminari
data
patient
characterist
diseas
impact
cmt
patient
collect
februari
respond
mostli
femal
mostli
us
median
age
rang
symptom
onset
year
year
diagnosi
year
year
present
year
year
sampl
repres
cmt
type
x
common
physic
clinic
manifest
cmt
problem
balanc
ankl
weaknessfoot
drop
loss
feel
abnorm
sensat
lower
legfoot
hand
muscl
weak
maintain
balanc
walk
long
distanc
climb
stair
key
challeng
associ
ankl
weaknessfoot
drop
foot
drop
consid
primari
factor
contribut
fall
averag
fall
ground
per
month
foot
drop
bilater
weak
major
respond
use
form
assist
devic
mobil
includ
leg
brace
caneswalk
stick
custom
foot
orthoticsinsert
common
drug
therapi
includ
pain
medic
foot
surgeri
common
surgic
procedur
receiv
toe
surgeri
common
surgeri
consid
key
symptom
affect
much
includ
problem
balanc
ankl
weak
foot
drop
fatigu
data
suggest
high
preval
lower
leg
muscl
weak
therefor
therapi
aim
improv
ankl
weak
result
foot
drop
imbal
may
benefici
patient
daili
function
qualiti
life
morano
gambarotta
ronchi
cillino
fornasari
fregnan
to
cordova
moschella
geuna
raimondo
clinic
biolog
scienc
univers
turin
orbassano
itali
institut
cavalieri
ottolenghi
foundat
nico
univers
turin
orbassano
itali
reconstruct
surgeri
depart
surgic
oncolog
oral
scienc
univers
palermo
palermo
itali
microsurgeri
surgeri
gaetano
pini
hospit
milan
itali
nerv
fiber
regener
complet
function
recoveri
peripher
nerv
injuri
alway
occur
influenc
mani
factor
includ
patient
age
gender
lesion
site
injuri
sever
size
gap
damag
nerv
stump
time
interv
elaps
perform
surgic
repair
poor
outcom
occur
long
delay
due
loss
neuron
abil
regener
loss
schwann
cell
abil
support
regener
cours
progress
muscl
atrophi
aim
studi
investig
nerv
regener
delay
repair
studi
degen
process
denerv
distal
nerv
stump
denerv
muscl
particular
analys
focus
role
nrgerbb
system
express
nerv
muscl
tissu
degener
regener
process
function
recoveri
analysi
perform
nerv
repair
show
group
repair
immedi
group
repair
delay
month
recov
partial
nevertheless
morpholog
analys
demonstr
despit
delay
nerv
fiber
still
abl
regener
even
fewer
smaller
immedi
repair
group
moreov
analysi
system
show
signific
decreas
solubl
degener
nerv
poor
outcom
delay
nerv
regener
might
explain
schwann
cell
impair
consequ
ineffect
support
nerv
regener
regard
denerv
muscl
analysi
result
show
erbb
receptor
express
relat
innerv
state
muscl
upregul
clearli
associ
denerv
state
interestingli
isoform
differ
regul
depend
type
nerv
injuri
futur
experi
need
address
vivo
efficaci
differ
isoform
injur
nerv
denerv
muscl
mori
francini
prada
signori
pareyson
padua
fabrizi
schenon
neurosci
rehabilit
ophthalmolog
genet
matern
child
health
univers
genoa
genoa
itali
health
scienc
biostatist
section
univers
genoa
genoa
itali
foundat
carlo
besta
neurolog
institut
milan
itali
carlo
gnocchi
foundat
onlu
centro
santa
maria
della
pace
rome
itali
univers
sacr
heart
rome
itali
rossi
policlin
depart
neurolog
visual
scienc
univers
verona
verona
itali
plan
multicent
prospect
random
singl
blind
control
studi
evalu
efficaci
safeti
innov
rehabilit
protocol
base
use
treadmil
train
popul
protocol
requir
subject
blindli
random
two
treatment
group
spe
three
month
respiratori
propriocept
stretch
exercis
tresp
treatment
plu
aerob
train
treadmil
subject
evalu
baselin
three
month
treatment
three
month
follow
free
therapi
full
assess
includ
primari
outcom
measur
short
physic
perform
batteri
sppb
lower
limb
dynamometr
strength
evalu
berg
balanc
scale
bb
cmt
neuropathi
score
medic
outcom
studi
short
form
total
subject
mean
age
year
recruit
found
signific
improv
group
p
p
bb
p
sppb
p
still
significantli
improv
p
spe
group
signific
differ
group
observ
outcom
measur
perform
walk
significantli
chang
concern
observ
consist
chang
consist
differ
compar
two
treatment
conclus
multicent
prospect
random
singl
blind
control
studi
show
combin
respiratori
propriocept
stretch
exercis
posit
impact
perform
cmt
patient
especi
regard
walk
test
aerob
exercis
treadmil
well
toler
appar
add
improv
convent
treatment
specul
rel
low
clinic
sever
patient
due
select
criteria
may
prevent
posit
effect
treadmil
exercis
dohrn
romanzetti
reetz
gess
rwth
aachen
depart
neurolog
aachen
germani
muscl
mri
increasingli
use
neuromuscular
patient
detect
chang
muscl
volum
muscl
fat
infiltr
edema
muscl
mri
mostli
analyz
qualit
mean
quantit
analysi
well
establish
develop
novel
method
segment
muscl
mri
data
set
base
axial
dixon
mri
stack
muscl
volum
quantifi
adapt
algorithm
muscl
volum
thigh
calv
determin
separ
ratio
thighcalf
calcul
myopathi
neuropathi
patient
healthi
control
includ
studi
muscl
volum
determin
segment
similar
manual
segment
data
set
differ
case
patient
well
healthi
control
effect
autom
segment
strong
vs
min
per
patient
muscl
volum
thigh
also
calf
myopathi
patient
show
highli
signific
differ
p
compar
healthi
subject
neuropathi
patient
signific
differ
p
muscl
volum
compar
healthi
patient
sustain
bonferroni
multipl
comparison
test
ratio
thighcalf
muscl
volum
significantli
differ
compar
patient
myopathi
neuropathi
p
subgroup
analys
differ
group
myopathi
patient
show
highli
signific
differ
p
myositi
dystrophi
metabol
myopathi
compar
healthi
patient
signific
differ
group
taken
togeth
data
show
autom
segment
muscl
mri
allow
exact
fast
quantif
muscl
volum
neuromuscular
patient
higher
patient
number
necessari
test
differ
specif
diseas
group
studi
also
address
possibl
use
marker
diseas
progress
clinic
studi
therapi
monitor
murakami
nishimura
nagai
hemmi
kutoku
sunada
neurolog
kawasaki
medic
school
kurashiki
japan
patholog
kawasaki
medic
school
kurashiki
japan
famili
amyloidot
polyneuropathi
fap
autosom
domin
hereditari
system
amyloidosi
caus
mutat
transthyretin
ttr
gene
usual
show
sensori
domin
polyneuropathi
autonom
neuropathi
initi
stage
pathogenesi
neuropathi
well
understood
explain
sever
mechan
includ
mechan
compress
vessel
occlus
ttr
toxic
schwann
cell
dysfunct
describ
sporad
patient
fap
due
ttr
notic
dysesthesia
first
foot
age
symptom
slowli
progress
abnorm
sensat
extend
upper
arm
knee
age
distal
muscl
weak
atrophi
also
observ
extrem
notic
difficulti
walk
frequent
diarrhea
echocardiogram
reveal
diffus
left
ventricular
hypertrophi
suggest
cardiac
amyloidosi
amyloid
deposit
detect
endoneurim
perineurium
sural
nerv
year
onset
diseas
mark
loss
myelina
unmyelin
nerv
fiber
observ
amyloid
deposit
confirm
peron
brevi
muscl
salivari
gland
heart
tissu
dna
analysi
reveal
heterozygot
mutat
ttr
gene
diagnosi
fap
find
suggest
proxim
part
peripher
nervou
system
might
strongli
involv
ttr
aggreg
amyloid
fibril
barrier
distal
part
peripher
nerv
could
preserv
later
patient
sever
biopsi
site
nerv
may
help
necessari
diagnosi
ttr
amyloidosi
mild
fap
case
nam
jung
choi
chung
nation
univers
gongju
korea
woman
univers
school
medicin
seoul
korea
univers
school
medicin
seoul
korea
mutat
nefh
gene
encod
heavi
neurofila
protein
usual
associ
neuron
damag
suscept
amyotroph
later
sclerosi
al
recent
frameshift
variant
nefh
report
underli
caus
axon
cmt
frameshift
mutat
result
stop
loss
translat
cryptic
amyloidgen
element
cae
encod
utr
studi
also
identifi
de
novo
frameshift
mutat
predict
nefh
famili
atyp
clinic
symptom
proxim
domin
weak
mutat
locat
near
previous
report
frameshift
mutat
suggest
mutat
hot
spot
rel
frequent
deletiondupl
event
resign
might
caus
put
hairpin
structur
patient
lower
limb
mri
reveal
mark
hyperintens
signal
chang
hip
muscl
thigh
lower
leg
muscl
studi
also
observ
anticip
pattern
earlier
onset
yr
old
mother
yr
old
daughter
sever
symptom
later
gener
therefor
studi
suggest
stop
loss
translat
elong
utr
nefh
mutat
may
rel
frequent
genet
caus
axon
peripher
neuropathi
specif
characterist
proxim
domin
weak
anticip
pattern
neil
haghi
ashtiani
choumet
musset
immunolog
hospit
pari
franc
neurolog
nation
referr
center
rare
neuromuscular
diseas
hospit
pari
franc
pasteur
emerg
diseas
epidemiolog
unit
pari
franc
glycoprotein
mag
transmembran
glycoprotein
local
periaxon
shwann
cell
oligodendrogli
membran
myelin
sheath
mag
contain
carbohydr
epitop
target
antigen
autoimmun
peripher
neuropathi
associ
monoclon
igm
gammopathi
neuropathi
numer
studi
report
absenc
correl
titer
antibodi
diseas
cours
titer
igm
level
diagnosi
alway
associ
diseas
sever
good
correl
treatment
titer
patient
respond
clinic
immunomodul
mag
belong
famili
linkag
sialic
acid
underli
sugar
import
determin
siglec
bind
mag
show
high
affin
sialic
acid
moreov
human
monoclon
igm
possess
heavi
chain
glycosyl
site
asn
sialyl
olidgosaccharid
type
oligosaccharid
igm
may
bind
mag
via
glycan
epitop
altern
addit
rout
antigen
bind
fab
v
region
igm
interact
may
clinic
neutral
could
lead
overvalu
biolog
result
studi
analyz
sera
patient
igm
reactiv
mag
neuropathi
variou
degre
sever
last
one
igm
monoclon
gammopathi
strong
serum
reactiv
neurolog
diseas
igm
extract
purifi
sera
affin
chromatographi
batch
aliquot
digest
jack
bean
reactiv
perform
elisa
indirect
immunofluoresc
iif
demannosyl
extract
test
iso
quantit
way
regard
origin
serum
show
decreas
activ
elisa
intens
iif
demannosyl
furthermor
elisa
carri
sera
patient
igm
monoclon
gammopathi
without
neurolog
impair
show
signific
biolog
respons
take
account
fact
antibodi
pathogen
anim
model
result
support
hypothesi
neutral
intermolecular
interact
igm
mag
ng
ng
tay
lb
loo
lin
school
medicin
nation
univers
singapor
singapor
kong
chian
school
medicin
nanyang
technolog
univers
singapor
neurosci
institut
singapor
recent
develop
valid
mean
measur
central
arteri
blood
pressur
casp
shown
casp
peripher
blood
pressur
pbp
unident
entiti
patient
postur
orthostat
tachycardia
syndrom
pot
mark
tachycardia
associ
decreas
pbp
ask
reflex
tachycardia
correspond
postur
dizzi
patient
could
result
decreas
casp
two
male
patient
year
age
clinic
featur
typic
pot
went
complet
batteri
autonom
screen
test
sympathet
parasympathet
respons
normal
heart
rate
increas
beat
per
minut
respect
stand
signific
decreas
increas
pbp
stand
minut
casp
measur
devic
bpror
imput
measur
radial
waveform
onto
brachial
blood
pressur
gener
pressur
waveform
numer
casp
valu
deriv
casp
measur
patient
decreas
stand
minut
preliminari
observ
suggest
basi
tachycardia
pot
patient
may
decreas
central
blood
pressur
proceed
systemat
studi
pot
patient
corrobor
observ
also
tri
compar
differ
pbp
casp
pot
age
normal
control
major
limit
studi
mathemat
deriv
rather
direct
measur
casp
proceed
systemat
stud
pot
patient
corrobor
find
ng
ng
kong
chian
school
medicin
nanyang
technolog
univers
singapor
loo
lin
school
medicin
nation
univers
singapor
singapor
neurosci
institut
singapor
recent
develop
valid
mean
measur
central
arteri
blood
pressur
casp
shown
casp
peripher
blood
pressur
pbp
unident
entiti
orthostat
hypotens
oh
promin
compon
autonom
dysfunct
ad
consequ
hypoperfus
vital
organ
respons
consider
morbid
mortal
structur
expos
casp
rather
pbp
sought
understand
relationship
casp
peripher
blood
pressur
pbp
patient
autonom
dysfunct
expos
orthostat
stress
review
autonom
function
test
patient
test
laboratori
period
patient
divid
cohort
ad
oh
ad
oh
mix
ad
parasympathet
dysfunct
sympathet
dysfunct
casp
measur
devic
bpror
imput
measur
radial
waveform
onto
brachial
blood
pressur
gener
form
numer
casp
valu
deriv
differ
ratio
casp
pbp
record
rest
minut
stand
patient
complet
data
definit
final
diagnosi
cohort
patient
respect
mean
differ
cohort
respect
minut
respect
minut
mean
casppbp
ratio
cohort
respect
minut
respect
minut
signific
differ
respons
casp
pbp
orthostat
stress
across
abnorm
cohort
comparison
normal
cohort
also
relationship
symptom
name
postur
dizzi
conclus
autonom
dysfunct
seem
affect
relationship
measur
mean
absenc
true
normal
control
exclus
signific
number
patient
incomplet
data
mathemat
deriv
rather
direct
measur
casp
limit
aim
address
studi
niu
guan
cui
guan
liu
depart
neurolog
peke
union
medic
colleg
hospit
chines
academi
medic
scienc
beij
china
aim
explor
correl
afterdischarg
motor
nerv
conduct
studi
clinic
motor
hyperexcit
patient
potassium
channel
vgkc
antibodi
six
patient
posit
serum
antibodi
orand
protein
recruit
includ
autoimmun
enceph
syndrom
electromyographi
emg
nerv
conduct
studi
nc
f
wave
perform
afterdischarg
assess
one
patient
follow
five
patient
clinic
evid
peripher
motor
nerv
hyperexcit
myokymia
cramp
four
abnorm
spontan
fire
concentr
needl
electromyographi
prolong
afterdischarg
follow
normal
wave
present
six
patient
includ
two
patient
emg
evid
peripher
nerv
hyperexcit
pnh
patient
follow
afterdischarg
disappear
treatment
intraven
immunoglobulin
ivig
afterdischarg
motor
nerv
conduct
studi
might
sensit
needl
electromyographi
detect
peripher
motor
nerv
hyperexcit
patient
vgkc
antibodi
could
disappear
gradual
accord
clinic
improv
reduct
antibodi
niu
cui
liu
depart
neurolog
peke
union
medic
colleg
hospit
chines
academi
medic
scienc
beij
china
research
multipl
site
measur
cross
section
area
csa
ultrasound
perform
differenti
type
chronic
inflammatori
demyelin
polyradiculoneuropathi
cidp
patient
cidp
patient
healthi
control
hc
recruit
prospect
consecut
ultrasonographi
scan
perform
wrist
axilla
median
ulnar
nerv
csa
measur
predetermin
site
nerv
significantli
larger
csa
site
median
ulnar
nerv
p
csa
increas
gradual
homogen
distal
proxim
along
nerv
except
potenti
entrap
site
cidp
display
three
differ
morpholog
pattern
includ
mild
enlarg
patient
promin
segment
enlarg
slight
enlarg
one
among
differ
treatment
respons
observ
patient
mild
nerv
enlarg
treat
intraven
immunoglobulin
ivig
respons
less
half
promin
segment
enlarg
respons
p
pattern
csa
enlarg
differ
cidp
patient
consecut
scan
along
nerv
multipl
site
measur
ultrasound
could
suppli
detail
morpholog
featur
nerv
help
differenti
cidp
niu
cui
ly
guan
liu
depart
neurolog
peke
union
medic
colleg
hospit
chines
academi
medic
scienc
beij
china
syndrom
gb
mainli
consist
acut
inflammatori
demyelin
polyradiculoneuropathi
aidp
acut
motor
axon
neuropathi
aman
aman
conduct
block
cb
could
revers
follow
axon
degener
aim
identifi
correl
exist
cb
function
outcom
patient
gb
gb
patient
prospect
recruit
serial
electrophysiolog
test
disabl
evalu
patient
receiv
treatment
intraven
immunoglobulin
ivig
disabl
evalu
hugh
function
grade
scale
month
treatment
patient
classifi
aidp
aman
equivoc
normal
accord
electrodiagnost
criteria
describ
rajab
et
al
aman
patient
nerv
conduct
studi
classifi
three
group
group
typic
aman
without
conduct
block
group
revers
conduct
block
group
conduct
block
subsequenti
axon
degener
electrophysiolog
studi
result
show
aidp
aman
equivoc
normal
probabl
definit
conduct
block
observ
aidp
patient
aman
patient
aman
cb
higher
reduct
hugh
grade
one
month
vs
lower
percentag
patient
slow
recoveri
unabl
walk
independ
six
month
vs
compar
aman
without
cb
signific
differ
aidp
cb
without
cb
reduct
hugh
grade
one
month
among
aman
patient
follow
typic
aman
without
cb
revers
cb
type
cb
subsequenti
axon
degener
type
hugh
grade
nadir
similar
patient
revers
cb
type
largest
hugh
grade
reduct
one
month
type
vs
type
vs
type
none
patient
axon
degener
show
rapid
recoveri
revers
cb
type
rapid
recoveri
improv
two
hugh
grade
within
four
week
onset
electrodiagnosi
aman
conduct
block
especi
revers
conduct
block
might
marker
good
recoveri
niu
guan
cui
yang
liu
depart
neurolog
peke
union
medic
colleg
hospit
chines
academi
medic
scienc
beij
china
report
studi
nerv
ultrasound
patient
primari
neurolymphomatosi
femal
present
histori
asymmetr
limb
pain
paresthesia
weak
electrodiagnost
studi
spinal
cord
mri
show
axon
neuropathi
involv
cervic
lumbosacr
root
brachial
plexu
left
median
nerv
detect
malign
b
lymphocyt
cytolog
flow
cytometri
cerebr
spinal
fluid
confirm
diagnosi
lymphoma
nerv
ultrasound
show
dramat
enlarg
upper
middl
lower
trunk
left
brachial
plexu
cross
section
respect
middl
trunk
right
brachial
plexu
csa
proxim
part
left
median
nerv
csa
five
month
later
five
chemotherapi
rituximab
methotrex
intrathec
inject
cytosin
arabinosid
dexamethason
patient
clinic
improv
nerv
ultrasound
also
show
allevi
nerv
enlarg
csa
upper
middl
lower
trunk
left
brachial
plexu
respect
csa
middl
trunk
right
brachial
plexu
csa
proxim
part
left
median
nerv
peripher
nerv
ultrasound
could
help
locat
distribut
nerv
involv
reveal
diseas
progress
nolano
provitera
stancanelli
caporaso
saltalamacchia
borreca
lullo
califano
lanzillo
iodic
manganelli
baron
santoro
salvator
maugeri
foundat
institut
teles
term
bn
itali
maugeri
clinic
scientif
institut
ircc
institut
teles
term
bn
itali
neurodegen
diseas
cemand
depart
medicin
surgeri
neurosci
section
univers
salerno
itali
peripher
nerv
involv
demonstr
pd
evid
small
fiber
patholog
possibl
intrins
featur
diseas
higher
occurr
larg
fiber
neuropathi
patient
longtim
treat
howev
role
diseas
ldopa
small
larg
fiber
patholog
pd
still
debat
studi
morpholog
function
cutan
innerv
idiopath
pd
patient
male
age
includ
treat
subject
without
electrophysiolog
sign
neuropathi
aim
assess
character
small
larg
fiber
involv
effect
patient
underw
screen
rule
potenti
neurotox
condit
glucos
intoler
dysendocrinopathi
vitamin
e
folic
acid
defici
hepat
renal
failur
hiv
connect
tissu
disord
skin
biopsi
obtain
thigh
leg
fingertip
affect
side
bilater
thigh
leg
patient
sampl
process
indirect
immunofluoresc
techniqu
use
primari
antibodi
mark
differ
sensori
autonom
fiber
popul
densiti
intrapapillari
myelin
end
ime
meissner
corpuscl
mc
epiderm
nerv
fiber
enf
obtain
well
assess
sudomotor
pilomotor
vasomotor
innerv
evalu
includ
sympathet
skin
respons
quantit
sensori
test
dynam
sweat
test
morpholog
function
find
compar
data
extract
age
sex
stratifi
norm
dataset
ienf
ime
mc
densiti
lower
p
compar
control
treat
patient
without
differ
except
mc
densiti
lower
treat
subject
vs
loss
autonom
nerv
also
found
group
compar
control
signific
abnorm
p
thermal
sensori
threshold
tactil
threshold
mechan
pain
percept
reduc
sweat
output
present
similar
group
work
confirm
pd
intrins
peripher
nerv
patholog
involv
small
larg
fiber
small
fiber
patholog
nt
affect
treatment
sensori
larg
fiber
involv
alreadi
present
patient
worsen
ldopa
treatment
noto
garg
li
timmin
park
shibuya
kiernan
mind
centr
univers
sydney
sydney
australia
diagnosi
amyotroph
later
sclerosi
al
progress
fatal
neurodegen
disord
defin
combin
upper
lower
motor
neuron
involv
remain
clinic
base
purpos
studi
determin
ultrasound
appear
peripher
nerv
al
patient
investig
whether
paramet
distalproxim
ratio
nerv
area
csa
may
effect
differenti
diseas
mimic
al
nerv
ultrasound
median
ulnar
tibial
nerv
perform
al
patient
compar
mimic
patient
patient
peripher
nerv
hyperexcit
syndrom
pnh
patient
multifoc
motor
neuropathi
mmn
comparison
nerv
distalproxim
ratio
undertaken
ultrasound
compar
across
clinic
neurophysiolog
parameterscompar
normal
control
csa
median
nerv
upper
arm
decreas
al
p
comparison
al
mimic
disord
csa
proxim
site
median
ulnar
tibial
nerv
forearmupp
arm
ratio
median
ulnar
nerv
diagnost
valu
addit
csa
median
ulnar
tibial
nerv
median
ulnar
nerv
forearmupp
ratio
may
provid
use
marker
diagnosi
al
nussbaum
fit
new
york
ny
usa
approxim
individu
diagnos
charcot
marietooth
cmt
diseas
make
common
hereditari
peripher
neuropathi
document
cure
cmt
howev
mani
affect
report
difficulti
mobil
imbal
weak
feet
hand
gener
popul
patient
report
difficulti
walk
fall
andor
fear
fall
poor
strength
often
refer
physic
pt
occup
therapist
ot
skill
address
impair
help
restor
function
qualiti
life
qol
patient
diagnos
cmt
unfortun
norm
often
leav
patient
without
skill
guidanc
manag
function
impair
patient
male
mean
age
year
went
progress
skill
pt
intervent
cours
month
program
includ
therapeut
activ
exercis
neuromuscular
reeduc
manual
techniqu
address
document
deficit
patient
progress
program
base
borg
scale
patient
assess
prior
post
commenc
program
berg
balanc
scale
minut
walk
test
time
go
sit
stand
second
foot
self
select
fast
gait
speed
lower
extrem
function
scale
activ
balanc
confid
form
upper
extrem
function
index
oswestri
qol
measur
patient
seen
skill
pt
week
week
patient
improv
measur
taken
indic
improv
function
overal
qualiti
life
particip
report
total
fall
month
prior
initi
studi
fall
report
month
pt
intervent
studi
make
strong
case
util
skill
pt
address
deficit
patient
cmt
addit
util
object
valid
reliabl
outcom
measur
popul
may
help
healthcar
practition
establish
baselin
function
respons
chang
larg
random
control
trial
recommend
studi
effect
specif
pt
intervent
outcom
measur
patient
cmt
ogata
fujita
yamasaki
matsushita
kira
neurolog
neurolog
institut
graduat
school
medic
scienc
kyushu
univers
fukuoka
japan
clinic
featur
chronic
inflammatori
demyelin
polyneuropathi
cidp
patient
autoantibodi
neurofascin
nf
one
paranod
protein
elucid
relat
antibodi
level
clinic
cours
patient
still
remain
elus
retrospect
collect
clinic
electrophysiolog
immunolog
data
three
cidp
patient
male
age
onset
year
old
clinic
sever
evalu
deep
tendon
reflex
dtr
grip
strength
hugh
function
scale
antibodi
level
measur
flow
cytometri
use
cell
line
stabli
express
human
immunotherapi
variou
combin
includ
intraven
immunoglobulin
plasmapheresi
corticosteroid
immunosuppress
introduc
clinic
paramet
gradual
improv
decreas
absent
dtr
normal
grip
strength
increas
kg
hugh
function
scale
score
decreas
least
one
point
compar
nadir
nc
find
three
patient
also
show
obviou
amelior
exampl
f
wave
latenc
right
ulnar
nerv
improv
ms
ms
ms
respect
antibodi
level
treatment
decreas
two
patient
whose
posttreat
sera
avail
dose
oral
prednisolon
taper
experienc
clinic
paramet
especi
dtr
grip
strength
nc
find
serum
antibodi
level
also
deterior
exacerb
laboratori
data
one
patient
preced
clinic
fluctuat
suggest
nc
serum
antibodi
level
could
use
earli
diseas
activ
marker
case
seri
clinic
also
laboratori
data
support
notion
cidp
patient
reactiv
combin
immunotherapi
includ
corticosteroid
even
though
variou
treatment
administ
efficaci
oral
corticosteroid
seem
optim
diseas
activ
marker
immunotherapi
mainten
remiss
cidp
identifi
evalu
deep
tendon
reflex
dtr
grip
strength
hugh
function
scale
start
immunotherapi
ohnmar
ng
medicin
yangon
myanmar
immunolog
network
star
singapor
neurosci
institut
singapor
singapor
zika
viru
zikv
outbreak
start
late
august
period
month
studi
patient
enrol
institut
prospect
syndrom
gb
databas
relationship
zikv
infect
also
studi
gb
control
seen
establish
outbreak
control
index
case
test
neg
zikv
pcr
blood
urin
proceed
test
zikv
igg
igm
dengu
viru
denv
igg
igm
neutral
assay
zikv
denv
one
patient
igg
posit
miller
fisher
syndrom
detect
zikv
igm
zikv
igg
serum
show
low
titr
denv
igm
denv
igg
serum
month
show
increas
zikv
igg
believ
patient
one
patient
acut
motor
sensori
axon
neuropathi
anoth
acut
inflammatori
demyelin
polyneuropathi
high
zikv
igm
low
denv
igm
igg
anoth
patient
mf
show
high
level
zikv
denv
igm
low
igg
latter
two
patient
gb
zikv
outbreak
singapor
suspect
patient
could
await
convalesc
sera
confirm
two
patient
seen
outbreak
detect
level
zikv
igg
serial
test
show
declin
period
month
initi
sera
show
rais
denv
igm
igg
level
one
rais
igg
level
addit
stronger
neutral
capac
denv
zikv
suggest
initi
detect
zikv
igg
level
due
cross
reactiv
previou
denv
infect
four
patient
gb
control
control
also
show
serolog
respons
consist
previou
exposur
denv
one
normal
control
show
nil
exposur
virus
summari
use
variou
overlap
serolog
method
diagnos
definit
suspect
zikv
gb
case
find
highlight
insensit
blood
urin
pcr
diagnos
problem
interpret
zikv
serolog
denv
serial
serolog
increas
diagnost
accuraci
okar
ergunay
tan
neurolog
hacettep
univers
ankara
turkey
unit
depart
medic
microbiolog
hacettep
univers
ankara
turkey
diseas
research
laboratori
hacettep
univers
ankara
turkey
syndrom
gb
acut
monophas
polyradiculoneuropathi
believ
acut
inflammatori
demyelin
poliradiculoneuropathi
caus
mediat
autoimmun
respons
target
peripher
nerv
myelin
molecular
mimicri
play
role
pathogenesi
gb
case
mechan
well
demonstr
acut
motor
axon
neuropathi
aman
variant
autoantibodi
camphylobact
jejuni
share
epitop
peripher
nerv
gangliosid
molecular
mimicri
mechan
attribut
case
atyp
trigger
zika
viru
west
nile
viru
infect
moreov
accumul
clinic
data
vector
born
viral
infect
trigger
gb
evalu
viral
infect
gb
aman
patient
eight
patient
gb
two
patient
aman
control
group
seven
patient
normal
pressur
hydrocephalu
includ
gb
aman
diagnos
clinic
electroneuromyograp
cerebrospin
fluid
csf
find
cerebrospin
fluid
serum
urin
sampl
examin
vector
born
viral
infect
via
gener
flaviviru
phleboviru
pcr
also
document
patient
prognost
score
modifi
erasmu
gb
outcom
score
mego
modifi
erasmu
gb
respiratori
insuffici
score
megri
mean
age
patient
year
six
femal
csf
serum
urin
sampl
patient
control
patient
neg
flaviviru
phleboviru
famili
preliminari
result
studi
small
cohort
show
correl
viral
infect
gb
studi
broad
number
patient
need
suggest
result
oliveira
santo
swash
de
carvalho
physiolog
unit
instituto
de
medicina
molecular
faculti
medicin
univers
lisbon
portug
neurolog
depart
neurosci
mental
heath
hospit
de
santa
maria
centro
hospitalar
lisboa
nort
lisbon
portug
neurolog
neurosci
bart
london
school
medicin
queen
mari
univers
london
uk
neuromyotonia
nmt
consist
spontan
motor
unit
activ
reflect
increas
peripher
nerv
excit
lead
involuntari
persist
muscl
activ
visibl
muscl
twitch
rest
gener
easili
provok
cramp
sinc
first
electrophysiolog
emg
descript
nmt
foley
discuss
origin
abnorm
electr
activ
record
needl
emg
studi
studi
two
patient
patient
nmt
aggrav
cold
associ
mild
polyneuropathi
demyelin
featur
follow
centr
year
neg
antibodi
firstli
treat
carbamazepin
phenylhydantoin
poor
respons
shown
major
improv
intraven
immunoglobulin
ivig
last
year
patient
man
nmt
follow
year
high
titter
antibodi
pmoll
normal
improv
ivig
last
month
screen
neoplasia
unremark
patient
neg
antibodi
particular
antibodi
normal
computer
tomographi
scan
chest
abdomen
addit
routin
studi
test
synchron
spontan
discharg
differ
motor
unit
simultan
record
made
two
needl
electrod
first
dorsal
interosseu
muscl
fascicul
doubl
record
would
repres
abnorm
ectop
activ
initi
nerv
trunk
ephapt
stimul
nearbi
axon
patient
research
protocol
appli
year
regular
ivig
treatment
patient
investig
year
ivig
patient
improv
ivig
mirror
strike
decreas
amount
spontan
activ
emg
moreov
techniqu
detect
synchron
spontan
activ
fascicul
second
assess
although
predomin
treatment
patient
nmt
abnorm
discharg
origin
distal
axon
branch
proxim
segment
appear
ivig
effect
block
antibodi
activ
proxim
axon
segment
perhap
relat
factor
barrier
temperatur
differ
ion
channel
distribut
oliveira
santo
ohana
de
carvalho
physiolog
unit
instituto
de
medicina
molecular
faculti
medicin
univers
lisbon
portug
neurolog
depart
neurosci
mental
heath
hospit
de
santa
maria
centro
hospitalar
lisboa
nort
lisbon
portug
celiac
diseas
cd
chronic
multisystem
disord
character
sensit
dietari
gluten
genet
predispos
individu
neurolog
manifest
may
occur
patient
includ
peripher
nerv
involv
recent
grow
evid
strongli
suggest
peripher
neuropathi
cd
may
autoimmun
associ
antibodi
woman
present
slowli
progress
weak
right
hand
finger
extensor
medic
famili
histori
unremark
examin
muscl
strength
medic
research
score
right
wrist
finger
extensor
right
abductor
pollici
longu
right
ankl
dorsiflexion
right
tricep
brachii
brachioradiali
reflex
weak
normal
elsewher
remaind
neurolog
examin
normal
neuroaxi
magnet
reson
unremark
specif
lesion
motor
sensori
nerv
conduct
studi
normal
conduct
block
abnorm
tempor
dispers
found
needl
electromyographi
show
sever
neurogen
chang
abnorm
spontan
activ
right
muscl
chronic
neurogen
chang
homolater
tibiali
anterior
peroneu
longu
extensor
digitorum
brevi
gangliosid
antibodi
test
posit
igg
antibodi
neg
antibodi
addit
blood
test
unremark
particular
cryoglobulin
test
neg
intraven
immunoglobulin
improv
weak
right
extensor
wrist
finger
score
mrc
monthli
treatment
initi
month
chang
everi
week
preserv
function
diagnosi
mama
establish
later
cd
diagnos
daughter
due
chronic
diarrhoea
patient
underw
transglutaminas
antibodi
determin
biopsi
year
diseas
durat
diagnosi
cd
made
diet
start
neurolog
pictur
chang
six
month
case
presenc
igg
antibodi
may
support
causal
link
mama
cd
lack
respons
diet
may
explain
chronic
axon
injuri
induc
memori
case
broaden
knowledg
neurolog
manifest
cd
rais
probabl
associ
pure
axon
multifoc
motor
neuropathi
antibodi
pogemil
acsadi
pierz
motion
analysi
connecticut
children
medic
center
farmington
ct
usa
medicin
univers
connecticut
farmington
ct
usa
neurolog
connecticut
children
medic
center
farmington
ct
usa
orthopaed
connecticut
children
medic
center
farmington
ct
usa
orthopaed
surgic
intervent
foot
ankl
perform
person
cmt
improv
foot
pain
ankl
instabl
orthosi
fittingcomfort
issu
shoe
wear
impact
surgeri
ankl
function
gait
known
therefor
goal
studi
measur
gait
chang
ankl
function
follow
surgic
intervent
mean
computer
motion
analysi
fourteen
patient
cmt
year
pre
year
bilater
orthopaed
surgeri
includ
patient
plantar
fascia
releas
plu
combin
posterior
tibiali
lengthen
extensor
halluci
longu
peroneu
longu
anterior
tibiali
transfer
boni
procedur
metatars
cuboid
osteotomi
patient
complet
two
gait
analys
pre
averag
year
barefoot
walk
use
standard
motion
analysi
protocol
chang
ankl
kinemat
kinet
paramet
analyz
refer
control
group
patient
cmt
without
interven
surgeri
year
gait
analys
well
normal
refer
data
surgic
group
show
signific
increas
height
pre
analys
chang
walk
veloc
pre
post
normal
cmsec
similarli
ankl
kinemat
kinet
show
chang
result
surgeri
howev
trend
increas
peak
ankl
dorsiflexion
pre
post
normal
degre
surgic
group
control
group
show
increas
height
simultan
increas
walk
veloc
test
test
cmsec
control
group
also
show
chang
ankl
kinemat
kinet
suggest
impact
diseas
part
notic
year
result
show
surgic
intervent
primarili
address
foot
align
neg
impact
ankl
kinemat
kinet
gait
comparison
control
group
support
find
howev
find
increas
peak
dorsiflexion
stanc
patient
need
examin
larger
cohort
pogemil
pierz
acsadi
motion
analysi
connecticut
children
medic
center
farmington
ct
usa
medicin
univers
connecticut
farmington
ct
usa
orthopaed
connecticut
children
medic
center
farmington
ct
usa
neurolog
connecticut
children
medic
center
farmington
ct
usa
afo
commonli
prescrib
patient
cmt
improv
gait
reduc
ankl
instabl
fall
studi
examin
brace
outcom
use
object
evalu
purpos
studi
examin
impact
variou
afo
design
gait
paramet
children
adolesc
cmt
predict
afo
would
improv
excess
delay
peak
dorsiflexion
stanc
equinu
swing
fifteen
patient
mean
age
year
analyz
barefoot
prescrib
afo
mean
standard
motion
analysi
protocol
full
clinic
examin
also
complet
includ
strength
passiv
rang
motion
measur
afo
includ
solid
hing
posterior
leaf
spring
taper
less
support
design
sagitt
plane
ankl
kinemat
kinet
paramet
analyz
comparison
normal
control
walk
veloc
improv
cmsec
demonstr
function
benefit
afo
ankl
plantar
flexion
angl
initi
contact
improv
degre
demonstr
improv
drop
foot
swing
initi
contact
reduc
risk
trip
howev
degre
peak
ankl
dorsiflexion
stanc
remain
excess
degre
barefoot
degre
afo
suggest
mani
patient
afo
design
suffici
support
peak
ankl
plantar
flexor
moment
show
improv
nmkg
highlight
improv
base
support
provid
afo
compens
ankl
plantar
flexor
weak
howev
peak
power
gener
reduc
wkg
indic
avail
ankl
strength
imped
afo
result
studi
suggest
orthos
provid
improv
gait
outcom
improv
overal
function
howev
individu
differ
patient
impair
strength
rang
motion
boni
deform
associ
gait
present
need
account
afo
design
afo
alway
function
intend
due
complex
interact
patient
impair
orthosi
stiff
orthosi
design
motion
analysi
assist
identifi
specif
afo
need
individu
cmt
painou
illa
querol
diseas
unit
neurolog
depart
hospit
de
la
santa
creu
sant
pau
barcelona
spain
san
pedro
la
rioja
spain
para
la
en
red
en
enfermedad
rara
ciber
madrid
spain
chronic
inflammatori
demyelin
polyradiculoneuropathi
cidp
autoimmun
neuropathi
heterogen
clinic
spectrum
specif
autoantibodi
defin
differ
clinic
phenotyp
cidp
antibodi
constitut
specif
cidp
subset
high
incid
postur
intent
tremor
describ
respond
poorli
immunoglobulin
report
patient
posit
cidp
present
head
voic
limb
tremor
improv
immunotherapi
man
unremark
medic
histori
present
age
progress
distal
weak
paraesthesia
numb
gait
ataxia
action
tremor
involv
voic
head
limb
appear
sequenti
emg
show
featur
acquir
demyelin
fulfil
cidp
diagnost
criteria
first
cours
intraven
immunoglobulin
ineffect
weak
ataxia
tremor
worsen
significantli
need
two
walk
aid
first
becom
wheelchair
bound
later
receiv
six
plasmapheresi
cycl
also
ineffect
oral
corticosteroid
start
mild
improv
corticosteroid
taper
patient
develop
sever
relaps
refer
centr
five
plasma
exchang
cycl
follow
rituximab
dose
ad
corticosteroid
three
month
later
weak
ataxia
tremor
includ
head
voic
tremor
start
improv
significantli
six
month
later
patient
present
signific
improv
abl
walk
unaid
antibodi
titr
fell
undetect
limb
tremor
known
occur
patient
inflammatori
neuropathi
specif
cidp
patient
knowledg
first
report
cidp
patient
present
head
voic
tremor
ever
report
improv
tremor
immunotherapi
strongli
suggest
autoantibodi
involv
pathogenesi
expand
phenotyp
specif
clinic
featur
palaima
peeter
l
gallardo
de
vriendt
infant
berciano
jordanova
univers
antwerp
center
molecular
neurolog
molecular
neurogenom
group
antwerp
belgium
hospit
de
valdecilla
santand
spain
diseas
type
autosom
domin
slowli
progress
inherit
neuropathi
first
describ
year
ago
attribut
singl
spanish
famili
consist
individu
affect
member
span
four
gener
initi
genet
defect
link
region
howev
extens
sequenc
structur
variant
analys
use
whole
genom
sequenc
wg
three
affect
individu
reveal
known
novel
genet
caus
within
region
last
decad
serial
clinic
entir
pedigre
perform
lead
chang
affect
statu
seven
individu
redefin
region
zmax
theta
addit
famili
member
submit
whole
exom
sequenc
led
identif
novel
missens
variant
ligas
previous
cover
wg
variant
diseas
absent
control
mutat
known
disrupt
ring
domain
previous
report
caus
autosom
domin
recess
cmt
type
unlik
prior
report
demonstr
mutat
influenc
overal
protein
level
ubiquityl
target
patient
deriv
lymphoblast
transcriptom
analysi
identifi
signific
upregul
anoth
ligas
key
regul
axon
degener
notabl
magnet
reson
imag
musculatur
systemat
show
fatti
atrophi
clinic
subclin
mutat
carrier
emphas
use
identif
mildli
affect
member
find
demonstr
isol
genet
entiti
caus
missens
mutat
reclassifi
moreov
reveal
novel
molecular
player
associ
dysfunct
highlight
pathway
therapeut
target
share
amyotroph
later
sclerosi
alzheim
diseas
pan
karlsson
liu
caterina
polydefki
neurolog
john
hopkin
univers
baltimor
usa
pain
research
center
depart
clinic
medicin
aarhu
univers
hospit
denmark
neurosurgeri
john
hopkin
univers
baltimor
usa
damag
peripher
nerv
prerequisit
neuropath
pain
howev
remain
unclear
neuropathi
patient
pain
other
ident
nerv
conduct
qst
ienfd
propos
examin
distribut
cgrp
sp
epiderm
nerv
fiber
patient
without
neuropath
pain
aim
defin
express
pattern
normal
healthi
subject
first
studi
cgrp
sp
normal
control
patient
pain
neuropathi
skin
biopsi
neuropathi
patient
normal
subject
util
antibodi
gener
univers
support
dept
neurosci
monoclon
core
use
combin
immunohistochemistri
perform
identifi
cgrp
sp
pgp
distribut
control
reveal
proxim
distal
gradient
similar
observ
ienf
label
pgp
stain
intens
nerv
termin
epidermi
combin
immunostain
reveal
pgp
label
fiber
epidermi
cgrp
fiber
patient
pain
higher
densiti
fiber
compar
patient
numb
greater
proport
cgrp
fiber
pain
patient
express
control
exhibit
distal
proxim
gradient
express
cgrp
alter
neuropath
pain
patient
suggest
receptor
play
import
role
patholog
state
pan
jostock
schwartz
polydefki
john
hopkin
univers
som
baltimor
usa
scienc
intellig
ws
biolog
biomark
research
unit
rj
gmbh
aachen
germani
congenita
project
salt
lake
citi
usa
activ
endogen
ligand
nociceptinorphanin
fq
agonist
modul
nocicept
analgesia
neuropath
pain
model
wide
distribut
endogen
ligand
repres
attract
treatment
target
sinc
pain
promin
featur
pc
defin
express
plantar
skin
biopsi
assess
whether
alter
exist
vs
anatom
match
control
skin
skin
biopsi
pc
control
subject
immunohistochem
stain
combin
immunostain
pgp
neurofila
h
nfh
cgrp
use
defin
nop
receptor
express
epidermi
upper
dermi
robust
detect
epiderm
keratinocyt
subset
fiber
epidermi
dermi
stain
inhibit
block
peptid
western
blot
analysi
use
homogen
human
skin
tissu
demonstr
band
consist
molecular
weight
express
occur
dermal
nfh
group
though
cgrp
fiber
skin
slightli
lower
express
skin
similar
pattern
anatom
match
locat
healthi
control
subject
observ
express
human
plantar
skin
epiderm
keratinocyt
well
subset
epiderm
dermal
nerv
fiber
fiber
pgp
mani
nfh
nop
receptor
viabl
pharmaceut
analges
target
pc
patient
irrespect
slight
compar
skin
work
support
gmbh
pareyson
stojkov
reilli
parman
battaloglu
tazir
bellatach
sacconi
attarian
latour
megarban
schenon
ursino
sabatelli
luigetti
santoro
manganelli
quattron
valentino
murakami
scherer
dankwa
shi
bacon
herrmann
pisciotta
previtali
bolino
itali
franc
unit
kingdom
turkey
algeria
franc
franc
franc
itali
itali
itali
itali
japan
usa
citi
usa
usa
character
recess
inherit
earli
onset
sever
cours
slow
nerv
conduct
myelin
outfold
associ
mutat
respect
involv
metabol
ptsin
p
phosphoinositid
key
regul
membran
traffick
multicentr
retrospect
studi
better
characteris
collect
minim
dataset
inform
includ
cmtescmtn
patient
unrel
famili
famili
patient
younger
earlier
onset
last
visit
perform
mean
age
year
sd
rang
year
diseas
onset
occur
mean
age
year
compar
year
delay
motor
mileston
occur
subject
eleven
patient
becam
wherea
subject
one
still
ambul
although
afo
patient
requir
unilater
support
two
case
diseas
type
characteris
vocal
cord
involv
respiratori
involv
seen
almost
exclus
patient
four
requir
ventil
one
tracheostomi
compar
one
patient
niv
age
two
subject
affect
rel
includ
present
studi
die
respiratori
complic
glaucoma
buphthalmo
occur
cmte
cmtn
score
higher
patient
spite
younger
age
indic
sever
diseas
cmte
mean
sd
rang
cmtn
mean
sd
rang
cmte
mean
sd
rang
cmtn
mean
sd
rang
data
confirm
sever
interestingli
interact
catalyt
activ
phosphatas
wherea
catalyt
inact
protein
known
increas
enzymat
activ
thu
nerv
residu
enzymat
activ
may
result
less
sever
clinic
phenotyp
compar
pareyson
calabres
santoro
manganelli
fabrizi
schenon
cavallaro
ursino
previtali
allegri
padua
pazzaglia
quattron
villani
pisciotta
mazzeo
vita
italian
cmt
network
foundat
c
besta
neurolog
institut
milan
federico
ii
univers
depart
neurosci
reproduct
scienc
odontostomatolog
napl
verona
depart
neurolog
biomed
motor
scienc
verona
genoa
depart
neurosci
rehabilit
ophthalmolog
genet
matern
infantil
scienc
genoa
san
raffael
vita
salut
san
raffael
univers
depart
neurolog
insp
milan
di
parma
uo
neurologia
parma
cattolica
del
sacro
cuor
rome
carlo
gnocchi
onlu
foundat
depart
neurosci
milan
graecia
univers
depart
medic
scienc
catanzaro
messina
unit
neurolog
depart
clinic
experiment
medicin
messina
itali
diseas
cmt
nation
registri
fulli
oper
http
wwwregistronmdit
collect
clinicalgenet
inform
minim
dataset
report
clinic
scale
cmt
patient
regist
thu
far
chosen
one
refer
center
inform
collect
ad
hoc
visit
enter
registri
regist
patient
chanc
particip
studi
requir
fill
onlin
questionnair
relat
five
import
issu
diseas
cours
complic
pregnanc
use
efficaci
toler
orthot
assist
devic
outcom
surgeri
skelet
deform
safeti
anesthesia
occurr
sleep
disord
includ
evalu
fatigu
anxieti
depress
februari
patient
relativesfriend
healthi
control
fill
questionnair
perform
first
explor
analysi
result
data
collect
questionnair
prolong
novemebr
obtain
larger
sampl
pregnanc
cmt
women
least
one
pregnanc
complic
rang
mild
sever
occur
pregnanc
vs
control
cmt
worsen
pregnanc
patient
recoveri
instanc
prenat
diagnosi
perform
pregnanc
satisfact
relat
surgic
procedur
foot
deform
assess
va
score
n
repeat
surgeri
requir
instanc
sleep
epworth
sleepi
scale
questionnair
reveal
abnorm
sleep
cmt
patient
control
vast
major
cmt
subject
mean
also
control
good
sleeper
accord
pittsburgh
sleep
qualiti
index
psqi
rang
good
sleep
fatigu
score
impact
scale
rang
fatigu
higher
cmt
mean
control
mean
hospit
scale
anxieti
depress
cmt
subject
anxieti
depress
compar
control
respect
data
analysi
orthot
anesthesia
ongo
conclus
first
data
analys
confirm
problem
relat
five
domain
explor
need
specif
address
patient
care
support
grant
park
choi
seok
min
kim
choi
medic
center
seoul
korea
republ
diseas
cmt
frequent
motor
sensori
peripher
neuropathi
known
uniform
demyelin
tradit
definit
conduct
block
reduct
neg
peak
compound
muscl
action
potenti
cmap
proxim
segment
rel
adjac
distal
segment
studi
tri
find
frequenc
conduct
block
patient
investig
differ
clinic
manifest
enrol
unrel
patient
male
femal
duplic
undertook
nerv
conduct
studi
stimul
site
wrist
elbow
axilla
median
nerv
studi
eleven
patient
enrol
patient
nc
featur
suggest
conduct
block
compar
patient
without
conduct
block
function
disabl
scale
significantli
higher
patient
conduct
block
p
howev
onset
age
diseas
durat
differ
patient
without
conduct
block
addit
conduct
block
frequent
observ
distal
segment
proxim
segment
suggest
frequenc
conduct
block
patient
low
heterogen
demyelin
patient
also
patient
conduct
block
might
relationship
clinic
disabl
park
park
univers
colleg
medicin
daegu
korea
subacut
combin
degener
scd
diagnos
characterist
clinic
manifest
spinal
mri
decreas
serum
vitamin
level
report
case
scd
elev
homocystein
methlymalon
acid
level
situat
spuriou
elev
vitamin
concentr
year
old
man
present
progress
gait
disturb
sensori
disturb
year
ago
felt
hand
feet
paresthesia
gait
disturb
four
month
visit
nerv
conduct
test
perform
elsewher
due
symptom
polyneuropathi
found
laboratori
test
show
megaloblast
anemia
howev
serum
vitamin
concentr
increas
pg
ml
normal
pg
ml
symptom
progress
gradual
present
neurolog
examin
show
spastic
lower
limb
without
weak
vibrat
posit
sensat
decreas
lower
limb
show
atax
gait
spinal
cord
mri
show
lesion
long
high
signal
intens
posterior
column
spinal
cord
laboratori
test
ad
folat
normal
level
homocystein
umol
normal
umol
methylmalon
acid
um
l
normal
um
l
increas
final
scd
caus
vitamin
defici
diagnos
addit
gastric
endoscopi
perform
find
caus
vitamin
defici
chronic
atroph
gastriti
found
cobalamin
treatment
month
hemoglobin
level
improv
symptom
improv
littl
gait
disturb
vitamin
level
could
lead
delay
diagnosi
caus
irrevers
chang
nervou
system
one
commonli
use
method
measur
vitamin
concentr
assay
may
result
normal
level
even
vitamin
defici
due
effect
factor
antibodi
vitamin
defici
suspect
even
vitamin
concentr
normal
addit
test
homocystein
methylmalon
acid
consid
parman
durmu
deymeer
battaloglu
univers
istanbul
faculti
medicin
depart
neurolog
istanbul
turkey
univers
istanbul
turkey
hereditari
motor
sensori
neuropathi
also
call
cmt
neuropathi
common
group
among
hereditari
neuropathi
cmt
subtyp
group
axon
demyelin
intermedi
phenotyp
ad
ar
inherit
consid
axon
character
distal
muscl
wast
mild
sensori
loss
normal
nerv
conduct
veloc
mutat
gene
known
abl
caus
autosom
domin
ad
recess
ar
date
genet
heterogen
cmt
challeng
genet
diagnost
clinic
clue
frequenc
mutat
cmt
gene
larg
cohort
may
help
develop
strategi
effici
genet
test
present
clinic
electrophysiolog
genet
featur
patient
turkey
diagnos
genet
confirm
depart
neurolog
istanbul
faculti
medicin
clinic
genet
test
perform
dna
sequenc
sampl
patient
exom
sequenc
we
male
ten
femal
patient
unrel
famili
investig
segreg
ar
eight
ad
six
famili
two
isol
case
interfamili
variabl
age
onset
rang
mean
year
diseas
progress
rate
strike
slowli
progress
weak
atrophi
distal
muscl
feet
andor
hand
common
present
symptom
found
four
unrel
ad
kinship
unrel
ar
kinship
common
gene
mutat
among
whole
cohort
commonli
mutat
gene
among
ar
famili
we
reveal
mutat
aar
nefl
howev
caus
mutat
could
identifi
known
gene
patient
data
indic
mark
phenotyp
variabl
previous
describ
literatur
mani
gene
caus
remain
discov
pasnoor
veerapaneni
murphi
statland
kimpl
hamasaki
glenn
herbelin
barohn
jawdat
dimachki
neurolog
neuromuscular
divis
univers
kansa
medic
center
kansa
citi
ks
usa
electrodiagnost
edx
studi
involv
electromyographynerv
conduct
studi
emgnc
use
diagnosi
neuromuscular
disord
although
safe
procedur
emg
nc
often
evok
anticip
pain
anxieti
publish
research
studi
support
notion
provid
detail
inform
patient
prior
procedur
would
reduc
procedur
pain
amelior
anxieti
level
afterward
object
studi
perform
prospect
survey
assess
anticip
pain
anxieti
patient
present
edx
studi
design
detail
patient
educ
form
assess
chang
perceiv
pain
anxieti
pre
post
procedur
standard
care
soc
educ
versu
print
detail
educ
instrument
group
complet
brief
painanxieti
questionnair
patient
randomli
assign
either
soc
verbal
educ
group
read
detail
educ
form
anoth
brief
questionnair
complet
post
procedur
patient
enrol
time
abstract
submiss
intervent
soc
group
mean
age
patient
enrol
year
pain
anticip
patient
visual
analog
scale
va
score
mean
signific
differ
group
pain
report
patient
mean
pain
score
signific
differ
two
group
anxieti
report
patient
mean
score
score
case
group
anxieti
frequenc
reduc
mean
level
group
patient
report
pain
emg
nc
found
edx
test
evok
moder
pain
case
moder
anxieti
level
detail
educ
intervent
attenu
frequenc
sever
pain
anxieti
expectedli
reduc
sever
frequenc
group
suggest
anxieti
sever
lesser
detail
educ
group
number
small
studi
detail
questionnair
perhap
educ
larger
popul
may
use
reduc
painanxieti
patient
present
edx
studi
pasnoor
roach
barohn
statland
jawdat
dick
glenn
dimachki
neurolog
neuromuscular
divis
univers
kansa
medic
center
kansa
citi
ks
usa
diagnost
criteria
chronic
inflammatori
demyelin
polyneuropathi
cidp
design
use
clinic
trial
limit
data
compar
diagnost
util
criteria
clinic
set
unknown
criteria
better
predict
treatment
respons
object
studi
compar
sensit
variou
diagnost
criteria
review
treatment
respons
obtain
local
irb
approv
perform
retrospect
chart
review
cidp
patient
seen
univers
kansa
medic
center
abstract
clinic
electrodiagnost
treatment
inform
determin
frequenc
patient
fulfil
follow
criteria
efn
aan
saperstein
incat
defin
treatment
respons
base
treat
physician
impress
chang
function
improv
one
point
grade
chang
mrc
grade
cidp
patient
chart
review
exclud
due
miss
data
mean
age
femal
elev
csf
protein
seen
fulfil
efn
definit
criteria
efn
probabl
aan
incat
saperstein
criteria
treatment
respons
patient
fulfil
efn
definiteprob
criteria
includ
ivig
iv
oral
corticosteroid
mycophenol
mofetil
among
patient
fulfil
aan
criteria
respect
among
meet
incat
criteria
saperstein
criteria
half
patient
respond
plex
base
differ
criteria
cidp
criteria
similarli
predict
ivig
treatment
respons
efn
criteria
sensit
clinic
diagnosi
cidp
pellegatta
canevazzi
fores
podini
quattrini
taveggia
neurosci
insp
interact
unit
san
raffael
scientif
institut
milan
itali
neurosci
insp
experiment
neuropatholog
unit
san
raffael
scientif
institut
milan
itali
axon
type
iii
essenti
instruct
signal
pn
myelin
sinc
express
determin
whether
axon
myelin
also
thick
myelin
sheath
previou
studi
shown
secretas
cleavag
control
type
iii
activ
level
specif
cleavag
type
iii
promot
myelin
wherea
tace
inhibit
pn
myelin
inactiv
type
iii
damag
axon
locat
distal
site
injuri
degener
lose
myelin
sheath
follow
process
term
wallerian
degener
unlik
cn
axon
pn
regener
regrow
sever
studi
shown
regener
favor
schwann
cell
start
creat
permiss
environ
axon
regrowth
addit
shown
regul
earli
stage
dedifferenti
process
essenti
creat
permiss
environ
regener
similarli
beta
secretas
promot
pn
regener
remyelin
present
studi
analyz
role
tace
wallerian
degener
data
indic
tace
upregul
sciatic
nerv
injuri
distal
site
damag
sinc
tace
express
schwann
cell
axon
analyz
role
glial
neuron
tace
degener
regener
process
thu
perform
crush
injuri
sciatic
nerv
two
differ
transgen
line
carri
condit
delet
tace
either
schwann
cell
neuron
analys
differ
phase
wallerian
degener
anim
suggest
role
glial
tace
earli
stage
process
fact
observ
increas
number
myelin
axon
mice
detect
substanti
differ
mutant
chatcretacefloxflox
mice
result
suggest
even
regener
tace
inhibitori
role
delet
tace
schwann
cell
like
induc
activ
program
current
investig
nizon
besnard
quinqui
boisseau
magot
mussini
mayrargu
barbarot
isidor
centr
neuromuscular
disord
genet
paediatr
surgeri
dermatolog
univers
hospit
nant
franc
hereditari
sensori
autonom
neuropathi
hsan
constitut
clinic
genet
heterogen
group
hsan
associ
sensori
dysfunct
alter
pain
temperatur
percept
vari
degre
autonom
dysfunct
abnorm
small
fiber
neurodevelop
ten
gene
describ
far
hsan
group
origin
classif
encompass
four
entiti
addit
subgroup
continu
describ
hereditari
sensori
neuropathi
hsan
type
ii
character
autosom
recess
inherit
onset
birth
behavior
one
homozyg
frameshift
variant
c
p
report
factor
protein
consanguin
famili
patient
present
spastic
paraplegia
diffus
sensori
motor
polyneuropathi
acromutil
disord
classifi
autosom
recess
spastic
paraplegia
describ
new
patient
congenit
insensit
pain
sensori
neuropathi
spastic
paraplegia
whole
exom
sequenc
show
homozyg
frameshift
variant
c
p
protein
harbour
short
hairpin
transmembran
domain
role
endoplasm
reticulum
shape
variant
caus
addit
hydrophob
domain
could
alter
function
interact
respons
hsan
type
report
highlight
role
pathophysiolog
insensit
pain
spastic
paraplegia
nguyen
fayet
nguyen
magot
dexplor
fonctionnel
nant
franc
de
statistiqu
nant
franc
carpal
tunnel
syndrom
ct
respons
sensori
andor
motor
symptom
may
increas
wrist
flexion
extens
phalen
sign
previou
studi
shown
short
durat
min
less
flexion
extens
respons
signific
chang
median
nerv
conduct
paramet
object
studi
determin
prolong
extens
revers
phalen
test
affect
median
ulnar
nerv
conduct
paramet
normal
subject
provid
inform
consent
normal
subject
femal
age
rank
year
underw
motor
sensori
test
median
ulnar
nerv
domin
side
edx
test
perform
use
standard
techniqu
wrist
neutral
posit
passiv
wrist
extens
minut
sequenti
record
motor
action
potenti
cmap
sensori
action
potenti
snap
latenc
amplitud
everi
minut
extens
onset
ulnar
nerv
conduct
paramet
remain
unchang
subject
regard
median
nerv
group
subject
could
individu
subject
chang
subject
signific
decreas
snap
amplitud
subject
snap
amplitud
veloc
decreas
subject
cmap
snap
signific
chang
present
chang
appear
min
snap
decreas
earliest
observ
abnorm
prolong
wrist
extens
respons
median
nerv
edx
paramet
modif
normal
subject
sensori
fiber
firstli
affect
correspond
chronolog
clinic
encount
ct
base
upon
result
protocol
use
patient
present
mild
clinic
ct
order
tri
identifi
addit
edx
techniqu
use
diagnosi
ct
one
could
also
wonder
whether
subject
import
chang
would
prone
present
ct
futur
drew
elli
kidambi
takata
r
c
hagerman
k
siskind
c
day
j
ginzberg
nicholson
kennerson
neurosci
laboratori
anzac
research
institut
sydney
australia
medic
school
univers
sydney
sydney
australia
medicin
laboratori
concord
repatri
gener
hospit
sydney
australia
network
rehabilit
hospit
brasilia
df
brazil
neurolog
stanford
health
care
stanford
ca
usa
neuromuscular
unit
wolfson
medic
center
holon
israel
mutat
gene
caus
hereditari
distal
motor
neuropathi
dhmnx
date
missens
mutat
copper
transport
atpas
confirm
mutat
caus
dhmnx
two
independ
famili
next
gener
sequenc
ng
includ
whole
exom
whole
genom
sequenc
increas
rapid
detect
variant
gene
known
caus
diseas
howev
absenc
size
addit
famili
make
challeng
determin
pathogen
benign
statu
variant
identifi
recent
identifi
new
variant
patient
progress
peripher
neuropathi
suggest
genet
heterogen
dhmnx
two
new
variant
locat
highli
conserv
amino
acid
within
domain
respect
critic
catalyt
cycl
copper
transport
also
identifi
third
variant
g
locat
base
upstream
exon
predict
abolish
conserv
consensu
intron
sequenc
necessari
process
immatur
rna
splice
recent
investig
use
patient
fibroblast
condit
knock
mous
model
dhmnx
express
orthologu
human
mutat
show
reduc
protein
level
defect
retrograd
traffick
patholog
hallmark
dhmnx
caus
mutat
elucid
newli
identifi
g
variant
pathogen
systemat
assess
patient
fibroblast
harbour
mutat
alter
paramet
previous
found
pathogen
mutat
predict
function
characteris
use
patient
fibroblast
harbour
newli
identifi
variant
provid
evid
ascertain
whether
variant
diseas
caus
establish
systemat
function
readout
variant
improv
accuraci
genet
counsel
patient
manag
dhmnx
case
genet
evid
limit
studi
repres
complementari
necessari
approach
use
ng
valid
pathogen
statu
variant
identifi
expand
genet
heterogen
dhmnx
peric
bjelica
berisavac
lukic
babic
jovanov
dominov
cvijanov
rakocev
stojanov
lavrnic
basta
clinic
clinic
center
serbia
school
medicin
univers
belgrad
belgrad
serbia
clinic
clinic
center
novi
sad
novi
sad
serbia
clinic
clinic
center
banjaluka
banaluka
republ
srpska
bosnia
herzegovina
month
birth
mob
defin
risk
factor
diseas
instanc
suscept
multipl
sclerosi
ms
seem
associ
born
may
lower
risk
ms
observ
born
novemb
studi
assess
potenti
associ
mob
risk
syndrom
gb
sought
determin
risk
gb
associ
mob
studi
includ
gb
patient
diagnos
serbia
montenegro
republ
srpska
period
januari
decemb
mob
patient
gener
popul
compar
patient
gb
tendenc
born
octob
increas
compar
gener
popul
less
like
born
june
decreas
consid
specif
season
gb
patient
like
born
winter
month
increas
p
associ
found
monthseason
birth
diseas
sever
result
pilot
studi
show
gb
patient
like
born
cold
month
less
like
born
june
might
explain
higher
exposur
differ
pathogen
pregnanc
cold
month
accord
well
known
earli
exposur
infect
agent
reduc
risk
allerg
autoimmun
diseas
studi
need
test
find
differ
cohort
region
differ
climat
result
may
shed
new
light
diseas
pathogenesi
peric
bozov
martic
komatina
djuric
petrov
vujov
cukic
djordjev
stevic
basta
clinic
clinic
center
serbia
school
medicin
univers
belgrad
belgrad
serbia
medic
academi
belgrad
serbia
clinic
clinic
center
ni
ni
serbia
clinic
clinic
center
kragujevac
kragujevac
serbia
clinic
clinic
center
montenegro
podgorica
montenegro
major
patient
syndrom
gb
tend
success
recoveri
number
signific
consequ
may
neg
affect
qualiti
life
aim
research
analyz
outcom
diseas
one
year
acut
episod
gb
among
patient
diagnos
gb
seven
tertiari
center
serbia
montenegro
republ
srpska
subject
retest
one
year
male
mean
age
year
function
disabl
patient
estim
base
gb
disabl
scale
gd
sever
form
diseas
gd
score
regist
patient
admiss
nadir
discharg
one
year
period
patient
symptom
gb
mild
symptom
abl
walk
run
need
unilater
support
walk
wheelchair
bound
bedridden
lethal
outcom
regist
three
patient
acut
phase
gb
four
paresthesia
present
gb
patient
musculoskelet
pain
fatigu
one
year
acut
phase
diseas
factor
associ
wors
function
outcom
gd
grade
one
year
age
preced
respiratori
infect
wors
gd
discharg
one
year
onset
diseas
signific
number
gb
patient
neurolog
impair
includ
sensori
symptom
pain
fatigu
muscl
weak
may
significantli
affect
patient
everyday
function
phetteplac
saad
bacon
shi
iowa
hospit
clinic
iowa
citi
ia
usa
cmt
diseas
also
known
hereditari
motor
sensori
neuropathi
herit
peripher
neuropathi
caus
genet
mutat
mani
differ
gene
cmt
type
common
form
cmt
individu
affect
commonli
distal
muscl
atrophi
foot
deform
abnorm
gait
reduc
nerv
conduct
veloc
caus
demyelin
peripher
nerv
known
caus
duplic
gene
propos
diseas
mechan
believ
increas
gene
dosag
gene
although
exact
function
known
previou
report
literatur
individu
carri
homozyg
duplic
therefor
four
copi
gene
howev
mani
report
focus
adult
patient
symptom
may
vari
significantli
individu
harbor
duplic
month
old
male
present
univers
iowa
hospit
due
famili
histori
concern
delay
independ
ambul
known
matern
patern
famili
histori
although
famili
believ
unrel
exam
unabl
walk
independ
could
take
step
hand
held
per
report
began
crawl
scoot
month
age
found
structur
abnorm
atrophi
upper
lower
extrem
electrodiagnost
test
reveal
demyelin
neuropathi
one
nerv
test
patient
unabl
toler
addit
shock
peron
nerv
found
nerv
conduct
veloc
ms
base
clinic
present
electrodiagnost
examin
famili
histori
delet
duplic
test
perform
test
reveal
homozyg
duplic
previous
report
caus
case
support
gene
dosag
diseas
mechan
patient
appear
sever
affect
typic
infant
toddler
affect
piscosquito
saveri
provitera
stancanelli
ciano
magri
taroni
fabrizi
nolano
pareyson
unit
maugeri
scientif
clinic
institut
scientif
institut
teles
term
bn
itali
rare
neurolog
diseas
adulthood
depart
clinic
neurosci
ircc
foundat
c
besta
neurolog
institut
milan
itali
epilepsi
centr
depart
diagnost
appli
technolog
ircc
foundat
c
besta
neurolog
institut
milan
itali
genet
neurodegen
metabol
diseas
depart
diagnost
appli
technolog
ircc
foundat
c
besta
neurolog
institut
milan
itali
neuropatholog
depart
neurolog
movement
scienc
univers
verona
verona
itali
mpz
mutat
associ
demyelin
cmt
type
axon
later
onset
paresthesiasdysesthesia
pain
alreadi
report
cmt
type
also
report
patient
famili
sporad
case
carri
mpz
mutat
predict
mutat
lead
haploinsuffici
subject
genet
ancestri
puglia
region
southern
itali
two
patient
carri
mutat
homozygos
show
sever
phenotyp
onset
birth
sever
scoliosi
proxim
weak
distal
limb
plegia
autonom
walk
cmt
examin
score
cmte
heterozyg
patient
mild
mean
age
rang
neuropathi
walk
without
aid
orthos
cmte
five
show
mild
foot
deform
foot
hand
weak
mrc
never
less
sensori
loss
lower
limb
paresthesiasdysesthesia
mostli
tingl
burn
type
local
hand
report
subject
neuropath
pain
homozyg
patient
cmap
sap
absent
subject
motor
conduct
veloc
cv
ms
rang
ms
sensori
cv
ms
rang
ms
cmap
well
sap
normal
moder
reduc
amplitud
indic
slight
axon
loss
confirm
heterozygos
associ
mild
cmt
wherea
homozygos
caus
sever
neuropathi
data
suggest
paresthesia
neuropath
pain
common
consid
part
phenotyp
although
clinic
pictur
suggest
small
fiber
neuropathi
evid
provid
current
literatur
attempt
investig
field
found
male
patient
seri
threshold
increas
quantit
sensori
test
sever
abnorm
small
nerv
fiber
present
skin
biopsi
appar
aneuplodi
caus
neuropathi
small
fiber
involv
mechan
differ
mpz
missens
mutat
poitra
chandrasekhar
singh
martinez
zochodn
mental
health
institut
divis
neurolog
depart
medicin
univers
alberta
edmonton
alberta
canada
microarray
mrna
analysi
dorsal
root
ganglia
examin
diabet
mice
yield
unexpect
upregul
uniqu
set
protein
known
major
urinari
protein
mup
origin
famili
barrel
shape
protein
describ
includ
mediat
pheromon
secret
urin
rodent
appar
unconnect
function
identifi
unanticip
express
sensori
neuron
adult
mice
rat
explor
potenti
impact
properti
neuron
analysi
rat
mous
sensori
neuron
show
widespread
cytosol
mup
express
cell
bodi
also
distal
sensori
project
locat
dermi
footpad
assess
role
mup
might
offer
growth
behaviour
adult
neuron
examin
knockdown
mup
dissoci
drg
primari
cultur
mup
knockdown
speci
show
signific
increas
neurit
outgrowth
follow
mup
sirna
treatment
compar
scrambl
sequenc
control
mice
treat
streptozotocin
stz
model
featur
human
type
diabet
polyneuropathi
includ
decreas
motor
sensori
measur
chang
thermal
sensat
extrem
explor
potenti
role
mup
upregul
specif
diabet
examin
impact
intranas
inject
mup
sirna
indic
neuropathi
chronic
type
diabet
mice
follow
treatment
mice
treat
mup
sirna
show
improv
motor
sensori
nerv
conduct
veloc
compar
scrambl
control
taken
togeth
data
suggest
mup
play
role
diabet
neuron
may
also
contribut
electrophysiolog
behavior
abnorm
associ
diabet
polyneuropathi
repurpos
mup
sensori
neuron
identifi
interest
role
suppos
pheromon
protein
support
cihr
cda
adi
poitra
chandrasekhar
mccoy
webber
zochodn
neurosci
mental
health
addict
divis
neurolog
depart
medicin
univers
alberta
edmonton
alberta
canada
activ
small
calib
ion
channel
associ
intens
sensori
activ
wherea
overactiv
induc
neurotox
subtox
activ
calcium
influx
electr
activ
neuron
associ
enhanc
outgrowth
properti
singh
et
al
ask
whether
similar
activ
use
low
dose
capsaicin
might
similarli
ramp
regen
activ
sensori
neuron
use
rat
adult
primari
sensori
neuron
identifi
dose
depend
relationship
capsaicin
exposur
outgrowth
enhanc
lower
dose
expect
neurotox
higher
dose
dose
enhanc
outgrowth
nonetheless
associ
rise
intraneuron
calcium
next
test
whether
similar
impact
activ
vivo
might
exist
use
high
sciatic
crush
injuri
mous
model
assess
impact
capsaicin
low
high
dose
appli
directli
site
axon
outgrowth
injuri
day
follow
singl
applic
capsaicin
low
dose
capsaicin
show
rapid
recoveri
thermal
mechan
sensat
wherea
high
dose
capsaicin
show
signific
differ
compar
vehicl
treat
mice
parallel
neurotox
observ
vitro
high
dose
capsaicin
result
decreas
sensori
nerv
conduct
veloc
low
dose
show
signific
differ
compar
vehicl
treat
anim
impact
motor
axon
recoveri
taken
togeth
subtox
activ
intraneuron
calcium
mobil
appli
regener
sensori
axon
enhanc
outgrowth
injuri
improv
behaviour
recoveri
similar
follow
extracellular
electr
stimul
support
cihr
polydefki
ebenez
adam
coelho
conceicao
waddington
cruz
schmidt
buad
campistol
pouget
berk
partisano
chen
gollob
suhr
hopkin
univers
baltimor
usa
refer
center
fap
nnerf
aphp
inserm
u
chu
franc
de
santo
centro
hospitalar
porto
porto
portug
de
santa
maria
lisbon
portug
feder
univers
rio
de
janeiro
rio
de
janeiro
brazil
hospit
munster
germani
son
llatzer
palma
spain
clinic
univers
barcelona
barcelona
spain
de
la
timon
marseil
franc
univers
boston
usa
pharmaceut
cambridg
usa
univers
sweden
hereditari
transthyretin
hattr
amyloidosi
rapidli
progress
diseas
caus
ttr
gene
variant
result
ttr
misfold
amyloid
deposit
multipl
organ
includ
peripher
nerv
hattr
amyloid
polyneuropathi
promin
small
fiber
involv
character
neuropath
pain
dysautonomia
measur
intraepiderm
sweat
gland
nerv
fiber
densiti
ienfd
sgnfd
skin
biopsi
use
identifi
small
fiber
abnorm
hattr
report
effect
patisiran
investig
rnai
therapeut
treatment
hattr
period
ienfd
sgnfd
dermal
amyloid
content
phase
extens
ole
studi
skin
biopsi
distal
leg
distal
thigh
obtain
everi
month
year
within
phase
ole
studi
patisiran
iv
analyz
blind
manner
central
laboratori
analys
exploratori
nomin
report
without
adjust
multipl
test
patient
enrol
preliminari
data
indic
patisiran
gener
well
toler
result
sustain
mean
serum
ttr
lower
mean
decreas
patient
underw
serial
skin
punch
biopsi
baselin
mean
ienfd
fibersmm
mean
sgnfd
distal
thigh
distal
leg
respect
amyloid
detect
skin
biopsi
mean
baselin
dermal
amyloid
content
distal
thigh
distal
leg
respect
invers
correl
ienfd
sgnfd
overal
ienfd
stabl
throughout
treatment
sgnfd
increas
time
rel
baselin
reach
statist
signific
month
distal
thigh
p
time
point
month
distal
leg
dermal
amyloid
content
decreas
time
reach
statist
signific
month
distal
thigh
p
time
point
month
distal
leg
p
time
point
summari
improv
sgnfd
dermal
amyloid
content
observ
period
suggest
paramet
potenti
serv
biomark
respons
patisiran
treatment
polydefki
neuhau
doherti
ebenez
neurolog
john
hopkin
univers
baltimor
md
usa
misdiagnosi
delay
identif
etiolog
sensori
neuropathi
hamper
adequ
manag
delay
initi
therapi
present
sever
case
illustr
variabl
present
amyloid
neuropathi
complic
amyloid
arthropathi
former
colleg
athlet
develop
painless
difficulti
walk
unabl
keep
famili
member
routin
outing
subsequ
unabl
navig
uneven
ground
hike
someth
previous
excel
balanc
decreas
make
bicycl
difficult
neurolog
evalu
symptom
onset
led
diagnosi
peripher
neuropathi
revers
neuropathi
panel
normal
though
elev
sever
month
strengthsens
deterior
despit
diet
improv
lose
improv
upon
referr
emg
reveal
sensorimotor
neuropathi
markedli
reducedabs
sural
peron
tibial
motor
amplitud
mild
orthostasi
ni
skin
biopsi
reveal
sever
ienfd
sgnfd
reduct
posit
congo
red
stain
confirm
birefring
sural
nerv
biopsi
confirm
amyloid
deposit
genet
test
reveal
variant
histori
suspicion
famili
histori
amyloid
male
histori
control
diabet
year
develop
abrupt
onset
rl
month
lymphoma
diagnosi
treatment
rituximab
led
radiograph
resolut
lymphoma
though
patient
develop
progress
peripher
neuropathi
confirm
ncvemg
earli
satieti
mild
orthostasi
ed
emerg
skin
biopsi
demonstr
lichenoid
pattern
amyloid
deposit
consist
old
woman
sinc
develop
progress
leg
weak
reduc
abil
walk
low
back
pain
emg
demonstr
progress
sensorimotor
neuropathi
superimpos
multilevel
radiculopathi
spine
mri
demonstr
sever
lumbar
stenosi
requir
surgic
decompress
postop
regain
strength
walk
easili
congo
red
stain
vertebr
bone
demonstr
widespread
posit
stain
birefring
consist
amyloid
arthropathi
case
illustr
wide
sprectrum
amyloid
neuropathi
present
exampl
amyloid
spinal
stenosi
util
skin
biopsi
diagnos
manag
amyloid
neuropathi
lukawska
kochanski
kabzinska
gawel
seroka
neurolog
medic
univers
warsaw
warsaw
poland
unit
mossakowski
medic
research
centr
polish
academi
scienc
warsaw
poland
differenti
hereditari
neuropathi
chronic
inflammatori
demyelin
polyneuropathi
cidp
children
especi
signific
complet
differ
treatment
possibl
prognosi
condit
aim
studi
compar
electrophysiolog
abnorm
group
children
young
adult
demyelin
neuropathi
chronic
subacut
onset
retrospect
analysi
clinic
nerv
conduct
studi
nc
data
includ
children
young
adult
neuropathi
x
type
children
neuropathi
type
children
cidp
studi
axon
demyelin
chang
nc
studi
aan
efn
electrophysiolog
cidp
criteria
fulfil
cidp
patient
addit
patient
classifi
efn
criteria
probableposs
cidp
distal
compound
muscl
action
potenti
dcmap
cidp
patient
none
abnorm
mediannorm
sural
snap
amn
paramet
observ
cidp
patient
patient
abnorm
suralnorm
median
snap
asnm
paramet
found
patient
cidp
differ
conduct
veloc
cv
two
correspond
nerv
ms
seen
cidp
patient
one
one
patient
especi
conspicu
differ
nerv
conduct
lower
limb
axon
neuropathi
demyelin
featur
upper
limb
chang
one
patient
genet
confirm
abnorm
nc
electrophysiolog
data
cidp
indic
diffus
demyelin
howev
axon
chang
coexist
seen
patient
asymmetr
abnorm
correspond
upper
lower
limb
observ
patient
studi
show
durat
dcmap
use
diagnos
inflammatori
neuropathi
also
differenti
cmtx
cidp
howev
presenc
homogen
abnorm
nc
patient
cmtx
may
mimic
inflammatori
neuropathi
prada
mori
francini
accogli
ursino
gemelli
schizzi
grandi
bellon
mandich
schenon
neurosci
rehabilit
ophthalmolog
genet
matern
child
health
univers
genoa
genoa
itali
overwork
weak
ow
problem
cmt
diseas
debat
long
time
report
hand
ndh
patient
cmt
diseas
stronger
domin
hand
dh
result
ow
author
verifi
hypothesi
use
mrc
differ
muscl
van
pomeren
recent
piscosquito
et
al
found
ow
phenomenon
exist
use
dynamomet
hole
peg
test
dexter
test
recruit
cmt
patient
healthi
control
evalu
strength
dynamomet
opposit
abil
thumb
opposit
test
tot
appli
instrument
test
hand
function
use
sensor
engin
glove
test
segt
previous
demonstr
sensit
measur
sever
hand
dysfunct
cmt
patient
tot
significantli
higher
ndh
compar
dh
p
cmt
patient
instead
differ
dh
ndh
healthi
control
evalu
ndh
perform
slightli
significantli
better
dh
n
n
n
n
p
ns
normal
control
confirm
rule
noguchi
demura
final
segt
result
similar
ndh
dh
cmt
patient
normal
control
better
perform
dh
conclus
studi
support
exist
overwork
weak
cmt
evid
everi
measur
dexter
overal
abil
hand
impair
dh
probabl
compens
movement
compar
healthi
control
weaker
hand
final
result
support
import
avoid
supramaxim
exercis
educ
cmt
patient
prevent
incorrect
movement
may
overload
hand
muscl
prasad
ohnmar
teng
cheng
umapathi
neurosci
institut
singapor
gener
hospit
yangon
myanmar
loo
lin
school
medicin
nation
univers
singapor
singapor
anteced
infect
link
syndrom
gb
includ
campylobact
jejuni
haemophilu
influenza
viru
cytomegaloviru
mycoplasma
pneumonia
influenza
viru
east
asia
burden
flaviviru
infect
consider
even
small
countri
like
singapor
popul
million
spite
excel
sanit
public
health
measur
dengu
viru
denv
infect
exceed
year
symptomat
asymptomat
denv
infect
associ
gb
zika
viru
zikv
infect
detect
singapor
late
august
doctor
work
asia
anecdot
report
gb
case
increas
raini
season
mosquito
breed
current
plan
studi
estim
hitherto
unknown
burden
gb
associ
denv
zikv
virus
region
preliminari
step
review
gb
case
seen
institut
evid
denv
zikv
three
test
case
posit
denv
serolog
one
also
posit
denv
pcr
patient
symptomat
dengu
two
acut
inflammatori
demyelin
polyneuropathi
aidp
acut
motor
axon
neuropathi
aman
subtyp
gb
none
patient
test
posit
zikv
pcr
serum
urin
one
patient
miller
fisher
syndrom
mf
serolog
evid
recent
zikv
clinic
zikv
symptom
mf
case
initi
detect
zikv
igg
later
proven
due
cross
reactiv
previou
denv
infect
case
amsan
mf
initi
zikv
igm
rais
await
analysi
convalesc
sera
decid
inde
zikv
result
relat
previou
denv
preliminari
find
indic
flaviviru
infect
may
account
least
gb
case
singapor
lack
symptom
case
interact
zikv
denv
antibodi
make
accur
diagnos
challeng
prior
benoy
vanden
bergh
van
den
bosch
leuven
depart
neurosci
experiment
neurolog
leuven
research
institut
neurosci
diseas
lind
leuven
belgium
brain
diseas
research
laboratori
neurobiolog
leuven
belgium
enter
neurosci
translat
research
center
gastrointestin
disord
ku
leuven
leuven
belgium
diseas
cmt
common
inherit
neurodegen
disord
peripher
nervou
system
divid
two
main
subtyp
demyelin
subtyp
cmt
type
axon
form
cmt
type
cmt
diseas
effect
longest
neuron
bodi
thu
muscl
peripher
region
affect
first
foremost
moreov
major
cmt
patient
share
classic
phenotyp
share
patholog
hallmark
distal
muscular
atrophi
reduct
nerv
conduct
etc
also
molecular
patholog
hallmark
like
breakdown
transport
organel
vesicl
neuron
process
call
axon
transport
current
cure
effect
treatment
avail
cmt
patient
histon
deacetylas
shown
key
regul
axon
transport
moreov
inhibit
demonstr
stabil
microtubul
act
molecular
track
motor
protein
facilit
axon
transport
cargo
lab
current
focu
cmt
type
main
caus
cmt
caus
duplic
segment
chromosom
contain
gene
encod
peripher
myelin
protein
mainli
express
schwann
cell
cell
myelin
neuron
peripher
nervou
system
work
present
commerci
mous
schwann
cell
transfect
overexpress
use
lentiviru
vector
system
mimic
patient
schwann
cell
overexpress
confirm
use
immunofluoresc
western
blot
techniqu
transfect
schwann
cell
primari
mous
dorsal
root
ganglion
neuron
drg
isol
adult
mice
analys
week
vitro
axon
transport
investig
group
drg
cell
drg
cell
transfect
drg
transfect
green
fluoresc
protein
use
lentiviru
vector
system
monocultur
drg
furthermor
work
demonstr
overexpress
schwann
cell
impair
axon
transport
drg
comparison
group
moreov
axon
transport
defect
abl
rescu
treatment
inhibitor
tubstatin
conclud
select
inhibitor
shown
benefici
treatment
number
cmt
subtyp
preclin
studi
lab
offer
viabl
treatment
current
untreat
debilit
diseas
provitera
caporaso
stancanelli
piscosquito
di
caprio
saltalamacchia
santoro
nolano
maugeri
clinic
scientif
institut
ircc
institut
teles
term
bn
itali
neurosci
reproduct
odontostomatolog
scienc
univers
federico
ii
napl
napl
itali
observ
rate
pattern
cutan
nerv
regrowth
mechan
pharmacolog
distal
axonotmesi
proven
excel
tool
studi
human
nerv
regener
normal
patholog
condit
observ
howev
refer
small
fiber
possibl
due
avail
excel
model
revers
distal
cutan
small
fiber
axonopathi
model
avail
studi
regener
myelin
fiber
human
studi
regrowth
cutan
larg
fiber
fingertip
patient
carpal
tunnel
syndrom
surgic
decompress
recruit
patient
mf
age
year
carpal
tunnel
syndrom
candid
surgeri
patient
underw
clinic
electrophysiolog
evalu
quantit
evalu
discrimin
threshold
fingertip
site
patient
also
underw
punch
skin
biopsi
skin
section
stain
immunohistochem
techniqu
cutan
innerv
analyz
confoc
microscopi
meissner
corpuscl
myelin
affer
assess
follow
previous
publish
procedur
twelv
month
surgeri
patient
repeat
function
evalu
underw
second
skin
biopsi
two
mm
apart
first
one
mean
densiti
time
mean
densiti
myelin
end
time
howev
patient
regener
occur
base
variat
mc
densiti
time
abl
identifi
patient
activ
regener
occur
subgroup
mean
densiti
time
p
mean
delta
group
mean
densiti
myelin
end
time
p
mean
delta
describ
morpholog
pattern
associ
nerv
regrowth
biopsi
patient
nerv
regener
occur
propos
vivo
model
studi
regener
larg
myelin
fiber
end
human
skin
addit
count
nerv
end
identif
pattern
associ
nerv
regener
increas
diagnost
yield
skin
biopsi
prukop
wernick
adam
schmidt
brureau
foucquier
guedj
cholet
nave
nabirotchkin
hajj
cohen
sereda
neurogenet
experiment
medicin
germani
clinic
pharmacolog
univers
medic
center
germani
franc
clinic
neurophysiolog
univers
medic
center
germani
neurolog
univers
medic
center
germani
common
type
diseas
caus
duplic
lead
dysmyelin
axon
loss
progress
muscl
weak
current
approv
treatment
patient
avail
among
other
preclin
therapeut
approach
aim
correct
overexpress
order
amelior
axon
loss
muscl
weak
previous
report
novel
polytherapeut
drug
combin
baclofen
naltrexon
sorbitol
improv
dysmyelin
axon
loss
applic
adult
transgen
rat
known
anim
model
interestingli
applic
young
rat
observ
prevent
muscl
weak
well
without
obviou
effect
dysmyelin
axon
loss
improv
distal
motor
latenc
electrophysiolog
record
shift
axon
diamet
distribut
rais
hypothesi
therapi
may
improv
neuromuscular
endplat
patholog
anoth
therapeut
target
report
preclin
trial
adult
rat
treat
postnat
week
consecut
week
effect
regimen
order
facilit
deeper
understand
therapi
effect
confirm
amelior
behavior
phenotyp
improv
distal
motor
latenc
also
nerv
conduct
veloc
electrophysiolog
record
histolog
analysi
reveal
increas
number
neuromuscular
endplat
lower
wildtyp
level
treatment
investig
includ
detail
analysi
peripher
nerv
myelin
thick
internod
nodal
length
termin
axon
sprout
neuromuscular
endplat
muscl
fiber
subtyp
treat
rat
prukop
pieper
thiel
walter
young
sereda
clinic
neurophysiolog
univers
medic
center
germani
clinic
pharmacolog
univers
medic
center
germani
neurogenet
experiment
medicin
germani
neurolog
munich
germani
sleep
medicin
neuromuscular
disord
univers
germani
diseas
cmt
rare
hereditari
neuropathi
novel
treatment
develop
urgent
need
clinic
trial
natur
histori
studi
perform
evalu
intervent
efficaci
hamper
slow
progress
lack
sensit
outcom
measur
interindividu
diseas
variabl
high
prognost
diseas
measur
establish
cmt
patient
previous
identifi
diseas
progress
biomark
larg
european
cohort
within
german
diseas
network
http
wwwcmtnetd
aim
establish
easier
access
biomark
blood
patient
blood
analysi
less
invas
repeatedli
perform
clinic
trial
routin
patient
care
start
clinic
assess
approxim
young
adolesc
adult
patient
clinic
centr
includ
larg
set
clinic
outcom
measur
onl
fss
psqi
ess
sampl
blood
skin
tissu
year
month
observ
period
year
tissu
sampl
analyz
transcript
translat
epigenet
level
envis
diagnost
progress
biomark
may
use
measur
therapeut
effect
within
clinic
trial
later
clinic
routin
monitor
first
trial
test
circul
biomark
blood
prospect
observ
trial
patient
prupper
merki
faber
lunn
noterman
behalf
imagin
studi
group
univers
medic
centr
maastricht
netherland
medic
centr
utrecht
utrecht
netherland
neuromuscular
diseas
nation
hospit
neurolog
neurosurgeri
queen
squar
london
uk
de
la
pari
franc
univers
humanita
clinic
institut
milan
itali
igm
peripher
neuropathi
slowli
progress
heterogen
diseas
symptom
rang
mild
foot
numb
minor
imbal
sever
neuropath
pain
sensori
motor
dysfunct
intern
consensu
regard
assess
treatment
patient
igm
peripher
neuropathi
lack
might
caus
repeat
use
suboptim
outcom
measur
small
trial
size
low
number
treat
patient
indol
diseas
cours
need
longer
period
captur
relev
chang
possibl
administ
treatment
aggress
enough
imagin
studi
intern
prospect
observ
cohort
studi
result
uniqu
collect
larg
number
prospect
collect
highli
standard
clinic
data
biobank
larg
popul
patient
igm
peripher
neuropathi
main
object
describ
detail
variat
clinic
subtyp
clinic
diseas
cours
past
current
practic
treatment
antibodi
titr
clinic
pictur
variou
level
assess
outcom
patient
least
year
fulfil
intern
criteria
igm
peripher
neuropathi
elig
exclus
primarili
base
concomit
diseas
influenc
peripher
nerv
function
sever
studi
paramet
measur
weak
sensat
activ
particip
ataxia
pain
qualiti
life
interest
februari
enmc
kick
meet
organ
bring
togeth
igm
peripher
neuropathi
studi
group
meet
focu
develop
core
set
outcom
measur
use
futur
studi
igm
peripher
neuropathi
imagin
studi
start
netherland
septemb
date
patient
includ
imagin
studi
start
unit
kingdom
itali
franc
begin
centr
recruit
least
patient
igm
peripher
neuropathi
elig
particip
studi
pn
global
recommend
enmc
meet
well
first
result
imagin
studi
present
puget
paolantonacci
burlot
le
uli
franc
biotechnolog
le
uli
franc
dysimmun
neuropathi
patient
mmn
cidp
gb
ivig
becom
gold
standard
due
efficaci
toler
acut
renal
impair
rare
seriou
advers
event
induc
ivig
incid
determin
precis
ivig
mostli
occur
patient
risk
condit
prior
renal
insuffici
diabet
mellitu
arteri
hypertens
elderli
year
old
dehydrat
hypervolemia
sepsi
paraproteinemia
concomit
use
nephrotox
drug
treat
immunomodulatori
dose
number
patient
increas
year
choic
ivig
associ
precautionari
measur
decis
reduc
avoid
occurr
advers
event
nephrotox
ivig
explain
tubular
toxic
relat
osmot
nephrosi
sucros
stabil
ivig
implic
one
caus
even
sever
new
ivig
without
sucros
use
renal
impair
case
describ
studi
highlight
sucros
ivig
stabil
associ
tubular
damag
howev
recent
studi
renal
impair
case
occur
cidp
elderli
patient
treat
ivig
occurr
renal
failur
seem
low
patient
treat
associ
precautionari
measur
hydrat
adapt
dosag
accord
bodi
mass
index
rate
infus
otherwis
sinc
case
renal
impair
secondari
hemolysi
increas
ivig
would
rare
full
ethanol
fraction
product
identifi
gener
low
occurr
hemolysi
occurr
renal
impair
relat
ivig
seem
multifactori
need
find
caus
mechan
differ
stabil
hemolysi
concentr
ivig
registri
would
help
physician
defin
incid
rel
risk
renal
impair
right
ivig
associ
precautionari
measur
patient
risk
puma
panicucci
cambieri
butori
garibaldi
soriani
desnuel
raffaelli
sacconi
de
nice
et
de
la
dazur
uca
peripher
nervou
system
muscl
al
depart
pasteur
hospit
nice
franc
neurolog
psychiatri
sapienza
univers
rome
rome
itali
clinic
experiment
patholog
pasteur
hospit
nice
franc
radiolog
pasteur
hospit
nice
franc
publish
ultrasound
us
studi
chronic
inflammatori
demyelin
polyradiculoneuropathi
cidp
report
diffus
increas
area
csa
nerv
data
correl
histolog
pattern
date
inform
us
ultrastructur
nerv
modif
provid
limit
frequenc
rang
mhz
us
probe
aim
preliminari
studi
evalu
correl
histolog
find
sural
nerv
biopsi
us
pattern
found
uhfu
mhz
sural
nerv
ankl
four
patient
cidp
underw
uhfu
nerv
evalu
clinic
affect
sural
nerv
undergo
sural
nerv
biopsi
us
find
includ
area
nerv
connect
tissu
depth
chang
echogen
fascicl
data
compar
histolog
find
obtain
transvers
longitudin
section
patient
uhfu
nerv
chang
follow
csa
increas
connect
tissu
thicken
two
four
patient
hyperechogen
fascicl
observ
also
thank
probe
direct
correl
histolog
us
imag
possibl
direct
measur
intern
microstructur
nerv
uhfu
may
adjunct
diagnost
valu
cidp
assess
detail
imag
sural
nerv
obtain
compar
us
allow
better
evalu
intern
structur
nerv
increas
csa
observ
subject
seem
relat
enlarg
connect
tissu
confirm
histolog
studi
particular
observ
hyperechogen
fascicl
sever
patient
case
histolog
confirm
increas
endoneuri
depth
specul
find
may
explain
preliminari
involv
connect
tissu
pathogenesi
cidp
find
nerv
enlarg
may
tool
monitor
diseas
activ
cidp
better
understand
diseas
pathogenesi
studi
need
confirm
find
addit
data
process
present
meet
puma
cambieri
panicucci
desnuel
raffaelli
sacconi
de
nice
et
de
la
dazur
uca
peripher
nervou
system
muscl
al
depart
pasteur
hospit
nice
franc
neurolog
psychiatri
sapienza
univers
rome
rome
itali
radiolog
pasteur
hospit
nice
franc
ultrasound
hfu
mhz
peripher
nerv
valuabl
painless
complement
neurophysiolog
especi
workup
cidp
nevertheless
current
spatial
resolut
echograph
imag
nt
allow
detail
studi
nerv
frequenc
ultrasound
uhfu
mhz
new
tool
time
higher
spatial
resolut
tradit
hfu
aim
preliminari
studi
evalu
sensori
motor
nerv
structur
characterist
found
uhfu
patient
definit
cidp
seven
patient
cidp
underw
uhfu
nerv
evalu
median
ulnar
peron
sural
nerv
bilater
us
find
includ
area
nerv
connect
tissu
depth
nerv
vascular
chang
echogen
fascicl
patient
also
underw
electroneurographi
eng
plexu
mri
patient
uhfu
nerv
chang
follow
csa
increas
connect
tissu
thicken
two
seven
patient
present
epineur
hypervascular
observ
doppler
evalu
none
treat
iv
immunoglobulin
echograph
chang
present
even
absenc
mri
abnorm
root
hypertrophi
eng
characterist
correl
us
pattern
uhfu
may
adjunct
diagnost
valu
cidp
assess
detail
imag
nerv
obtain
compar
us
allow
better
evalu
intern
structur
nerv
increas
csa
observ
subject
seem
relat
enlarg
connect
tissu
particular
uhfu
allow
detail
studi
nerv
demonstr
structur
abnorm
hit
connect
tissu
convers
previou
studi
fascicl
anatomi
seem
spare
show
nerv
vascular
except
patient
specul
find
may
explain
preliminari
involv
connect
tissu
pathogenesi
cidp
find
nerv
enlarg
may
tool
monitor
diseas
activ
cidp
better
understand
diseas
pathogenesi
studi
need
confirm
find
addit
data
process
purcel
wojciechowski
gibbon
jamil
menez
burn
children
hospit
network
randwick
westmead
new
south
wale
australia
sydney
new
south
wale
australia
kebangsaan
kuala
lumpur
malaysia
children
cmt
report
hip
dysplasia
aim
investig
relationship
radiolog
hip
dysplasia
indic
walk
pattern
children
cmt
thirti
children
femal
underw
gait
analysi
pelvi
radiograph
within
month
assess
radiograph
review
two
orthopaed
surgeon
reliabl
measur
domin
limb
hip
health
via
radiograph
assess
measur
measur
intraclass
correl
coeffici
rater
experienc
surgeon
measur
use
analysi
measur
acetabular
index
ai
centr
edg
angl
cea
neck
shaft
angl
nsa
medial
joint
space
head
width
later
uncoverag
migrat
percentag
triradi
use
investig
correl
kinemat
kinet
variabl
pelvi
domin
limb
hip
knee
ankl
plane
tempor
spatial
paramet
gait
profil
score
data
captur
vicon
nexu
motion
captur
system
use
lower
bodi
model
gait
data
compar
typic
develop
children
femal
five
affect
children
migrat
percentag
repres
sampl
maximum
hip
abductor
moment
termin
stanc
significantli
lower
norm
refer
valu
moder
correl
radiograph
measur
ai
nsa
medial
joint
space
walk
speed
normalis
leg
length
correl
medial
joint
space
head
width
triradi
gait
cycl
percentag
doubl
support
correl
medial
joint
space
head
width
triradi
result
suggest
evid
relationship
radiograph
indic
hip
dysplasia
hip
abductor
function
gait
children
cmt
pyal
sireesha
neeharika
meena
neurolog
nizam
institut
medic
scienc
hyderabad
telangana
india
ganglionopathi
uniqu
group
disord
vari
etiolog
includ
autoimmun
disord
paraneoplast
syndrom
toxin
induc
caus
observ
despit
extens
investig
caus
sensori
neuronopathi
often
idiopath
approxim
case
electrodiagnost
criteria
diagnos
possibl
ganglionopathi
requir
least
one
sensori
action
potenti
absent
three
sensori
action
potenti
lower
limit
normal
upper
limb
plu
less
two
nerv
abnorm
motor
nerv
conduct
studi
lower
limb
ulnar
amplitud
ratio
valu
usmar
lower
use
differenti
ganglionopathi
axon
neuropathi
perform
retrospect
analysi
patient
either
admit
evalu
outpati
depart
depart
neurolog
nizam
institut
medic
scienc
possibl
ganglionopathi
per
diagnost
criteria
propos
camdessanch
et
al
consecut
patient
sought
treatment
year
period
clinic
pattern
sensori
neuronopathi
analys
retrospect
review
electrodiagnost
studi
patient
calcul
ulnar
amplitud
ratio
valu
comparison
patient
clinic
electrophysiolog
diagnosi
diabet
axon
sensorimotor
neuropathi
clinic
profil
ganglionopathi
indian
subcontin
compris
promin
sensori
ataxia
initi
present
clinic
manifest
predilect
toward
involv
sensori
modal
electrophysiolog
pattern
absent
snap
characterist
encount
signific
valu
usmar
less
enabl
differenti
axon
neuropathi
rahman
jahan
nahar
khalid
jahan
hayat
islam
scienc
servic
divis
intern
centr
diarrheal
diseas
research
bangladesh
icddr
b
dhaka
bangladesh
biochemistri
erasmu
univers
medic
centr
rotterdam
netherland
physiolog
molecular
biolog
bangladesh
univers
health
scienc
dhaka
bangladesh
biochemistri
molecular
biolog
univers
dhaka
dhaka
bangladesh
syndrom
gb
autoimmun
polyradiculoneuropathi
immun
respons
trigger
molecular
mimicri
glycolipid
antigen
express
infect
agent
campylobact
jejuni
c
jejuni
human
peripher
nerv
gangliosid
molecul
structur
special
captur
present
varieti
glycolipid
lymphocyt
object
studi
investig
possibl
role
code
region
polymorph
gene
pathogenesi
gb
bangladeshi
popul
singl
nucleotid
polymorph
snp
exon
well
defin
gb
patient
healthi
control
studi
delin
effect
develop
gb
genotyp
exon
cystryp
glnarg
gene
valid
find
direct
sequenc
pcr
product
perform
least
sampl
posit
found
differ
genotyp
allel
frequenc
gene
gb
patient
compar
control
howev
compar
control
individu
haplotyp
time
like
develop
gb
wherea
individu
haplotyp
reduc
rel
risk
time
posit
associ
haplotyp
observ
axon
form
gb
vs
p
haplotyp
preval
among
antibodi
posit
gb
patient
compar
antibodi
neg
patient
vs
though
statist
signific
snp
associ
anteced
c
jejuni
infect
diseas
sever
diseas
outcom
month
follow
conclus
polymorph
suscept
diseas
caus
factor
gb
convers
increas
knowledg
field
may
offer
new
dimens
research
elucid
better
answer
diseas
pathogenesi
also
contribut
conduct
high
power
rebelo
feeli
bi
tao
shi
zuchner
shi
john
macdonald
foundat
depart
human
genet
john
p
hussman
institut
human
genom
univers
miami
miller
school
medicin
miami
usa
neurolog
carver
colleg
medicin
univers
iowa
iowa
citi
usa
extens
genet
test
perform
uniqu
patient
receiv
nation
media
attent
due
sever
cmt
phenotyp
index
patient
never
abl
walk
independ
difficulti
breath
swallow
demonstr
aspir
barium
swallow
studi
nerv
conduct
veloc
test
reveal
veloc
ms
upper
extrem
requir
continu
posit
airway
pressur
cpap
upper
respiratori
infect
develop
bilater
vocal
cord
paralysi
use
combin
brief
assess
motor
function
bamf
scale
evalu
disabl
fine
motor
scale
upper
extrem
gross
motor
scale
lower
extrem
gross
motor
scale
unfortun
die
age
sleep
presum
respiratori
arrest
proband
father
asymptomat
howev
neurolog
exam
show
pe
cavu
bilater
mild
atrophi
first
dorsal
interossei
muscl
hand
nerv
conduct
veloc
slow
ms
upper
extrem
cmt
neuropathi
score
perform
whole
exom
subsequ
whole
genom
sequenc
trio
comprehens
structur
variant
analysi
copi
number
variat
larg
delet
recombin
complet
combin
softwar
tool
known
cmt
gene
exclud
underli
caus
viabl
candid
gene
remain
show
express
peripher
nerv
schwann
cell
paralogu
caus
recess
inherit
dysmyelin
form
sanger
sequenc
confirm
variant
famili
c
show
segreg
heterozyg
variat
hypothes
heterozyg
patern
allel
minim
effect
let
mild
subclin
form
peripher
neuropathi
interest
recess
gene
also
shown
caus
mild
aberr
form
peripher
nerv
degener
carrier
heterozyg
diseas
allel
summari
paper
present
genet
molecular
evid
extens
studi
propos
novel
gene
rocha
tomaselli
gouvea
figueiredo
marqu
w
neuromuscular
diseas
depart
neurosci
behaviour
scienc
clinic
hospit
preto
univers
paulo
preto
brazil
depart
neurosci
behaviour
scienc
univers
paulo
preto
brazil
cmt
import
caus
morbid
worldwid
heterogen
diseas
manifest
progress
weak
wast
loss
feel
pattern
increas
number
gene
literatur
recent
recess
mutat
gene
report
caus
predomin
motor
axon
neuropathi
associ
neuromyoton
discharg
emg
one
characterist
autosom
recess
cmt
vari
frequenc
differ
popul
ethnic
group
sought
evalu
frequenc
mutat
gene
brazilian
cohort
axon
hereditari
neuropathi
patient
includ
studi
born
within
south
east
area
brazil
group
consist
consecut
patient
axon
neuropathi
screen
recess
sporad
axon
neuropathi
neurogenet
laboratori
clinic
hospit
preto
direct
sequenc
code
region
gene
done
among
patient
screen
suspect
recess
axon
neuropathi
without
neuromyothon
discharg
two
axon
neuropathi
associ
neuromyothon
discharg
emg
find
diseas
caus
mutat
among
patient
previous
report
studi
report
high
frequenc
mutat
gene
among
recess
axon
neuropathi
european
countri
result
demonstr
frequenc
mutat
underli
genet
hereditari
neuropathi
differ
differ
ethnic
group
implic
organ
servic
manag
cmt
genet
counsel
gene
flow
differ
world
popul
fund
cnpq
fapesp
faepa
prona
ministri
health
ballarini
malacrida
ceresa
semperboni
mereg
cavaletti
nicolini
medicin
surgeri
experiment
neurolog
unit
univers
monza
itali
program
neurosci
univers
monza
itali
bortezomib
btz
proteasom
inhibitor
wide
use
multipl
myeloma
treatment
btz
induc
peripher
neuropathi
bipn
frequent
advers
effect
bipn
human
dose
depend
pain
sensori
neuropathi
character
nerv
axonopathi
tendenc
recov
period
btz
withdraw
bipn
affect
princip
dorsal
root
ganglia
drg
differ
rodent
model
shown
alter
sensori
neuron
small
unmyelin
axon
larg
myelin
axon
axon
mitochondria
schwann
cell
work
evalu
effect
btz
vitro
drg
neuron
isol
adult
mice
interest
focus
dystonin
protein
abl
interact
three
compon
cytoskeleton
microtubul
microfila
intermedi
filament
abl
bind
protein
influenc
golgi
apparatu
morpholog
differ
neuron
isoform
dystonin
particular
abl
modul
tubulin
acetyl
stabil
interact
noteworthi
underlin
express
matur
nervou
system
restrict
sensori
neuron
western
blot
analysi
demonstr
treatment
btz
induc
statist
signific
decreas
tubulin
acetyl
result
go
along
previou
studi
observ
tubulin
polymer
increas
btz
treatment
therefor
decid
focu
interest
soma
organel
organ
well
known
depend
cytoskeleton
structur
immunofluoresc
imag
show
alter
distribut
acetyl
tubulin
soma
cytoplasm
hour
treatment
moreov
confoc
analysi
ci
golgi
demonstr
btz
treat
neuron
normal
golgi
structur
lost
show
non
perinuclear
label
distribut
addit
dystonin
distribut
seem
compar
ci
golgi
apparatu
suggest
btz
could
induc
chang
dystonin
local
turn
affect
golgi
organ
probabl
data
suggest
cytoskeleton
alter
induc
btz
could
probabl
caus
wrong
matur
traffick
alter
golgi
vesicl
consequ
impair
correct
sensori
function
aleixo
wedemann
herculano
prado
cal
pupe
bittar
nascimento
feder
fluminens
uff
rio
de
janeiro
brazil
acut
motor
sensori
axon
neuropathi
amsan
clinic
variant
syndrom
gb
rare
report
associ
human
immunodefici
viru
hiv
neurosyphili
describ
case
woman
start
muscl
weak
left
leg
follow
weak
right
leg
upper
limb
one
month
motor
symptom
follow
urinari
fecal
incontin
preced
symptom
diarrhea
fever
refer
neurolog
examin
show
global
areflexia
impair
vibratori
tactil
modal
well
loss
propriocept
pinprick
sensat
moder
compromis
impair
higher
mental
function
observ
caus
neuropathi
rule
cerebrospin
fluid
csf
examin
show
increas
protein
level
normal
glucos
level
neg
vdrl
test
blood
analysi
show
hiv
posit
serolog
test
vdrl
posit
pallidum
hemagglutin
assay
igm
cytomegaloviru
antibodi
neg
normal
rang
hiv
load
undetect
cranial
spinal
cord
magnet
reson
imag
reveal
extens
involv
posterior
spinal
cord
tract
support
diagnosi
neurosyphili
nerv
conduct
studi
show
signific
reduct
compound
motor
action
potenti
amplitud
particularli
lower
limb
absent
sural
nerv
respons
electromyographi
reveal
posit
wave
fibril
lower
limb
treatment
methylprednisolon
human
intraven
immunoglobulin
ceftriaxon
settl
result
improv
upper
limb
paresi
sphincter
dysfunct
antiretrovir
therapi
initi
amsan
case
associ
central
nervou
system
involv
encompass
encephalomyeloradiculopathyrel
hivt
pallidum
cjejuni
main
etiolog
agent
associ
amsan
report
hivcmv
patient
present
gb
variant
face
patient
amsan
mainli
cn
involv
present
crucial
import
undergo
investig
ongo
infecti
process
hiv
syphili
consid
impact
earli
treatment
prognosi
roodbol
yiu
doet
de
wit
mong
van
ne
van
den
berg
jacob
behalf
consortium
neurolog
erasmu
medic
center
rotterdam
netherland
paediatr
neurolog
sophia
children
hospit
rotterdam
netherland
immunolog
erasmu
medic
center
rotterdam
netherland
paediatr
neurolog
royal
children
hospit
melbourn
australia
paediatr
neurolog
hospit
de
jp
garrahan
bueno
air
argentina
neurolog
havenziekenhui
rotterdam
netherland
prospect
cohort
studi
far
investig
clinic
present
cours
syndrom
gb
children
use
outcom
score
start
studi
base
igo
protocol
adjust
children
gb
pediatr
neurologist
argentina
australia
netherland
join
forc
determin
clinic
biolog
determin
diseas
progress
recoveri
gb
children
differ
geograph
area
age
categori
specif
pain
scale
use
includ
comfort
score
children
year
old
pain
face
revis
age
year
old
numer
rate
scale
children
year
old
outcom
measur
new
strength
score
develop
gb
kid
score
score
use
valid
addit
score
onl
fss
also
use
qualiti
life
questionnair
ad
protocol
name
pedsql
pedsql
multidimension
fatigu
scale
scale
avail
children
year
old
activ
score
valid
neuromuscular
disord
children
year
old
also
ad
current
children
includ
eight
children
australia
five
netherland
addit
clinician
research
interest
gb
children
welcom
particip
roodbol
korinthenberg
de
wit
lingsma
jacob
neurolog
neurolog
health
erasmu
sophia
children
hospit
univers
medic
center
rotterdam
netherland
neuropaediatr
muscular
disord
depart
paediatr
adolesc
medicin
univers
hospit
freiburg
freiburg
germani
prognost
model
develop
predict
highli
variabl
clinic
cours
syndrom
gb
adult
clinic
cours
gb
equal
variabl
children
current
prognost
model
valid
children
studi
aim
identifi
children
gb
characterist
hospit
admiss
predict
clinic
sever
outcom
studi
conduct
two
patient
cohort
europ
one
larg
german
cohort
children
one
dutch
cohort
children
clinic
inform
obtain
regard
preced
infect
first
symptom
neurolog
deficit
admiss
nadir
result
addit
investig
cerebrospin
fluid
nerv
conduct
studi
clinic
sever
cours
outcom
defin
gb
disabl
score
especi
abil
walk
unaid
month
month
month
month
onset
symptom
univari
multivari
regress
analys
perform
initi
two
separ
cohort
combin
cohort
consist
children
age
median
year
rang
year
includ
boy
median
durat
onset
symptom
hospit
admiss
day
rang
pain
admiss
remark
frequent
present
children
combin
cohort
children
develop
respiratori
failur
one
child
die
multivari
regress
analysi
show
cohort
strong
predictor
respiratori
failur
avail
hospit
admiss
cranial
nerv
involv
higher
gb
disabl
score
shorter
period
day
onset
symptom
admiss
inform
use
develop
valid
prognost
model
children
gb
present
confer
conclus
base
analysi
two
independ
cohort
patient
predictor
respiratori
failur
clinic
recoveri
identifi
valid
similar
factor
identifi
adult
patient
although
prognosi
children
gener
better
adult
inform
use
develop
simpl
prognost
model
current
clinic
practic
predict
chanc
respiratori
failur
outcom
children
gb
rossor
sandeliu
adiutori
malaspina
blennow
zetterberg
reilli
centr
neuromuscular
diseas
ucl
institut
neurolog
nation
hospit
neurolog
neurosurgeri
london
uk
psychiatri
neurochemistri
sahlgrenska
academi
univers
gorthenburg
sweden
neurosci
centr
blizard
institut
bart
london
school
medicin
dentistri
queen
mari
univers
london
london
uk
molecular
neurosci
ucl
institut
neurolog
queen
squar
london
uk
neg
trial
vitamin
c
highlight
lack
sensit
outcom
measur
diseas
cmt
neurofila
abund
neuron
cytoskelet
protein
concentr
blood
like
reflect
axon
breakdown
therefor
examin
plasma
neurofila
light
chain
nfl
concentr
potenti
biomark
cmt
blood
sampl
collect
patient
cmt
age
match
healthi
control
period
diseas
sever
measur
use
weight
cmt
examin
neuropathi
score
plasma
nfl
concentr
determin
use
hous
develop
simoa
assay
base
nfl
antibodi
light
elisa
kit
umandiagnost
plasma
nfl
concentr
significantli
higher
cmt
patient
median
pgml
iqr
control
median
pgml
iqr
p
correl
diseas
sever
estim
weight
cmt
examin
p
neuropathi
score
concentr
also
significantli
higher
subdivid
cmt
patient
genet
subtyp
p
p
demyelin
p
axon
p
form
compar
healthi
control
signific
differ
plasma
nfl
concentr
year
patient
cmt
mean
differ
pgml
confid
interv
healthi
volunt
mean
differ
pgml
confid
interv
unsurpris
cmt
slowli
progress
diseas
rate
axon
degener
like
constant
elev
summari
shown
plasma
nfl
level
significantli
rais
patient
cmt
correl
diseas
sever
relev
field
cmt
peripher
neuropathi
gener
suggest
plasma
nfl
hold
promis
biomark
peripher
neuropathi
routin
practic
clinic
trial
roussellet
vallat
maisonob
gachard
rizzo
armand
jaccard
magi
de
neurologi
chu
limog
franc
de
neurophysiologi
cliniqu
gh
pari
franc
chu
limog
franc
biologiqu
gh
pari
franc
cliniqu
et
cellulair
chu
limog
franc
neurolymphomatosi
infiltr
peripher
nervou
system
lymphoma
cell
rare
usual
devast
condit
belong
spectrum
neuropathi
cerebrospin
fluid
examin
cytolog
examin
flow
cytometri
clonal
test
pcr
may
show
malign
cell
especi
nerv
root
involv
promin
howev
nerv
biopsi
remain
use
tool
confirm
presenc
malign
cell
invad
nerv
neuropatholog
featur
import
immunoglobulin
receptor
clonal
test
nerv
fragment
may
add
notabl
valu
diagnosi
neurolymphomatosi
although
systemat
investig
retrospect
studi
clinicopatholog
data
clonal
result
nerv
biopsi
sampl
patient
nl
centr
perform
among
patient
nl
found
lymphoma
one
lymphoma
nl
first
manifest
patient
main
clinic
pattern
symmetr
progress
sensorimotor
polyneuropathi
patient
pain
promin
featur
clonal
test
show
monoclon
rearrang
case
oligoclon
rearrang
amplif
main
histolog
pattern
perivascular
infiltr
predomin
epineurium
without
sign
vascul
extent
axon
loss
highli
variabl
patient
variou
chemotherapeut
regimen
use
median
overal
surviv
month
one
case
show
monoclon
pattern
among
control
nerv
sampl
patient
type
neuropathi
includ
vascul
cidp
overal
found
clonal
test
nerv
biopsi
specimen
may
provid
decis
inform
presenc
neurolymphomatosi
sensit
specif
posit
predict
valu
neg
predict
valu
confirm
util
nerv
biopsi
diagnosi
nl
show
great
yield
clonal
test
assess
malign
featur
peripher
nervou
system
lymphoid
infiltr
despit
accur
diagnosi
neurolymphomatosi
still
remain
devast
diseas
overal
poor
prognosi
rubio
vilch
navarro
unit
depart
neurolog
hospit
del
mar
barcelona
spain
cell
biolog
physiolog
immunolog
institut
neurosci
cibern
universitat
de
barcelona
bellaterra
spain
last
year
cumul
data
shown
patient
amyotroph
later
sclerosi
al
mous
model
diseas
present
loss
small
epiderm
dermal
nerv
fiber
sensori
dysfunct
addit
classic
motor
symptom
object
character
small
fiber
neuropathi
clarifi
axon
loss
involv
sort
fiber
equal
specif
purpos
perform
immunohistochem
character
total
intraepiderm
nerv
end
protein
gene
product
peptiderg
calcitonin
peptid
cgrp
nonpeptiderg
nerv
epiderm
end
isolectin
mous
differ
stage
presymptomat
stage
week
diseas
onset
week
symptomat
stage
week
sympathet
sweat
gland
innerv
immunolabel
vasoact
intestin
peptid
vip
earli
stage
week
diseas
onset
week
result
show
mark
reduct
intraepiderm
nerv
fiber
alreadi
presymptomat
stage
compar
wildtyp
litterm
p
axon
loss
affect
markedli
nonpeptiderg
axon
diseas
onset
stage
axon
loss
p
wherea
signific
differ
found
cgrp
posit
fiber
axon
loss
reduct
sympathet
innerv
sweat
gland
also
found
diseas
onset
stage
axon
loss
p
summari
found
nonpeptiderg
sympathet
innerv
skin
predominantli
affect
mous
model
find
suggest
specif
could
use
access
biomark
diseas
ruiz
lessi
cacciavillani
riva
salvalaggio
campagnolo
briani
depart
neurosci
univers
padua
padua
itali
clinic
immunolog
unit
depart
medicin
univers
padua
padua
itali
data
medica
group
padua
itali
arsen
trioxid
ato
highli
effect
treatment
acut
promyelocyt
leukemia
apl
licens
itali
treatment
apl
first
line
chemotherapi
low
risk
patient
ato
frequent
side
effect
well
describ
less
known
ato
induc
describ
apl
patient
treat
retino
acid
atra
ato
first
line
therapi
characterist
ato
induc
neuropathi
prospect
analyz
neurolog
evalu
use
total
neuropathi
score
clinic
version
tnsc
valid
scale
chemotherapi
induc
peripher
neuropathi
neurophysiolog
assess
patient
evalu
baselin
end
induct
phase
end
atoatra
treatment
year
discontinu
treatment
baselin
neurophysiolog
perform
end
induct
phase
patient
men
respect
none
patient
previou
histori
neuropathi
baselin
tnsc
clinic
sign
neuropathi
patient
neurophysiolog
evalu
perform
end
induct
cycl
reveal
sign
peripher
neuropathi
patient
patient
receiv
mg
ato
induct
total
mg
patient
receiv
mg
ato
induct
total
patient
develop
leg
numb
consolid
cycl
patient
also
hand
numb
tnsc
end
therapi
patient
patient
neurophysiolog
end
therapi
detect
sign
sensit
axon
neuropathi
patient
receiv
full
dose
ato
consolid
mgkgday
daysweek
altern
month
total
month
tretinoin
week
week
first
year
tnsc
neurophysiolog
year
end
consolid
cycl
consist
full
recoveri
patient
develop
sensori
axon
neuropathi
ato
therapi
clinic
manifest
consolid
cycl
improv
complet
recoveri
publish
case
report
show
outcom
may
good
patient
multicent
prospect
studi
evalu
characterist
neuropathi
apl
ongo
ruiz
campagnolo
salvalaggio
cacciavillani
taioli
fabrizi
briani
neurosci
neurolog
unit
univers
padua
padua
itali
medica
group
emg
unit
ceme
padua
itali
neurolog
movement
scienc
univers
verona
verona
itali
hereditari
inflammatori
neuropathi
peripher
nerv
disord
differ
pathophysiolog
whose
identif
crucial
therapeut
approach
diagnosi
cmt
easi
famili
histori
diseas
cours
slowli
progress
neurophysiolog
find
homogen
abnorm
case
patient
phenotyp
lead
misdiagnosi
chronic
inflammatori
demyelin
polyradiculoneuropathi
cidp
describ
presenc
red
flag
sign
slowli
progress
declin
mild
sensori
symptom
minim
electrophysiolog
progress
respons
therapi
prompt
diagnosi
cidp
introduct
nerv
neuroimag
contribut
diagnost
describ
cmt
patient
men
women
mean
age
yr
mean
neuropathi
durat
yr
genet
confirm
cmt
initi
diagnos
cidp
neurophysiolog
show
demyelin
featur
patient
remain
patient
axon
featur
csf
analysi
show
dissoci
patient
oligoclon
igg
band
present
patient
nerv
ultrasound
patient
demyelin
neuropathi
show
diffus
increas
area
one
patient
confirm
diffus
nerv
hypertrophi
increas
signal
intens
support
hypothesi
overlap
syndrom
patient
treat
immunomodulatori
therapi
among
patient
demyelin
featur
patient
underw
ivig
month
without
benefit
remain
treat
steroid
show
temporari
improv
patient
axon
neuropathi
complain
progress
histori
underw
ex
adjuvantibu
plasma
exchang
ivig
without
benefit
given
lack
benefit
therapi
screen
hereditari
neuropathi
perform
among
patient
demyelin
neuropathi
among
patient
axon
neuropathi
one
diagnos
cmt
patient
overlap
syndrom
present
sever
clinic
laboratori
featur
csf
protein
elev
might
contribut
misdiagnosi
cidp
cmt
patient
refractori
treatment
rise
suspicion
hereditari
neuropathi
overlap
cmtcidp
syndrom
may
consid
front
acutesubacut
deterior
andor
proxim
muscl
involv
two
patient
overlap
syndrom
show
benefit
either
steroid
ivig
ruiz
tripodi
campagnolo
zara
salvalaggio
ruggero
toffanin
anglani
briani
depart
neurosci
univers
padua
padua
itali
padua
hospit
padua
itali
facial
diplegia
rare
region
subtyp
syndrom
character
rapidli
progress
bilater
facial
palsi
absenc
cranial
neuropathi
ataxia
limb
weak
diagnosi
base
histori
clinic
examin
laboratori
data
outcom
variant
appear
better
classic
gb
although
gb
patient
clinic
exhibit
facial
nerv
involv
report
demonstr
mri
gadolinium
facial
nerv
enhanc
previous
healthi
man
sought
neurolog
advic
acut
onset
right
perior
paresthesia
hyposthenia
extensor
halluci
longu
bilater
previou
month
trip
china
japan
suffer
gastroenter
neurolog
examin
present
bilater
extensor
halluci
longu
hyposthenia
ankl
jerk
reflex
absent
one
week
later
develop
bilater
facial
palsi
neurophysiolog
disclos
absenc
activ
facial
nerv
innerv
muscl
bilater
sign
mild
partial
denerv
right
metam
csf
analysi
show
increas
protein
level
mg
serolog
test
infecti
agent
neg
serum
level
angiotensin
convert
enzym
normal
antibodi
monosialogangliosid
igg
isotyp
posit
brain
mri
show
gadolinium
administr
mark
bilater
enhanc
facial
nerv
segment
lumbosacr
mri
scan
rule
presenc
disc
diseas
well
signal
modif
within
conu
medullari
cauda
equin
nerv
root
patient
treat
iv
immunoglobulin
gkgdie
day
benefit
facial
weak
examin
month
later
patient
present
improv
facial
diplegia
neurophysiolog
disclos
partial
recoveri
activ
facial
nerv
persist
axonopat
damag
bilater
extensor
halluci
longu
hyposthenia
persist
conclus
report
region
subtyp
syndrom
curiou
associ
facial
diplegia
bilater
extensor
halluci
longu
hyposthenia
igg
antibodi
commonli
describ
facial
diplegia
moreov
provid
brain
mri
evid
facial
nerv
involv
rumora
tabbey
lograsso
dolkowski
haidar
lentz
feldman
neurolog
univers
michigan
ann
arbor
usa
intern
medicin
divis
metabol
endocrinolog
diabet
univers
michigan
ann
arbor
usa
diabet
neuropathi
dn
common
complic
diabet
affect
diabet
patient
pathogenesi
dn
type
diabet
directli
relat
metabol
syndrom
associ
western
diet
compos
elev
level
long
chain
satur
fatti
acid
sfa
low
level
medium
chain
sfa
long
chain
sfa
associ
insulin
resist
dyslipidemia
medium
chain
sfa
associ
decreas
lipid
accumul
improv
mitochondri
function
sinc
dn
primarili
disord
sensori
dorsal
root
ganglion
drg
neuron
sought
evalu
impact
sfa
hydrocarbon
chain
length
mitochondri
traffick
mechan
critic
distribut
atp
throughout
drg
axon
provid
energi
synapt
transmiss
hypothes
sfa
longer
hydrocarbon
chain
impair
mitochondri
traffick
wherea
medium
length
sfa
impact
mitochondri
movement
along
drg
axon
studi
examin
impact
sfa
hydrocarbon
chain
length
mitochondri
traffick
direction
veloc
primari
mous
drg
neuron
drg
neuron
treat
increas
concentr
long
chain
sfa
stearat
palmit
medium
chain
sfa
laurat
rang
micromolar
hour
drg
neuron
treat
sfa
palmit
stearat
show
signific
decreas
percentag
motil
mitochondria
wherea
medium
chain
sfa
laurat
alter
mitochondri
motil
next
assess
whether
motil
mitochondria
drg
neuron
treat
palmit
stearat
exhibit
alter
direction
veloc
mitochondri
traffick
palmit
stearat
treatment
result
trend
decreas
number
mitochondria
traffick
anterograd
retrograd
direct
furthermor
micromolar
palmit
stearat
induc
signific
decreas
mitochondri
veloc
laurat
treatment
hand
retain
direction
veloc
mitochondri
traffick
result
suggest
hydrocarbon
chain
length
satur
fatti
acid
play
import
role
regul
mitochondri
traffick
mechan
dorsal
root
ganglion
neuron
impair
mitochondri
traffick
drg
neuron
expos
elev
level
sfa
may
play
critic
role
progress
dn
rumora
hay
lograsso
haidar
dolkowski
lentz
feldman
neurolog
univers
michigan
ann
arbor
mi
usa
intern
medicin
divis
metabol
endocrinolog
diabet
univers
michigan
ann
arbor
usa
dyslipidemia
critic
factor
contribut
develop
diabet
neuropathi
dn
progress
nerv
damag
associ
dn
correl
dyslipidem
state
character
elev
circul
level
harm
satur
fatti
acid
fa
low
level
benefici
unsatur
fa
dn
primari
sensori
dorsal
root
ganglion
drg
neuron
exhibit
energi
dyshomeostasi
mitochondri
dysfunct
howev
littl
known
differenti
impact
satur
unsatur
fa
mitochondri
mechan
drg
neuron
mitochondri
traffick
essenti
mechan
transport
mitochondria
throughout
drg
axon
provid
cellular
atp
neuron
function
neurotransmiss
sinc
mitochondri
traffick
regul
metabol
flux
sought
determin
whether
satur
fa
palmit
unsatur
fa
oleat
differenti
effect
mitochondri
traffick
drg
neuron
evalu
mitochondri
traffick
pattern
mitochondri
membran
potenti
mmp
primari
drg
neuron
treat
physiolog
relev
concentr
palmit
oleat
combin
fa
primari
drg
neuron
treat
micromolar
palmit
induc
signific
reduct
percentag
motil
mitochondria
palmit
treatment
also
induc
reduct
mitochondri
veloc
impact
direction
mitochondri
movement
altern
micromolar
oleat
treatment
impair
percent
motil
mitochondria
direct
mitochondri
movement
mitochondri
veloc
sinc
palmit
oleat
differenti
effect
mitochondri
motil
next
assess
whether
oleat
could
counter
inhibitori
effect
palmit
mitochondri
traffick
surprisingli
oleatepalmit
mixtur
ratio
prevent
impair
mitochondri
traffick
assess
impact
palmit
oleat
mmp
stain
palmit
drg
neuron
tetramethylrhodamin
methyl
ester
drg
neuron
treat
micromolar
palmit
exhibit
increas
percentag
depolar
mitochondria
mitochondria
drg
neuron
retain
mmp
interestingli
drg
neuron
treat
oleatepalmit
mixtur
also
maintain
polar
mitochondria
result
suggest
satur
unsatur
fa
distinct
impact
mitochondri
traffick
mechan
drg
neuron
equimolar
ratio
oleatepalmit
prevent
impair
mitochondri
traffick
saad
pereira
shon
mora
zuchner
shi
rebelo
neurolog
carver
colleg
medicin
univers
iowa
iowa
citi
usa
neurolog
univers
miami
miami
usa
neurolog
columbia
univers
medic
center
new
york
usa
john
macdonald
foundat
depart
human
genet
john
p
hussman
institut
human
genom
univers
miami
miller
school
medicin
miami
usa
mutat
mitochondri
protein
cytochrom
c
oxidas
assembl
protein
report
sever
case
fatal
infantil
cardioencephalomyopathi
cox
defici
identifi
compound
heterozyg
variant
two
unrel
patient
isol
length
depend
axon
sensorimotor
polyneuropathi
variabl
clinic
sever
axon
autosom
recess
diseas
type
whole
exom
sequenc
although
peripher
neuropathi
describ
secondari
featur
case
fatal
infantil
cardioencephalomyopathi
diseas
onset
clinic
phenotyp
surviv
patient
differ
significantli
previous
describ
case
patient
develop
predominantli
motor
neuropathi
moreov
still
aliv
develop
cardiomyopathi
main
phenotyp
caus
death
earli
infanc
report
patient
patient
harbor
mutat
adjac
near
conserv
motif
cxxxc
includ
common
report
pathogen
variant
novel
chang
addit
patient
carri
second
mutat
locat
loop
region
protein
western
blot
fibroblast
cmt
patient
show
reduc
level
subunit
complex
iv
indic
cox
defici
find
demonstr
predomin
phenotyp
associ
mutat
point
broader
phenotyp
heterogen
mechan
link
mitochondri
respiratori
chain
dysfunct
isol
axon
loss
variabl
sever
remain
elucid
sabbir
calcutt
fernyhough
neurodegen
disord
st
bonifac
hospit
albrechtsen
research
centr
winnipeg
mb
canada
patholog
univers
california
san
diego
california
usa
pharmacolog
therapeut
univers
manitoba
mb
canada
muscarin
acetylcholin
ach
type
receptor
metabotrop
g
receptor
express
adult
sensori
neuron
cholinerg
signal
muscarin
receptor
modul
axon
plastic
invertebr
lower
vertebr
recent
shown
select
pirenzepin
specif
muscarin
toxin
antagonist
elev
neurit
outgrowth
protect
small
larg
fiber
neuropathi
adult
sensori
neuron
variou
anim
model
calcutt
et
al
furthermor
demonstr
excess
cholinerg
signal
due
overexpress
caus
signific
reduct
neurit
outgrowth
calcutt
et
al
mechan
driven
neurit
outgrowth
remain
poorli
understood
howev
propos
ach
constrain
axon
outgrowth
via
activ
cholinerg
signal
mediat
via
recruit
trimer
g
protein
g
g
regul
cytoskeleton
dynam
control
tubulin
polymer
activ
protein
destabil
microtubul
increas
intrins
gtpase
activ
tubulin
therefor
test
hypothesi
cholinerg
signal
regul
neurit
outgrowth
via
modul
g
protein
mobil
dynam
tubulin
cytoskeleton
found
adult
sensori
neuron
induc
dissolut
tubulin
cytoskeleton
distal
neurit
g
express
adult
sensori
neuron
significantli
higher
p
g
subsequ
knockdown
g
overexpress
sensori
neuron
significantli
revers
reduct
rel
level
total
neurit
outgrowth
control
vs
g
knockdown
p
neuron
treatment
overexpress
neuron
pirenzepin
sequest
g
protein
significantli
revers
impair
reduct
total
neurit
outgrowth
control
micromolar
pirenzepin
neuron
respect
treat
group
p
vs
control
anova
pirenzepin
also
significantli
restor
mitochondri
traffick
abund
mitochondria
distal
neurit
find
suggest
novel
mechan
modul
influenc
tubulin
polymer
mitochondri
distribut
nerv
termin
control
axon
outgrowth
regener
fund
cihr
nih
sabbir
fernyhough
neurodegen
disord
st
bonifac
hospit
albrechtsen
research
centr
winnipeg
mb
canada
pharmacolog
therapeut
univers
manitoba
mb
canada
muscarin
receptor
group
five
coupl
receptor
gpcr
target
drug
treatment
sever
human
pathophysiolog
condit
recent
shown
select
pirenzepin
specif
muscarin
toxin
antagonist
muscarin
acetylcholin
receptor
induc
elev
neurit
outgrowth
protect
small
larg
fiber
neuropathi
adult
sensori
neuron
variou
anim
model
calcutt
et
al
one
major
cellular
effector
activ
gpcr
extracellular
kinas
erk
erk
signal
cascad
regul
varieti
cellular
process
includ
growth
prolifer
g
protein
mediat
signal
pathway
lead
erk
activ
phosphoryl
differ
kinas
activ
erk
turn
phosphoryl
cellular
substrat
therebi
mediat
divers
function
studi
analyz
recruit
part
receptor
intern
process
induc
agonistantagonist
bind
addit
studi
phosphoryl
erk
pirenzepin
use
isoelectr
focus
specif
antibodi
varieti
assay
includ
g
protein
knockout
cell
line
studi
reveal
recruit
upon
pirenzepin
treatment
treatment
micromolar
pirenzepin
significantli
increas
dual
phosphoryl
residu
primari
rat
sensori
neuron
p
comparison
muscarin
agonist
carbachol
micromolar
gener
antagonist
atropin
micromolar
identifi
multipl
distinct
phosphoryl
event
isoelectr
focus
specif
pirenzepin
induct
shown
erk
phosphoryl
depend
g
protein
recruit
final
reveal
increas
erk
phosphoryl
pirenzepin
significantli
respect
increas
phosphoryl
camp
respons
element
bind
protein
creb
result
show
first
time
antagonist
activ
erk
signal
pathway
possibl
drive
phenotyp
chang
adult
sensori
neuron
fund
cihr
saghira
bi
rebelo
abreu
stanek
zuchner
inherit
neuropathi
consortium
human
genet
hussman
institut
human
genom
univers
miami
miami
usa
laboratori
depart
paediatr
neurolog
faculti
medicin
charl
univers
pragu
univers
hospit
motol
pragu
czech
republ
diseas
cmt
repres
inherit
neuropathi
affect
estim
peopl
immens
advanc
gene
discoveri
gain
sequenc
ng
project
reveal
extent
cmt
genet
heterogen
loci
alreadi
identifi
knowledg
rapidli
translat
clinic
comprehens
gene
test
panel
often
contain
gene
larg
genom
space
invariantli
yield
variant
uncertain
clinic
signific
vu
nearli
person
test
rise
number
vu
creat
major
challeng
genet
counsel
addit
less
individu
mutat
alreadi
known
gene
publish
academ
merit
decreas
test
happen
clinic
laboratori
propos
captur
data
cmt
field
gain
complet
collect
allel
cmt
gene
ideal
conjunct
detail
phenotyp
data
repres
ration
approach
eventu
reduc
number
vu
thu
creat
uniqu
variant
databas
cmt
research
clinician
inherit
neuropathi
variant
browser
provid
simpl
access
current
report
cmt
variat
includ
genotyp
phenotyp
inform
also
design
interact
rate
system
genet
variat
assist
commun
interpret
vu
initi
releas
collect
genet
variat
along
genotyp
phenotyp
data
avail
publish
literatur
clinic
lab
report
databas
highli
encourag
new
submiss
observ
pathogen
variat
also
variat
unknown
signific
goal
provid
platform
cmt
commun
store
share
discuss
genet
data
order
resolv
variat
uncertain
signific
activ
particip
aim
provid
commun
complet
mutat
spectrum
cmt
gene
assist
allel
interpret
patient
diagnosi
sainio
ylikallio
auranen
palmio
tyynismaa
program
unit
molecular
neurolog
univers
helsinki
helsinki
finland
neurosci
neurolog
univers
helsinki
helsinki
univers
hospit
helsinki
finland
research
center
univers
tamper
tamper
univers
hospit
tamper
finland
neurofila
strictli
intermedi
filament
crucial
maintain
axon
architectur
pathogen
mutat
nefl
encod
light
chain
neurofila
caus
dominantli
recess
inherit
neuropathi
cmt
neuropathi
either
axon
type
demyelin
type
pathogen
nefl
variant
dominantli
inherit
missens
mutat
thought
caus
diseas
induc
nefl
aggreg
lead
disrupt
axon
transport
howev
investig
diseas
mechan
caus
mutat
complic
neuron
specif
nefl
identifi
homozyg
nefl
variant
c
predict
nonsens
chang
patient
cmt
elucid
diseas
mechan
use
pluripot
stem
cell
reprogram
patient
skin
fibroblast
differenti
spinal
motor
neuron
motor
neuron
reveal
near
complet
loss
nefl
mrna
absenc
nefl
protein
result
establish
nefl
essenti
develop
human
nervou
system
absenc
caus
progress
axon
neuropathi
current
profil
transcriptom
alter
motor
neuron
lack
nefl
use
singl
cell
rna
sequenc
identifi
compensatori
pathway
salvalaggio
coraci
cacciavillani
ruiz
manganelli
antenora
filla
santoro
gasparotti
padua
briani
neurosci
univers
padua
padua
itali
physic
medicin
rehabilit
depart
orthopaed
scienc
sapienza
univers
rome
itali
lab
data
medica
group
padua
itali
neurosci
reproduct
scienc
odontostomatolog
univers
federico
ii
napl
napl
itali
medic
surgic
specialti
radiolog
scienc
public
health
univers
brescia
brescia
itali
geriatr
neurosci
orthopaed
cattolica
del
sacro
cuor
rome
itali
friedreich
ataxia
frda
common
autosom
recess
ataxia
due
trinucleotid
expans
within
frataxin
gene
within
wide
phenotyp
frda
patient
present
also
axon
neuropathi
whose
patholog
mechan
complet
known
eight
patient
women
mean
age
yr
rang
genet
confirm
frda
underw
neurophysiolog
nerv
ultrasound
evalu
four
limb
bilater
echogen
area
csa
median
ulnar
radial
peron
tibial
sural
nerv
record
mr
neurographi
diffus
tensor
imag
dti
analysi
perform
one
patient
fraction
anisotropi
fa
radial
rd
axial
ad
diffus
median
radial
ulnar
nerv
calcul
proxim
intermedi
distal
site
patient
present
sensori
axon
neuropathi
seven
patient
present
increas
csa
median
ulnar
nerv
arm
axilla
mean
median
nerv
csa
arm
normal
valu
mean
ulnar
nerv
csa
arm
normal
valu
mean
median
nerv
csa
axilla
normal
valu
mean
ulnar
nerv
csa
axilla
normal
valu
mr
neurographi
perform
one
patient
confirm
diffus
swell
signal
hyperintens
median
ulnar
nerv
arm
dti
analysi
show
abnorm
valu
fa
ad
rd
along
whole
cours
evalu
nerv
thu
suggest
wide
alter
nerv
structur
frda
patient
present
axon
neuropathi
character
ultrasound
nerv
enlarg
strictli
limit
limb
patient
find
sole
explain
axonopathi
suggest
sever
author
neither
dorsal
root
ganglia
neural
loss
could
explain
find
diffus
csa
reduct
would
expect
whole
find
repres
peculiar
featur
frda
pathophysiolog
mean
remain
unclear
sampl
salamat
muir
hao
ryland
eminaga
binversi
baker
hoffman
piazza
volstad
han
svaren
wisconsin
school
veterinari
medicin
madison
wisconsin
usa
wisconsin
school
medicin
public
health
madison
wisconsin
usa
inherit
peripher
neuropathi
import
health
concern
current
therapi
dog
affect
varieti
peripher
neuropathi
indic
strong
genet
compon
use
popul
dog
advantag
genet
dissect
diseas
acquir
peripher
neuropathi
apn
inherit
gener
polyneuropathi
high
preval
labrador
retriev
promin
featur
apn
laryng
paralysi
pelvic
limb
weak
associ
longest
peripher
motor
nerv
dog
patholog
featur
apn
similar
human
peripher
neuropathi
aim
understand
genet
patholog
featur
apn
develop
condit
natur
occur
larg
anim
model
human
diseas
perform
associ
studi
gwa
whole
genom
sequenc
wg
investig
genet
underpin
apn
labrador
gwa
data
indic
apn
autosom
domin
diseas
initi
analysi
wg
studi
result
potenti
causal
variant
autosom
domin
pattern
variant
associ
axon
gene
neuropatholog
progress
histolog
featur
apn
poorli
defin
use
genet
marker
gwa
studi
abl
confid
identifi
labrador
apn
nerv
biopsi
obtain
preliminari
analysi
biopsi
labrador
suggest
apn
axonopathi
histolog
data
preclin
symptomat
dog
obtain
defin
pathogenesi
model
defin
causal
genet
variant
understand
patholog
featur
progress
apn
necessari
develop
apn
natur
occur
canin
model
peripher
neuropathi
sancho
lupo
sevilla
chrast
genet
genom
neuromuscular
neurodegen
disord
centro
de
felip
cipf
valencia
spain
ii
la
fe
rare
diseas
joint
unit
valencia
spain
genom
traslat
genet
centro
de
felip
cipf
valencia
spain
genom
depart
centro
de
princip
felip
cipf
valencia
spain
neurolog
hospit
universitari
la
fe
valencia
spain
rare
diseas
ciber
spain
neurosci
karolinska
institutet
stockholm
sweden
mutat
lead
axon
form
neuropathi
date
nine
famili
publish
mutat
gene
show
gene
frequent
involv
cmt
recent
genet
data
clearli
establish
caus
role
phenotyp
consequ
patient
role
neuron
biolog
remain
clarifi
therefor
aim
look
alter
genet
biochem
pathway
transcriptom
approach
order
investig
role
hereditari
peripher
neuropathi
perform
transcriptom
analysi
use
human
gene
express
microarray
agil
technolog
three
cell
line
control
kd
overexpress
common
mutat
kr
differenti
gene
express
assess
carri
use
limma
moder
standard
analysi
techniqu
perform
one
test
gene
thu
gene
statist
report
togeth
correspond
analysi
use
convent
multipl
test
correct
procedur
propos
benjamini
hochberg
deriv
adjust
preliminari
result
reveal
kd
show
gene
involv
transmiss
nerv
impuls
cilium
metabol
suggest
might
act
level
peripher
nervou
system
otherwis
kr
show
major
alter
main
axon
metabol
pathway
includ
overexpress
gene
relat
gener
neuron
action
potenti
transport
axon
target
synaps
format
kr
also
show
mark
alter
gene
express
relat
organ
assembl
cilium
movement
axonem
dynein
complex
assembl
studi
provid
import
step
toward
understand
pathomechan
underli
role
fund
isciii
arec
sancho
marco
camacho
knecht
lupo
genet
genom
neuromuscular
neurodegen
disord
centro
de
felip
cipf
valencia
spain
ii
la
fe
rare
diseas
joint
unit
valencia
spain
structur
enzymopatholog
instituto
de
biomedicina
de
valencia
spain
rare
diseas
ciber
centro
de
felip
cipf
valencia
spain
neurolog
hospit
de
octubr
madrid
spain
neuropediatr
hospit
de
octubr
madrid
spain
intracellular
protein
degrad
centro
de
felip
cipf
valencia
spain
genom
traslat
genet
centro
de
felip
cipf
valencia
spain
encod
mitochondria
associ
apoptosi
induc
factor
mutat
lead
wide
spectrum
neurodegen
disord
cowchock
syndrom
combin
oxid
phosphoryl
defici
sever
encephalomyopathi
deaf
peripher
sensori
neuropathi
spondyloepimetaphys
dysplasia
semd
mental
retard
infantil
motor
neuron
diseas
previou
studi
show
sever
defect
mitochondri
metabol
relat
redox
function
mitochondri
fragment
respiratori
defici
addit
mutat
impair
protein
express
caus
increas
apoptosi
target
sequenc
detect
mutat
confirm
affect
brother
electromyographi
nerv
conduct
veloc
studi
reveal
axon
polyneuropathi
exclus
involv
motor
fiber
earli
children
current
show
normal
cognit
cranial
nerv
function
silico
structur
model
human
show
mutat
phenylalanin
serin
posit
disrupt
hydrophob
interact
consequ
destabil
domain
cartoon
protein
superposit
two
differ
human
structur
suggest
lack
constraint
region
could
affect
interact
helix
region
import
stage
function
activ
protein
fibroblast
use
investig
patholog
effect
mutat
fibroblast
patient
show
similar
mrna
differ
protein
express
compar
healthi
control
fibroblast
howev
aberr
morpholog
fibroblast
polygon
shape
larger
control
fibroblast
mitochondria
mutant
fibroblast
markedli
fragment
compar
control
viabil
patient
fibroblast
lower
correl
increas
apoptosi
instead
seem
caus
increas
express
gene
activ
senesc
program
like
studi
confirm
variabl
effect
differ
mutat
protein
function
may
contribut
clinic
variabl
observ
patient
fund
isciii
per
amor
lart
sango
takaku
niimi
yako
neuropathi
project
tokyo
metropolitan
institut
medic
scienc
tokyo
japan
cocultur
model
neuron
schwann
cell
util
studi
myelin
demyelin
peripher
nervou
system
previou
studi
howev
cell
obtain
primari
cultur
embryon
neonat
anim
recogn
biolog
properti
neuron
schwann
cell
chang
matur
age
cultur
system
adult
anim
cell
appear
mimic
peripher
nerv
degener
regener
better
immatur
anim
cell
establish
spontan
immort
schwann
cell
line
cultur
adult
fischer
rat
peripher
nerv
one
cell
line
design
shown
retain
distinct
schwann
cell
phenotyp
morpholog
express
glial
cell
marker
synthesi
secret
neurotroph
factor
cytokin
fundament
abil
myelin
neurit
cocultur
adult
rat
dorsal
root
ganglion
neuron
nerv
growth
cell
current
investig
focus
establish
cocultur
system
cell
motor
cell
cell
seed
low
densiti
x
maintain
week
medium
supplement
amino
acid
neurotroph
factor
bdnf
ngml
overnight
exposur
mitomycin
c
mmc
micro
gml
cell
cocultur
cell
x
maintain
medium
supplement
bdnf
ngml
ciliari
neurotroph
factor
cntf
ngml
coenzym
micro
cultur
condit
overgrowth
cell
prevent
gradual
movement
cell
toward
neurit
emerg
cell
bodi
observ
stain
carri
day
cocultur
show
myelin
protein
cell
surround
beta
iii
neurit
cocultur
system
benefici
tool
studi
pathogenesi
motor
neuron
diseas
eg
amyotroph
later
sclerosi
diseas
demyelin
neuropathi
novel
therapeut
approach
santo
torezani
maciero
pagliarini
abunahman
ferreira
bittar
pupe
nascimento
feder
fluminens
uff
rio
de
janeiro
brazil
zika
viru
zikv
flaviviru
relat
dengu
yellow
fever
west
nile
virus
recent
associ
occurr
neurolog
complic
children
adult
previou
studi
link
zikv
develop
syndrom
gb
myeliti
meningoenceph
ophthalmolog
manifest
adult
syndrom
gb
encompass
spectrum
neuropathi
character
differ
distribut
weak
sensori
impair
serum
antibodi
often
found
relat
differ
clinic
pattern
recent
encount
patient
rio
de
janeiro
brazil
distal
edema
lower
limb
acut
weak
pain
sensori
disturb
acut
stage
acut
febril
exanthemat
ill
symptom
persist
complet
resolut
afterward
without
specif
therapi
blood
concentr
muscl
enzym
show
normal
valu
electromyographi
nerv
conduct
studi
emgnc
usual
unremark
note
case
posit
zika
viru
indic
ill
occur
virem
phase
arboviru
infect
complet
recoveri
within
expect
timefram
resolut
system
viremia
subset
patient
develop
acut
weak
earli
initi
viral
symptom
clinic
laboratori
electrophysiolog
find
substanti
differ
gb
describ
three
case
similar
featur
suggest
acut
infect
polyneur
aipn
one
might
hypothes
zikv
might
lead
direct
neurotrop
injuri
signific
enough
caus
weak
sensori
complaint
sever
enough
caus
perman
damag
resolv
conjunct
decreas
blood
viremia
consid
patient
differ
classic
gb
ill
begin
acut
febril
stage
infect
ill
clinic
cours
rapid
lead
complet
resolut
day
savranski
mozzoni
massaro
sanchez
reisin
mong
neurolog
hospit
de
pediatria
jp
garrahan
bueno
air
argentin
physic
therapi
hospit
de
pediatria
j
p
garrahan
bueno
air
argentin
neurolog
britain
hospit
bueno
air
argentin
object
describ
seri
children
guillain
syndrom
gb
includ
igo
protocol
part
igo
multicent
protocol
pediatr
patient
meet
gb
diagnost
criteria
consult
within
first
week
symptom
onset
parent
consent
particip
studi
includ
patient
also
offer
particip
extend
protocol
patient
evalu
accord
igo
protocol
patient
recruit
octob
june
patient
eight
girl
particip
age
rang
month
year
mean
year
patient
agre
particip
extend
protocol
complet
eight
patient
complet
still
evalu
five
patient
lost
classic
variant
gb
two
miller
fisher
radicular
pain
back
lower
limb
report
patient
underw
lumbar
punctur
dissoci
found
case
csf
store
proteom
studi
patient
underw
emg
show
aidp
amsan
aman
one
patient
aidp
develop
cidp
patient
mri
perform
cauda
equina
enhanc
found
everi
case
three
patient
requir
ucip
two
invas
one
ventil
patient
treat
gammaglobulin
second
dose
week
case
poor
respons
patient
follow
protocol
evalu
gb
disabl
score
median
score
baselin
assess
describ
seri
children
gb
part
intern
protocol
includ
patient
differ
age
pain
frequent
earli
symptom
could
determin
despit
young
age
patient
patient
fulli
recov
invit
particip
igo
kid
better
assess
age
group
saysavath
somchit
hospit
vientian
lao
pdr
hospit
vientian
neurosci
institut
singapor
singapor
lao
peopl
democrat
republ
countri
million
peopl
south
east
asia
larg
agricultur
capit
metropoli
vientian
adult
neurolog
servic
concentr
mittaphab
hospit
vientian
servic
three
neurologist
averag
six
case
syndrom
gb
seen
per
year
believ
patient
seek
medic
attent
case
appear
cluster
raini
season
patient
present
late
often
second
week
ill
recoveri
unappar
seek
treatment
tradit
medicin
doctor
district
hospit
substanti
number
patient
seek
treatment
hospit
across
border
neighbor
provinc
thailand
common
anteced
symptom
viral
prodrom
diarrhea
miller
fisher
syndrom
appear
rare
possibl
mild
deficit
prompt
patient
seek
medic
attent
diagnosi
made
larg
clinic
featur
spinal
fluid
analysi
nerv
conduct
studi
avail
patient
often
treat
steroid
internist
intraven
immunoglobulin
plasma
exchang
avail
common
complic
includ
pneumonia
autonom
dysfunct
fluctuat
blood
pressur
pressur
sore
depress
patient
develop
respiratori
failur
nurs
intens
care
unit
plan
afoot
set
prospect
gb
databas
systemat
studi
anteced
infect
includ
flavivirus
develop
plasma
exchang
feasibl
therapeut
modal
schiza
markoulli
richter
tryfono
kagiava
sargiannid
christodoul
kleopa
laboratori
molecular
virolog
clinic
cypru
institut
neurolog
genet
cypru
school
molecular
medicin
nicosia
cypru
type
frequent
form
among
recess
inherit
demyelin
neuropathi
result
mutat
gene
mutat
caus
loss
function
protein
suggest
gene
replac
therapi
may
use
treat
mice
develop
major
aspect
human
patholog
includ
earli
onset
progress
peripher
neuropathi
demyelin
along
decreas
motor
sensori
nerv
conduct
veloc
offer
relev
model
test
treatment
order
develop
gene
replac
strategi
gener
novel
lentivir
vector
drive
express
human
cdna
control
myelin
protein
zero
promot
specif
myelin
schwann
cell
myc
tag
includ
facilit
express
analysi
control
vector
mock
also
produc
cdna
replac
egfp
report
gene
first
confirm
express
hela
cell
transfect
vector
immunofluoresc
analysi
confirm
strong
express
specif
plasma
membran
addit
local
dot
pattern
intracellularli
vivo
gene
deliveri
use
intraneur
intrathec
inject
vector
old
mice
express
viral
deliv
assess
week
inject
immunofluoresc
analysi
show
immunoreact
perinuclear
schwann
cell
cytoplasm
sciatic
nerv
teas
fiber
mice
follow
intraneur
intrathec
deliveri
lumbar
intrathec
gene
deliveri
result
addit
express
lumbar
root
real
time
pcr
analysi
confirm
mrna
express
lumbar
root
sciatic
nerv
thu
develop
novel
lentivir
vector
schwann
cell
target
gene
deliveri
treat
test
possibl
therapeut
effect
mous
model
diseas
fund
cmt
associ
usa
schmidt
gess
rwth
aachen
germani
hereditari
neuropathi
group
disord
characteris
system
impair
peripher
nerv
neuropathi
associ
caus
gene
defect
charcot
mari
tooth
neuropathi
frequent
hereditari
neuropathi
trigger
mutat
peripher
myelin
protein
gene
lead
primari
loss
myelin
sheath
afterward
degener
axon
symptom
appear
degener
axon
wherea
demyelin
thought
larg
asymptomat
reason
investig
mechan
axon
degener
analysi
use
purifi
axoplasma
without
detect
myelin
protein
sciatic
nerv
week
old
mice
earli
stage
axon
degener
significantli
increas
nad
concentr
axoplasma
dramat
reduc
correl
previou
find
promot
axon
degener
cleavag
nad
addit
studi
show
increas
axon
protect
factor
sciatic
nerv
known
activ
compon
wallerian
degener
slow
gene
unaffect
axoplasma
sciatic
nerv
summaris
result
indic
pathway
nad
may
play
critic
role
axon
degener
neuropathi
wei
j
et
al
toward
function
patholog
hereditari
neuropathi
acta
neuropathologica
p
krajewski
km
et
al
neurolog
dysfunct
axon
degener
diseas
type
brain
p
seeman
mazanec
senderek
pediatr
neurolog
medic
faculti
charl
univers
pragu
czech
republ
neurolog
medic
faculti
charl
univers
pragu
czech
republ
baur
institut
ludwig
maximilian
univers
munich
germani
type
rare
autosom
recess
demyelin
neuropathi
caus
biallel
mutat
gene
pathogen
mutat
describ
sinc
truncat
report
two
unrel
czech
patient
sporad
case
famili
patient
year
old
man
congenit
glaucoma
ophthalmolog
surgeri
earli
motor
develop
normal
age
year
parent
note
gait
problem
first
neurolog
examin
age
year
emg
show
diffus
motor
sensori
neuropathi
sever
decreas
ncv
ms
develop
foot
deform
pe
cavovaru
underw
correct
orthoped
surgeri
age
year
sever
dna
test
demyelin
cmt
gene
sanger
sequenc
novel
missens
mutat
found
homozyg
state
patient
heterozyg
state
parent
patient
later
test
also
ng
panel
gene
causal
hereditari
neuropathi
potenti
causal
variant
detect
patient
year
old
man
normal
earli
motor
develop
age
year
parent
note
gait
problem
distal
leg
weak
progress
distal
leg
plegia
age
year
hand
weak
notic
sinc
age
year
sever
atrophi
distal
muscl
extrem
self
ambul
age
emg
show
unrecord
respons
nerv
lower
limb
ncv
measur
ulnar
nerv
ms
age
year
increas
intraocular
pressur
diagnos
use
anti
glaucoma
eye
drop
mani
singl
gene
test
demyelin
cmt
use
ng
panel
gene
known
causal
hereditari
neuropathi
two
novel
heterozyg
probabl
pathogen
variant
affect
invari
splice
site
detect
g
confirm
sanger
sequenc
first
variant
also
father
second
probabl
detect
parent
despit
correct
parent
sekiguchi
kikuchi
konno
sekiguchi
orthopaed
surgeri
fukushima
medic
univers
school
medicin
fukushima
japan
carpal
tunnel
syndrom
ct
common
entrap
neuropathi
ultrasonographi
use
detect
anatom
chang
ct
recent
shown
doppler
ultrasonographi
detect
increas
intraneur
blood
flow
ct
purpos
studi
determin
suitabl
find
oper
ct
ultrasonographi
total
wrist
patient
nerv
conduct
studi
nc
proven
ct
evalu
ultrasonographi
measur
median
nerv
area
csa
intraneur
blood
flow
median
nerv
ultrasonographi
correl
ultrasonograph
measur
nc
sever
durat
clinic
ct
symptom
analyz
csa
mean
significantli
reduct
success
carpal
tunnel
releas
morpholog
median
nerv
chang
may
persist
longer
period
regardless
success
surgeri
clinic
improv
howev
intraneur
blood
flow
increas
success
carpal
tunnel
releas
conclud
doppler
ultrasonographi
result
strongli
correl
post
oper
ct
improv
henc
doppler
ultrasonographi
use
method
function
improv
post
ct
oper
senger
chan
olson
webber
alberta
edmonton
canada
benefici
effect
preinjuri
crush
condit
lesion
cl
peripher
nerv
regener
anim
model
human
studi
attempt
date
given
ethic
dilemma
deliber
injur
intact
nerv
difficulti
predict
time
nerv
injuri
recent
studi
demonstr
hour
electr
stimul
es
produc
effect
similar
cl
neuron
cultur
coupl
surgic
environ
favor
nerv
transfer
intact
nerv
deliber
cut
reinnerv
denerv
muscl
mean
es
may
clinic
translat
enhanc
regener
studi
hypothes
es
prior
nerv
injuri
enhanc
nerv
regener
twelv
rat
divid
four
group
base
peron
cp
nerv
es
crush
one
week
follow
condit
underw
cutcoapt
cp
nerv
sciatic
trifurc
day
nerv
dorsal
root
ganglia
drg
collect
axon
count
nerv
stain
reveal
similar
regener
es
crush
vs
mm
superior
mm
mm
p
greater
number
axon
distal
tip
present
anim
receiv
either
type
condit
compar
uncondit
cohort
drg
stain
neuron
injuri
marker
growth
associ
satellit
cell
glial
cell
glial
fibrillari
acid
protein
gfap
signific
increas
express
three
day
observ
es
crush
cohort
compar
sham
p
cohort
satellit
glial
cell
es
crush
condit
show
signific
increas
gfap
express
respect
compar
sham
drg
demonstr
similar
improv
axon
regener
proof
principl
project
suggest
es
condit
may
produc
regen
outcom
compar
classic
crush
injuri
model
turn
suggest
es
may
promis
method
deliv
condit
lesion
clinic
trial
condit
nerv
prior
surgic
intervent
serban
clinic
turda
cluj
romania
report
uniqu
case
newli
develop
waldenstrom
macroglobulinemia
wm
patient
chronic
inflammatori
demyelin
polyneuropathi
cidp
antibodi
glycoprotein
mag
sulfatid
undergo
treatment
intraven
immunoglobulin
subsequ
rituximab
infus
posit
impact
patient
wm
develop
demyelin
axon
polyneuropathi
patient
andor
antibodi
antibodi
wm
associ
sensorimotor
axon
loss
demyelin
wm
sensori
axon
loss
rare
antibodi
present
sever
clinic
phenotyp
cidp
associ
antibodi
repres
independ
entiti
associ
wm
report
date
patient
cidp
associ
antibodi
develop
wm
immunomodulatori
therapi
addit
subsequ
rituximab
infus
stop
proven
benefici
previous
report
cidp
patient
year
old
gentleman
present
persist
numb
left
foot
three
month
follow
artifici
disc
placement
lumbar
spine
gradual
develop
sensori
ataxia
radicular
sign
present
exam
imping
serial
spine
mri
ncsemg
studi
consist
cidp
variant
sever
prolong
distal
motor
latenc
serum
antibodi
elev
chronic
therapi
abl
partial
stabil
symptom
howev
six
year
later
newli
develop
wm
subsequ
infus
rituximab
stop
improv
clinic
pictur
ncsemg
find
wm
newli
develop
autoimmun
set
cidp
associ
antibodi
particular
case
ongo
immunomodulatori
therapi
cidp
patient
monthli
infus
may
reflect
possibl
induct
patholog
b
cell
clone
prolifer
treatment
subsequ
rituximab
infus
stop
improv
symptom
demyelin
featur
ncsemg
continu
symptomat
despit
effort
sereda
walter
martini
young
medic
centr
germani
experiment
medicin
germani
ludwig
maximilian
univers
munich
germani
hospit
germani
univers
germani
diseas
cmt
inherit
neuropathi
without
known
cure
preval
duplic
gene
encod
peripher
myelin
protein
underli
common
subtyp
sever
affect
cmt
patient
suffer
sensori
motor
symptom
clinic
phenotyp
highli
variabl
determin
amount
axon
loss
molecular
mechan
disturb
interact
poorli
understood
risk
factor
investig
therefor
german
network
fund
german
ministri
educ
research
bmbf
bonn
germani
includ
interdisciplinari
expertis
molecular
biolog
neurolog
neuropatholog
human
genet
order
identifi
genet
risk
factor
diseas
sever
cmt
examin
mechan
disturb
neuron
vulner
ii
identif
genet
modifi
iii
novel
therapeut
target
iv
valid
outcom
measur
children
adult
v
establish
biobank
vi
explor
diseas
burden
via
intern
harmonis
patient
registri
includ
three
servic
structur
focu
also
includ
rarer
subform
provid
scientif
basi
develop
translat
approach
therapi
patient
approach
bridg
cut
edg
molecular
screen
techniqu
transgen
anim
model
alter
interact
fli
chick
mous
rat
genom
technolog
human
patient
trial
order
understand
treat
diseas
aggrav
cmt
sezer
tekol
sezer
univers
ziya
eren
genom
stem
cell
centr
kayseri
turkey
univers
school
medicin
pharmacolog
depart
kayseri
turkey
univers
good
clinic
practic
research
centr
kayseri
turkey
analges
effect
antidepress
drug
well
known
long
time
howev
system
side
effect
limit
usag
analges
venlafaxin
antidepress
drug
differ
structur
purpos
investig
whether
system
analges
effect
prove
drug
venlafaxin
local
peripher
antinocicept
action
appli
vanlafaxin
male
rat
paw
intraplantar
inject
also
intraperiton
rout
mgkg
formalin
test
model
acut
tonic
pain
also
pretreat
anoth
group
rat
mgkg
naloxon
opioid
receptor
antagonist
mgkg
cpt
adenosin
receptor
antagonist
salin
ip
venlafaxin
inject
check
effect
local
determin
blood
level
venlafaxin
differ
time
point
local
system
applic
method
data
express
number
flinch
total
time
bitinglick
inject
paw
phase
min
phase
min
analyz
use
student
venlafaxin
induc
antinocicept
concentr
local
peripher
applic
mgkg
dose
system
applic
formalin
test
effect
compar
pretreat
naloxon
diminish
effect
venlafaxin
phase
howev
statist
signific
pretreat
cpt
decreas
venlafaxin
induc
antinocicept
phase
neither
naloxon
cpt
chang
formalin
induc
nocicept
behavior
alon
first
determin
peripher
antinocicept
action
venlafaxin
rat
formalin
test
role
opioid
adenosin
receptor
action
result
suggest
venlafaxin
local
peripher
antinocicept
effect
activ
may
led
trial
use
drug
formul
analgesia
clinic
futur
topic
applic
might
permit
attain
higher
efficaci
concentr
region
sensori
nerv
termin
limit
system
side
effect
shah
hoffman
klein
staff
clinic
rochest
usa
cipn
common
complic
patient
cancer
diseas
burden
cipn
compound
increas
cancer
survivorship
yet
minim
data
long
term
outcom
follow
onset
cipn
especi
studi
util
rochest
epidemiolog
project
examin
incid
diseas
burden
cipn
among
individu
olmst
counti
minnesota
neurotox
chemotherapi
exposur
clinic
record
queri
presenc
neuropath
sign
symptom
diagnost
code
well
patient
provid
inform
impair
activ
daili
live
use
pain
medic
total
individu
incid
exposur
neurotox
chemotherapi
agent
identifi
base
aan
criteria
identifi
peripher
neuropathi
individu
determin
cipn
control
median
time
incid
exposur
report
symptom
onset
day
iqr
patient
cipn
receiv
neuropathi
diagnosi
mere
case
median
surviv
follow
incid
chemotherapi
exposur
among
case
control
year
significantli
longer
mean
surviv
case
cipn
compar
control
year
vs
year
p
addit
acut
effect
cipn
individu
surviv
greater
year
follow
exposur
neurotox
chemotherapi
continu
increas
symptom
numb
ci
pain
ci
extrem
util
patient
provid
inform
studi
abl
collect
data
impair
associ
previou
histori
exposur
neurotox
chemotherapi
result
consist
previou
report
high
incid
cipn
first
two
year
follow
incid
exposur
addit
result
provid
evid
high
incid
cipn
independ
individu
chemotherapeut
agent
use
addit
result
indic
diagnost
code
attribut
may
dramat
underestim
magnitud
cipn
increas
surviv
follow
exposur
neurotox
chemotherapi
diseas
burden
necessit
studi
among
survivor
shahrizaila
noto
simon
huynh
shibuya
matamala
dharmadasa
devenney
kennerson
nicholson
kiernan
mind
centr
univers
sydney
camperdown
australia
neurolog
faculti
medicin
univers
malaya
kuala
lumpur
malaysia
vincent
clinic
school
univers
new
south
wale
darlinghurst
australia
research
institut
sydney
medic
school
univers
sydney
sydney
australia
util
quantit
muscl
ultrasound
marker
diseas
sever
cmt
diseas
subtyp
investig
muscl
ultrasound
prospect
perform
individu
muscl
cmt
patient
compar
muscl
age
control
muscl
ultrasound
record
echogen
thick
repres
muscl
includ
first
dorsal
interosseu
fdi
tibiali
anterior
ta
muscl
volum
fdi
thick
ta
correl
mrc
strength
muscl
echogen
significantli
increas
fdi
vs
p
ta
vs
p
cmt
patient
ta
significantli
higher
muscl
thick
vs
vs
mm
p
lower
muscl
echogen
vs
vs
p
compar
correspond
diseas
sever
base
muscl
strength
mrc
grade
vs
vs
vs
vs
cmt
quantit
muscl
ultrasound
distal
limb
muscl
use
marker
diseas
sever
current
find
suggest
quantit
muscl
ultrasound
potenti
surrog
marker
diseas
progress
futur
intervent
trial
cmt
shi
huang
zheng
lu
pei
su
huang
ke
lai
xiang
li
yao
neurolog
first
affili
hospit
sun
univers
guangzhou
china
neurosurg
intens
care
unit
depart
critic
care
medicin
first
affili
hospit
sun
univers
guangzhou
china
center
stem
cell
biolog
tissu
engin
key
laboratori
stem
cell
tissu
engin
ministri
educ
sun
univers
guangzhou
china
key
laboratori
qualiti
research
chines
medicin
institut
chines
medic
scienc
univers
macau
macao
china
biochemistri
zhongshan
medic
school
sun
univers
guangzhou
china
cmt
diseas
frequent
inherit
peripher
neuropathi
current
avail
cure
common
subtyp
cmt
complet
associ
duplic
gene
encod
peripher
myelin
protein
schwann
cell
previou
studi
mainli
reli
rodent
model
yet
clear
overexpress
lead
phenotyp
patient
base
induc
pluripot
stem
cell
ipsc
technolog
herein
develop
brand
new
vitro
cell
model
call
hope
simul
development
progress
diseas
gain
new
insight
pathogenesi
effici
deriv
ncsc
assess
potenti
isol
crest
stem
cell
ncsc
differenti
peripher
neuron
schwann
cell
use
defin
media
found
unlik
normal
control
ncsc
rare
gener
schwann
cell
instead
produc
numer
endoneuri
fibroblast
schwann
cell
differenti
system
establish
ipsc
model
obtain
similar
result
subject
schwann
cell
differenti
result
suggest
develop
schwann
cell
patient
interrupt
duplic
except
process
development
disabl
schwann
cell
consid
underli
caus
shimoi
yamada
univers
health
welfar
tochigi
japan
japan
tokyo
japan
cmt
diseas
common
hereditari
motor
sensori
neuropathi
preliminari
report
suggest
certain
cmt
patient
recruit
disord
motor
unit
muscl
fatigu
disord
may
factor
super
fatig
motor
neuropathi
patient
super
fatig
occur
would
expect
patient
characterist
becom
slower
recoveri
muscl
fatigu
patient
without
characterist
order
verifi
hypothesi
measur
characterist
recoveri
muscl
fatigu
patient
electromyograph
studi
twenti
three
particip
ask
maintain
maxim
voluntari
isometr
contract
mvc
elbow
flexor
exhaust
fatigu
exercis
addit
particip
ask
perform
mvc
fatigu
exercis
recoveri
task
surfac
emg
semg
signal
bicep
brachii
muscl
determin
exercis
task
muscl
forc
median
power
frequenc
mdpf
root
mean
squar
semg
amplitud
rm
use
object
paramet
muscl
fatigu
borg
scale
use
subject
paramet
muscl
fatigu
six
twenti
three
particip
show
signific
decreas
rm
fatigu
exercis
consider
result
compar
alter
mdpf
recoveri
task
six
particip
decreas
rm
abnorm
group
seventeen
particip
increas
rm
normal
group
result
abnorm
group
least
recoveri
time
muscl
fatigu
contrast
normal
group
recoveri
time
muscl
fatigu
subject
paramet
shorter
time
object
paramet
group
data
support
super
fatig
hypothesi
hypothesi
may
induc
hidden
muscl
fatigu
shin
moon
sung
nation
univers
hospit
seoul
republ
korea
complex
region
pain
syndrom
crp
constant
region
neuropath
pain
character
variou
kind
motor
sensori
autonom
chang
convent
crp
divid
type
ii
accord
absenc
presenc
nerv
injuri
pathogenesi
crp
fulli
understood
yet
still
systemat
compar
studi
crp
type
ii
compar
crp
type
ii
use
multimod
approach
includ
electrophysiolog
imag
clinic
find
patient
type
type
ii
diagnos
crp
use
intern
associ
studi
pain
iasp
diagnost
criteria
includ
type
ii
divid
electromyographi
nerv
conduct
studi
obtain
clinic
inform
continu
pain
allodynia
hyperalgesia
edema
temperatur
skin
color
sweat
trophic
chang
patient
patient
evalu
bone
scan
thermographi
quantit
sudomotor
axon
reflex
test
qsart
quantit
somatosensori
test
qst
ratio
qsart
temperatur
threshold
abnorm
type
ii
higher
compar
type
vs
vs
respect
p
among
clinic
symptom
sweat
chang
significantli
high
type
ii
compar
type
vs
p
electrophysiolog
imag
clinic
find
significantli
differ
type
studi
identifi
crp
type
ii
distinguish
nerv
injuri
also
sudomotor
function
qsart
serv
good
techniqu
differenti
crp
type
ii
estim
two
distinct
pathogenesi
crp
result
may
help
diagnos
crp
correctli
understand
pathogenesi
crp
shu
california
lo
angel
medic
center
lo
angel
california
usa
sjogren
syndrom
ss
autoimmun
inflammatori
disord
exocrin
gland
result
xerophthalmia
xerostomia
ross
syndrom
rare
entiti
character
tonic
pupil
hyporeflexia
segment
anhidrosi
present
hispan
woman
debilit
sensori
autonom
neuropathi
persist
elev
antibodi
without
classic
sicca
complex
initi
develop
diarrhea
ear
infect
felt
toe
later
leg
numb
eventu
spread
cheek
tongu
month
four
year
later
thumb
index
finger
start
tingl
also
develop
orthostat
lightheaded
tachycardia
segment
hypohidrosi
right
abdomen
hyperhidrosi
remain
trunk
intermitt
erythema
chronic
diarrhea
weight
loss
exam
demonstr
orthostat
hypotens
bilater
tonic
pupil
dissoci
sector
palsi
right
iri
sphincter
diminish
sensat
modal
pseudoathetosi
areflexia
dysmetria
intent
tremor
romberg
sensori
gait
ataxia
mri
neuraxi
demonstr
hyperintens
dorsal
spinal
cord
lower
thorac
level
mild
atrophi
electrodiagnost
test
consist
asymmetr
sensori
polyganglionopathi
csf
show
oligoclon
band
serolog
show
elev
antinuclear
antibodi
refer
refer
u
refer
u
rheumatoid
factor
refer
iuml
titer
remain
workup
neg
infect
syphili
hiv
htlv
hepat
lyme
diseas
paraneoplast
syndrom
ganglion
nicotin
acetylcholin
receptor
antibodi
pyridoxin
intox
malign
chestabdomenpelvi
ct
breast
ultrasound
axillari
lymph
node
flow
cytometri
colon
esophagu
biopsi
celiac
diseas
vitamin
defici
autoimmun
diseas
antibodi
adrenoleukodystrophi
patient
receiv
ivig
steroid
gait
improv
current
take
mycophenol
midodrin
fludrocortison
resolv
dizzi
case
highlight
import
treatabl
sensori
ganglionopathi
system
autonom
neuropathi
due
sjogren
syndrom
illustr
overlap
clinic
triad
ross
syndrom
may
guid
futur
manag
sile
assylbekova
cort
gallardo
illa
querol
diseas
unit
neurolog
depart
hospit
de
la
santa
creu
sant
pau
univeristat
de
barcelona
barcelona
spain
para
la
en
red
en
enfermedad
rara
ciber
madrid
spain
inflammatori
neuropathi
heterogen
group
peripher
nerv
diseas
respond
chronic
inflammatori
polyradiculoneuropathi
cidp
multifoc
motor
neuropathi
mmn
two
chronic
inflammatori
neuropathi
respond
intraven
immunoglobulin
ivig
b
lymphocyt
involv
pathogenesi
wide
use
clinic
practic
ivig
mechan
remain
complet
understood
ivig
report
lead
anergi
increas
regulatori
function
frequenc
regulatori
b
cell
breg
rare
subset
b
lymphocyt
suppress
immunopatholog
act
upon
sever
target
cell
immun
system
impair
breg
yield
describ
plethora
autoimmun
condit
presenc
regulatori
b
cell
inflammatori
neuropathi
effect
ivig
therapi
frequenc
studi
aim
studi
describ
frequenc
breg
cidp
mmn
effect
ivig
frequenc
patient
fulfil
diagnost
criteria
cidp
mmn
match
control
includ
pbmc
obtain
gradient
centrifug
ivig
infus
one
week
treatment
isol
neg
select
magnet
bead
cultur
activ
agonist
odn
iggigaigm
secret
capac
assess
patient
includ
cidp
mmn
patient
includ
receiv
ivig
suitabl
pre
post
ivig
breg
frequenc
comparison
breg
frequenc
differ
patient
ivig
treatment
control
p
mann
whitney
test
howev
frequenc
breg
significantli
increas
treatment
ivig
wilcoxon
match
pair
test
stratifi
diseas
subtyp
breg
frequenc
increas
cidp
patient
ivig
wilcoxon
match
pair
test
mmn
wilcoxon
match
pair
test
although
result
reach
statist
signific
mmn
first
studi
studi
breg
frequenc
cidp
first
studi
address
effect
ivig
breg
frequenc
studi
provid
proof
principl
breg
could
becom
biomark
respons
ivig
would
need
larger
prospect
studi
sile
gallardo
illa
grau
querol
diseas
unit
neurolog
depart
hospit
de
la
santa
creu
sant
pau
univeristat
de
barcelona
barcelona
spain
para
la
en
red
en
enfermedad
rara
ciber
madrid
spain
program
august
pi
sunyer
biomed
research
institut
idibap
hospit
univers
barcelona
spain
paraneoplast
neuropathi
pn
rare
disord
peripher
nerv
import
prognost
implic
ectop
express
neural
antigen
tumor
lead
develop
onconeur
antibodi
sever
autoantibodi
associ
pn
includ
antibodi
signific
proport
pn
lack
identifi
antigen
adhes
molecul
autoantigen
neuropathi
like
present
sever
type
tumor
studi
propos
systemat
screen
autoantibodi
neural
molecul
neural
structur
detect
novel
antigen
reactivi
pn
patient
follow
centr
sclerosi
unit
hospit
de
barcelona
pn
fulfil
diagnost
criteria
possibl
definit
paraneoplast
diseas
includ
serum
sampl
obtain
test
immunocytochemistri
neurofascin
complex
primari
cultur
ganglia
drg
rat
schwann
cell
incub
patient
sera
detect
antibodi
target
neural
structur
ten
individu
present
tumor
neuropathi
involv
sensori
motor
symptom
remain
patient
present
tumor
classic
sensori
neuronopathi
without
onconeuron
antibodi
among
latter
patient
diagnos
lung
carcinoma
rest
individu
associ
divers
malign
detect
sera
react
complex
igg
antibodi
screen
experi
patient
react
drg
neuron
react
strongli
patient
react
mildli
rat
schwann
cell
igm
experi
patient
react
slightli
drg
neuron
patient
rat
schwann
cell
featur
strong
stain
experi
screen
antibodi
motor
neuron
immunoprecipit
assay
ongo
overal
patient
react
strongli
either
neuron
schwann
cell
studi
detect
antibodi
neural
adhes
molecul
complex
patient
pn
howev
signific
proport
pn
patient
harbour
antibodi
target
neural
structur
suggest
novel
antigen
remain
discov
simmon
tao
abreu
zuchner
li
neurolog
vanderbilt
univers
school
medicin
nashvil
tennesse
usa
institut
human
genom
univers
miami
miami
florida
usa
object
despit
share
genet
mutat
trisomi
chromosom
patient
present
high
variabl
diseas
sever
underli
caus
variabl
still
unclear
studi
test
hypothesi
whether
second
genet
mutat
known
damag
nervou
system
also
present
patient
earli
onset
sever
phenotyp
method
cohort
patient
mutat
chromosom
duplic
identifi
patient
earli
onset
year
age
diseas
four
eleven
also
dna
test
panel
known
gene
sequenc
mitochondri
dna
addit
dna
test
duplic
result
besid
duplic
identifi
three
addit
mutat
four
patient
earli
onset
mutat
missens
mutat
mpz
gene
mutat
mitochondri
trna
glycin
homozyg
mutat
duplic
three
four
symptomat
onset
birth
one
show
symptom
year
age
conduct
veloc
sever
reduc
four
patient
interpret
tradit
approach
identifi
genet
modifi
includ
snp
associ
assum
modifi
cluster
small
region
human
genom
share
studi
patient
howev
studi
suggest
genet
modifi
may
highli
divers
scatter
throughout
genom
could
make
convent
approach
via
genet
variant
associ
difficult
support
grant
nind
nation
center
advanc
translat
scienc
sireesha
meena
pyal
sandeep
megha
mridula
jabeen
varaprasad
liza
neeharika
rupam
institut
medic
scienc
hyderabad
india
sjogren
syndrom
ss
system
diseas
apart
exocrin
gland
may
affect
organ
involv
peripher
nervou
system
result
wide
spectrum
neuropath
manifest
aim
studi
evalu
pattern
patholog
characterist
neuropathi
sjogren
syndrom
ss
patient
present
neuromuscular
clinic
tertiari
hospit
south
india
retrospect
studi
depart
neurolog
rheumatolog
patholog
nizam
institut
medic
scienc
twenti
one
patient
diagnosi
ss
peripher
neuropathi
analys
clinic
record
convent
nerv
conduct
studi
lip
nerv
biopsi
report
collectedin
patient
ss
associ
neuropathi
male
femal
ratio
neuropathi
initi
manifest
exocrinopathi
preced
neuropathi
pattern
neuropathi
includ
mononeuropathi
multiplex
mnm
patient
ganglionopathi
length
depend
trigemin
autonom
neuropathi
cidp
cranial
neuropathi
eighteen
seroposit
schirmer
test
posit
nerv
biopsi
show
vascul
patient
demyelin
axonopathi
patient
eachw
conclud
neuropathi
frequent
initi
present
ssmnm
common
pattern
follow
ganglionopathi
pattern
neuropathi
help
arriv
diagnosi
ss
confirm
ss
mere
serolog
schirmer
test
lip
biopsi
equal
essenti
diagnosi
especi
seroneg
patient
clinic
index
suspicion
high
siskind
tesi
rocha
health
care
palo
alto
ca
usa
univers
stanford
ca
usa
report
first
case
human
found
homozyg
presum
diseas
caus
variant
gene
caus
charcot
mari
tooth
diseas
cmt
central
nervou
system
find
proband
born
term
apgar
minut
found
iugr
hospit
day
weight
gain
develop
respiratori
distress
admiss
intub
due
inabl
extub
transfer
stanford
children
hospit
remain
three
month
note
admiss
hypotonia
areflexia
minim
voluntari
movment
sinu
tachycardia
dysautonomia
brain
mri
found
polymicrogyria
cerebr
underdevelop
gener
brainstem
moder
ventriculomegali
nc
found
length
depend
polyneuropathi
axon
degener
follow
muscl
nerv
biopsi
found
immatur
muscl
amyelin
neuropathi
patient
normal
plasma
amino
acid
acylcarnitin
lactat
pyruv
urin
organ
acid
test
opththalmolog
exam
newborn
screen
normal
array
cgh
genet
order
whole
exom
sequenc
baylor
genet
laboratori
houston
tx
usa
found
homozyg
nonsens
variant
second
child
identifi
baylor
two
variant
gene
child
hypotonia
respiratori
distress
seizur
muscl
biopsi
consist
sma
parent
child
chose
withdraw
care
month
age
patient
parent
continu
aggress
therapi
includ
tracheostomi
feed
sever
subsequ
hospit
respiratori
distress
possibl
seizur
activ
buldg
anterior
fontenel
two
year
age
made
development
progress
live
home
famili
abl
smile
reach
toy
swat
object
littl
voluntari
movement
longer
respond
light
touch
stimuli
overal
first
pictur
child
affect
sever
amyelin
form
cmt
caus
weak
hypotonia
possibl
seizur
main
concern
featur
sever
respiratori
distress
may
life
threaten
manag
extrem
care
skorupinska
bull
byrn
reilli
centr
neuromuscular
diseas
ucl
institut
neurolog
london
uk
women
infant
univers
hospit
dublin
ireland
charcot
mari
tooth
cmt
diseas
common
inherit
peripher
neuropathi
patient
frequent
ask
whether
pregnanc
affect
cmt
whether
cmt
affect
pregnanc
optim
deliveri
whether
child
higher
risk
complic
pregnanc
deliveri
far
studi
address
question
current
guidelin
exist
manag
pregnanc
deliveri
postnat
care
cmt
patient
aim
studi
assess
impact
pregnanc
cmt
assess
cmt
affect
pregnanc
deliveri
care
new
born
babi
design
retrospect
questionnair
expert
help
obstetrician
special
interest
pregnanc
patient
medic
condit
questionnair
divid
four
part
prior
pregnanc
deliveri
includ
question
impair
fall
pain
fatigu
respiratori
complic
period
type
deliveri
possibl
complic
detail
anaesthesia
difficulti
look
babi
first
month
postpartum
far
women
pregnanc
cmt
relat
disord
answer
questionnair
patient
remain
variou
subtyp
cmt
relat
disord
patient
report
deterior
cmt
symptom
pregnanc
pregnanc
resolut
symptom
pregnanc
pregnanc
symptom
question
walk
balanc
hand
function
deterior
increas
use
orthos
walk
aid
pregnanc
major
women
natur
deliveri
assist
caesarian
section
similar
uk
popul
complic
anaesthesia
report
survey
current
ongo
plan
survey
consecut
patient
data
acquir
survey
provid
valuabl
inform
current
practic
inform
futur
guidelin
standard
care
charcot
mari
tooth
diseas
sleutj
kovalchuk
van
schelven
van
den
berg
franssen
neuromuscular
disord
univers
medic
center
utrecht
utrecht
netherland
multifoc
motor
neuropathi
mmn
slowli
progress
disord
adult
character
asymmetr
limb
weak
mainli
affect
arm
despit
benefici
effect
immunoglobulin
weak
gradual
progress
major
determin
muscl
weak
degener
affect
motor
axon
treatment
aim
reduc
loss
motor
axon
requir
object
tool
quantifi
effect
therefor
appli
compound
muscl
action
potenti
cmap
scan
electrophysiolog
method
increas
transcutan
success
activ
motor
unit
mu
muscl
captur
contribut
enlarg
mu
due
reinnerv
presenc
rel
larg
discontinu
scan
aim
present
studi
identifi
pathophysiolog
chang
reinnerv
mmn
patient
mean
record
obtain
mmn
patient
record
perform
median
nerv
wrist
motor
respons
record
thenar
muscl
determin
number
largest
discontinu
mean
novel
marker
low
number
indic
enlarg
mu
furthermor
appli
recent
develop
method
professor
hugh
bostock
obtain
estim
median
peak
cmap
amplitud
mv
rang
mv
median
rang
three
mmn
patient
normal
maximum
cmap
amplitud
mv
reduc
found
indic
enlarg
mu
furthermor
estim
mu
number
significantli
relat
r
p
n
find
suggest
sensit
tool
detect
underli
patholog
chang
reinnerv
mmn
standard
maximum
cmap
amplitud
quick
easi
perform
potenti
use
studi
smith
thurgood
rever
hauer
aperghi
singleton
utah
salt
lake
citi
utah
usa
corneal
confoc
microscopi
ccm
directli
quantit
assess
corneal
innerv
includ
nerv
fiber
length
nfl
densiti
nfd
ccm
shown
promis
diagnost
test
previous
demonstr
ccm
diagnost
perform
diabet
neuropathi
dpn
similar
skin
biopsi
assess
intraepiderm
nerv
fiber
densiti
ienfd
nerv
conduct
studi
nc
respons
surrog
measur
dpn
progress
relat
clinic
meaning
outcom
well
explor
diabet
patient
undergo
annual
retinopathi
examin
recruit
underw
ccm
ienfd
nc
includ
sural
sensori
peron
motor
respons
utah
earli
neuropathi
score
uen
norfolk
qualiti
life
diabet
neuropathi
valid
neuropathi
specif
qol
scale
minut
walk
test
dpn
base
symptom
sign
underw
repeat
test
month
month
baselin
correl
sural
sensori
amplitud
ssa
p
peron
motor
conduct
veloc
pcv
p
ienfd
p
ccm
metric
relat
qol
distanc
correl
ssa
p
nfl
p
nfd
p
month
signific
worsen
dpn
sign
assess
uen
increas
p
ssa
declin
uv
p
ienfd
fibersmm
p
chang
ccm
metric
pcv
find
suggest
measur
distal
axon
integr
sensit
neuropathi
progress
ienfd
greatest
respons
contrast
ccm
respons
dpn
progress
nc
ienfd
ccm
significantli
correl
qol
wherea
nc
ccm
measur
correl
physic
function
respons
ienfd
ssa
relationship
qol
support
select
endpoint
dpn
clinic
trial
smith
trout
montgomeri
howard
su
north
carolina
chapel
hill
chapel
hill
usa
chronic
inflammatori
demyelin
polyradiculoneuropathi
cidp
affect
peopl
mark
chronic
autoimmun
infiltr
peripher
nerv
destruct
myelin
sheath
current
therapi
cidp
patient
achiev
complet
remiss
produc
effect
therapi
studi
mice
partial
loss
function
substitut
autoimmun
regul
air
gene
diabet
nod
background
nodairegw
develop
spontan
autoimmun
peripher
polyneuropathi
sapp
resembl
cidp
autoimmun
result
defect
immunosuppress
potent
immunosuppress
cytokin
interleukin
increas
peripher
blood
mononuclear
cell
pbmc
activ
phase
cidp
patient
rel
remiss
phase
patient
pbmc
cidp
patient
produc
respons
myelin
protein
despit
find
whether
import
cidp
pathogenesi
known
thu
sought
determin
role
sapp
highli
upregul
sciatic
nerv
nodairegw
mice
sapp
suggest
may
play
immunosuppress
role
pathogenesi
howev
genet
ablat
nodairegw
mice
lead
paradox
delay
diseas
develop
nodairegw
mice
exhibit
sciatic
nerv
infiltr
reduct
nerv
conduct
electrodiagnost
studi
interestingli
delay
sapp
specif
sinc
incid
five
autoimmun
manifest
nodairegw
mice
unchang
rel
nodairegw
control
importantli
nodairegw
mice
coliti
consist
previou
studi
defici
nod
background
known
perform
effector
function
autoimmun
promot
b
cell
secret
immunoglobulin
howev
genet
ablat
b
cell
affect
neuropathi
develop
nodairegw
mice
suggest
b
cell
dispens
pathogenesi
unlik
mediat
protect
effect
defici
nodairegw
cell
suffici
transfer
sapp
exhibit
increas
activ
increas
interferon
gamma
secret
preserv
cell
activ
data
suggest
cell
activ
prime
unperturb
mechan
protect
summari
data
show
paradox
effector
cytokin
sapp
sohn
lee
hong
kim
neurolog
eulji
univers
hospit
daejeon
republ
korea
endocrinolog
eulji
univers
hospit
daejeon
republ
korea
urolog
eulji
univers
hospit
daejeon
republ
korea
long
exercis
test
let
use
especi
myoton
syndrom
muscl
channelopathi
mark
decrement
compound
muscl
action
potenti
cmap
amplitud
prolong
exercis
previous
report
patient
paramyotonia
congenita
hyperkalem
hypokalem
period
paralysi
describ
patient
secondari
hypokalem
paralysi
show
abnorm
let
result
man
present
ascend
flaccid
paralysi
evolv
hyperacut
fashion
patient
becam
quadripleg
two
hour
initi
laboratori
evalu
reveal
sever
hypokalemia
normal
thyroid
function
perform
electrodiagnost
studi
includ
long
exercis
test
propos
mcmani
et
al
nerv
conduct
studi
normal
mark
decrement
cmap
amplitud
decreas
minut
note
prolong
exercis
despit
oral
intraven
potassium
replac
serum
potassium
level
correct
expect
unusu
clinic
cours
prompt
evalu
secondari
etiolog
abdomen
comput
tomographi
scan
reveal
x
mass
left
adren
gland
aldosteron
renin
ratio
elev
suggest
primari
hyperaldosteron
genet
studi
mutat
turn
neg
receiv
laparoscop
adrenalectomi
patient
experienc
attack
also
abl
stop
antihypertens
medic
let
may
show
abnorm
result
condit
reduc
membran
excit
even
without
true
channelopathi
sopacua
hoeijmak
dickman
nuijt
merki
faber
univers
medic
center
maastricht
netherland
elisabeth
hospit
willemstad
accord
intern
criteria
diagnosi
small
fiber
neuropathi
sfn
base
clinic
symptom
combin
reduc
intraepiderm
nerv
fiber
densiti
ienfd
skin
biopsi
andor
abnorm
temperatur
threshold
test
ttt
sensit
skin
biopsi
moder
good
although
ienfd
normal
patient
sfn
complaint
furthermor
ttt
wide
avail
diagnost
tool
lack
specif
corneal
confoc
microscopi
ccm
describ
use
clinic
practic
object
diagnost
tool
detect
small
nerv
fiber
damag
patient
diabet
mellitu
studi
examin
applic
ccm
patient
sfn
valu
ccm
addit
diagnost
tool
sfn
includ
healthi
particip
compar
result
recent
publish
ccm
norm
valu
patient
refer
sfn
center
maastricht
clinic
pictur
sfn
corneal
nerv
fiber
densiti
cnfd
branch
densiti
cnbd
fiber
length
cnfl
tortuos
coeffici
cnft
determin
particip
result
compar
ienfd
ttt
preliminari
result
present
southanalinh
health
scienc
vientian
capit
lao
pdr
locat
south
east
asia
lao
pdr
landlock
countri
popul
million
inhabit
health
indic
among
lowest
south
east
asia
total
health
caregiv
consist
person
correspond
ratio
health
worker
per
inhabit
main
network
health
care
servic
provis
remain
public
system
health
care
facil
consist
four
central
teach
referr
hospit
five
region
hospit
includ
one
teach
hospit
provinci
hospit
district
hospit
health
center
one
seven
sick
peopl
receiv
modern
health
care
treatment
peopl
reli
andor
relianc
neurolog
care
new
field
knowledg
common
neurolog
disord
among
lao
popul
medic
staff
begin
spread
three
neurologist
countri
six
neurolog
resid
current
train
program
support
associ
pour
la
promot
de
au
lao
associ
promot
lao
asean
neurolog
associ
inde
resourc
scarc
peripher
nerv
diseas
domain
exampl
one
electromyographi
machin
temporari
use
emg
expert
franc
singapor
came
teach
resid
signific
mismatch
provis
special
neurolog
servic
need
exist
especi
rural
area
also
health
insur
avail
major
consequ
patient
bear
cost
constitut
limit
access
avail
healthcar
facil
neurolog
train
center
laboratori
facil
equip
limit
optim
avail
human
resourc
integr
primari
secondari
tertiari
healthcar
tier
make
medic
treatment
afford
need
improv
neurolog
care
develop
world
certain
countri
limit
human
financi
resourc
may
difficult
govern
appli
recommend
circumst
suggest
countri
work
intern
agenc
nongovernment
organ
partner
put
plan
practic
spillan
englez
rossor
lunn
manji
reilli
carr
centr
neuromuscular
diseas
nation
hospit
neurolog
queen
squar
london
uk
observ
data
suggest
intraven
immunoglobulin
ivig
increas
risk
thromboembol
event
tee
tradit
vascular
risk
factor
influenc
individu
risk
mechan
ivig
understood
aim
ascertain
frequenc
risk
factor
tee
arteri
ate
venou
thromboembol
event
vte
neuromuscular
patient
receiv
regular
ivig
perform
retrospect
review
inflammatori
neuropathi
patient
receiv
regular
ivig
treatment
collect
follow
data
month
studi
period
januari
event
occurr
date
neuropathi
diagnosi
dose
frequenc
vascular
risk
factor
pre
igg
level
plasma
viscos
cohort
made
cidp
mmn
sensori
neuropathi
neuronopathi
patient
receiv
mean
sd
dose
gkgmonth
mean
sd
interv
week
week
twelv
tee
document
studi
period
includ
mi
cva
individu
occurr
tia
dvt
pe
svc
obstruct
due
central
line
thrombosi
ivig
cohort
tee
incid
ci
higher
estim
uk
hospit
code
record
time
period
incid
uk
incid
uk
incid
ivig
patient
event
age
score
higher
dose
day
lower
event
differ
dose
kg
month
treatment
interv
plasma
viscos
igg
level
analysi
suggest
tee
incid
higher
ivig
treat
patient
compar
rate
examin
tee
occurr
age
vascular
risk
factor
match
individu
requir
appreci
excess
risk
associ
ivig
treatment
spina
topa
iodic
tozza
dubbioso
ruggiero
santoro
manganelli
neurosci
odontostomatolog
reproduct
scienc
univers
napl
federico
ii
napl
itali
chronic
inflammatori
demyelin
polyradiculoneuropathi
cidp
disabl
diseas
patient
may
becom
persist
disabl
time
aim
identifi
clinic
prognost
factor
disabl
larg
seri
cidp
patient
collect
data
cidp
patient
definit
diagnosi
accord
efnspn
criteria
posit
respons
therapi
immunoglobulin
corticosteroid
includ
sex
age
onset
phenotyp
diseas
durat
cours
diseas
chronic
progress
disabl
time
diagnosi
assess
use
modifi
rankin
scale
baselin
mr
patient
clinic
assess
disabl
mr
within
last
month
last
mr
ordin
logist
regress
model
appli
evalu
relationship
among
clinic
paramet
last
mr
consid
ordin
outcom
anova
test
repeat
measur
appli
test
overal
effect
differ
cours
disabl
accumul
perform
evalu
differ
parametr
variabl
found
signific
relationship
last
mr
cours
diseas
p
disabl
accumul
greater
patient
chronic
progress
cours
cours
diseas
moreov
patient
progress
cours
older
data
suggest
chronic
progress
cours
diseas
may
major
neg
prognost
factor
disabl
cidp
patient
note
chronic
progress
cours
diseas
also
associ
older
age
begin
pronounc
worsen
cours
diseas
sprenger
lichtenstein
hen
lehmann
neurolog
univers
hospit
cologn
cologn
germani
diagnost
intervent
radiolog
univers
hospit
cologn
cologn
germani
neurolog
univers
hospit
cologn
cologn
germani
unresolv
problem
treatment
inflammatori
neuropathi
lack
valid
reliabl
diagnost
biomark
evalu
axon
damag
investig
diffus
tensor
imag
dti
mri
multi
echo
dixon
imag
elig
method
determin
proxim
nerv
injuri
chronic
inflammatori
demyelin
polyneuropathi
cidp
prospect
observ
cohort
studi
sciatic
nerv
cidp
patient
age
match
healthi
control
investig
subject
underw
multimod
mri
imag
determin
fraction
anisotropi
fa
muscl
fat
fraction
bicep
femori
quadricep
femori
muscl
patient
evalu
mri
clinic
examin
nerv
conduct
studi
baselin
six
month
mean
fraction
anisotropi
fa
valu
significantli
lower
sciatic
nerv
cidp
patient
compar
control
fat
fraction
bicep
femori
quadricep
femori
muscl
significantli
higher
cidp
patient
compar
control
mri
outcom
paramet
remain
unchang
six
month
studi
demonstr
util
mri
imag
differenti
healthi
function
constrict
proxim
nerv
segment
postul
dti
dixon
mri
might
elig
method
assess
proxim
nerv
damag
cidp
stettner
zenker
klingler
mausberg
kleinschnitz
chrast
kieseier
neurolog
univers
hospit
essen
essen
germani
molecular
cell
biolog
star
biopoli
drive
singapor
singapor
neurolog
medic
faculti
dusseldorf
germani
neurosci
depart
clinic
neurosci
karolinska
institutet
stockholm
sweden
presenc
peripher
myelin
protein
known
decad
function
role
uncov
recent
recent
character
mice
reveal
role
lipid
homeostasi
myelin
schwann
cell
studi
analyz
function
impact
myelin
deciph
role
experiment
demyelin
perform
myelin
dorsal
root
ganglia
cultur
vivo
assess
experiment
peripher
nerv
damag
use
myelin
dorsal
root
ganglia
drg
model
schwann
cell
cultur
combin
establish
remyelin
protocol
order
analyz
myelin
vitro
also
perform
experiment
nerv
crush
mice
morphometr
paramet
defin
experi
function
paramet
nerv
conduct
veloc
clinic
score
addit
measur
vivo
experi
structur
analys
drg
cultur
reveal
fiber
express
myelin
basic
protein
mbp
well
fiber
posit
mbp
alon
contrast
previou
vivo
data
also
abl
detect
myelin
segment
stain
posit
neg
mbp
demonstr
slightli
greater
nodal
length
control
cultur
trend
significantli
augment
vitro
remyelin
also
result
decreas
internod
length
conserv
intact
myelin
structur
concomitantli
vivo
nerv
crush
give
rise
sever
phenotyp
mice
control
consist
nerv
conduct
studi
show
delay
remyelin
analysi
section
demonstr
alter
fiber
structur
peripher
nerv
biopsi
togeth
data
suggest
addit
role
glial
cell
lipid
homeostasi
also
play
role
remyelin
injur
peripher
nervou
system
stino
efebra
state
univers
depart
neurolog
columbu
usa
state
univers
divis
hematolog
columbu
usa
neuropathi
remain
difficult
diagnosi
treat
given
limit
therapeut
option
intervent
rituximab
emerg
effect
although
effect
mix
result
especi
patient
advanc
axon
loss
lenalidomid
anoth
promis
immun
modul
therapi
whose
effect
well
demonstr
neuropathi
associ
poem
polyneuropathi
endocrinopathi
organomegali
protein
skin
chang
syndrom
condit
sever
strike
parallel
neuropathi
use
lenalidomid
previous
describ
neuropathi
herein
describ
case
neuropathi
patient
advanc
axon
loss
suichi
misawa
sato
beppu
sekiguchi
shibuya
watanab
amino
kuwabara
neurolog
graduat
school
medicin
chiba
univers
chiba
japan
research
center
chiba
univers
hospit
chiba
japan
polyneuropathi
organomegali
endocrinopathi
skin
chang
poem
syndrom
rare
caus
demyelin
neuropathi
associ
plasma
cell
dyscrasia
vegf
overproduct
sever
diagnost
criteria
disord
publish
sensitivityspecif
analys
valid
never
perform
aim
studi
establish
valid
diagnost
criteria
poem
syndrom
consecut
poem
patient
seen
chiba
univers
hospit
sinc
screen
set
gold
standard
group
poem
syndrom
base
treatment
respons
exclus
criteria
patient
diagnos
definit
poem
syndrom
also
collect
patient
cidp
demyelin
neuropathi
control
multipl
myeloma
primari
amyloidosi
mgu
control
criteria
poem
syndrom
defin
two
three
major
criteria
polyneuropathi
elev
serum
vegf
level
least
two
four
minor
criteria
extravascular
volum
overload
skin
chang
sclerot
bone
lesion
thrombocytosi
determin
logist
regress
analys
accord
criteria
sensit
specif
result
indic
propos
criteria
excel
diagnost
accuraci
use
clinic
practic
presum
lead
earli
diagnosi
treatment
suzuki
baba
kon
funamizu
ueno
haga
nishijima
arai
nunomura
tomiyama
neurolog
aomori
prefectur
central
hospit
aomori
japan
intraepiderm
electr
stimul
i
new
techniqu
assess
function
fiber
epidermi
use
techniqu
previous
report
epiderm
pain
threshold
asymptomat
diabet
patient
normal
subject
muscl
nerv
subsequ
report
elev
pain
threshold
neg
correl
intraepiderm
nerv
fiver
densiti
jpn
empir
known
lower
skin
temperatur
make
less
like
feel
pain
therefor
necessari
investig
whether
result
i
affect
skin
temperatur
aim
studi
investig
influenc
low
skin
temperatur
pain
threshold
recruit
subject
mean
age
year
nocicept
stimul
use
i
method
concentr
electrod
develop
specif
select
stimul
cutan
fiber
place
i
electrod
onto
extensor
digitorum
brevi
began
stimul
intens
strong
enough
subject
feel
prick
sensat
reduc
current
step
sensat
felt
defin
pain
threshold
minimum
electr
intens
subject
felt
prick
sensat
firstli
measur
pain
threshold
skin
temperatur
degre
celsiu
put
ice
pack
extensor
digitorum
brevi
min
lower
skin
temperatur
measur
pain
threshold
skin
temperatur
degre
mean
pain
threshold
valu
degre
degre
skin
temperatur
p
respect
data
indic
elev
pain
threshold
epidermi
low
skin
temperatur
one
common
method
nocicept
stimul
pain
laser
stimul
laser
stimul
studi
report
pain
threshold
increas
low
skin
temperatur
result
similar
laser
stimul
pain
threshold
use
i
easi
techniqu
may
use
evalu
small
fiber
neuropathi
bobylev
sprenger
zhang
sheikh
lehmann
neurolog
univers
hospit
cologn
cologn
germani
neurolog
univers
texa
houston
usa
intraven
immunoglobulin
ivig
effect
treatment
gb
patient
optim
ivig
dose
regim
unknown
serum
ivig
prepar
immunoglobulin
ig
g
form
igg
dimer
assum
consist
antibodi
pair
howev
data
kinet
igg
dimer
format
gb
lack
studi
igg
dimer
format
mice
inject
ivig
antibodi
pb
blood
sera
collect
week
post
inject
third
cohort
receiv
antibodi
blood
collect
post
inject
igg
extract
subtyp
polymer
dimer
monomer
fraction
use
fplc
system
dialys
dimer
monomer
igg
fraction
examin
presenc
antibodi
antibodi
elisa
blood
sampl
gb
patient
collect
treatment
ivig
post
ivig
serum
sampl
examin
igg
dimer
monom
use
fplc
system
mous
model
maximum
peak
igg
dimer
format
observ
post
inject
gb
patient
sampl
igg
serum
level
igg
dimer
content
significantli
higher
treatment
ivig
demonstr
feasibl
assess
igg
dimer
format
anim
model
gb
patient
sampl
treatment
ivig
ivig
treatment
appear
optim
time
point
assess
igg
dimer
format
studi
warrant
determin
util
igg
dimer
format
surrog
marker
treatment
respons
gb
svaren
moran
wu
gutmann
shi
madison
wisconsin
usa
iowa
iowa
citi
iowa
usa
develop
outcom
measur
clinic
trial
major
challeng
given
slowli
progress
natur
diseas
outcom
measur
use
measur
target
engag
given
therapi
well
b
diseas
process
c
diseas
burden
sever
candid
therapi
shown
reduc
level
rodent
model
therebi
amelior
symptom
overexpress
measur
mrna
reduct
human
trial
far
limit
analysi
skin
biopsi
demonstr
clear
elev
mrna
reduct
follow
ascorb
acid
trial
analysi
skin
biopsi
hamper
variabl
amount
schwann
cell
sc
skin
biopsi
well
variabl
amount
sc
previous
establish
skin
biopsi
katona
et
al
therefor
import
develop
optim
normal
criteria
address
variabl
inher
skin
biopsi
analysi
ideal
employ
normal
gene
alter
statu
optim
normal
perform
analysi
skin
biopsi
patient
control
skin
biopsi
sampl
analysi
data
normal
read
depth
indic
level
fold
higher
patient
sampl
compar
control
skin
biopsi
howev
signific
variabl
level
particularli
sampl
may
due
variabl
amount
schwann
cell
skin
use
combin
gene
normal
abl
reduc
appar
variabl
optim
differenti
level
control
skin
biopsi
sampl
also
identifi
gene
appar
induc
skin
biopsi
rel
control
studi
provid
new
framework
gene
express
analysi
skin
biopsi
enabl
precis
evalu
level
clinic
trial
measur
target
engag
addit
normal
framework
may
also
applic
type
cmt
svorc
wietek
pharmazeutika
produktionsgesmbh
vienna
austria
chronic
inflammatori
demyelin
polyneuropathi
cidp
common
chronic
autoimmun
neuropathi
estim
preval
per
peopl
caus
temporari
disabl
affect
individu
may
eventu
lead
perman
disabl
death
cidp
commonli
treat
intraven
immunoglobulin
ivig
therapi
corticosteroid
licens
cidp
franc
licens
cidp
germani
belgium
analysi
present
data
three
open
multicent
studi
safeti
surveil
pass
program
subset
patient
receiv
neurolog
indic
focus
patient
cidp
briefli
data
austria
franc
germani
uk
treat
neurolog
disord
collect
physician
analyz
assess
safeti
toler
treatment
patient
includ
three
studi
patient
receiv
neurolog
indic
patient
mean
age
year
rang
cidp
mean
dose
per
cours
gkg
bw
patient
cidp
neurolog
indic
dose
rang
multipl
sclerosi
gkg
bw
syndrom
premed
need
patient
develop
clinic
appear
sinc
last
observ
mean
everi
month
assess
cidp
patient
treat
physician
major
observ
assess
patient
stabl
show
even
improv
clinic
appear
observ
period
result
deterior
advers
drug
reaction
rare
infus
receiv
patient
neurolog
disord
infus
associ
adr
infus
cidp
patient
overal
treatment
effect
patient
cidp
result
consist
data
overal
patient
popul
includ
patient
primari
secondari
immunodefici
dermatolog
diseas
szepanowski
szepanowski
kleinschnitz
kieseier
stettner
neurolog
medic
faculti
univers
essen
germani
neurolog
medic
faculti
germani
lysophosphatid
acid
lpa
pleiotrop
signal
lipid
act
ligand
least
six
specif
g
protein
coupl
receptor
schwann
cell
sc
known
mainli
express
receptor
subtyp
emerg
bodi
vivo
evid
link
lpa
injuri
induc
peripher
nerv
demyelin
well
neuropath
pain
howev
molecular
mechan
underli
demyelin
effect
remain
larg
unclear
myelin
dorsal
root
ganglia
drg
cultur
treat
either
lpa
lpa
antagonist
vehicl
assess
myelin
basic
protein
tumor
necrosi
factor
alpha
well
sc
differenti
marker
immunocytochemistri
addit
myelin
investig
sudan
black
stain
better
understand
relev
signal
demyelin
vivo
perform
sciatic
nerv
crush
mice
treat
mgkg
order
studi
schwann
cell
express
marker
sc
dedifferenti
immunohistochemistri
drg
cultur
lpa
caus
signific
reduct
myelin
demonstr
sudan
black
stain
immunocytochem
analysi
myelin
basic
protein
demyelin
parallel
upregul
well
downregul
lpa
mediat
effect
found
block
addit
receptor
antagonist
mice
treatment
prior
crush
injuri
increas
express
sc
distal
nerv
stump
reduc
number
cell
express
data
indic
lpa
may
critic
factor
shift
sc
toward
phenotyp
contribut
onset
wallerian
degener
szepanowski
szepanowski
kleinschnitz
stettner
neurolog
univers
hospit
essen
essen
germani
formul
compris
world
commonli
use
herbicid
plant
glyphos
exert
toxic
effect
like
via
inhibit
aromat
amino
acid
synthesi
interf
shikim
pathway
glyphos
activ
ingredi
herbicid
formul
contain
sever
adjuv
includ
polyethoxl
alkylamin
poea
although
glyphos
long
consid
safe
use
human
anim
sever
studi
implic
glyphos
andor
commonli
use
adjuv
cytotox
carcinogen
endocrin
disrupt
furthermor
base
herbicid
report
mediat
neurotox
immatur
rat
hippocampu
involv
glutam
excitotox
howev
remain
unclear
whether
glyphos
alon
combin
adjuv
may
detriment
effect
myelin
integr
peripher
nervou
system
myelin
dorsal
root
ganglia
drg
cultur
treat
cours
ten
day
either
pure
glyphos
herbicid
concentr
concentr
herbicid
match
regard
glyphos
content
control
treat
equal
amount
vehicl
adjust
ph
subsequ
cultur
stain
sudan
black
myelin
content
assess
determin
number
internod
per
neuron
glyphos
regardless
concentr
show
effect
myelin
content
herbicid
caus
signific
demyelin
depend
manner
notabl
drg
cultur
complet
devoid
myelin
appear
sever
necrot
data
rais
possibl
glyphos
rather
adjuv
herbicid
formul
may
caus
demyelin
open
question
whether
demyelin
direct
effect
adjuv
consequ
increas
cellular
glyphos
uptak
due
permeabil
warrant
investig
tan
tan
yeoh
goh
shahrizaila
medicin
univers
malaya
kuala
lumpur
malaysia
syndrom
gb
autonom
dysfunct
common
account
signific
morbid
mortal
mani
studi
investig
electrodiagnosi
gb
studi
autonom
dysfunct
gb
current
studi
comprehens
investig
quantit
autonom
function
patient
gb
variant
ten
gb
patient
prospect
recruit
result
compar
healthi
control
seri
autonom
function
test
includ
comput
power
spectrum
analysi
heart
rate
variabl
hrv
baroreflex
sensit
br
rest
challeng
test
deep
breath
eyebal
compress
activ
stand
valsalva
manoeuvr
isometr
exercis
hand
immers
perform
parasympathet
function
repres
high
frequenc
hf
hrv
heart
rate
respons
deep
breath
eyebal
compress
valsalva
manoeuvr
activ
stand
sympathet
function
repres
low
frequenc
lf
hrv
blood
pressur
respons
activ
stand
sustain
handgrip
hand
immers
frequenc
domain
analysi
hrv
low
frequenc
lf
vs
high
frequenc
hf
vs
total
power
spectral
densiti
psd
vs
significantli
reduc
patient
compar
control
mean
slope
vs
slope
vs
total
br
slope
vs
significantli
lower
gb
group
diastol
rise
blood
pressur
upon
hand
immers
significantli
lower
gb
group
compar
control
vs
find
suggest
comput
depend
test
hrv
br
sensit
detect
autonom
dysfunct
baroreceptor
reflex
insensit
gb
patient
contrast
hand
immers
reliabl
challeng
test
make
use
bedsid
measur
autonom
function
gb
patient
jowi
cindi
neurolog
wan
fang
hospit
taipei
medic
univers
taipei
taiwan
program
neural
regen
medicin
colleg
medic
scienc
technolog
taipei
medic
univers
nation
health
research
institut
taipei
taiwan
allergi
immunolog
rheumatolog
depart
intern
medicin
taipei
veteran
gener
hospit
taipei
taiwan
allergi
immunolog
rheumatolog
wan
fang
hospit
taipei
medic
univers
taipei
taiwan
neurosci
depart
physiolog
school
medicin
scienc
faculti
medicin
univers
new
south
wale
sydney
australia
neurolog
school
medicin
colleg
medicin
taipei
medic
univers
taipei
taiwan
syndrom
ss
autoimmun
diseas
affect
east
west
nevertheless
still
limit
knowledg
autoantibodi
ss
affect
peripher
nervou
system
studi
investig
peripher
neuropathi
ss
sicca
complex
use
nerv
excit
test
elucid
peripher
nerv
affect
enrol
total
patient
ss
sicca
complex
two
patient
exclud
due
carpal
tunnel
syndrom
patient
receiv
clinic
evalu
examin
ssassb
antibodi
titer
nerv
excit
test
convent
thermal
quantit
sensori
test
convent
nerv
conduct
studi
compar
normal
control
subject
motor
nerv
excit
test
ss
patient
posit
ssa
ssb
antibodi
n
found
increas
rheobas
p
increas
rel
refractori
period
rrp
p
increas
refractori
ms
p
increas
accommod
toward
depolar
current
threshold
electrotonu
te
p
decreas
superexcit
p
sensori
axon
studi
seroposit
ss
also
reveal
increas
rrp
p
increas
refractori
ms
p
increas
accommod
toward
hyperpolar
current
threshold
electrotonu
te
p
meanwhil
seroneg
ss
sicca
complex
n
found
signific
axon
properti
chang
present
studi
reveal
peripher
nerv
affect
differ
seroposit
ss
seroneg
sssicca
complex
seroposit
ss
motor
axon
tend
depolar
sensori
motor
axon
increas
refractori
find
suggest
ssa
ssb
antibodi
might
play
role
inactiv
transient
sodium
channel
effect
antibodi
transient
sodium
channel
might
basi
peripher
neuropathi
even
cardiac
arrhythmia
heart
block
ss
tao
beecham
blanton
abreu
baa
choi
pareyson
reilli
shi
zuchner
inherit
neuropathi
consortium
jt
macdonald
depart
human
genet
hussman
institut
human
genom
univers
miami
miami
florida
usa
genom
analysi
academ
medic
centr
amsterdam
netherland
neurolog
samsung
medic
center
sungkyunkwan
univers
school
medicin
seoul
korea
clinic
neurosci
c
besta
neurolog
institut
milan
itali
centr
neuromuscular
diseas
ucl
institut
neurolog
london
uk
neurolog
univers
iowa
iowa
citi
iowa
usa
diseas
type
caus
duplic
chromosom
common
subtyp
inherit
peripher
neuropathi
affect
individu
worldwid
share
genet
caus
patient
often
present
great
variabl
phenotyp
present
diseas
sever
caus
phenotyp
variabl
larg
unclear
studi
perform
associ
studi
gwa
identifi
novel
genet
modifi
variou
phenotyp
dna
sampl
patient
genotyp
illumina
omniexpress
platform
standard
qualiti
control
dataset
includ
marker
individu
individu
european
ancestri
individu
asian
ancestri
focus
analys
european
popul
logist
regress
plink
use
analyz
associ
clinic
outcom
patient
genotyp
addit
model
cmt
neuropathi
score
cmtn
analysi
perform
use
linear
regress
plink
adjust
patient
age
analys
yield
sever
suggest
associ
signal
associ
peak
chromosom
identifi
difficulti
eat
utensil
lead
snp
odd
peak
locat
within
gene
hear
loss
show
associ
peak
chromosom
lead
snp
odd
locat
intergen
region
near
gene
foot
plantar
flexion
associ
signal
identifi
dscam
gene
chromosom
lead
snp
odd
cmtn
show
associ
signal
chromosom
lead
snp
locat
within
intergen
region
close
dffb
suggest
signal
requir
valid
studi
provid
novel
insight
genet
architectur
novel
genet
modifi
may
serv
potenti
target
therapeut
intervent
futur
teng
kalpana
chai
umapathi
loo
lin
school
medicin
nation
univers
singapor
singapor
neurolog
nation
neurosci
institut
singapor
present
intrigu
diagnost
puzzl
eventu
crack
serendipit
man
seen
bilater
ptosi
evalu
myasthenia
gravi
neg
nevertheless
diagnosi
ocular
myasthenia
gravi
made
put
pyridostigmin
respond
ptosi
progress
worsen
sought
second
opinion
evalu
note
complex
ophthalmoplegia
without
diplopia
bilater
facial
weak
mild
bulbar
weak
sensori
complaint
limb
examin
remark
slightli
reduc
reflex
normal
strength
increas
vibrat
threshold
toe
intact
sensori
examin
repeat
serolog
electrodiagnost
myasthenia
gravi
neg
myopath
disord
chronic
progress
extern
ophthalmoplegia
consid
serum
creatin
kinas
lactat
normal
underw
bicep
muscl
biopsi
show
increas
sdh
posit
fiber
support
clinic
impress
mitochondri
cytopathi
point
underw
blepharoplasti
improv
vision
routin
histolog
examin
levat
palpebra
muscl
show
amyloid
deposit
prompt
review
earlier
bicep
biopsi
reveal
amyloid
deposit
appreci
point
signific
patient
son
histori
lattic
corneal
dystrophi
becam
appar
also
report
late
mother
similar
facial
appear
patient
nerv
conduct
studi
show
sensori
axon
polyneuropathi
right
carpal
tunnel
syndrom
bilater
facial
neuropathi
definit
symptom
autonom
neuropathi
cardiac
evalu
unremark
final
diagnosi
famili
gelsolin
amyloid
polyneuropathi
made
genet
confirm
patient
famili
plan
highlight
key
clinic
featur
gelsolin
neuropathi
symmetr
cranial
neuropathi
resembl
muscl
neuromuscular
junction
disord
rel
spare
cardiac
muscl
somat
autonom
nerv
contrast
amyloid
polyneuropathi
themistocl
blesneac
fratter
cox
tesfay
shillo
ramirez
rice
bennett
depart
clinic
neurosci
univers
oxford
uk
medic
genet
laboratori
oxford
univers
hospit
nh
foundat
trust
churchil
hospit
oxford
uk
nocicept
group
univers
colleg
london
london
uk
research
unit
sheffield
teach
hospit
nh
foundat
trust
sheffield
uk
research
group
pain
medicin
imperi
colleg
london
chelsea
westminst
hospit
campu
london
uk
neuropathi
one
common
complic
diabet
furthermor
diabet
neuropathi
patient
develop
neuropath
pain
pathophysiolog
neuropath
pain
diabet
peripher
neuropathi
complex
fulli
understood
potenti
mechan
chang
voltag
gate
sodium
channel
loss
function
mutat
channel
caus
insensit
pain
wherea
gain
function
mutat
link
differ
pain
syndrom
includ
small
fiber
neuropathi
cohort
patient
diabet
peripher
neuropathi
investig
whether
mutat
associ
diabet
neuropath
pain
twelv
variant
identifi
nine
particip
within
cohort
particip
pain
diabet
peripher
neuropathi
five
variant
previous
associ
pain
disord
among
variant
two
met
criteria
potenti
pathogen
base
predict
algorithm
studi
function
analysi
whole
cell
patch
clamp
show
one
variant
drastic
impair
inactiv
channel
shift
toward
depolar
potenti
phenotyp
differ
particip
pathogen
variant
particip
without
pathogen
variant
rare
variant
found
particip
painless
diabet
peripher
neuropathi
observ
suggest
mutat
may
contribut
pain
diabet
peripher
neuropathi
tholanc
rosier
f
psimara
kuntzer
taieb
delmont
antoin
hospit
franc
hospit
lyon
franc
hospit
pari
franc
hospit
lausann
switzerland
hospit
montpelli
franc
hospit
creteil
franc
hospit
marseil
franc
dysimmun
sensori
neuronopathi
snn
encompass
paraneoplast
snn
snn
associ
system
autoimmun
diseas
syndrom
lupu
inflammatori
bowel
rheumat
diseas
also
number
appar
idiopath
case
biomark
antibodi
paraneoplast
snn
lack
non
paraneoplast
case
retrospect
studi
identifi
antibodi
potenti
biomark
dysimmun
patient
idiopath
system
autoimmun
diseas
associ
sensori
neuropathi
identifi
patient
frequent
women
non
lenthg
depend
neuropathi
suggest
snn
antibodi
immunolog
marker
case
initi
although
patient
eventu
develop
time
system
autoimmun
diseas
confirm
incid
clinic
pattern
patient
antibodi
launch
prospect
multicent
french
studi
includ
patient
sensori
neuropathi
suspect
snn
paraneoplast
genet
metabol
origin
present
result
first
includ
patient
compar
healthi
blood
donor
antibodi
search
elisa
use
trk
intracellular
domain
protein
found
patient
posit
antibodi
patient
women
men
age
year
mean
neuropathi
acut
subacut
one
patient
respect
progress
other
six
patient
fulfil
diagnosi
criteria
snn
last
one
sensori
neuropathi
lower
limb
abnorm
sensori
action
potenti
four
limb
suggest
snn
without
reach
request
criteria
one
patient
develop
uveiti
new
symptom
ab
unclassifi
dysimmun
context
present
initi
work
patient
one
patient
develop
syndrom
whole
clinic
pattern
patient
consist
initi
publish
seri
lower
preval
posit
sera
may
due
stringent
criteria
use
elisa
need
confirm
complet
prospect
seri
thoma
dimachki
freeman
simpson
smith
hoke
hopkin
school
medicin
baltimor
usa
univers
medic
center
chicago
usa
univers
medic
center
kansa
citi
usa
israel
deaco
medic
center
boston
usa
school
medicin
mount
sinai
medic
center
new
york
usa
utah
medic
center
salt
lake
citi
utah
usa
peripher
neuropathi
research
registri
pnrr
multicent
collabor
research
project
sponsor
foundat
peripher
neuropathi
advanc
scienc
distal
symmetr
polyneuropathi
dsp
registri
design
prospect
character
clinic
phenotyp
natur
histori
patient
dsp
obtain
biofluid
identifi
new
caus
genet
modifi
dsp
care
genotypephenotyp
correl
develop
biomark
enrol
registri
still
ongo
interim
analysi
carri
end
decemb
elig
studi
particip
year
older
diagnosi
idiopath
diabet
peripher
neuropathi
examin
physician
one
six
consortium
member
john
hopkin
univers
school
medicin
icahn
school
medicin
mount
sinai
medic
center
beth
israel
deaco
medic
center
northwestern
univers
medic
center
univers
utah
medic
center
kansa
univers
medic
center
collect
data
set
includ
detail
questionnair
discuss
symptom
medic
histori
famili
histori
standard
neurolog
examin
form
electrodiagnost
evalu
diagnost
laboratori
test
blood
sampl
whole
blood
plasma
serum
collect
futur
biomark
genotyp
evalu
end
complet
data
set
blood
sampl
collect
patient
diabet
pn
pn
chemotherapi
induc
pn
diagnos
idiopath
pn
detail
analysi
clinic
present
examin
find
diagnost
investig
discuss
present
standard
phenotyp
link
bank
help
establish
minimum
data
set
requir
neuropathi
diagnosi
support
correl
next
gener
sequenc
technolog
develop
novel
biomark
pnrr
data
improv
understand
diseas
mechan
pave
way
new
therapeut
discoveri
pain
neuropathi
timmin
li
kiernan
horvath
harrison
grimison
cox
boyl
goldstein
park
mind
centr
univers
sydney
nsw
australia
obrien
lifehous
sydney
nsw
australia
medic
school
univers
sydney
nsw
australia
oncolog
royal
princ
alfr
hospit
nsw
australia
ritchi
centr
cancer
care
research
mater
hospit
nsw
australia
nurs
school
univers
sydney
nsw
australia
wale
clinic
school
unsw
nsw
australia
medic
oncolog
princ
wale
hospit
sydney
nsw
australia
peripher
neuropathi
cipn
major
side
effect
treatment
typic
present
sensori
neuropathi
symptom
includ
pain
paraesthesia
numb
extrem
result
function
impair
increasingli
patient
report
outcom
pro
util
accur
examin
impact
cipn
symptom
patient
function
howev
link
object
neurolog
assess
pro
measur
remain
ill
defin
studi
aim
identifi
link
neurophysiolog
measur
pro
patient
treat
neurotox
chemotherapi
assess
conduct
patient
f
mean
age
year
complet
neurotox
chemotherapi
averag
month
previous
taxaneplatinum
combin
therapi
patient
report
presenc
sever
neuropath
symptom
via
valid
patient
questionnair
clinic
neurolog
assess
score
use
total
neuropathi
score
clinic
version
tnsc
compris
pinprick
vibrat
sensibl
deep
tendon
reflex
strength
patient
symptom
report
compound
sensori
action
potenti
csap
amplitud
record
antidrom
later
malleolu
stimul
sural
nerv
total
sampl
report
lower
limb
neuropathi
patient
report
quit
bit
much
sever
tingl
numb
feet
averag
sural
csap
amplitud
patient
sural
amplitud
lower
limit
normal
age
total
tnsc
score
correl
pro
score
r
p
sural
amplitud
r
p
vibrat
sensibl
correl
overal
score
r
p
sural
amplitud
r
p
sural
amplitud
correl
patient
report
sever
numb
tingl
lower
limb
r
p
overal
score
patient
report
neuropath
symptom
lower
limb
correl
object
neurophysiolog
clinic
measur
neuropathi
sever
identifi
link
object
neurophysiolog
marker
patient
report
outcom
critic
assess
impact
clinic
intervent
tomaselli
gouvea
nyshyama
nicolau
n
marqu
w
neuromuscular
diseas
depart
neurosci
behaviour
scienc
clinic
hospit
preto
univers
paulo
preto
brazil
depart
neurosci
behaviour
scienc
univers
paulo
preto
brazil
mutat
gab
junction
beta
gene
second
frequent
caus
diseas
cmt
account
approxim
cmt
case
worldwid
code
connexin
protein
peripher
nervou
system
express
schwann
cell
allow
intercellular
traffic
ion
small
molecul
oppos
cell
analys
retrospect
detail
clinic
neurophysiolog
data
five
famili
carri
novel
mutat
submit
test
neurogenet
laboratori
mutat
identifi
bidirect
sanger
sequenc
analysi
code
region
identifi
total
subject
five
differ
kindr
novel
mutat
five
novel
mutat
segreg
phenotyp
locat
highli
conserv
amino
acid
among
gab
junction
protein
sequenc
among
differ
speci
present
public
databas
exac
dbsnp
genom
databas
found
normal
brazilian
control
silico
analysi
predict
variant
pathogen
transmiss
male
sever
affect
femal
four
seven
femal
subclin
neuropathi
identifi
clinic
electrophysiolog
evalu
conduct
veloc
intermedi
rang
male
patient
higher
femal
includ
studi
describ
five
new
pathogen
mutat
caus
brazilian
popul
expand
number
caus
mutat
gene
fund
cnpq
cape
fapesp
faepa
prona
ministri
healthi
tomaselli
marqu
do
santo
lavign
toscano
barreira
foss
frade
marqu
w
neuromuscular
diseas
depart
neurosci
behaviour
scienc
clinic
hospit
preto
univers
paulo
preto
brazil
depart
intern
medicin
clinic
hospit
preto
univers
paulo
preto
brazil
depart
neurosci
behaviour
scienc
univers
paulo
preto
brazil
pure
neural
leprosi
pnl
slowli
progress
predominantli
sensori
patchi
neuropathi
present
posit
andor
neg
sensori
symptom
usual
follow
time
distal
asymmetr
weak
despit
rare
monomel
involv
leprosi
alreadi
report
sought
describ
clinic
electrophysiolog
pattern
unusu
leprosi
neuropathi
present
clinic
data
retrospect
collect
nine
patient
monomel
involv
refer
investig
emg
lab
seven
nine
patient
male
four
patient
brachial
plexu
like
present
five
lumbosacr
plexu
like
present
initi
complaint
hypoesthesia
four
patient
tingl
two
patient
hypoesthesia
tingl
two
patient
sever
pain
observ
one
patient
individu
group
patient
lumbosacr
present
three
brachial
present
sensori
nerv
action
potenti
snap
nerv
test
affect
limb
without
motor
involv
one
patient
brachial
present
focal
slow
conduct
veloc
tempor
dispers
median
ulnar
nerv
affect
limb
one
patient
present
snap
low
amplitud
nerv
affect
limb
diagnosi
leprosi
confirm
nerv
biopsi
find
antibodi
posit
respons
specif
treatment
nerv
biopsi
perform
four
patient
bacillu
found
two
antibodi
posit
four
patient
plexu
mri
perform
two
patient
normal
found
distribut
motor
sensori
symptom
restrict
limb
group
patient
typic
patchi
disord
pnl
may
affect
nerv
although
reason
damag
restrict
one
limb
elucid
descript
case
increas
clinic
spectrum
leprosi
neuropathi
possibl
consid
differenti
diagnosi
patient
plexopathi
endem
area
exclud
caus
fund
cnpq
cape
fapesp
faepa
prona
ministri
healthi
tomaselli
cintra
barreira
marqu
w
neuromuscular
diseas
depart
neurosci
behaviour
scienc
clinic
hospit
preto
univers
paulo
preto
brazil
depart
neurosci
behaviour
scienc
univers
paulo
preto
brazil
ataxia
oculomotor
apraxia
type
complex
disord
character
progress
cerebellar
ataxia
cerebellar
atrophi
peripher
neuropathi
caus
recess
mutat
aprataxin
gene
aptx
neuropathi
present
describ
case
primarili
axon
describ
case
due
compound
heterozyg
mutat
aptx
associ
demyelin
neuropathi
patient
born
healthi
parent
present
first
decad
progress
cerebellar
ataxia
multidirect
ophtalmoparesia
oculomotor
apraxia
choreiform
movement
limb
peripher
neuropathi
normal
cognit
stop
walk
age
blood
test
unremark
normal
level
leucocyt
serum
protein
immunoglobulin
cholesterol
vitamin
e
protein
brain
mri
show
sever
cerebellar
atrophi
motor
conduct
veloc
upper
limb
slow
preserv
amplitud
distal
latenc
minim
f
wave
latenc
prolong
evid
superimpos
acquir
demyelin
neuropathi
direct
sequenc
aptx
gene
reveal
two
variant
g
p
first
variant
novel
affect
highli
conserv
acceptor
splice
site
exon
variant
common
portugues
variant
nonsens
mutat
locat
exon
parent
dna
test
confirm
variant
differ
allel
presenc
demyelin
neuropathi
suggest
phenotyp
variabl
condit
may
larger
previous
consid
time
increas
differenti
diagnosi
inherit
condit
cerebellar
ataxia
demyelin
neuropathi
final
find
open
function
effect
aptx
gene
fund
cnpq
fapesp
faepa
prona
ministri
health
topa
spina
iodic
tozza
ruggiero
dubbioso
esposito
santoro
manganelli
napl
federico
ii
napl
itali
report
experi
subcutan
immunoglobulin
scig
cohort
patient
chronic
inflammatori
demyelin
polyneuropathi
cidp
tertiari
care
neuromuscular
center
analyz
data
cidp
patient
male
femal
mean
age
year
mean
age
onset
year
diseas
durat
year
treat
scig
period
month
patient
previous
respond
intraven
immunoglobulin
ivig
eight
patient
typic
cidp
five
patient
atyp
variant
cidp
five
patient
switch
weekli
mainten
scig
therapi
continu
regimen
respons
ivig
therapi
eight
patient
longer
last
respons
ivig
receiv
scig
puls
regimen
similar
use
ivig
cycl
per
year
seven
difficulti
hospit
one
allerg
reaction
ivig
chang
clinic
statu
assess
period
use
clinic
evalu
muscl
strength
modifi
rankin
scale
overal
neuropathi
scale
inflammatori
neuropathi
caus
treatmentsum
score
patient
evalu
also
six
minut
walk
test
meter
walk
test
five
patient
treat
continu
regimen
scig
remain
clinic
stabl
throughout
period
among
patient
receiv
puls
scig
treatment
respond
scig
similarli
ivig
three
patient
worsen
need
treat
ivig
one
stop
therapi
subcutan
administ
immunoglobulin
well
toler
patient
complain
advers
event
conclus
find
confirm
continu
scig
therapi
efficaci
maintain
clinic
stabil
patient
respons
ivig
moreov
data
suggest
puls
therapi
scig
may
repres
altern
therapeut
option
treatment
subset
cidp
patient
touvier
ferri
mastrangelo
glimcher
wrabetz
dantonio
biolog
unit
divis
genet
cell
biolog
san
raffael
scientif
institut
dibit
milan
itali
cancer
immunolog
virolog
cancer
institut
boston
usa
medicin
harvard
medic
school
boston
usa
jame
kelli
research
institut
univers
buffalo
buffalo
usa
biochemistri
univers
buffalo
buffalo
usa
jacob
school
medicin
biomed
scienc
univers
buffalo
buffalo
usa
mpz
glycoprotein
abund
product
termin
differenti
myelin
schwann
cell
mutant
caus
cmt
diseas
human
similar
demyelin
neuropathi
transgen
mice
protein
retain
endoplasm
reticulum
er
schwann
cell
induc
unfold
protein
respons
upr
character
activ
perk
pathway
previous
report
activ
chop
two
downstream
mediat
perk
pathogenet
mice
pennuto
dantonio
role
upr
branch
remain
investig
studi
investig
role
er
stress
sensor
enzym
transcript
factor
specif
activ
pathogenesi
gener
new
mous
model
schwann
ablat
parallel
exploit
dorsal
root
ganglia
drg
explant
cultur
signal
modul
gainloss
function
approach
observ
absenc
dramat
worsen
hypomyelin
electrophysiologicallocomotor
paramet
young
adult
neuropath
anim
interestingli
observ
perk
ridd
signal
upregul
neuropath
anim
lack
suggest
activ
target
essenti
role
limit
toxic
compens
stress
respons
moreov
demonstr
drg
cultur
inhibit
splice
cross
decreas
myelin
wherea
activ
splice
quercetin
wiseman
slightli
amelior
myelin
altogeth
data
demonstr
pathway
critic
adapt
role
neuropathi
suggest
activ
pathway
may
benefici
perhap
broad
rang
neuropathi
character
upr
activ
tozza
bruzzes
iodic
esposito
dubbioso
ruggiero
topa
spina
santoro
manganelli
neurosci
reproduct
scienc
odontostomatolog
univers
napl
federico
ii
napl
itali
public
health
univers
federico
ii
napl
napl
itali
patient
clinic
impair
progress
increas
time
correl
axon
loss
evid
suggest
declin
physic
perform
patient
may
reflect
process
normal
age
aim
studi
describ
design
progress
physic
impair
age
patient
enrol
patient
rang
year
healthi
control
assess
physic
perform
patient
control
underw
walk
test
walk
test
peg
test
domin
nd
side
moreov
assess
clinic
disabl
impair
qualiti
life
group
use
neuropathi
score
cmtn
mrc
sum
score
short
questionnair
linear
regress
model
use
evalu
chang
time
clinic
measur
patient
control
chow
test
use
determin
whether
age
differ
impact
clinic
measur
two
group
physic
perform
worsen
age
patient
control
greater
slope
patient
differ
slope
ci
p
ci
p
ci
p
ci
p
rate
deterior
physic
perform
differ
patient
control
year
age
year
age
rate
deterior
becam
greater
group
differ
slope
ci
p
ci
p
ci
p
ci
p
moreov
patient
also
cmtn
mrc
sum
score
worsen
age
greater
rate
deterior
year
age
studi
demonstr
clinic
declin
patient
goe
parallel
normal
age
process
year
age
whereupon
clinic
deterior
acceler
tsouni
devic
moura
planqu
devaux
steck
delmont
hotting
kuntzer
chuv
lausann
switzerland
de
maladi
neuromusculair
hospic
civil
de
lyon
lyon
franc
epin
franc
de
neurologi
chu
de
rouen
rouen
franc
marseil
franc
de
maladi
neuromusculair
et
sla
la
timon
marseil
franc
new
therapeut
option
allow
signific
progress
manag
melanoma
treatment
usual
consist
combin
two
monoclon
antibodi
target
cytotox
protein
program
cell
result
immunolog
barrier
protect
tumor
cell
overcom
allow
antitumor
respons
report
cancer
patient
immun
checkpoint
neuropathi
complic
immunomodul
oncolog
treatment
case
report
index
patient
develop
sever
myalgia
day
introduct
follow
pain
paresthesia
face
extrem
day
cycl
treatment
gener
areflex
quadriparesi
gowerssign
distal
loss
vibratori
sensat
found
cours
ivig
plu
corticosteroid
cs
effect
three
monthli
ivig
cours
necessari
improv
deficit
month
survey
sfnp
member
reveal
patient
similar
acut
cours
phenotyp
vari
sensorimotor
deficit
areflexia
myalgia
pure
sensori
atax
form
follow
immunomodul
treatment
includ
antibodi
neg
patient
abnorm
csf
necrot
myopathi
detail
repeat
nc
demonstr
sign
nerv
hyperexcit
demyelin
conduct
block
evolut
slowli
favor
follow
ivig
cs
discuss
report
underscor
atyp
acut
gener
demyelin
neuropathi
induc
novel
treatment
may
associ
sever
myalgia
system
toxic
effect
discontinu
oncolog
treatment
depend
sever
symptom
outcom
slowli
favor
follow
ivig
cs
albeit
slower
case
primari
inflammatori
neuropathi
probabl
given
long
monoclon
antibodi
tympanid
kagiava
kleopa
laboratori
clinic
cypru
school
molecular
medicin
cypru
institut
neurolog
genet
nicosia
cypru
gap
junction
gj
membran
channel
found
tissu
connect
adjac
cell
differ
cell
compart
schwann
cell
involv
electr
connect
metabol
homeostasi
allow
passag
small
molecul
ion
second
messeng
nucleotid
peptid
import
function
role
peripher
nerv
connexin
suggest
involv
inherit
neuropathi
well
acquir
neuropathi
caus
oxaliplatin
although
gj
play
role
electr
connect
specif
role
format
sciatic
nerv
compound
action
potenti
cap
remain
unclear
aim
studi
investig
role
peripher
nerv
connexin
electr
respons
mous
sciatic
nerv
normal
stress
condit
purpos
use
sciatic
nerv
three
differ
mous
model
knockout
ko
ko
doubl
knockout
dko
mice
use
ex
vivo
model
extracellular
record
expos
sciatic
nerv
differ
genotyp
three
differ
gj
blocker
octanol
acid
gra
octano
acid
oa
record
cap
amplitud
durat
cap
use
indic
effect
differ
blocker
cap
format
gj
blocker
caus
gradual
decreas
cap
without
chang
durat
cap
genotyp
suggest
progress
disturb
axon
membran
excit
absenc
one
two
gj
protein
comparison
three
genotyp
show
may
play
domin
role
mainten
cap
format
sinc
nerv
mice
prove
sensit
gj
blocker
compar
nerv
show
faster
declin
cap
amplitud
moreov
effect
gj
blocker
similar
dko
nerv
final
effect
gj
blocker
dko
nerv
impli
presenc
anoth
gj
protein
conclus
result
confirm
direct
function
involv
gj
channel
hemichannel
cap
format
indic
exist
least
one
connexin
peripher
nerv
uchibori
gyohda
chiba
univers
tokyo
japan
background
report
igg
antibodi
patient
fisher
syndrom
relat
disord
patient
convent
assay
use
salin
without
turn
seroposit
antigen
assay
use
salin
object
investig
whether
antibodi
present
also
patient
clinic
diseas
type
syndrom
gb
method
subject
follow
patient
final
clinic
diagnosi
gb
acut
motor
axon
neuropathi
aman
n
acut
inflammatori
demyelin
polyradiculoneuropathi
aidp
n
patient
final
clinic
diagnosi
sensori
atax
neuropathi
san
n
subject
convent
assay
assay
serum
igg
antibodi
variou
gangliosid
includ
elisa
use
salin
basal
buffer
condit
increas
optic
densiti
od
condit
compar
one
taken
signific
ie
posit
antibodi
result
antibodi
neg
aman
san
patient
aidp
antibodi
titer
od
significantli
increas
patient
increas
patient
condit
howev
titier
antibodi
low
level
conclus
clinic
diseas
type
gb
igg
antibodi
gangliosid
detect
patient
aidp
posit
rate
antibodi
titer
low
compar
case
antibodi
gangliosid
consid
specif
unal
ozturk
emir
tosun
kutlu
sitki
kocman
univers
faculti
medicin
depart
neurolog
mugla
turkey
sitki
kocman
univers
faculti
medicin
depart
biostatist
mugla
turkey
aim
studi
investig
relationship
median
sensori
conduct
median
nerv
ulnar
nerv
patient
diagnos
carpal
tunnel
syndrom
two
hundr
hand
carpal
tunnel
syndrom
hand
control
group
investig
patient
stage
clinic
electrophysiolog
diagnosi
carpal
tunnel
syndrom
made
accord
presenc
paresthesia
pain
innerv
area
median
nerv
weak
atrophi
median
nerv
innerv
muscl
posit
phalen
tinel
test
median
motor
sensori
nerv
conduct
studi
includ
first
second
third
finger
palm
ulnar
motor
sensori
nerv
conduct
fifth
finger
studi
perform
patient
control
group
ratio
distal
latenc
veloc
nerv
conduct
first
second
third
palmar
branch
fifth
finger
calcul
distal
latenc
first
second
third
finger
palm
patient
ct
longer
veloc
slowli
control
addit
find
veloc
fifth
finger
also
slower
distal
latenc
one
longer
healthi
subject
sensit
method
classifi
carpal
tunnel
syndrom
normal
mild
moder
ratio
distal
latenc
veloc
second
finger
p
carpal
tunnel
syndrom
common
encount
neuropathi
nerv
conduct
studi
use
ratio
distal
latenc
veloc
second
finger
determin
degre
carpal
tunnel
syndrom
surpris
find
report
nerv
conduct
studi
fifth
finger
subclin
suscept
fifth
finger
explain
overus
wrist
ursino
gemelli
grandi
reni
bellon
geroldi
got
ta
mandich
ferrara
schenon
univers
genoa
genoa
itali
san
martino
hospit
genoa
genoa
itali
cmt
neuropathi
repres
clinic
genet
heterogen
group
hereditari
peripher
neuropathi
character
chronic
motor
sensori
impair
date
mutat
gene
may
caus
cmt
aim
studi
describ
larg
popul
cmt
patient
within
highlight
specif
phenotyp
cmt
clinic
genova
start
year
patient
underw
complet
neurolog
rehabilit
neurophysiolog
examin
genet
test
patient
routin
test
common
gene
mpz
specif
case
follow
candid
gene
approach
test
singl
gene
base
correl
howev
ng
techniqu
use
routin
genet
test
neg
clear
correl
could
identifi
case
present
date
databas
cmt
patient
patient
spite
clinic
diagnosi
cmt
genet
diagnosi
still
lack
patient
altern
diagnosi
ie
hereditari
spastic
paraparesi
etc
instead
patient
defin
genet
diagnosi
reach
femal
male
among
except
common
hnpp
phenotyp
frequent
observ
patient
affect
accord
literatur
data
observ
patient
patient
affect
first
visit
phenotyp
clearli
patient
show
impair
lower
limb
save
upper
limb
term
sever
neuropathi
mean
cmtn
mean
age
year
similarli
patient
affect
present
phenotyp
mean
cmtn
first
visit
mean
age
year
conclus
base
experi
genova
cmt
clinic
describ
larg
popul
cmt
patient
specif
phenotyp
patient
character
involv
lower
limb
select
spare
upper
one
may
help
address
diagnost
algorithm
vale
symmond
polydefki
rice
themistocl
bennett
depart
clinic
neurosci
univers
oxford
uk
neurolog
john
hopkin
univers
school
medicin
usa
research
group
imperi
colleg
london
uk
cold
injuri
nfci
develop
follow
sustain
exposur
cold
temperatur
result
tissu
cool
freez
result
persist
sensori
disturb
hand
feet
includ
numb
paraesthesia
chronic
pain
vascular
neurolog
aetiolog
pain
suggest
remain
unproven
prospect
approach
patient
refer
clinic
assess
chronic
pain
follow
cold
injuri
februari
novemb
patient
approach
consent
undergo
detail
neurolog
evalu
includ
questionnair
detail
pain
locat
characterist
structur
neurolog
examin
quantit
sensori
test
nerv
conduct
studi
skin
biopsi
fibr
assess
studi
particip
experienc
nfci
whilst
serv
unit
kingdom
arm
servic
major
african
descent
male
mani
patient
report
multipl
exposur
cold
median
time
initi
injuri
referr
year
pain
princip
localis
hand
feet
neuropath
natur
studi
particip
associ
cold
hypersensit
clinic
examin
quantit
sensori
test
consist
sensori
neuropathi
case
larg
fibr
nerv
conduct
studi
normal
nerv
fibr
densiti
howev
markedli
reduc
subject
count
centil
publish
norm
control
use
neuropath
pain
special
interest
group
neupsig
intern
associ
studi
pain
iasp
grade
neuropath
pain
probabl
definit
neuropath
pain
chronic
cold
injuri
disabl
neuropath
pain
disord
due
sensori
neuropathi
individu
develop
acut
pain
sensori
neuropathi
sustain
cold
exposur
yet
known
individu
african
descent
appear
vulner
screen
tool
questionnair
treatment
algorithm
neuropath
pain
use
manag
patient
fund
wellcom
trust
uk
ministri
defenc
van
den
berg
verboon
doet
chavada
davidson
willison
harbo
gorson
hartung
lehmann
kusunoki
querol
illa
reisin
reddel
islam
islam
deen
mohammad
van
den
bergh
feasbi
shahrizaila
hsieh
bateman
dardioti
wang
van
doorn
hugh
cornblath
jacob
igo
consortium
neurolog
erasmu
medic
centr
rotterdam
netherland
neurolog
univers
glasgow
glasgow
uk
neurolog
aarhu
univers
hospit
aarhu
denmark
neurolog
tuft
univers
school
medicin
boston
usa
neurolog
univers
germani
neurolog
univers
hospit
cologn
germani
neurolog
kindai
univers
faculti
medicin
osaka
japan
neurolog
hospit
sant
pau
uab
ciber
barcelona
spain
neurolog
milan
univers
humanita
istitut
milan
itali
neurolog
hospit
britanico
bueno
air
argentina
neurolog
concord
repatri
gener
hospit
sydney
australia
neurolog
icddr
b
dhaka
bangladesh
scienc
servic
divis
icddr
b
dhaka
bangladesh
institut
neurosci
hospit
dhaka
bangladesh
neurolog
univers
hospit
st
luc
brussel
belgium
clinic
neurosci
univers
calgari
calgari
canada
centr
neuromuscular
diseas
nant
univers
hospit
nant
franc
neurolog
univers
malaya
kuala
lumpur
malaysia
neurolog
nation
taiwan
univers
hospit
taipei
taiwan
neurolog
univers
cape
town
cape
town
south
africa
neurolog
univers
thessali
larissa
thessali
greec
neurolog
affili
hospit
jine
medic
colleg
jine
china
neurolog
institut
neurolog
univers
colleg
london
uk
neurolog
john
hopkin
univers
baltimor
usa
immunolog
erasmu
medic
centr
rotterdam
netherland
syndrom
gb
highli
heterogen
regard
clinic
present
cours
electrophysiolog
subtyp
outcom
part
varieti
associ
differ
geograph
region
although
investig
singl
compar
studi
one
aim
igo
defin
influenc
geograph
origin
heterogen
gb
igo
gb
patient
within
week
onset
particip
independ
age
variant
sever
treatment
februari
patient
includ
countri
first
inclus
igo
use
analysi
patient
exclud
altern
diagnos
includ
protocol
violat
miss
data
remain
patient
male
femal
median
age
year
iqr
entri
present
tetraparesi
paraparesi
need
mechan
ventil
die
gb
patient
receiv
treatment
ivig
pe
remain
receiv
support
care
mild
gb
low
statu
anteced
event
report
patient
includ
upper
respiratori
tract
infect
frequent
event
pure
motor
form
predomin
subtyp
patient
bangladesh
europeamerica
asia
without
bangladesh
predomin
subtyp
sensorimotor
form
europeamerica
asia
asia
without
bangladesh
rel
larger
proport
patient
syndrom
region
p
proport
patient
abl
walk
unaid
month
europeamerica
bangladesh
asia
without
bangladesh
analysi
compar
electrophysiolog
subtyp
gb
report
neurologist
show
patient
inexcit
nerv
axon
neuropathi
need
time
regain
abil
walk
unaid
patient
demyelin
equivoc
result
test
p
find
demonstr
extens
geograph
differ
gb
futur
igo
studi
investig
role
genet
environment
factor
addit
could
explain
differ
van
den
bergh
attarian
grapperon
nicola
cassereau
rajab
delmont
woodard
univers
louvain
gb
electrodiagnosi
studi
group
refer
centr
univers
hospit
brussel
belgium
de
de
maladi
neuromusculair
et
la
sla
de
la
timon
marseil
franc
de
neurologi
raymond
garch
franc
de
maladi
neuromusculair
de
lenfant
et
de
ladult
centr
hospitali
universitair
danger
anger
franc
neuromuscular
servic
neurolog
univers
hospit
birmingham
birmingham
uk
psycholog
wayn
state
univers
detroit
michigan
usa
elisabeth
hospit
brussel
belgium
univers
louvain
gb
electrodiagnosi
studi
group
p
k
van
den
bergh
v
van
parij
univers
hospit
brussel
f
st
elisabeth
hospit
brussel
verougstraet
parc
leopold
hospit
brussel
ph
jacquery
j
raymack
hospit
ottigni
c
redant
hospit
boug
c
michel
jolimont
hospit
mon
studi
examin
whether
gb
subtyp
diagnos
singl
electrophysiolog
studi
edx
accord
criteria
rajab
ra
compar
ho
ho
hadden
ha
whether
tempor
dispers
td
paramet
help
patient
diagnos
accord
asburi
cornblath
prospect
includ
januari
septemb
perform
day
diseas
onset
respect
differ
classif
consist
ho
ha
patient
classifi
aman
compar
ra
ho
ha
p
ra
classifi
patient
equivoc
ho
p
aman
ha
p
ad
td
dcmap
pdcmap
durat
prolong
ra
led
increas
aidp
differ
two
edx
ho
ha
ra
ra
td
revers
conduct
failur
rcf
defin
increas
dcmap
pcmap
relat
subtyp
ho
fisher
exact
test
te
ra
fe
ra
td
fe
ho
fe
ha
fe
ra
fe
ra
td
fe
igg
antibodi
test
willison
delmont
ho
show
mayb
antibodi
aman
compar
aidp
fe
aman
compar
equivoc
case
fe
ha
may
antibodi
frequent
aman
compar
aidp
fe
conclus
serial
edx
time
interv
substanti
effect
differ
gb
subtyp
proport
regardless
criteria
use
sinc
correl
factor
associ
axon
gb
casu
rcf
antibodi
far
exclus
use
edx
subtyp
classif
use
specif
criteria
set
remain
doubt
frequenc
rcf
indic
nodalparanod
alter
may
repres
main
pathophysiolog
gb
patient
current
thought
uncini
kuwabara
van
helleputt
kater
cook
haeck
jasper
geen
vanden
bergh
geyseman
robberecht
van
damm
cavaletti
jarp
van
den
bosch
neurosci
experiment
neurolog
leuven
research
institut
neurosci
diseas
lind
ku
leuven
leuven
belgium
center
brain
diseas
research
laboratori
neurobiolog
leuven
belgium
experiment
endocrinolog
ku
leuven
leuven
belgium
enter
neurosci
targid
ku
leuven
leuven
belgium
neurolog
leuven
univers
hospit
leuven
belgium
neurolog
unit
milan
center
neurosci
school
medicin
surgeri
univers
monza
itali
pharmaceut
inc
boston
usa
import
neurolog
side
effect
larg
number
drug
pain
peripher
neuropathi
mainli
chemotherapeut
interfer
microtubul
includ
plant
deriv
vincristin
well
known
caus
peripher
neuropathi
cipn
date
treatment
avail
focu
symptom
allevi
pain
reduct
rather
prevent
neuropathi
togeth
first
time
highlight
potenti
specif
histon
deacetylas
inhibitor
prevent
therapi
cipn
use
novel
rodent
model
peripher
neuropathi
vipn
character
sensori
axonopathi
one
reason
therapi
avail
exact
pathophysiolog
mechan
poorli
understood
mount
evid
propos
axon
transport
pathway
frequent
disturb
neurolog
disord
major
player
pathophysiolog
vipn
proper
axon
transport
requir
dynam
microtubul
highli
modul
modif
sinc
vincristin
interfer
polymer
microtubul
reason
disturb
microtubul
dynam
extens
axon
transport
could
contribut
vipn
illustr
increas
acetyl
restor
defect
axon
transport
cultur
dorsal
root
ganglion
neuron
also
vivo
acetyl
restor
saphen
nerv
dorsal
root
ganglia
two
sensori
tissu
affect
vincristin
ultim
correl
reduc
sever
neurolog
symptom
electrophysiolog
behavior
level
moreov
discov
protect
neurotox
also
reduc
tumor
progress
mous
model
acut
lymphoblast
leukemia
taken
togeth
result
show
ideal
strategi
prevent
vipn
benefici
effect
neurotox
well
tumor
growth
van
lieverloo
basta
verhamm
gallia
stevic
peric
nikol
liberator
bianco
doneddu
van
schaik
eftimov
medic
center
amc
amsterdam
netherland
clinic
clinic
center
serbia
school
medicin
univers
belgrad
belgrad
serbia
neuroimmunolog
servic
humanita
clinic
research
center
depart
medic
biotechnolog
translat
medicin
milan
univers
rozzano
milan
itali
corticosteroid
consid
one
first
line
treatment
chronic
inflammatori
demyelin
polyneuropathi
cidp
differ
type
corticosteroid
use
compar
studi
assess
improv
rate
remiss
rate
toler
side
effect
profil
treatment
regimen
addit
current
reliabl
predictor
favor
treatment
respons
steroid
would
greatli
eas
choic
first
line
treatment
retrospect
studi
compar
efficaci
toler
safeti
three
differ
corticosteroid
regimen
use
first
line
treatment
three
larg
cidp
center
netherland
serbia
itali
treatment
cidp
patient
receiv
either
puls
dexamethason
puls
methylprednisolon
daili
prednison
includ
studi
data
extract
patient
chart
primari
outcom
percentag
treatment
respond
month
start
first
treatment
treatment
respons
defin
subject
improv
treatment
either
without
treatment
six
month
still
treat
first
chosen
therapi
secondari
endpoint
includ
remiss
rate
case
relaps
mean
durat
remiss
relaps
discontinu
rate
within
month
treatment
due
inefficaci
advers
event
intoler
frequenc
advers
event
seriou
advers
event
sae
treatment
within
month
stop
treatment
furthermor
explor
valu
previous
report
potenti
predictor
treatment
respons
result
present
peripher
nerv
societi
meet
van
lieverloo
muster
adrichem
esveldt
doorenspleet
klarenbeek
van
schaik
de
vri
eftimov
medic
center
depart
neurolog
amsterdam
netherland
medic
centerunivers
amsterdam
depart
clinic
rheumatolog
immunolog
amsterdam
netherland
follow
report
pathogen
antibodi
present
minor
patient
chronic
demyelin
inflammatori
neuropathi
cidp
studi
whether
oligoclon
expans
clone
present
patient
cidp
recent
develop
new
method
receptor
bcr
repertoir
landscap
base
high
throughput
sequenc
ht
rna
extract
blood
bcr
repertoir
analyz
patient
cidp
patient
activ
diseas
start
treatment
group
patient
stabl
diseas
use
intraven
immunoglobulin
ivig
treatment
treatment
withdraw
attempt
group
patient
remiss
ie
treatment
last
month
group
clinic
paramet
sampl
perform
baselin
group
month
start
treatment
group
month
earlier
case
relaps
group
baselin
group
cidp
patient
highli
expand
bcr
clone
regardless
diseas
activ
respons
treatment
howev
group
expand
clone
baselin
show
overlap
expand
bcr
clone
improv
base
preliminari
data
expand
bcr
clone
observ
peripher
blood
cidp
patient
regardless
diseas
activ
activ
stabl
diseas
remissioncur
function
character
expand
clone
remain
perform
van
rij
fokkink
brem
jacob
huizinga
mc
univers
medic
centr
rotterdam
netherland
myeloid
cell
includ
monocyt
macrophag
dendrit
cell
critic
involv
induct
adapt
immun
respons
clearanc
pathogen
initi
tissu
repair
syndrom
gb
macrophag
present
peripher
nerv
phagocytos
damag
myelin
axon
dendrit
cell
dc
increas
cerebrospin
fluid
patient
gb
howev
composit
phenotyp
monocyt
dc
subset
peripher
blood
unclear
unknown
cell
use
biomark
monitor
diseas
activ
respons
treatment
investig
frequenc
phenotyp
six
myeloid
subset
peripher
blood
mononuclear
cell
pbmc
use
advanc
flow
cytometri
pbmc
isol
patient
gb
immunomodulatori
treatment
age
healthi
control
frequenc
total
monocyt
determin
percentag
cell
increas
gb
patient
compar
control
p
monocyt
popul
skew
toward
intermedi
p
less
p
monocyt
classic
intermedi
monocyt
well
dc
express
significantli
higher
level
compar
healthi
control
contrast
express
significantli
higher
monocyt
gb
patient
compar
control
differ
observ
express
immunomodulatori
treatment
strongli
reduc
frequenc
monocyt
dc
popul
pbmc
express
reduc
classic
monocyt
treatment
addit
express
reduc
sever
monocyt
dc
popul
treatment
summari
data
identifi
signific
chang
monocyt
compart
gb
decreas
monocyt
may
suggest
cell
migrat
peripher
tissu
promot
differenti
classic
monocyt
intermedi
monocyt
analysi
reveal
whether
chang
relat
preced
infect
diseas
sever
respons
treatment
van
schaik
bril
van
geloven
hartung
lewi
sobu
lawo
mielk
durn
cornblath
merki
behalf
path
studi
group
neurolog
academ
medic
centr
univers
amsterdam
amsterdam
netherland
medicin
neurolog
univers
health
network
univers
toronto
toronto
canada
biostatist
bioinformat
leiden
univers
medic
center
leiden
netherland
neurolog
heinrich
hein
univers
germani
neurolog
medic
center
lo
angel
ca
usa
neurolog
nagoya
univers
graduat
school
medicin
nagoya
japan
behr
marburg
germani
king
prussia
pa
usa
neurolog
john
hopkin
univers
school
medicin
baltimor
md
usa
neurolog
maastricht
univers
medic
center
maastricht
netherland
approxim
cidp
subject
need
corticosteroid
intraven
immunoglobulin
ivig
ivig
slightli
prefer
base
safeti
profil
subcutan
ig
scig
altern
option
ig
deliveri
previous
investig
clinic
trial
cidp
perform
random
trial
cidp
investig
gkg
weekli
dose
scig
csl
behr
versu
placebo
subject
mainten
treatment
adult
definit
probabl
cidp
accord
efnspn
criteria
elig
primari
outcom
percentag
subject
cidp
relaps
deterior
adjust
incat
disabl
score
withdrawn
reason
period
multipl
secondari
endpoint
assess
superior
least
one
dose
placebo
test
use
trend
test
primari
outcom
test
secondari
outcom
primari
outcom
occur
scig
scig
placebo
subject
p
cidp
relaps
occur
scig
scig
placebo
subject
p
respect
scig
dose
superior
placebo
vs
placebo
p
high
dose
vs
placebo
p
median
incat
score
mrc
sum
score
grip
strength
remain
stabl
scig
subject
scig
prevent
declin
seen
scig
placebo
p
placebo
subject
deterior
measur
strength
disabl
causal
relat
advers
event
occur
subject
placebo
low
dose
high
dose
scig
efficaci
safe
mainten
treatment
scig
superior
placebo
high
dose
potenti
show
better
efficaci
fund
csl
behr
sponsor
studi
trial
registr
http
clinicaltrialsgov
number
vegezzi
cortes
callegari
rossor
houlden
reilli
consortium
univers
pavia
monza
policlinico
pavia
mondino
itali
centr
neuromuscular
diseas
nation
hospit
neurolog
neurosurgeri
ucl
institut
neurolog
queen
squar
london
uk
molecular
neurosci
ucl
institut
neurolog
london
uk
nation
hospit
neurolog
neurosurgeri
queen
squar
london
uk
mutat
metalloendopeptidas
mme
gene
associ
date
patient
least
one
truncat
mutat
either
homozygos
tran
missens
mutat
recent
missens
heterozyg
mutat
also
identifi
cmt
report
case
previous
healthi
caucasian
woman
born
healthi
unrel
parent
present
age
numb
cold
sensat
lower
limb
subsequ
develop
progress
gait
disturb
impair
hand
dexter
homozyg
twin
present
age
similar
symptom
famili
histori
otherwis
unev
particular
neither
neuropathi
dementia
describ
neurolog
examin
age
reveal
steppag
gait
distal
upper
lower
limb
atrophi
weak
distal
sensori
loss
bilater
pe
cavu
deep
tendon
reflex
normal
upper
limb
absent
lower
limb
nerv
conduct
studi
reveal
axon
sensori
motor
neuropathi
sural
nerv
biopsi
reveal
reduct
myelin
nerv
fiber
activ
axon
degener
target
sanger
sequenc
mpz
nefl
fkrp
neg
sureselect
focus
exom
sequenc
therefor
perform
identifi
two
missens
heterozyg
mutat
c
mme
two
mutat
absent
control
databas
eg
exac
affect
highli
conserv
aminoacid
predict
deleteri
effect
silico
analysi
unfortun
parent
deceas
therefor
unabl
prove
two
mutat
resid
separ
allel
mme
encod
metalloproteas
neprilysin
whose
role
peripher
nervou
system
still
unclear
higuchi
colleagu
describ
japanes
famili
axon
neuropathi
recess
mutat
mme
report
two
novel
missens
mutat
mme
case
hypothes
mode
inherit
like
given
clinic
phenotyp
absenc
famili
histori
vegezzi
cortes
zardini
devaux
franciotta
consortium
univers
pavia
monza
policlinico
pavia
mondino
itali
centr
neuromuscular
diseas
nation
hospit
neurolog
neurosurgeri
ucl
institut
neurolog
queen
squar
london
uk
gener
neurolog
c
mondino
nation
institut
neurolog
foundat
ircc
pavia
itali
cnr
marseil
franc
antibodi
recent
identifi
subgroup
patient
chronic
inflammatori
demyelin
polyneuropathi
cidp
show
acutesubacut
onset
sever
neuropathi
poor
respons
intraven
immunoglobulin
ivig
corticosteroid
antibodi
belong
isotyp
interact
complex
paranod
lead
loss
nodal
integr
man
present
acut
onset
distal
weak
lower
limb
four
limb
paraesthesia
sensori
ataxia
clinic
examin
ankl
swell
also
observ
nerv
conduct
studi
show
demyelin
polyneuropathi
examin
reveal
dissoci
sural
nerv
biopsi
disclos
diffus
loss
myelin
fibr
routin
blood
test
serum
albumin
reduc
proteinuria
hour
thu
lead
diagnosi
nephrot
syndrom
kidney
biopsi
show
chang
consist
membran
glomerulonephr
togeth
deposit
immun
complex
complement
deposit
treatment
ivig
corticosteroid
improv
neurolog
statu
membran
glomerulonephr
show
moder
respons
ivig
cours
cyclophosphamid
start
lead
normal
renal
function
muscl
strength
partial
improv
sensori
ataxia
patient
requir
treatment
year
condit
remain
stabl
antibodi
test
recent
collect
patient
serum
result
posit
elisa
assay
patient
report
show
typic
clinic
featur
anti
cidp
includ
older
age
acut
onset
sever
motor
impair
sensori
ataxia
contemporari
occurr
membran
glomerulonephr
report
one
case
express
low
level
kidney
direct
damag
antibodi
could
hypothes
altern
renal
damag
might
secondari
unspecif
immun
complex
deposit
good
respons
rituximab
recent
report
patient
cidp
associ
antibodi
notwithstand
observ
report
suggest
also
cyclophosphamid
may
consid
effect
therapi
cidp
membran
glomerulonephr
lead
persist
clinic
remiss
velasco
besora
santo
sala
izquierdo
pardo
calvo
palmero
bruna
unit
depart
neurolog
univers
hospit
institut
oncolog
lhospitalet
barcelona
spain
neurosci
depart
cell
biolog
physiolog
immunolog
universitat
de
barcelona
centro
de
en
red
sobr
enfermedad
neurodegenerativa
cibern
bellaterra
spain
medic
oncolog
hospit
duran
reynal
catalan
institut
oncolog
lhospitalet
barcelona
spain
clinic
hematolog
hospit
duran
reynal
catalan
institut
oncolog
lhospitalet
barcelona
spain
duloxetin
agent
demonstr
effect
treat
pain
relat
peripher
neuropathi
cipn
patient
symptomat
cipn
treat
duloxetin
retrospect
collect
aim
studi
evalu
drug
efficaci
rate
complianc
patient
cipn
distress
posit
symptom
pain
numb
andor
paresthesia
diseas
includ
cipn
grade
employ
total
neuropathi
score
nation
cancer
toxic
criteria
respons
duloxetin
assess
patient
global
impress
chang
pigc
scale
benefit
excel
respons
consecut
first
cipn
patient
treat
duloxetin
analyz
median
age
receiv
platinum
taxan
bortezomib
regimen
respect
median
sever
neuropathi
grade
grade
grade
sixteen
patient
treatment
analges
agent
median
time
finish
chemotherapi
duloxetin
initi
month
median
pigc
score
among
respond
score
low
high
benefit
respect
patient
discontinu
earli
duloxetin
due
intoler
side
effect
lack
efficaci
frequent
report
advers
event
cognit
gastrointestin
genitourinari
discontinu
due
percept
lack
efficaci
frequent
report
men
vs
women
present
higher
punctuat
pigc
scale
compar
men
vs
pigc
score
significantli
higher
patient
receiv
taxan
platinum
agent
signific
differ
accord
sever
neuropathi
neither
type
chemotherapi
observ
retent
rate
patient
cipn
month
report
lower
pigc
score
vs
higher
frequenc
suspens
due
advers
event
vs
less
rate
continu
duloxetin
vs
patient
disturb
cipn
discontinu
duloxetin
prematur
due
intoler
low
toler
male
gender
cipn
may
limit
duloxetin
use
treatment
symptomat
cipn
verboon
jacob
igo
consortium
neurolog
erasmu
medic
centr
rotterdam
netherland
immunolog
erasmu
medic
centr
rotterdam
netherland
efficaci
intraven
immunoglobulin
ivig
syndrom
gb
demonstr
sever
affect
patient
unabl
walk
independ
although
proof
ivig
effect
milder
form
gb
neurologist
treat
patient
ivig
consid
even
milder
form
gb
may
result
poor
recoveri
residu
deficit
fatigu
pain
determin
effect
singl
cours
ivig
gkg
day
rel
mild
form
gb
ongo
observ
intern
gb
outcom
studi
igo
gb
disabl
score
mrc
sum
score
patient
report
outcom
measur
prom
compar
week
ordin
logist
regress
analysi
use
determin
effect
ivig
gb
disabl
score
adjust
previous
identifi
prognost
factor
data
analyz
first
patient
enrol
igo
decemb
includ
patient
mild
gb
entri
patient
treat
support
care
patient
receiv
ivig
start
ivig
onset
symptom
day
median
iqr
baselin
patient
ivig
treat
group
compar
untreat
group
less
frequent
pure
motor
gb
versu
p
axon
damag
unrespons
nerv
versu
wors
gb
disabl
score
nadir
adjust
common
odd
ratio
better
gb
disabl
score
week
ci
week
median
mrc
sum
score
prom
significantli
differ
treat
untreat
patient
howev
patient
ivig
group
show
complet
recoveri
muscl
strength
week
patient
control
group
versu
frequent
show
full
neurolog
recoveri
gb
disabl
scale
versu
addit
result
present
confer
base
result
interim
analysi
observ
data
conclud
patient
rel
mild
form
gb
may
benefit
singl
cours
ivig
verboon
van
den
berg
cornblath
walgaard
gorson
lunn
hartung
steyerberg
lingsma
jacob
van
doorn
igo
consortium
neurolog
erasmu
mc
univers
medic
center
rotterdam
netherland
neurolog
john
hopkin
univers
baltimor
usa
neurolog
tuft
univers
school
medicin
boston
usa
centr
neuromuscular
diseas
nation
hospit
neurolog
neurosurgeri
london
uk
neurolog
heinrich
hein
germani
public
health
erasmu
medic
centr
rotterdam
netherland
immunolog
erasmu
medic
centr
rotterdam
netherland
despit
treatment
intraven
immunoglobulin
ivig
mani
patient
syndrom
gb
recov
insuffici
primarili
aim
determin
whether
second
ivig
cours
gkg
day
patient
poor
prognosi
improv
outcom
gb
disabl
scale
week
includ
patient
prospect
observ
intern
gb
outcom
studi
igo
treat
ivig
poor
prognosi
modifi
erasmu
gb
outcom
score
mego
patient
enrol
igo
patient
elig
patient
treat
one
ivig
cours
control
group
patient
receiv
earli
second
ivig
cours
week
start
first
cours
patient
late
second
ivig
cours
within
week
one
week
studi
entri
patient
receiv
earli
late
second
ivig
cours
significantli
wors
gb
disabl
score
mrc
sum
score
control
impli
need
adjust
baselin
characterist
adjust
common
odd
ratio
better
gb
disabl
score
week
ci
earli
group
ci
late
group
suggest
wors
outcom
second
cours
ivig
compar
control
month
patient
earli
second
ivig
group
patient
control
group
late
second
ivig
group
abl
walk
unaid
adjust
common
odd
ratio
better
gb
disabl
score
week
ci
earli
second
ivig
group
ci
late
second
ivig
group
gb
patient
poor
prognosi
find
benefici
effect
second
cours
ivig
week
result
suggest
earli
administ
second
ivig
cours
might
improv
outcom
week
given
limit
observ
studi
random
control
trial
larger
number
gb
patient
poor
prognosi
treat
earli
diseas
cours
need
confirm
refut
result
vidal
bhatt
agudelo
mahapatra
saporta
neurolog
univers
miami
miller
school
medicin
miami
usa
multifoc
motor
neuropathi
mmn
inflammatori
demyelin
chronic
neuropathi
character
progress
asymmetr
weak
distribut
two
peripher
nerv
without
object
sensori
loss
upper
motor
neuron
sign
cardin
neurophysiolog
find
conduct
block
outsid
usual
site
nerv
compress
support
clinic
criteria
includ
high
titer
antibodi
good
respons
ivig
increas
cerebrospin
fluid
csf
protein
magnet
reson
imag
mri
diffus
swell
brachial
plexu
report
case
year
old
woman
two
month
histori
progress
muscular
weak
began
right
upper
extrem
describ
difficulti
grip
object
write
type
comput
follow
progress
lower
extrem
weak
difficulti
rise
chair
left
foot
drop
also
complain
pain
right
trapeziu
scapular
area
deni
tingl
numb
neurolog
examin
right
scapular
wing
asymmetr
weak
predominantli
involv
right
upper
left
lower
extrem
reflex
absent
throughout
lumbar
punctur
reveal
albuminocytolog
dissoci
wbc
protein
gdl
nc
reveal
slow
conduct
veloc
ulnar
median
nerv
median
nerv
conduct
block
forearm
segment
sensori
nerv
action
potenti
normal
test
nerv
needl
emg
reveal
acut
denerv
right
periscapular
muscl
brachial
plexu
mri
show
symmetr
bilater
thicken
trunk
peripher
nerv
iggigm
neg
two
day
lumbar
punctur
begin
ivig
patient
present
binocular
diplopia
extrem
left
later
gaze
brain
mri
without
contrast
show
intracrani
patholog
five
day
ivig
patient
discharg
signific
clinic
improv
recoveri
right
scapular
wing
diplopia
improv
week
discharg
report
atyp
multifoc
motor
neuropathi
case
although
patient
fulfil
clinic
criteria
mmn
report
featur
usual
found
mmn
scapular
wing
mild
transient
left
vi
nerv
palsi
mmn
includ
differenti
diagnosi
scapular
wing
vlckova
raputova
srotova
sommer
birklein
rebhorn
rittner
kovalova
nekvapilova
belobradkova
olsovski
weber
dusek
jarkovski
bednarik
european
institut
technolog
masaryk
univers
brno
czech
republ
neurolog
univers
hospit
brno
brno
czech
republ
neurolog
univers
germani
neurolog
univers
medic
center
mainz
germani
anesthesiolog
centr
interdisciplinari
pain
medicin
univers
hospit
germani
diabetolog
centr
depart
intern
medicin
gastroenterolog
univers
hospit
brno
brno
czech
repub
centr
st
ann
univers
hospit
brno
czech
republ
intern
medicin
geriatr
practic
medicin
univers
hospit
brno
brno
czech
republ
biostatistist
analys
masaryk
univers
brno
czech
republ
despit
mani
studi
address
biomark
pain
diabet
polyneuropathi
dpn
littl
known
affect
certain
proport
dpn
patient
somatosensori
system
play
key
role
pathophysiolog
neuropath
pain
neup
subgroup
differ
sensori
profil
might
respond
differ
pain
treatment
aim
character
sensori
phenotyp
patient
pain
painless
diabet
neuropathi
assess
demograph
clinic
metabol
electrophysiolog
psycholog
paramet
relat
presenc
neup
larg
cohort
dpn
subject
observ
cohort
studi
perform
part
ncrnapain
eu
consortium
subject
dpn
ndpn
pain
pdpn
associ
diabet
mellitu
type
median
age
year
rang
year
women
compris
detail
histori
take
neurolog
examin
laboratori
test
quantit
sensori
test
nerv
conduct
studi
neuropathi
sever
score
neuropsycholog
questionnair
paramet
analys
regard
presenc
sever
neup
presenc
sever
neup
posit
correl
sever
neuropathi
thermal
hyposensit
p
minor
pdpn
patient
sensori
profil
indic
thermal
hypersensit
associ
less
sever
neuropathi
better
respons
pain
therapi
presenc
neup
also
associ
femal
gender
p
higher
cognit
apprais
pain
assess
pain
catastroph
scale
p
paramet
relat
diabet
durat
microangiopathi
show
influenc
neup
presenc
sever
studi
confirm
necess
comprehens
dpn
phenotyp
underlin
import
sever
neuropathi
taken
account
stratif
patient
pdpn
analges
treatment
drug
trial
wallac
pietrusz
dewar
dudziec
jone
henni
sterr
baio
butcher
skorupinska
skorupinska
trenel
hanna
reilli
ramdharri
centr
neuromuscular
diseas
ucl
institut
neurolog
london
uk
health
social
care
educ
kingston
universityst
georg
univers
london
uk
sport
exercis
health
ucl
uk
psycholog
univers
surrey
guildford
uk
statist
scienc
ucl
london
uk
mari
tooth
unit
kingdom
regist
chariti
number
uk
newcastl
univers
uk
peopl
charcot
mari
tooth
diseas
cmt
experi
slowli
progress
muscl
weak
sensori
loss
musculoskelet
chang
time
lead
disabl
risk
comorbid
due
inact
exercis
import
maintain
gener
health
may
also
help
improv
symptom
cmt
conduct
randomis
control
crossov
trial
aerob
exercis
ascertain
effect
train
fit
level
muscl
strength
function
gener
addit
monitor
safeti
train
feasibl
particip
type
exercis
local
commun
gym
motiv
confid
barrier
exercis
explor
use
qualit
interview
recruit
target
peopl
total
peopl
cmt
approach
particip
unabl
commit
trial
meet
studi
criteria
initi
screen
peopl
underw
detail
screen
three
fail
meet
studi
criteria
five
peopl
withdrew
start
three
withdrew
part
way
studi
data
peopl
start
studi
analys
use
random
effect
model
particip
level
train
well
toler
increas
pain
blood
serum
creatin
kinas
increas
mlminkg
observ
cmt
group
pre
train
ci
post
train
ci
pre
control
ci
post
control
ci
wide
subject
variat
lead
small
overal
effect
size
cohen
ci
tent
regress
model
show
effect
group
time
point
major
chang
measur
impair
function
patient
report
outcom
measur
pilot
studi
show
commun
base
model
train
small
effect
cardiopulmonari
fit
well
toler
good
particip
wang
wu
bai
zaidman
grider
kamholz
lupski
connolli
shi
neurolog
neuromuscular
divis
univers
iowa
hospit
clinic
iowa
citi
iowa
usa
neurolog
neurogenet
divis
univers
iowa
hospit
clinic
iowa
citi
iowa
usa
neurolog
pediatr
washington
univers
school
medicin
neuromuscular
divis
st
loui
mo
usa
depart
pediatr
baylor
colleg
medicin
houston
texa
usa
two
author
contribut
equal
goal
studi
determin
whether
predict
fork
stall
templat
switch
fost
mitosi
delet
exon
peripher
myelin
protein
kd
caus
mutat
associ
peripher
neuropathi
famili
charcot
mari
tooth
diseas
type
two
sibl
previous
report
genom
predict
involv
exon
evalu
clinic
electrophysiolog
skin
biopsi
proband
studi
determin
effect
exon
exon
mrna
express
myelin
schwann
cell
transient
transfect
studi
wild
type
mutant
perform
cell
determin
fate
result
mutant
protein
affect
sibl
demyelin
neuropathi
sever
slow
nerv
conduct
veloc
msec
studi
schwann
cell
rna
one
sibl
demonstr
complet
frame
delet
exon
transfect
studi
demonstr
protein
retain
within
endoplasm
reticulum
transport
plasma
membran
result
confirm
fost
mediat
genom
rearrang
produc
delet
exon
result
express
mrna
protein
lack
sequenc
addit
provid
direct
experiment
evid
endoplasm
reticulum
retent
mutant
protein
suggest
mutat
mechan
consist
observ
famili
anoth
exampl
mutat
myelin
protein
misfold
thu
like
contribut
pathogenesi
neuropathi
wang
litchi
mauermann
dyck
dispenzieri
mandrekar
dyck
klein
neurolog
mayo
clinic
rochest
mn
usa
neurolog
friendship
hospit
beij
china
hematolog
mayo
clinic
rochest
mn
usa
statist
informat
mayo
clinic
rochest
mn
usa
poem
cidp
distal
limb
nerv
conduct
studi
limit
identifi
demyelin
detect
treatment
effect
sever
affect
patient
blink
reflex
latenc
may
help
identifi
demyelin
also
provid
meaning
treatment
outcom
measur
especi
sever
affect
patient
poem
cidp
patient
undergon
routin
nerv
conduct
blink
reflex
test
identifi
correl
latenc
limb
nerv
conduct
studi
neuropathi
impair
score
ni
calcul
treatment
blink
reflex
perform
patient
poem
cidp
ni
rang
point
overal
latenc
prolong
occur
patient
poem
cidp
patient
prolong
sever
affect
nerv
conduct
poem
ulnar
cmap
vs
cidp
ulnar
cmap
vs
p
latenc
correl
ni
sever
poem
better
cidp
vs
p
vs
ni
latenc
evalu
treatment
avail
patient
poem
cidp
latenc
chang
concord
ni
chang
poem
cidp
patient
sever
affect
patient
ulnar
cmap
amplitud
except
one
prolong
allow
treatment
follow
initi
diagnosi
blink
reflex
latenc
valuabl
defin
demyelin
sever
affect
poem
cidp
patient
also
provid
sensit
earli
treatment
outcom
measur
among
sever
affect
patient
watson
martinez
wallenhorst
hubsch
shebl
simon
behr
llc
king
prussia
usa
epidemiolog
statist
informat
gmbh
frankfurt
germani
behr
ag
bern
switzerland
behr
gmbh
marburg
germani
chronic
inflammatori
demyelin
polyneuropathi
cidp
rare
occur
children
clinic
trial
pediatr
patient
perform
littl
data
therapi
intraven
immunoglobulin
ivig
perform
observ
trial
investig
risk
advers
event
special
interest
aesi
ivig
ie
hemolyt
anemia
asept
mening
acut
renal
failur
thromboembol
event
anaphylact
reaction
studi
cohort
deriv
us
premier
perspect
databas
consist
patient
year
diagnosi
cidp
cm
diagnosi
code
treat
ivig
csl
behr
bern
switzerland
jan
dec
identifi
pediatr
cidp
patient
preschool
children
age
year
first
treatment
cidp
children
year
adolesc
year
femal
male
white
one
black
two
alloc
race
six
patient
histori
ivig
use
syndrom
one
patient
myasthenia
gravi
one
immunodefici
diagnosi
cidp
mean
dose
calcul
cumul
quantiti
per
treatment
episod
correspond
gender
specif
median
us
popul
bodi
weight
estim
gkg
bodi
weight
number
record
treatment
episod
per
patient
rang
use
period
day
hemolyt
anemia
day
aesi
administr
aesi
observ
patient
cidp
total
ha
aesi
observ
studi
show
ivig
use
treatment
cidp
pediatr
patient
without
concomit
condit
reveal
particular
safeti
issu
patient
group
wilson
kalmar
kugathasan
clark
bennett
abramov
reilli
greensmith
depart
motor
neurosci
movement
disord
centr
neuromuscular
diseas
neurosci
ucl
institut
neurolog
queen
squar
london
uk
injuri
group
nuffield
depart
clinic
neurosci
univers
oxford
oxford
uk
peripher
neuropathi
frequent
caus
missens
mutat
gene
code
two
subunit
enzym
serin
palmitoyltransferas
spt
spt
catalyz
first
rate
limit
step
de
novo
sphingolipid
synthesi
shown
mutat
spt
caus
chang
enzym
substrat
specif
result
product
two
atyp
sphinganin
deoxysphinganin
dsp
deoxymethylsphinganin
dmsp
rather
normal
enzym
product
sphinganin
sp
level
deoxysphingolipid
elev
blood
patient
shown
caus
peripher
nerv
damag
characterist
diseas
affect
sensori
well
motor
axon
howev
underli
pathomechan
deoxysphingolipid
damag
neuron
remain
elus
dsp
neurotox
examin
primari
mous
motor
sensori
neuron
assess
cell
surviv
neurit
outgrowth
follow
exposur
differ
concentr
sp
dsp
dmsp
abnorm
enzym
product
found
rapid
neurotox
effect
primari
neuron
also
explor
potenti
mechan
underli
deoxysphingolipid
neurotox
character
mitochondri
function
chang
calcium
handl
found
mitochondri
dysfunct
calcium
handl
deficit
may
key
mediat
abnorm
sphingolipid
neurotox
motor
sensori
cell
model
specif
reveal
mitochondri
abnorm
sign
endoplasm
reticulum
stress
dysfunct
calcium
channel
propos
earli
deficit
mitochondria
calcium
handl
may
underli
deoxysphingolipid
neurotox
thu
present
potenti
therapeut
target
wojciechowski
littl
menez
hogan
burn
sydney
new
south
wale
australia
children
hospit
network
randwick
westmead
new
south
wale
australia
orthos
afo
commonli
prescrib
children
diseas
cmt
manag
foot
drop
howev
type
sever
function
impair
result
gait
deviat
might
requir
altern
orthot
design
aim
studi
identifi
gait
pattern
children
cmt
base
sever
function
weak
base
heel
walk
toe
walk
foot
drop
item
gait
use
cmt
pediatr
scale
inform
design
pipelin
print
orthos
gait
data
captur
vicon
nexu
motion
captur
system
use
lower
bodi
model
children
cmt
male
variou
cmt
type
cmt
compar
typic
develop
children
male
data
subdivid
three
group
denot
increas
sever
dorsiflexion
plantarflexion
weak
difficulti
heel
toe
walk
cmtnd
difficulti
heel
walk
cmtdh
difficulti
toe
heel
walk
cmtdth
cmtnd
group
show
gait
pattern
signific
differ
note
ankl
reduc
peak
dorsiflexion
stanc
p
indic
orthot
intervent
may
requir
addit
reduc
peak
dorsiflexion
cmtdh
group
demonstr
significantli
reduc
dorsiflexion
swing
reduc
dorsiflexor
moment
load
respons
p
suggest
cmtdh
group
would
requir
flexibl
afo
allow
activ
plantarflexor
prevent
restor
heel
rocker
load
respons
contrast
cmtdth
group
present
significantli
delay
increas
peak
dorsiflexion
stanc
reduc
plantarflexion
power
p
also
significantli
increas
mean
knee
extensor
moment
p
reveal
earli
sign
crouch
gait
therefor
cmtdth
group
would
requir
rigid
afo
limit
amount
dorsiflexion
assist
movement
ground
reaction
forc
anterior
knee
stanc
three
distinct
gait
pattern
ankl
identifi
children
cmt
indic
orthot
design
pathway
target
specif
function
impair
wojciechowski
chang
cheng
littl
menez
hogan
burn
sydney
new
south
wale
australia
children
hospit
network
randwick
westmead
new
south
wale
australia
children
cmt
often
prescrib
orthos
afo
manag
lower
limb
impair
foot
drop
foot
deform
handmad
plaster
cast
follow
thermoplast
mould
tradit
approach
provid
limit
design
option
costli
long
outpati
wait
time
print
also
known
addit
manufactur
potenti
transform
way
orthos
prescrib
design
manufactur
aim
review
evalu
evid
print
afo
compar
tradit
manufactur
method
children
cmt
current
studi
evalu
applic
print
afo
children
cmt
howev
small
emerg
evid
base
exist
print
afo
adult
studi
includ
healthi
particip
popul
rheumatoid
arthriti
syndrom
foot
drop
ankl
weak
secondari
injuri
sampl
size
rang
particip
studi
relat
orthos
studi
relat
afo
method
print
includ
sterolithographi
select
laser
sinter
fuse
deposit
model
use
materi
nylon
nylon
polylactid
polycarbon
ab
print
afo
compar
tradit
manufactur
orthos
term
comfort
paramet
plantar
pressur
measur
gait
analysi
howev
effect
usag
durabl
print
afo
investig
print
orthos
potenti
advantag
includ
increas
design
possibl
improv
product
higher
complianc
reduc
labour
need
disadvantag
includ
redesign
clinic
pathway
limit
evid
base
clinic
effect
limit
biocompat
materi
occup
safeti
consider
high
level
expertis
requir
softwar
oper
fabric
devic
research
requir
determin
feasibl
print
afo
children
cmt
appropri
effect
print
pathway
materi
improv
health
outcom
affect
patient
wong
koh
lee
chng
pawa
subramaniam
cheng
umapathi
kong
chian
school
medicin
nanyang
technolog
univers
singapor
neurosci
institut
singapor
loo
lin
school
medicin
nation
univers
singapor
singapor
teck
puat
hospit
singapor
neuropathi
diabet
mellitu
dm
tind
complic
rapid
glycaem
control
individu
present
neuropath
pain
autonom
dysfunct
within
week
improv
glucos
control
use
insulin
oral
hypoglycaem
agent
associ
tind
sever
determin
rate
quantum
declin
predispos
factor
includ
anorexia
weight
loss
studi
incid
tind
dm
patient
undergon
massiv
weight
loss
declin
bariatr
surgeri
screen
electron
record
patient
dm
underw
bariatr
surgeri
dm
patient
fulfil
tind
criteria
decreas
month
month
one
patient
exclud
decreas
contemporan
weight
loss
mean
median
decreas
bmi
per
month
respect
mean
median
interv
surgeri
decreas
day
respect
record
patient
scrutin
classifi
probabl
tind
acut
pain
neuropathi
acut
dysautonomia
tempor
relationship
decreas
possibl
tind
acut
pain
neuropathi
acut
dysautonomia
tempor
relationship
decreas
uncertain
unlik
tind
altern
explan
exist
symptom
one
patient
classifi
possibl
tind
woman
develop
neuropath
pain
lower
limb
month
rapid
declin
month
bariatr
surgeri
document
autonom
symptom
studi
limit
small
cohort
size
retrospect
design
relianc
hospit
record
nonetheless
demonstr
besid
nutrit
neuropathi
tind
also
consid
dm
patient
develop
peripher
neuropathi
bariatr
surgeri
anoth
studi
found
tind
uncommon
gener
cohort
diabet
patient
occurr
possibl
tind
dm
patient
corrobor
earlier
data
weight
loss
may
act
tandem
increas
risk
tind
woolum
tabuchi
sung
sullivan
mamah
yang
blum
wu
sumner
lloyd
hopkin
univers
baltimor
usa
domin
missens
mutat
gene
encod
cation
channel
transient
receptor
vanilloid
famili
member
caus
inherit
neuropathi
includ
diseas
vitro
mutat
caus
caus
gain
channel
function
increas
intracellular
calcium
subsequ
lead
cellular
toxic
howev
mechan
mutat
lead
neuron
dysfunct
vivo
remain
poorli
understood
gener
transgen
drosophila
express
either
caus
mutant
assess
effect
neuron
function
vivo
select
express
drosophila
ccap
neuron
nccap
result
failur
drosophila
wing
expans
block
genet
inactiv
channel
pore
demonstr
requir
channel
function
mediat
phenotyp
perfor
patch
clamp
analysi
nccap
reveal
caus
increas
nccap
neuron
excit
hyperexcit
restor
control
level
applic
select
antagonist
high
level
express
caus
synapt
dendrit
degener
rescu
genet
inactiv
channel
pore
pharmacolog
feed
larva
select
antagonist
conduct
genet
screen
nccap
found
camkii
knockdown
potent
suppress
mediat
wing
expans
phenotyp
select
rescu
degener
synaps
dendrit
also
find
control
disrupt
mitochondri
transport
axon
increas
number
stationari
mitochondria
data
demonstr
elev
neuron
intracellular
calcium
disrupt
mitochondri
transport
mediat
neurodegener
signal
pathway
support
investig
antagonist
potenti
therapeut
treatment
wu
yang
christianson
wright
kansa
medic
center
kansa
citi
usa
mood
disord
includ
anxieti
depress
commonli
observ
among
chronic
pain
patient
preval
estim
rang
comorbid
mood
chronic
pain
disord
link
alter
limbic
regul
hpa
axi
stress
activ
hpa
axi
initi
andor
exacerb
symptom
relat
chronic
pain
mood
disord
previou
studi
laboratori
investig
influenc
earli
life
stress
mechan
pain
hypersensit
viscer
hypersensit
behavior
evid
mood
disord
later
life
test
hypothesi
chronic
stress
exposur
adulthood
increas
somat
viscer
sensit
anhedon
behavior
mous
strain
genet
predisposit
anxieti
adult
femal
aj
mice
expos
repeat
foot
shock
stress
continu
day
test
alter
mechan
sensit
sucros
prefer
visceromotor
respons
vmr
urinari
bladder
distens
serum
corticosteron
level
mice
underw
shock
stress
significantli
decreas
mechan
withdraw
threshold
hind
paw
compar
baselin
sham
group
measur
sucros
prefer
measur
prior
shock
exposur
throughout
shock
paradigm
indic
anhedon
behavior
mice
underw
shock
stress
display
trend
toward
decreas
sucros
prefer
indic
anhedonia
comparison
mice
sham
group
display
anhedonia
mice
underw
shock
stress
display
signific
increas
vmr
bladder
distens
compar
sham
mice
final
serum
corticosteron
level
significantli
higher
mice
underw
shock
stress
compar
sham
mice
indic
increas
hpa
axi
output
togeth
data
suggest
chronic
stress
exposur
induc
mechan
allodynia
viscer
hypersensit
behavior
mous
strain
futur
studi
incorpor
gene
express
hypothalamu
amygdala
hippocampu
well
investig
possibl
downstream
peripher
neuroimmun
modul
neuron
morpholog
chang
yamagishi
suzuki
masahiro
satoshi
takanori
kyoichi
atsuro
ryuji
takashi
kenichi
shuichi
tatsuro
junichi
hiroshi
makoto
gen
kazutoshi
kusunoki
neurolog
kindai
univers
osakasayama
japan
univers
tokyo
japan
univers
chiba
japan
medic
dental
univers
tokyo
japan
medic
univers
iruma
gun
japan
univers
mitaka
japan
univers
tokushima
japan
univers
ube
japan
defens
medic
colleg
univers
tokorozawa
japan
univers
matsumoto
japan
health
univers
toyoak
japan
univers
fukuoka
japan
univers
kagoshima
japan
medic
univers
kahoku
gun
japan
univers
nagoya
japan
univers
sagamihara
japan
syndrom
gb
acut
monophas
neuropathi
prognost
marker
gb
modifi
erasmu
gb
outcom
score
mego
erasmu
gb
respiratori
insuffici
score
egri
report
howev
proport
subtyp
gb
known
differ
western
countri
japan
remain
elucid
whether
marker
also
appli
gb
japan
investig
retrospect
gb
patient
determin
mego
egri
case
among
could
obtain
case
evalu
prognosi
use
gb
outcom
score
function
grade
fg
month
call
good
prognosi
fg
month
less
poor
prognosi
result
case
higher
score
mego
admiss
case
poor
prognosi
case
higher
score
mego
day
admiss
case
poor
prognosi
case
higher
score
egri
case
need
mechan
ventil
patient
good
prognosi
higher
averag
patient
poor
prognosi
calcul
valu
patient
mgdl
patient
higher
mgdl
could
significantli
walk
independ
six
month
p
patient
poor
prognosi
patient
lower
mgdl
patient
treat
singl
cycl
intraven
immunoglobulin
ivig
patient
treat
combin
therapi
intra
venou
methylprednisolon
andor
plasmapheresi
second
cycl
ivig
addit
ivig
although
differ
prognosi
patient
singl
cycl
intraven
immunoglobulin
ivig
patient
combin
therapi
patient
fg
mego
admiss
combin
therapi
made
better
prognosi
singl
cours
ivig
p
found
mego
egri
also
avail
japan
efficaci
combin
therapi
sever
gb
patient
investig
futur
larg
scale
prospect
studi
yiu
burn
menez
ryan
paediatr
cmt
best
practic
guidelin
consortium
children
hospit
melbourn
melbourn
victoria
australia
children
research
institut
melbourn
victoria
australia
melbourn
melbourn
victoria
australia
sydney
new
south
wale
australia
children
hospit
network
randwick
westmead
new
south
wale
australia
diseas
cmt
often
present
childhood
common
symptom
includ
weak
limb
pain
cramp
foot
deform
balanc
impair
guidelin
optim
manag
common
problem
experienc
children
cmt
current
exist
develop
guidelin
provid
evid
base
manag
monitor
children
cmt
seri
systemat
literatur
review
utilis
grade
grade
recommend
assess
develop
evalu
approach
conduct
answer
key
clinic
question
relat
manag
paediatr
cmt
includ
treatment
recommend
symptom
weak
pain
balanc
impair
joint
deform
impair
upper
limb
function
anticipatori
monitor
associ
complic
hip
dysplasia
yield
minim
evid
clinic
question
manag
recommend
could
made
statement
therefor
formul
via
delphi
process
conduct
delphi
panel
consist
local
intern
medic
alli
health
profession
experi
manag
children
cmt
attarian
sevilla
van
damm
de
visser
thoma
robert
young
studi
group
hospit
la
timon
marseil
franc
universitari
la
fe
valencia
spain
hospit
leuven
belgium
medic
centr
amsterdam
netherland
univers
medic
center
hackensack
usa
royal
nh
foundat
trust
manchest
uk
hospit
munster
germani
efficaci
treatment
adult
patient
shown
multicent
random
phase
ii
studi
attarian
et
al
taken
oral
consecut
month
well
toler
safe
signific
improv
disabl
observ
highest
test
dose
thought
indic
earli
meaning
chang
diseas
cours
mandel
et
al
form
rational
initi
multicent
random
pivot
phase
iii
studi
http
clinicaltrialsgov
mildli
moder
affect
patient
decemb
primari
object
assess
efficaci
dose
compar
placebo
disabl
measur
mean
chang
baselin
overal
neurolog
limit
scale
onl
score
month
furthermor
efficaci
proport
respond
ie
improv
onl
impair
function
test
qmt
electrophysiolog
paramet
cmap
snap
ncv
qualiti
life
va
secondari
endpoint
pursuant
studi
patient
elig
extens
studi
assign
patient
continu
previous
assign
dose
wherea
placebo
patient
random
one
two
dose
studi
conduct
investig
site
countri
eu
canada
us
decemb
patient
random
complet
screen
failur
rate
expect
patient
screen
independ
dsmb
recommend
continu
studi
plan
follow
safeti
analysi
first
patient
treat
month
preliminari
baselin
characterist
base
patient
data
clean
studi
popul
mean
age
year
rang
male
confirm
genet
diagnosi
mean
mean
motor
nerv
conduct
ulnar
nerv
ms
ten
patient
withdrew
studi
due
advers
event
unrel
studi
treatment
last
patient
complet
studi
expect
march
zhang
ghosh
lin
ghauri
sheikh
neurolog
univers
texa
health
scienc
center
houston
houston
tx
usa
assess
epiderm
nerv
fiber
densiti
structur
integr
critic
diagnosi
evalu
effect
potenti
therapi
small
fiber
neuropathi
current
skin
biopsi
multipl
site
commonli
use
assess
diseas
studi
expens
time
consum
due
cumbersom
process
quantif
techniqu
serial
biopsi
time
often
feasibl
due
cost
patient
accept
moreov
vast
major
norm
data
skin
biopsi
human
avail
distal
site
signific
proport
patient
small
fiber
neuropathi
focal
region
symptom
involv
commonli
biopsi
site
leg
live
imag
could
overcom
limit
provid
noninvas
real
time
assess
epiderm
nerv
fiber
bodi
previous
found
antibodi
aga
effect
neuron
deliveri
vector
transport
variou
cargo
fluoresc
dye
peripher
nerv
current
proof
concept
studi
examin
whether
multiphoton
microscopi
use
probeimag
epiderm
nerv
fiber
live
anim
system
andor
local
deliveri
fluoresc
conjug
aga
found
individu
nerv
end
skin
cornea
distinctli
label
visual
microscop
epiderm
nerv
fiber
label
aga
valid
use
transgen
mice
select
express
yellow
fluoresc
protein
nervou
system
multiphoton
imag
provid
tool
potenti
dynam
longitudin
evalu
small
fiber
neuropathi
includ
nerv
degener
regener
without
tissu
remov
thu
use
multiphoton
microscopi
conjunct
fluoresc
label
aga
neuron
vector
mani
research
clinic
applic
label
live
visual
epiderm
nerv
fiber
assess
small
sensori
nerv
fiber
health
diseas
zhou
tavori
lee
al
salihi
fazio
notterpek
brain
institut
univers
florida
gainesvil
florida
usa
cardiovascular
institut
oregon
health
scienc
univers
portland
oregon
usa
major
hereditari
neuropathi
due
abnorm
peripher
myelin
protein
whose
genet
variant
includ
increas
express
gene
duplic
haploinsuffici
gene
delet
point
mutat
phenotyp
heterogen
clinic
present
common
among
hereditari
neuropathi
patient
even
within
famili
caus
determin
investig
role
pathogenesi
neuropathi
gener
character
null
mice
amici
et
al
whose
peripher
nerv
show
alter
lipid
metabol
lee
et
al
examin
molecular
chang
underli
abnorm
determin
express
cholesterol
synthesi
pathway
cholesterol
uptak
transport
efflux
gene
lxr
pathway
affect
nerv
found
cholesterol
synthesi
pathway
inhibit
lxr
pathway
particularli
apo
upregul
mrna
protein
level
sinc
express
low
level
liver
central
organ
regul
cholesterol
bodi
studi
liver
tissu
form
mice
liver
mice
show
signific
hepatomegali
clear
featur
microvesicular
steatosi
well
mark
increas
lxr
pathway
gene
protein
apo
compar
wt
ultrastructur
studi
identifi
lipid
droplet
significantli
enlarg
mitochondria
liver
male
mice
due
mitochondria
fusion
level
mfn
remain
similar
wt
disturb
hepat
cholesterol
homeostasi
induc
activ
kupffer
stellat
cell
determin
extent
inflamm
nerv
liver
tissu
mice
leukocyt
macrophag
marker
nerv
section
detect
increas
number
cell
confirm
western
blot
liver
mice
found
signific
increas
kupffer
cell
elev
level
sever
dysregul
cholesterol
metabol
nerv
liver
includ
hepat
inflamm
absenc
dysregul
cholesterol
metabol
inflamm
may
act
diseas
modifi
neuropathi
